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Abstract 
 
Clinical insulin resistance (IR) is commonly seen in the obese adolescent and precedes a 
diagnosis of Type 2 diabetes (T2DM). Early detection and management of young people 
at risk of T2DM is essential to prevent disease progression and reduce later 
cardiovascular complications. Yet, despite greater recognition of clinical IR in youth and 
the potential implications for later metabolic health, treatment options are limited to 
weight management with a minor role for adjunctive pharmacotherapy. Moreover, the 
best activity prescription to optimise metabolic health in these young people remains 
unclear.  Paediatric weight management programs including aerobic based exercise have 
shown improvements in insulin sensitivity (Si) and metabolic profile, with or without 
body composition change. Resistance-based training is gaining favour as a safe 
therapeutic option as research demonstrates it to be equally effective and possibly easier 
to perform in the obese adolescent whose fitness may be decreased. Strength training 
may produce benefits to peripheral glucose uptake by regionally increasing lean tissue 
mass. However, this remains to be fully explored in adolescents with IR. 
 
This thesis, centred on a randomised controlled trial designed to investigate whether 
whole body vibration training (WBVT), a novel resistance exercise could enhance insulin 
sensitivity in a cohort of obese adolescents, in addition to a contemporary lifestyle 
intervention. To investigate change in insulin sensitivity we used validated proxy 
measures including whole body insulin sensitivity (WBISI) and homeostasis model of 
insulin resistance (HOMA-IR), measures which can be readily replicated in the clinical 
setting. Whilst the primary outcome was change in insulin sensitivity (Si), we also 
examined interval change in secondary outcome measures including: anthropometry, 
cardiorespiratory fitness and musculoskeletal parameters.  
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Participants in our study were recruited from tertiary hospital clinics and derived from 
Greater Western Sydney (GWS), a multi-ethnic community, with high genetic metabolic 
risk. Detailed clinical anthropometry, medical history and examination taken at baseline 
confirmed that the obese participants had high-risk ethnicities for the development of 
T2DM and the metabolic syndrome. Extended family members who reported a history 
of T2DM were more likely to report additional metabolic risk factors as shown in 30.2% 
of first and 60.2% of second-degree relatives. Participants had central adiposity as 
demonstrated by increased waist circumference and waist to height ratio (WtHR), in the 
majority of cases exceeding national adult guidelines 1. Adverse anthropometry was 
associated with poorer insulin sensitivity, increased weight and BMI. Insulin resistance 
was correlated with greater inflammation as measured by hs-CRP. Acanthosis nigricans 
(AN) could, in dark skinned individuals, detect biochemical hyperinsulinaemia but was 
not a reliable clinical feature in Caucasian participants. 
 
Obesity is not gender specific, yet over two thirds of the VIBRATE participants were 
female, with males having the highest body mass index (BMI). This disparity in accessing 
healthcare during adolescence mirrors adult trends and may represent cultural, social and 
peer influences with regards to the recognition of obesity in young people. The average 
fasting insulin within the group was 33.8mU/L and significantly higher than adult cut-off 
levels <15mU/L, likely due to the increased weight but also exacerbated by the 
physiological changes occurring in puberty. Calculated proxy measures for insulin 
resistance showed the group to be highly insulin resistant at baseline with HOMA-IR 
7.62 and WBISI 1.74, elevated, when compared to contemporary adult and adolescent 
published normative data. Metabolic profile indicators taken at baseline, showed high 
prevalence of the metabolic syndrome particularly in pubertal participants, ranging from 
23-44% dependent on the definition applied. Early evidence of sexual dimorphism was 
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seen with males displaying higher systolic blood pressure (SBP) z score at baseline. The 
group demonstrated mild elevation in aspart aminotransferase (AST), which may suggest 
early possible hepatic derangements associated with Non Alcoholic Fatty Liver Disease 
(NAFLD). Triglycerides (TG), also implicated in the pathogenesis of NAFLD, positively 
correlated with alanine aminotransaminase (ALT), more strongly in males. Participants 
were inactive with increased sedentary times. Further highlighting the de-conditioning in 
these adolescents and not unexpectedly, cardiorespiratory fitness was reduced as 
determined by VO2peak. LeonardoTM Mechanography, a new technique for analysing 
functional muscle performance showed lower muscle force and power generation, 
indicating that the ability to perform day-to-day activities may be compromised.  
 
Two techniques were employed to assess bone and mineral parameters including areal 
bone mineral density analysis with dual energy x-ray absorptiometry (DXA) and 
volumetric analysis with peripheral quantitative computed tomography (pQCT). The 
impact of early skeletal maturation in the obese adolescent was evident with obese 
individuals having higher areal bone mineral density (BMD) and bone mineral content 
(BMC) for age but normal values when adjusted for height. The effects of an earlier 
puberty, body composition and hormonal changes were demonstrated with females 
having a higher BMD and BMC compared to males. The integrity of the muscle bone 
unit was confirmed with lean tissue mass being an important predictor of BMD. 
Interestingly, increased waist circumference, suggestive of visceral adiposity, negatively 
affected both bone mineral content and bone mineral density, suggesting a possible 
impact of inflammation on bone accrual. 
 
The VIBRATE randomised controlled trial, confirmed the benefits of short-term 
lifestyle intervention in the management of insulin resistance and obesity. With lifestyle 
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intervention leading to significant decrease in BMI z score (-0.8 vs. -0.08, p<0.039) in the 
lifestyle and WBVT group respectively, which was associated with significant 
improvements in fasting glucose (-0.3 vs. -0.0, p<0.047) and clinically beneficial but non-
significant changes in proxy markers of insulin resistance. WBVT, despite increasing lean 
tissue mass by almost 0.5kg, with demonstrated positive effects to muscle bone 
interaction (significant increase in BMD for height) did not lead to enhancements in 
glucose homeostasis, demonstrating the complex nature of insulin dynamics particularly 
during puberty which is accompanied by physiological changes to Si. There was no 
association between bone and mineral turnover markers and energy homeostasis in our 
study, though we did see a significant association between low vitamin D levels, dark 
skin and greater insulin resistance (higher fasting insulin, lower WBISI and higher 
HOMA-IR).  Adolescent obesity studies are associated with poor adherence and ours 
was no exception, whilst retention to the study was high with a dropout rate of just 2.3%, 
the compliance to the WBVT exercise intervention was poor but is likely to reflect real 
life challenges in the management of the adolescent with obesity.  
 
This thesis contributes further knowledge about the metabolic characteristics, bone 
health, exercise capabilities and musculoskeletal limitations of the obese adolescent. This 
information will help to identify and target those individuals at risk of progressing to 
T2DM and may aid in the development of an individualised lifestyle intervention to 
assist in the transition of the obese adolescent to a more active lifestyle. We confirmed 
the role of lifestyle measures in the management of obesity and insulin resistance and 
provide further evidence of the safety of WBVT as a possible efficient method of 
improving lean tissue mass in adolescents with increased weight.  
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1.1 Obesity 
1.1.1 Prevalence and trends in obesity 
Australian data suggests that 20-25% of young people under the age of 18 can be 
characterised as overweight or obese2 3, with slightly higher rates seen in the United 
States4 5. Whilst prevalence continues to increase with age in Australian indigenous 
children 6, data suggests a plateau in child and adolescent obesity rates in Australia 7-9. 
Similarly, other OECD countries have also shown decline in rates of abdominal 10-12 and 
generalised obesity5. In Australian children, Indigenous heritage 6, ethnicity and socio-
economic status are related to obesity risk 13, 14 which is expected to increase to almost 
one in every three children by 2025 15.  
 
According to the International Obesity Taskforce (IOTF) now World Obesity Clinical 
Care (WOCC) definition, 10% of the world’s youth, aged 5-17 years are overweight or 
obese, with higher prevalence rates being seen in the developed countries16. 
Disconcertingly, two national surveys showed a doubling of the prevalence of obesity 
and overweight in Australian children between 1985 and 1995 17. In the United States 
(USA), the prevalence of adolescent obesity in the most recent survey 2013-14 was 17% 
and extreme obesity 5.8%, since 2003-04 this obesity in adolescents has continued to rise 
despite plateauing in younger children18. The public health issue of overweight is also 
increasing in developing countries of the world16. Worldwide, 110 million children are 
affected by overweight 19 and 2013 estimates from the World Health Organisation 
(WHO), classified 42 million children under the age of 5 years as overweight, three 
quarters of these children lived in developing nations, with higher incidences being seen 
in urban areas 20. Demographic trends in overweight have been seen according to socio-
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economic status and ethnicity 21-23 13 24 and parental education 25 26. In developed countries, 
lower socioeconomic status appears to confer an increased risk of overweight (and 
obesity); this is in contrast to poorer nations where the prevalence is higher in children of 
more affluent families 16 27-29 24. In the United States, children of Hispanic, African 
American (AA) and Native American background display higher prevalence of obesity 
compared to white children, confirming this socioeconomic divide 30 4 5. These data 
demonstrate the extent of the obesity epidemic both nationally and globally, a greater 
awareness of which may halt this upward progression.  
 
Apart from the physical and metabolic morbidity of the condition, weight issues, impact 
greatly upon the psychological health of the young person and may compromise social 
functioning 31 32 33. Adolescents with increased BMI are at greater risk of depression and 
those who are morbidly obese are most vulnerable 34 35. Therefore, early-targeted 
intervention in young people may reduce immediate and long-term physical and 
psychosocial sequelae. 
 
1.1.2 Aetiology of obesity 
The aetiology of obesity is multi-factorial and remains poorly understood. In simple 
terms, overweight and obesity are due to an imbalance in energy intake and expenditure 
with the excess energy stored as body fat. This new body weight set point is then actively 
defended by a complex neuroendocrine response that leads to changes in metabolism, 
decreases in physical activity or increases in appetite. This phenomenon has been 
demonstrated in adults where resting metabolic rate and total energy expenditure 
decrease to counteract dietary weight loss 36 37. 
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Appetite, satiety and energy balance is mediated by a complex array of neuroendocrine 
mediators within the hypothalamus and higher brain centres. The obese state leads to 
changes in regulatory hormone release from the pancreas, adipose tissue, gastrointestinal 
system and the brain 38.  
 
In addition to other hormones, adipose tissue secretes leptin, an anorexigenic hormone, 
with multi-fold effects leading to increased satiety and energy expenditure and decreased 
appetite and food intake. The amount of leptin secreted is in direct proportion to the 
amount of fat tissue, however with well-established obesity, a state of leptin resistance 
develops. The gastrointestinal system is the source of additional anorexigenic hormones, 
including: obestatin which influences gastrointestinal motility, food intake and metabolic 
processes; peptide YY (PYY) which influences the secretion of neuropeptide Y from the 
hypothalamus and glucagon like peptide (GLP-1) which acts in the pancreas to increase 
insulin and decrease glucagon secretion. Ghrelin is the main orexigenic hormone secreted 
by the gut, it has an antagonistic effect to ghrelin leading to increased hunger 39 . 
 
Environmental and individual factors also play a role in the development of obesity. 
Individual risk factors associated with obesity include: nutritional intake with increased 
consumption of energy dense foods, genetic predisposition, ethnicity, medical conditions 
and medications. Secular trends leading to decreased physical activity and an increased in 
sedentary activities such as television viewing also contribute to reduced energy 
expenditure 14. Increasing the duration and quality of sleep 40 41, decreasing energy intake 
and increasing physical activity are modifiable risk factors to prevent overweight in later 
childhood 40. Although single gene mutations may lead to significant obesity in isolation 
or in the context of an inherited genetic syndrome, they account for less than 1% of 
obesity referrals 42.  
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There is rising interest in the role of endocrine disrupting chemicals (EDCs) and their 
putative role in the development of obesity as shown in Figure 1.1. These products 
coined as “obesogens” are commonly found in the environment with exposures 
occurring through ingestion, dermal absorption or inhalation. Obesogens such as 
Bisphenol A (BPA) and phthalates, present in plastics can leach out to produce 
endocrine disrupting effects in humans affecting metabolic pathways for both glucose 
and fat homeostasis leading to T2DM and obesity. Epigenetic changes that occur 
through the ingestion or absorption of chemical may be combining to increase obesity 
prevalence rates 43-45.  
 
Figure 1.1 The actions of endocrine disrupting chemicals (EDCs)  
The possible actions of endocrine disrupting chemicals (EDCs) in the pathogenesis of human obesity 
Adapted from Stojanoska et al 46 
 
 
EDCs 
Synergistic efffects of exposure to multiple chemicals   
Bioaccumulation effects 
Dose response U shaped or inverse U shaped Transgenerational epigenetic inheritance 
In utero and developmental exposure effects 
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An “obesogenic” environment that is, an environment conducive to overweight and 
obesity is thought to provide a catalyst for the phenotypic expression of overweight and 
obesity in individuals with and without a genetic predisposition. The global trend toward 
a more sedentary lifestyle along with a change in dietary patterns is thought to be the 
overriding influence in the worldwide development of overweight and obesity 16.  
 
Other prenatal and early life factors that may influence the development of obesity 
include the intrauterine environment, birth size, rapid weight gain during infancy and 
early rebound of BMI 22 47 48. Excessive weight gain during pregnancy is positively 
associated with heavier birth weight and increased BMI at 2 and 8 years of age. Maternal 
diabetes in pregnancy is also associated with heavier birth weight and the development of 
obesity in childhood 49. Further studies in Australian children have confirmed the role of 
pregnancy related factors including maternal smoking, large birth weight as well as single 
child status50. Placental weight may mediate some of these maternal factors 51. 
Socioeconomic factors such as low parental education and SES level have been shown to 
influence early childhood obesity rates and may contribute to the above demographic 
trends 52 53 26. Parental obesity, particularly that of the mother may also increase the 
obesity risk of Australian children 54 55. Furthermore, lack of parental recognition of 
obesity and risks to the child may also contribute to high prevalence rates 56 57. These data 
reveal that whilst the problem of childhood obesity is multifactorial and complex, there 
are many potential areas for intervention including lifestyle modification.  
 
1.1.3 Measurement of overweight and obesity in adolescents 
An ideal clinical tool for the assessment of body fatness in young people has not yet been 
developed 58 59.  Furthermore, a general consensus for the measurement of adiposity has 
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not been reached and there are wide variations across the world, resulting in difficulties 
in the definition of obesity. This lack of standardisation makes it difficult to quantify the 
global impact of the condition and to establish worldwide trends 16 60. The assessment of 
body fatness in the paediatric cohort relies on indirect measures of adiposity such as 
anthropometry. In research settings, a more direct analysis of body composition with 
tools such as dual energy x-ray absorptiometry (DXA) or underwater weighing may be 
possible however, these gold standard measures require specialised equipment and 
personnel rendering them costly and impractical for day to day clinical use. Indirect 
measures that include anthropometry have greater clinical utility and can be easily applied 
by health professionals 1.  
1.1.3.1 Indirect Measurement of Adiposity  
Several indirect measures of adiposity are available including Body Mass Index (BMI), 
waist circumference (WC), waist-hip ratio, waist-height ratio (WtHR) and skinfold 
thickness. Only BMI, WC and WtHR will be discussed as these techniques are employed 
in the VIBRATE research study. 
a. BMI 
The BMI is a calculated ratio and is used as a proxy measure of body fatness. The BMI is 
calculated by dividing the weight of the child in kilograms (kg) by the height of the child 
in metres2; the result is a numeric value with units of kg/m2. It has greater applicability in 
the adult population, where well-defined cut-off thresholds exist for normal, overweight, 
obese and morbid obesity. In adults, a higher BMI is associated with increased risk of 
cardiovascular health problems 61 48 62 similar trends for childhood obesity have not been 
clearly proven 63-66. In Caucasian adults, a BMI greater than 25kg/m2 is characterised as 
overweight and a BMI over 30kg/m2 is classified as obese.  However, these definitions 
may not be appropriate for all ethnic populations, for example in Asian populations, a 
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BMI of 23kg/m2 and 25kg/m2, for overweight and obesity respectively, may better 
characterise individuals at metabolic risk given marked variations in body composition 
and increased genetic susceptibility to the metabolic syndrome 16 62 67. The percentage of 
body fat varies with gender, race (different distribution of body fat) and pubertal status 
and therefore the assessment of body fatness using BMI may not provide a true 
representation of total body fat in all populations 68 69 70. 
 
To determine if an adolescent is overweight, the calculated BMI should be plotted on an 
age and gender specific population reference standard. There is no local reference 
standard in Australia and therefore the BMI for age percentile charts from the US 
Centers for Disease Control and Prevention (CDC) have been adopted for routine 
clinical use 71. A BMI that lies above the 85th centile classifies the child as overweight; if 
the ratio is greater than 95th centile an adolescent can be considered obese 1 22. BMI 
assessment can be performed for children aged 2-18 years using these charts. 
b. Waist circumference 
The WC is an easily obtained, non-invasive, surrogate measure for central adiposity and 
correlates well (R>0.8) with similar measures of truncal fat obtained using DXA.  It 
provides good reliability, with low inter-observer error 16. Waist circumference is also a 
strong proxy measure for visceral fat in children 72-74 and adults. The regional distribution 
of adiposity confers additional risk and increased WC is often associated with adverse 
metabolic profile 75 76 77.  
 
The WC may also provide clues to adverse lipid partitioning and associated 
intramyocellular lipid (IMCL) and intrahepatic lipid (IHCL) lipid deposition 78 79. It has a 
recognised correlation with visceral adipose tissue deposition (R2 =0.64)80. In adults, 
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visceral adiposity has been associated with increased metabolic risk73 81-83. In contrast, in 
children the association between visceral fat and metabolic risk is still to be determined 
but it is likely to parallel those seen in adults 73 76 84 72.  The WC can independently predict 
decreased insulin sensitivity (Si) and it may be a strong predictor of the more 
metabolically adverse visceral fat component in children 85 and adults 86. Waist 
circumference may also prove better than BMI z score in predicting cardiovascular risk 
as demonstrated in studies of Australian 75 and Greek-Cypriot children 75 87. Watts et al 
showed that children with a WC ≥ 90th centile 88 had increased cardiovascular risk. An 
increased waist circumference may identify children with high metabolic risk to a greater 
extent that BMI measurement as it better represents visceral adiposity 72 89. 
 
There is a lack of reference standards for waist circumference that can be partially 
overcome by the use of the waist to height ratio (WHtR). This measure is easy to 
calculate and provides an individual with clinical feedback about metabolic risk. It is 
calculated by dividing the waist circumference in centimetres (around a well-defined 
reference point e.g. umbilicus or midpoint between the costal margin or ileal crests) by 
the height of the adolescent in centimetres.  A waist to height ratio ≥ 0.5 has been shown 
to correlate with cardiovascular disease risk (CDR) clustering in young people 90 91. More 
recently however, some have suggested age specific cut off values for WHtR are 
preferable in the growing child 92 93. An elevated WHtR was superior to BMI 
measurement in assessing cardiovascular risk factors 94.  Similarly, cross-sectional data 
from the Bogalusa Heart Study demonstrated CDR clustering with increased waist 
circumference. This study showed children with an android distribution of adipose tissue 
had higher fasting insulin levels and adverse lipid profiles, independent of race or 
gender95. In the clinical setting, the simple message “keep your waist circumference to 
less than half your height”96 90 is readily understood, provides immediate feedback to the 
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family and young person and provides a tool to monitor progress. Whilst BMI is useful 
to measure overall body fatness, it is clear that centripetal adiposity is related to CDR in 
both adults 97 and children 76 91 and therefore the measures of WC and WtHR may allow 
better characterisation of childhood metabolic risk.  
1.1.3.2 Direct measures of adiposity 
Bioelectrical impedance analysis (BIA), Dual energy x-ray Absorptiometry (DXA), 
Magnetic resonance imaging (MRI), Computerised axial tomography (CT) and 
underwater weighing are research tools for evaluation of adiposity. They are costly and 
require specialised personnel 1. DXA was the only direct measure of adiposity employed 
in the VIBRATE study and is discussed further. 
a. Dual energy x-ray absorptiometry (DXA) 
 
DXA is a useful tool to measure total and regional body composition and provides a 
direct measure of adiposity in the research setting. A DXA scan can provide information 
about total and regional fat, fat free mass and bone mineral compartments. The method 
relies on the variable attenuation of low dose x-ray radiation passing through each of 
these body compartments, which is recorded by specialised software. In addition to low 
radiation exposure, the scan is relatively easy to perform and has good accuracy and 
reproducibility. The DXA scanning bed has an upper weight thus limiting the ability of 
severely obese adolescents to be assessed via this method. Further limitations include an 
underestimation of percent body fat in the obese adolescent when compared to the  
4-compartment method (divides the body into fat, water, protein and mineral.) 98 In the 
growing adolescent, changes in the hydration and density of lean tissue may affect 
analysis of DXA 99 . Small changes to body composition seen during short-term 
intervention trials may not be accurately detected by this method 100 101.  
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1.1.4 Complications of obesity 
Obesity and overweight have significant impact on many systems of the body 33,102. This 
literature review will focus on the development of the endocrine complications of insulin 
resistance, its involvement in the metabolic syndrome and the development of T2DM. 
The musculoskeletal effects of obesity will be briefly examined along with the possible 
role of bone as an endocrine organ with putative influences on insulin sensitivity. 
1.1.4.1 Obesity and the metabolic syndrome 
In the seminal Banting Lecture, Reaven first described the “metabolic syndrome” as a 
constellation of metabolic risk factors that heighten an individual’s risk for diabetes and 
cardiovascular disease (CVD) 103. This syndrome has also become known by a variety of 
other names including “insulin resistance syndrome”, “syndrome X” and the “multiple 
metabolic syndrome”.  
 
Cardiovascular risk factors such as dyslipidaemia, hypertension (HT), abdominal obesity 
and insulin resistance/ glucose intolerance are increased in obese individuals. These 
adverse cardiovascular indicators are also key defining elements of the metabolic 
syndrome. Obesity often precedes the development of the metabolic syndrome and 
insulin resistance. Presence of metabolic risk factors may predict glucose response in pre 
and post pubertal children 104. The atherosclerotic process, a cardinal feature of 
cardiovascular disease has been shown to be present in youth with the metabolic 
syndrome 105. Carotid femoral pulse wave analysis, a measure of arterial wall stiffness, is 
reduced in children who have increased BMI and central adiposity 106 and insulin 
resistance 107. Atherosclerosis, HT and adverse lipid profile predisposes the young person 
to increased CVD. 60 105 108. Furthermore, in obese adolescents, the pre diabetic state is 
already associated with reduced cardiovascular function109. Adolescent males with 
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elevated BMI within the top 10th centile are 7 times more likely to develop coronary heart 
disease at age 25-45 years, than counterparts who are in the lowest 10th centile of the 
BMI charts. The excess cardiovascular risk is present even within the normal range, 
rising 12% for every unit increment in the BMI 66. As the weight of an individual 
increases, there is a concomitant increase in risk of developing a risk factor for 
cardiovascular disease, with half of overweight adolescents having a least one 
cardiovascular risk factor 110. This suggests that an elevated BMI in childhood contributes 
independently to the risk of later CVD. 
 
Although influenced by many modifiable ‘obesogenic’ environmental factors, metabolic 
risk, may also be pre-determined by intrauterine factors including; maternal gestational 
diabetes 111 112, intrauterine growth retardation 49 113, genetic and ethnic specific factors. 
Nutritional influences such as infant feeding and the development of early adiposity 
rebound may also contribute to metabolic risk in later life 114 115.  
 
There exists much confusion regarding the definition of the metabolic syndrome in the 
adult population, making it difficult to gauge global estimates of metabolic syndrome 
prevalence. In 2001, the National Cholesterol Education Program Adult Treatment Panel 
III (NCEP ATPIII) 116 guidelines were released as a tool to allow clinicians to classify 
adults with the metabolic syndrome. It is difficult to adapt an adult definition to the 
paediatric population as metabolic indicators such as blood pressure; lipid profile and 
growth parameters are highly variable with age. In addition, the advent of puberty causes 
body composition change that confers a physiological decrease in insulin sensitivity. This 
necessitates the use of age, gender and pubertal specific values rather than single cut-off 
thresholds 117 118.  
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As no consensus guidelines for the metabolic syndrome in children exist, adult guidelines 
had been modified for use in the paediatric population with age specific limits. Cook et al 
reported that 6.8% of overweight adolescents and 28.7% of obese youngsters were 
defined as having the metabolic syndrome 119; suggesting that the degree of overweight is 
an important factor in the development of the metabolic risk. Data from the National 
Health and Nutrition Examination Study (NHANES) 1999-2000 showed a slight 
increased overall prevalence in the metabolic syndrome in adolescents from 4.2% to 
6.4% from the previous NHANES study conducted in 1988-1992 120. Similar to Cook et 
al119, they found 32.1% of individuals with BMI>95th centile could be classified with the 
metabolic syndrome. Shaibi et al examined the prevalence of the metabolic syndrome 
using three different published definitions of the metabolic syndrome and discovered 
aggregations of risk factors consistent with the metabolic syndrome in 25.7%-39% 
depending on which definition was applied 121. Various definitions of the metabolic 
syndrome in children and adolescents may be seen in Table 1.1. 
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Table 1.1 Definitions of the metabolic syndrome in children  
 
This table is taken from 122 
 
In an attempt to clarify the situation, the International Diabetes Federation (IDF) 
proposed a consensus definition of the metabolic syndrome in children in 2007, 
incorporating clinically relevant metabolic profile indicators in children 122 (Table 1.2). 
The definition clarified aspects of the metabolic syndrome in children aged 10 years and 
older; adult guidelines may be applied to adolescents aged ≥ 16 years 123. Abdominal 
adiposity is central to the IDF definition of the metabolic syndrome in both adults and 
children. A further two or more metabolic profile indicators including: elevated 
triglycerides (TG), low levels of high-density lipoprotein cholesterol (HDL-C), increased 
blood pressure (BP), and elevated plasma glucose are also required to diagnose the 
metabolic syndrome in childhood 122.  
 
Adverse metabolic profile indicators persist from childhood into young adulthood 124. 
The Fels longitudinal study confirmed this tracking phenomenon by showing that 
elevated WC in boys was associated with increased WC as an adult and heightened 
metabolic risk. They also demonstrated a sexual dimorphism with regard to metabolic 
risk. The divergence of risk was different for boy and girls, occurring earlier in childhood 
for boys and later during puberty for girls 125. 
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Table 1.2 IDF definition of the metabolic syndrome in children  
 
This table is taken from 122 
1.1.4.2 Obesity and insulin resistance  
A direct relationship between obesity and insulin resistance has been shown in adults and 
children126 127. Overweight individuals are more likely to have elevated fasting insulin 
levels due to resistance of insulin hormone action in the body which results in higher 
circulating levels of insulin and the development of hyperinsulinaemia128. Insulin 
resistance is a precursor to the development of pre-diabetes, including impaired fasting 
glucose (IFG) and impaired glucose tolerance (IGT) that may progress to T2DM 129 130. 
An obese state, independent of the presence of insulin resistance can lead to ß cell 
dysfunction, with elevated 2 hour glucose levels within the normal range seen during oral 
glucose tolerance test in obese children and adolescents 131. 
 
In the USA, the prevalence of pre diabetes and T2DM in US adolescents increased from 
9% to 23% from 1999-2008 but other factors associated with the metabolic syndrome 
such as hypertension and adverse lipid profile remained stable 110. These rates are 
comparable to adults where 8.3% of the population has been diagnosed with T2DM and 
many more are still undiagnosed 132. A recent study has shown that during mid-
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adolescence, progression from normoglycaemia to pre diabetes occurs at a rate of 1% in 
a random selection of the population 133.  
1.1.4.3 Obesity and the musculoskeletal system 
Children with obesity are at risk of orthopaedic side effects such as slipped capital 
femoral epiphyses, tibia vara, pes planus and scoliosis of the spine 33 102. In addition, 
overweight may also influence the mechanical properties of bone with alterations in bone 
mineral density (BMD) and bone mineral content (BMC). In children, there are opposing 
viewpoints with regard to the effect of increased body mass index on bone parameters. A 
cross sectional study by Goulding et al showed that overweight and obese children had 
reduced BMC and areal BMD for weight when compared to normal weight controls. 
This unexplained difference resulted in up to 10% less BMC and bone area in obese 
adolescents for body weight. One possible explanation for this mismatch between BMI 
and bone may relate to a delay in bone development and growth during a period of rapid 
weight gain 134. Overweight children are more likely to present with fractures with an 
increased odds ratio of 4.5 compared to healthy weight counterparts 135 136. The increased 
fracture risk may be explained by altered bone structure and increased force experienced 
during a fall. Poor balance in the obese child may predispose them to increased falls 137. 
However, other studies have demonstrated the positive effects of obesity 138 secondary to 
increased fat derived hormones 139.  The above findings have important implications for 
integrating overweight children into physical activity given possible disruption to bone 
properties and an increase fracture risk. 
 
In contrast to children 140, studies in adults have mostly shown a protective effect of 
increased BMI on fracture risk with a positive correlation between weight and 
osteoporosis, BMD and fracture risk 141-143. Furthermore, the positive influence on BMD 
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may be related to independent changes in fat and lean body mass. It remains unclear 
whether lean tissue or fat mass or both influence the apparent differences in BMD. 
1.1.5 Strategies for the prevention and management of overweight  
The prevention of overweight needs to commence in early life with public health 
strategies facilitating change in the “obesogenic” environment and modifying behaviours 
at the individual and family level. The environment, family and peer influences play key 
roles in the development of obesity and overweight 144 145. Therefore, intervention 
programmes aimed at reducing the problem of childhood overweight and obesity must 
mutually consider these factors. It is often difficult to extrapolate results from research 
studies to real life because children often achieve weight loss under the ideal conditions 
of a clinical trial. In real life however, many of these weight loss goals are not met often 
due to poor adherence. Recruitment challenges and high dropout rates are characteristic 
of clinical trials involving overweight adolescents 146. This is likely due to intrinsic 
characteristics of the patient population, including poor mood and lack of self-esteem32 33. 
There are often psychosocial difficulties and economic constraints inherent that make 
management more difficult 13 50.  
 
At the family level, supporting parenting skills, educating parents and promoting 
breastfeeding may be useful to prevent excessive weight gain in infancy and the 
preschool years 22. In an RCT of 12 months duration, Golley et al showed young children 
aged 6-9 years whose parents were involved in intensive lifestyle and parenting skills 
courses, had a 10% reduction in BMI z-score compared to 5% decrease in the parenting 
skills alone and control groups 147. This and other studies suggest a family focused 
intervention may be more successful for weight management. Adolescents whose parents, 
particularly mothers, have poor levels of education appear vulnerable to obesity 26 47 148. 
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Therefore targeting mothers for further education may prove useful to successfully 
manage weight. 
 
Adolescents must grapple with peer group pressure and also struggle to gain 
independence. Physiologic changes including puberty may also influence body weight 
during adolescence. In view of these age specific tasks, counselling sessions for 
adolescents on their own may be more successful 149. Increasing physical activity and 
altering dietary habits in the school-aged child may assist with lifestyle change and 
decrease prevalence of overweight and obesity. Childhood obesity management requires 
the dedicated input of a multidisciplinary team that will often include a physician, weight 
management dietitian, exercise physiologist and psychologist or social worker. The 
therapeutic process requires engagement with not only the child but also the family and 
caregivers. If family motivation is lacking then successful outcomes are less likely, 
particularly with the pre-pubertal child.  
 
Weight management often presents a challenge for the children, their families and health 
care workers. Young children and those with mild overweight may achieve success with 
weight stabilisation, as ongoing growth will allow them to “grow into their weight” 150. 
However, to prevent metabolic complications in severely obese adolescents lifestyle 
change should target weight loss with referral to specialist clinics if these measures fail 14. 
Population based strategies should evaluate food advertising directed at children on the 
mass media. In Australia, children from ethnic minority groups, particularly Middle 
Eastern and European backgrounds have been found to have a higher prevalence of 
weight issues and therefore culturally appropriate strategies with consideration of 
socioeconomic variances may be required151. 
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1.1.5.1 Dietary modification 
Dietary modification in paediatric obesity remains controversial and there is no 
consensus regarding the most appropriate diet for weight management, improved insulin 
sensitivity 152 153 and metabolic health 154. Given that childhood and adolescence are 
associated with growth and physiological changes such as puberty, adequate nutritional 
intake should be not be compromised. Age specific caloric intake is generally maintained 
through the inclusion of foods low in total and saturated fat and cholesterol 22. Australian 
guidelines suggest inclusion of fruit and vegetables, cereals, lean meats and dairy products 
for adequate calcium intake, water should be considered the standard beverage 155 . 
Breastfeeding infants born to mothers with gestational diabetes appears to have a 
protective effect against later obesity as shown by the results of a retrospective cohort 
study 156. Children were followed up at ages 6 and 13 years and were found to have 
significantly lower BMI, WC, subcutaneous abdominal (SAAT) and visceral abdominal 
adipose tissue (VAAT) than those who breastfed less. The results suggest that any 
programming effects due to the exposure of intrauterine diabetes may be attenuated by 
breastfeeding. Health promotion encouraging breastfeeding in mothers may be an 
effective strategy to reduce the increased risk of obesity in offspring of mothers with 
diabetes 55.  
 
Nutritional counselling using the elements of the “Stop Light/ Traffic Light” diet can 
effect BMI change in paediatric patients. This diet, colour codes food into red, orange 
and green choices based on caloric density with an emphasis on an overall less 
prescriptive and lower energy diet. Reduction of sugar sweetened beverages, 
recommendation of water as the main beverage, appropriate portion sizes and a regular 
breakfast are also encouraged as first line nutritional measures 102. A family based 
approach with nutritional education to caregivers may be more appropriate in the 
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younger child 157 158. In the older adolescent a different approach may be required. A 
recent RCT showed that meal replacements to adolescents increased weight loss 
compared with a conventional diet after 4 months suggesting that adolescents may need 
more prescriptive nutritional guidance 159. Modifying the macronutrient composition of 
the nutritional component of lifestyle programs has not found to be superior to standard 
nutritional coaching as shown by Gow et al 160 and reduction in overall energy intake may 
assist in BMI reduction 161. 
 
Dairy products are an invaluable source of dietary calcium and are required for 
attainment of peak bone mass during childhood and adolescence. The intake of dairy 
appears to decrease during adolescence due to concerns about weight gain due to the 
increased caloric density of these foods 162. A recent meta-analysis has however shown 
that obesity rates may decrease by 16% for each 200g/day increment in dairy intake 163. 
The effects on weight loss may be mediated through increased satiety and reduced 
appetite 164.  
1.1.5.2 Lifestyle management 
The most appropriate physical activity prescription or dose of activity for health benefits 
in young people with overweight or obesity is unknown, however, behavioural lifestyle 
interventions were found to be associated with positive weight loss outcomes in a recent 
Cochrane Review 29. Adolescents are encouraged to incorporate 60 minutes of moderate 
intensity physical activity on most days 14 165 but a lack of time is increasingly cited as a 
barrier to achieving this target. Therefore, time efficient and shorter duration activities 
have been explored to determine their utility in paediatric based lifestyle programs. These 
activities may be more appealing to children who have shorter attention spans and 
different levels of development.   
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High intensity interval training (HIIT) 166 is one such method to improve muscle power. 
HIIT involves burst of high intensity activity with interspersed low intensity or rest 
periods and has been shown to increase muscle power 167 168, decrease body fat 169 and 
improve cardiorespiratory fitness 170 in obese adults. In adolescents, a HIIT program had 
similar effects to a standard school based physical education class and maintained 
cardiorespiratory fitness 171. HIIT may produce similar improvements to 
cardiorespiratory fitness in the obese adolescent but may lead to greater BMI reductions 
when compared with endurance training 172. 
 
Decreasing sedentary activities with a concomitant increase in incidental activity may 
prove to have similar outcomes to increasing physical activity. Although television 
viewing, internet use and electronic games are engrained in the social culture, reduction 
in total small screen time to less than 2 hours per day may change may increase activity 
165 and reduce consumption of excessive calories 173. 
1.1.6 Conclusions  
Childhood obesity has risen to critical rates both in Australia and internationally, with 
almost one in four children being classified as overweight or obese. As a consequence 
there is an increasing prevalence of complications such as insulin resistance, T2DM and 
CVD. Childhood overweight and obesity is more often than not, a precursor to body 
mass issues in adult life 174. The “tracking” phenomenon has been well established in 
childhood overweight and obesity, meaning that adolescents will carry weight issues into 
adulthood. Thus, the impact to the health system will be most apparent in the next 
generation of young adults as overweight and obese children become adults with obesity 
related health problems such as T2DM, CVD and other manifestations of the metabolic 
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syndrome 16.  In addition to the increased risk of health problems as an adult, childhood 
overweight and obesity is associated with immediate serious health consequences and has 
a directly impacts on the psychological welfare of young people 175 176. Hence, early 
targeted intervention in the paediatric and adolescent populations may be reduce the 
future economic burden associated with the complications of obesity and overweight but 
will also lead to immediate direct health improvements for the paediatric population. 
 
1.2 Insulin resistance 
1.2.1 Definition 
Insulin, secreted by beta cells in the pancreatic islets, is the primary glucose-lowering 
hormone. It maintains glucose homeostasis by: suppressing endogenous glucose 
production, inhibiting hepatic glycogenolysis and gluconeogenesis and reducing renal 
glucose production. It stimulates and enhances peripheral glucose utilisation by insulin 
sensitive tissues including muscle and fat 177. An insulin resistant state exists when 
physiologically normal levels of insulin produce a reduced biological response at the 
tissue level, resulting in reduced insulin dependent glucose uptake. An individual with 
insulin resistance requires higher levels of circulating insulin to maintain euglycaemia. 
The liver, muscle and adipose tissue are the primary organs and tissues that determine 
the degree of insulin resistance.  
 
A variety of factors contribute to the development of an insulin resistant state including:  
genetic predisposition, obesity, puberty, adverse fat partitioning and inflammatory 
cytokines178 179. Insulin resistance is a term often used descriptively to describe the clinical 
status of the individual. Insulin resistance and Si are often used interchangeably, however, 
Si is a derived value obtained during dynamic biochemical testing. An individual who has 
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been investigated and has low Si is often highly insulin resistant and vice versa, an 
individual with high insulin sensitivity is less insulin resistant. 
 
1.2.2 Aetiology and prevalence 
Insulin resistance and subsequent ß cell failure are antecedents to the development of 
T2DM. Insulin resistance is the most common metabolic feature of the obese adolescent 
but may also be seen in normal weight children, particularly those with a family history of 
metabolic disease 61 103 180. The prevalence of insulin resistance varies according to the 
measurement adopted and population studied. As BMI progresses into the obese range 
the prevalence of insulin resistance in the adolescent increases 181-183. High prevalence 
rates of insulin resistance as measured by HOMA-IR (Homeostasis Model Assessment 
of Insulin Resistance) have been described in the literature, ranging from 10-60% in 
overweight and 45-80% in obese children and adolescents 183-186. 
 
Similarly, in a large cross sectional study of eighth grade students in the US, almost half 
had a BMI in the overweight range ≥85th centile, with mean fasting insulin of 
30.1µU/mL, a level highly suggestive of biochemical insulin resistance.  Of these 
participants, a high proportion, 40.5% had evidence of glucose dysregulation with 
evidence of impaired fasting glucose ≥5.6mmol/L 187. In the USA, the NHANES study 
showed 51.1% of obese children (BMI>95th centile) were found to have biochemical 
evidence of insulin resistance 185. A hyperbolic relationship between insulin sensitivity 
and insulin response preserves normal glucose tolerance; the product of the two is 
known as the Disposition Index (DI) 188 as shown in Figure 1.2 and will be further 
discussed in 1.2.3. 
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Figure 1.2 The hyperbolic relationship between insulin sensitivity and ß cell function. 
Different hyperbolas reflect differing degrees of tolerance. The product of ß cell function and insulin 
sensitivity is known as the Disposition Index = constant. (I) Normal state (II) Decreased insulin sensitivity 
is compensated for by increasing insulin secretion. The DI remains the same and there is normal glucose 
tolerance. Failure of the ß-cell to compensate with increased secretion leads to decreased insulin sensitivity 
and glucose intolerance as shown in (2) taken from 189. 
 
Ethnicity, particularly African American (AA) and Hispanic background and family 
history of T2DM are associated with decreased Si in adolescents 190 191 and may predict 
progression from prediabetes to T2DM in obese adolescents192. Furthermore, offspring 
of individuals with T2DM have a higher prevalence of insulin resistance highlighting the 
heritability of this disease process 193 194. After 25 year follow up period, offspring of 
couples with T2DM who developed T2DM had evidence of reduced Si and glucose 
effectiveness (SG) at least 10 years prior to presentation with disease confirming defects 
in insulin dependent and independent uptake 195.  
 
Individuals with prediabetes are more likely to progress to T2DM and have adverse 
cardio-metabolic profile. Adolescents with a fasting glucose level even within the upper 
normal range demonstrate risk factors for the metabolic syndrome including insulin 
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resistance; elevated BP and increased WC, independent of BMI z score 196. Similarly, an 
elevated 2-hour glucose level after an oral glucose tolerance test was associated with a 
decline in beta cell function 197.  
 
In adults from high-risk populations such as the Pima Indian, the progression to T2DM 
evolves over a protracted period of time 5-10 years 198. Prospective analysis of studies in 
adults showed high variability of progression from IGT to T2DM ranging from 35.8 to 
87.3 per 1000 person-years 199. A pre-diabetic state may also co-exist in the obese, insulin 
resistant adolescent. Sinha et al found that almost one quarter of severely obese 
adolescents had evidence of pre-diabetes with IGT 129. Further studies have confirmed 
that pre-diabetic adolescents have marked insulin resistance 200. Disconcertingly, the 
progression from prediabetes to T2DM is accelerated in youth with 24% progressing 
from IGT to T2DM after only 2 years 192, however longitudinal data in this cohort is 
limited.  
 
In utero and early life factors may also contribute to increased risk of insulin resistance in 
later life. Barker proposed the developmental origins of health and disease hypothesis 
whereby the intra-uterine environment particularly maternal nutrition and obesity can 
influence an individual’s metabolic health in later life by altering physiology and 
epigenetic change 201 202. Intra-uterine factors such as prematurity (regardless of birth 
weight) 203-205small206 and large 207for gestational age, maternal obesity208 gestational 
diabetes 111 and twin pregnancy 209 210have been shown to increase the risk of developing 
insulin resistance and other elements of the metabolic syndrome supporting the notion 
of foetal programming 49 211 212 and epigenetic change213 214 215 Individuals born small for 
gestational age have reduced Si that is persistent at age 20 years independent of their 
BMI 203 and first born children may have higher metabolic risk compared to siblings 216.  
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Genetic factors such as ethnicity and the in utero environment contributing to insulin 
resistance may be more difficult to modify. However, as a sedentary lifestyle and obesity, 
work in concert to exacerbate the inherited tendency towards insulin resistance, careful 
weight management in these patients may lessen risk. In addition, attention to maternal 
health and feeding practices may attenuate the presence of adverse metabolic phenotype 
in later life. Although limited, studies in adolescents suggest that there is more rapid 
progression from IGT to T2DM making this population high risk compared to adults 217. 
Furthermore, longer duration of dysglycaemia may also indicate likelihood of progressive 
disease 218. Therefore, screening of adolescents for evidence of clinical insulin resistance 
and prediabetes is essential. 
1.2.3 Physiological and pathological insulin resistance 
Puberty is a time of rapid somatic growth and sexual maturation. This transitional stage is 
accompanied by changes in body composition and an increase in truncal adiposity 219. 
Physiologic changes during puberty result in a transient 30% decrease in insulin 
sensitivity, which peaks around Tanner stage III with recovery at Tanner stage V 220.  The 
exact process that underlies these changes has not been elucidated however, the β cells in 
the pancreas compensate by increased endogenous insulin secretion. Adolescents from 
AA and Hispanic backgrounds may have a blunted physiological compensatory response 
thus increasing their propensity to develop T2DM 221 222. During puberty, an increase in 
sex steroid secretion and physical maturity, results in increased BMI and adiposity, which 
worsen insulin resistance. The increased central adiposity in puberty expands the visceral 
adipose tissue compartment, which is pro-inflammatory and has a negative influence on 
Si 223.  
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Goran et al 222 showed that progression from Tanner stage I to III was accompanied by a 
32% reduction in Si that could not be attributed to body composition changes or the 
altered hormonal milieu, apart from rising androstenedione levels. Jeffery et al in their 
longitudinal study showed that the insulin resistance often attributed to pubertal change 
actually precedes any pubertal biochemical signals and physical change by 3-4 years 224. 
The above theories do not explain the nadir of Si and recovery at Tanner Stage V. The 
sequential changes in Si during puberty appear to best correspond to the pubertal growth 
spurt that is accompanied by increases in growth hormone (GH) and insulin like growth 
factor-1 (IGF-1) levels 225 226.  
 
Puberty is a time of physiological stress and it is not surprising that most cases of 
childhood T2DM are diagnosed in late adolescence particularly in those children with 
exogenous obesity. During puberty, metabolism shifts in favour of fat oxidation rather 
than glucose oxidation, resulting in lowered glucose utilisation, with decompensation 
more likely 226.  
 
Pathological insulin resistance may result from inherited gene defects or acquired as part 
of the metabolic syndrome. Insulin resistance is a key pathology of the metabolic 
syndrome or syndrome X as coined by Reaven 103. The metabolic syndrome is an 
aggregation of multiple risk factors that cumulatively increase the risk of CVD. Insulin 
resistance may also be found in certain rare genetic syndromes including Type A 
leprechaunism and Rabsen-Mendenhall syndromes due to mutations in the insulin 
receptor gene. The insulin resistance is often severe in nature and may present from birth 
leading to early death.  
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1.2.4 Pathophysiology of Insulin Resistance 
Insulin, secreted by the pancreatic ß cell is involved in the maintenance of glucose 
homeostasis. In healthy individuals, normal glucose tolerance is maintained by dynamic 
interplay between endogenous glucose production and insulin dependent and 
independent glucose uptake.  
 
1.2.3 Assessment of insulin sensitivity 
Given the variety of tissues involved in insulin action and glucose homeostasis, the 
assessment of ß cell function remains a challenge. Single measures of glucose and insulin 
provide limited information and fail to account for the dynamic processes occurring as 
the ß cell responds to the rise and fall in postprandial glucose. The glucose tolerance of 
an individual is related to both the ß cell function and insulin sensitivity, which in turn 
are related by a hyperbolic relationship. The product is known as a disposition index (DI) 
(Figure 1.1).  A low disposition index is a marker of poor ß cell compensation.  
 
Insulin resistance often develops insidiously in an attempt to maintain blood glucose 
levels within the normal range and is influenced by several factors including: increasing 
overweight, in-utero programming, lifestyle factors and genetic predisposition. In the 
early stages, the ß cell compensates with increased insulin secretion. The compensatory 
hyperinsulinaemia and reduced hepatic clearance of insulin may manifest in higher 
fasting insulin levels227 228. The raised insulin levels may lead to the development of 
clinical features such as acanthosis nigricans (AN) or polycystic ovary syndrome (PCOS) 
in females. With worsening insulin resistance, the ß cell decompensates which may 
unmask abnormalities in glucose tolerance with eventual progression to a pre-diabetic 
state and T2DM. As an adolescent becomes more insulin resistant the compensatory 
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insulin release from the pancreas may not be sufficient to preserve the status quo, 
resulting in fasting or post-prandial hyperglycaemia. 
 
In the post-absorptive state and during fasting, glucose uptake occurs in the brain, red 
blood cells, renal medulla and gastrointestinal tract via insulin-independent processes. 
This uptake is matched to endogenous hepatic glucose production with the fasting 
plasma glucose primarily representing the liver production of glucose that is modified by 
circulating levels of glucose and insulin 229. In the fed state, rising levels of glucose and 
amino acids trigger insulin release leading to active glucose disposal by skeletal muscle, 
gut and liver and to a much lesser extent adipose tissue with concomitant decreased 
hepatic gluconeogenesis and glycogenolyis.  Approximately, 70-75% of insulin mediated 
glucose disposal in the post-prandial state occurs in the peripheral tissues, predominately 
skeletal muscle with minimal amounts taken up by adipose tissue. The release of insulin 
results in active translocation of glucose transporters to the cell membrane to facilitate 
glucose disposal and this is the rate-limiting step in the glucose metabolic pathway. The 
cellular mechanism of insulin resistance is likely to be multifactorial but may include 
insulin receptor and pathway signalling defects of varying aetiology; obesity; sedentary 
lifestyle and genetic factors Aberrations in the insulin-signalling pathway may include: 
reduced number of insulin receptors at the cell membrane as seen in obese individuals; 
pathological conformation changes in the receptor after insulin binding due to the effect 
of plasma membrane glycoproteins; post translation impairments including 
phosphorylation defects from free fatty acid accumulation and modulating effects of 
adipocytokines including tumour necrosis factor-α (TNF- α) and interleukin 6 (IL-6) 230. 
There are varying degrees of insulin resistance and insulin secretory dysfunction in 
individuals with disorders of glucose homeostasis; knowledge of the differential 
contribution may be useful in treatment 231. 
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1.2.5 Adipose tissue as an endocrine organ 
Obesity is associated with increased total fat. The adipose tissue contributes minimally to 
glucose disposal however provides a major substrate for the generation of potentially 
harmful free fatty acids which contribute to insulin resistance and impaired ß cell 
function through lipotoxicity.  
 
Adipose tissue is now considered to play an active role in the development of obesity and 
eventual insulin resistance and secretes over a hundred products involved in energy 
homeostasis. These hormones and adipocytokines are involved in energy regulation and 
have both paracrine or local effects and endocrine actions in distant target organs. Leptin 
and adiponectin are two products secreted by adipose tissue. Adiponectin, derived from 
adipose tissue cells, improves Si and is cardio-protective 232; a deficiency of leptin leads to 
pathological obesity and increased food intake 22. Adolescents with T2DM have much 
lower adiponectin levels compared with leaner individuals with type 1 diabetes 233. 
Adiponectin reduces insulin resistance by increasing glucose uptake, enhancing FFA 
oxidation and reduces endogenous hepatic glucose production 234.  
 
In healthy individuals, insulin has varied physiologic effects including: inhibition of 
lipolysis, reduced hepatic gluconeogenesis and increased peripheral glucose disposal in 
skeletal muscle. With increasing obesity and worsening insulin resistance, insulin fails to 
completely suppress lipolysis and gluconeogenesis and there is a reduced uptake of 
glucose in the periphery.  
 
FFAs play an integral role in the development of insulin resistance (Figure 1.3) and 
T2DM (Figure 1.4). In the insulin resistant state, FFAs are more readily available as the 
anti-lipolytic effect of insulin is reduced, particularly in the visceral compartment. This 
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results in FFA release into the hepatic vein and exposure of the hepatic cells in the liver 
to high FFA concentrations235. In the pancreas, there is a hyperbolic relationship between 
insulin secretion and sensitivity. High levels of FFAs may impair ß cell activity and may 
blunt any compensatory responsiveness as shown in Figure 1.3. 
 
 
 
 
Figure 1.3 The role of free fatty acids in the development of insulin resistance 
Taken and adapted from 235and 236 Top arrow - ß-cell sensitivity to glucose is preserved by up-regulation of 
secretion.  Middle arrow - (upper dashed line) lipid infusion results in insulin resistance and blockage of ß-
cell compensation that results in a horizontal and left shift. Bottom arrow - (lower dashed curve) lipid 
infusion results in insulin resistance and lipotoxicity of ß-cell. 
 
The greater availability of FFAs act in skeletal muscle to further worsen the degree of 
insulin resistance and have deleterious effects on glucose homeostasis by providing 
energy and substrate for gluconeogenesis 227. In addition, FFAs have independent 
lipotoxic effects on pancreatic ß cell. Adipose tissue that accumulates in skeletal muscle 
and liver is a source of FFAs and adipocytokines. Adipocytokines released by adipose 
tissue may trigger an inflammatory cascade resulting in macrophage infiltration of 
adipose tissue. C-reactive protein is a marker of inflammation, however lower levels can 
be associated with obesity related inflammation and can be measured via a high sensitive 
assay hs-CRP, which in adults correlates with cardiovascular risk 237 238. Adolescents with 
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increased central adiposity have elevated levels of hs-CRP further demonstrating that 
visceral fat is pro-inflammatory 239.  
1.2.6 Lipid partitioning and insulin resistance 
The location of fat within the body determines metabolic risk and this may explain why 
some obese adults have less metabolic co-morbidities 240.  Fat is partitioned into 2 main 
compartments. Visceral abdominal adipose tissue (VAAT) surrounds the organs, 
omentum and mesenteric layers. VAAT is associated with greater insulin resistance 
compared with subcutaneous adipose tissue (SAAT) as it is less sensitive to insulin and 
therefore undergoes lipolysis contributing to serum FFAs to a greater extent than SAAT. 
These FFAs are released into the portal vein contributing to hepatic insulin resistance 230 
235. Intrahepatocellular lipid (IHCL) and intramyocellular lipid (IMCL), the accumulation 
of lipid within the liver and muscle respectively, disrupt glucose access to muscle cells, 
and interfere with glucose metabolism heightening the insulin resistance state. This is 
discussed further in section 1.2.6.1.  
 
Similar to adults, obese adolescents of equal BMI can differ in terms of metabolic risk 241, 
suggesting that regional fat distribution, particularly central adiposity important in risk 
determination in the paediatric cohort 242. Weiss et al, found when they compared two 
groups of adolescents with similar BMI, those with higher levels of intramyocellular and 
visceral fat were more insulin resistant and had lower levels of adiponectin 241. In another 
study, obese adolescent girls displayed reduced fatty oxidation, impaired glucose disposal 
and reduced glucose oxidation in response to an insulin infusion compared to young 
women of normal weight 243. In this cohort, those with greater visceral adiposity had 
higher fasting insulin, higher stimulated insulin secretion and greater overall insulin 
resistance. The deleterious effect of visceral fat accumulation was seen in a multi-ethnic 
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cohort of obese adolescents who were stratified into groups based on amount of fat in 
the visceral compartment. Adolescents in the highest tertile demonstrated high metabolic 
risk but were not necessary the most overweight, with the authors suggesting the 
phenotype was akin to partial lipodystrophy 244. Weight loss accompanied by reduced 
VAAT may be associated with improvements in Si 245. In contrast to the above findings, 
Maffeis et al found that this relationship may not be consistent in pre-pubertal children as 
lower Si showed correlation with subcutaneous fat 246.  
 
It is important to note that BMI whilst clinically useful and easily measured provides a 
good surrogate measure of overall adiposity and an estimate of subcutaneous fat, which 
is largely metabolically inert. On the other hand, it is the VAAT and fatty deposits within 
the liver and muscle, which heightens metabolic risk and is more difficult to measure 
with anthropometric techniques 247. Therefore, waist circumference, rather than BMI, 
may correlate better with metabolic risk allowing a more accurate representation of 
adverse fat distribution 91 248. Racial factors and ethnicity are also important contributors 
to the development of insulin resistance, due to differing proportions of VAAT as 
shown in children 249 and adults 250 251. In AA children, IMCL varies independently of 
insulin resistance unlike Americans of European extraction. AA have less visceral fat, 
which is associated with inflammation and insulin resistance, but have higher incidence 
of T2DM most likely due to a lower threshold of visceral fat required for an insulin 
resistant state 252 
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Figure 1.4 The role of free fatty acids (FFA) in the development of T2DM 
adapted from 230  
 
1.2.6.1 Intramyocellular lipid (IMCL) and Extramyocellular lipid (EMCL) 
The accrual of IMCL in the skeletal muscle affects insulin-mediated glucose uptake by 
interfering with glucose transporter 4 (GLUT 4) receptor transport in the cell membrane; 
a similar process is also responsible for hepatic insulin resistance 253. FFAs accumulate in 
skeletal muscle and through a series of intracellular events, preventing GLUT4 
translocation to the cell membrane. The increased circulating levels of FFAs generated 
from lipolysis lead to mitochondrial dysfunction and impaired lipid oxidation, which in 
turn perpetuates the vicious cycle by leading to accumulation of further IMCL. The net 
result is decreased glucose transport, glycogen synthesis and a blunting of the insulin-
signalling cascade 230.  
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IMCL can be differentiated from EMCL using proton nuclear magnetic resonance 
spectroscopy. Studies have shown ICML has a higher correlation with insulin sensitivity 
when compared to the visceral compartment, independent of obesity. Paradoxically, elite 
athletes who are highly insulin sensitive have increased IMCL to meet their higher 
oxidative requirements during intense activity suggesting actual location and size of the 
lipid particles may also modulate the clinical presentation of insulin resistance.  
 
Adolescents who are insulin resistant have higher visceral and IMCL deposits 241. There 
is a direct relationship between the accumulation of IMCL and the degree of insulin 
resistance when assessed with surrogate markers of insulin sensitivity 254. Recent studies 
investigating children prior to puberty have demonstrated a correlation between IMCL 
deposition, metabolically adverse visceral fat and markers of the metabolic syndrome 78. 
Indirect assessment of visceral adiposity might be possible through WC measures.  
 
Exercise training of skeletal muscle can improve Si without significant weight loss or 
change in body composition likely the result of increased expression of GLUT 4 proteins 
in the cell membrane 255 256. Enhanced Si is evident in insulin resistant individuals after a 
single episode of training as insulin and exercise activate glucose uptake by different 
mechanisms. The hallmark of hepatic insulin resistance is the inability of insulin to 
inhibit gluconeogenesis with concomitant changes in lipid metabolism. Hepatocellular 
dysfunction occurs when lipid accumulates within the hepatocytes. This contributes to 
insulin resistance and in severe cases may lead to non-alcoholic fatty liver disease 
(NAFLD). Intra-abdominal, visceral fat rather than generalised obesity seems to 
contribute more to hepatic lipid accumulation. Lipid accumulation within the hepatocyte 
impairs suppression of hepatic glucose production by insulin, clinically this may manifest 
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as an elevated fasting glucose level. There is also an associated dyslipidaemia with 
increased very low-density lipoprotein cholesterol and reduced HDL-C from increased 
clearance. Interestingly, patients with insulin receptor mutations do not manifest the 
metabolic sequelae seen with IHCL despite the known correlation of insulin resistance 
and IHCL.  
1.2.7 Insulin resistance and prediabetes 
Prediabetes is an intermediate state of glucose intolerance whereby the glucose level is 
above the normal range but does not satisfy the criteria for T2DM. A single abnormal 
reading during formal testing is sufficient to make a diagnosis of prediabetes. The pre-
diabetic state includes several entities including: impaired fasting glucose (IFG) and or/ 
impaired glucose tolerance (IGT) (Table 1.3). Individuals with prediabetes are at high risk 
of progressing to T2DM but may also revert to normal glucose tolerance 257.  
 
IFG and IFG represent carbohydrate dysregulation and are due to different aetiology. 
Individuals with IFG have a high degree of liver insulin resistance and relatively normal 
muscle insulin sensitivity; conversely patients with IGT have significant contribution of 
muscle insulin resistance but demonstrate only mild hepatic insulin resistance. The 
differing pathophysiology may require therapeutic interventions that specifically target 
the site of greatest insulin resistance. 
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Table 1.3 Definition of glucose tolerance states  
Categories of glucose 
tolerance Normal IFG T2DM 
Fasting plasma glucose 
mmol/L  5.6-6.9 ≥7.0 
2 hour plasma glucose 
mmol/L <7.8 7.8-11.1 ≥11.1 
Haemoglobin A1c % <5.7 5.7-6.4 ≥6.5 
Adapted from 258 259 
IFG (Impaired fasting glucose) T2DM (Type 2 Diabetes Mellitus) 
1.2.8 Measurement of insulin resistance 
Early targeted intervention of adolescents at high risk of insulin resistance is necessary to 
delay progression to T2DM. Therefore, reliable methods to quantify insulin resistance 
and reference standards are necessary in the paediatric population. To date, due to 
insufficient paediatric studies in this area and the variety and variability of tests, no such 
practical standard exists. Furthermore, there are no clear guidelines with regards to 
normal and abnormal results.  
 
The euglycaemic-hyperinsulinaemic clamp is considered the gold standard to which other 
measures of insulin are compared 260. Several validated derived proxy measures have been 
developed to estimate Si with variable correlation with clamp studies. The frequently 
sampled intravenous glucose tolerance test (FSIVGTT) with minimal modelling 261 262 
MINIMOD analysis 263 is also considered a gold standard and shows high correlation 
with the gold standard 264-266. 
 
Some relatively less invasive measures of insulin resistance include: fasting plasma insulin 
level, HOMA-IR, Quantitative Insulin Sensitivity Check Index (QUICKI), Whole Body 
Insulin Sensitivity Index (WBISI or Matsuda Index), fasting plasma Glucose-to-Insulin 
Ratio (G/I) 266. These derived proxy measures have the advantage of being economical as 
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well as simple and easy to perform; this is in contrast with clamp and FSIVGTT studies, 
which are intensive, expensive and require specialised personnel. However, very few 
paediatric studies have been conducted to validate these derived measures 267-270 and 
consequently there is no consensus with regard to the optimal surrogate measures in this 
population. In this thesis, insulin sensitivity (Si) will be used when describing measures 
derived from these calculations.  
1.2.8.1 Invasive measures of insulin sensitivity 
Invasive measures of Si are expensive and time consuming and most often performed in 
research settings. Three such methods, the euglycaemic-hyperinsulinaemic clamp, 
frequent-sample IV glucose tolerance test and oral glucose tolerance test are discussed 
below.  
a. Euglycaemic-hyperinsulinaemic clamp study  
The euglycaemic-hyperinsulinaemic clamp is considered the gold standard technique for 
quantifying the degree of insulin resistance and determining Si.  There are two variations 
of the glucose clamp: the hyperinsulinaemic-euglycaemic and hyperglycaemic clamp. The 
hyperinsulinaemic-euglycaemic clamp is used to measure peripheral (skeletal muscle) Si 
whilst the hyperglycaemic clamp assesses β cell function and insulin secretion 260. During 
the hyperinsulinaemic-euglycaemic clamp, glucose disposal predominately occurs in 
skeletal muscle (~80-90%). A simultaneous intravenous infusion of insulin ensures that 
endogenous hepatic glucose production is suppressed, allowing calculation of peripheral 
Si that is predominately determined by skeletal muscle 271.  
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b. FSIVGTT (with Minimal model analysis MINIMOD) 
The FSIVGTT is another invasive method 262 and via a minimal model analysis 263 
produces a result which correlates well with the gold standard clamp study; the result 
reflects a mixture of hepatic and peripheral Si 261 262.  
c. Oral glucose tolerance test  
The oral glucose tolerance test (OGTT) can be used to diagnose diabetes when there is 
clinical suspicion of glucose impairment, particularly in the overweight adolescent with 
clinical signs of insulin resistance such as AN or in a female with features of PCOS. An 
adolescent may be referred for an OGTT when they show an elevated fasting glucose 
5.5-6.9mmol/L or a random level suspicious of glucose intolerance 5.5-11.0mmol/L. 
The OGTT is affected by carbohydrate intake, fasting period and activity and is generally 
undertaken first thing in the morning after an overnight fast. Venesection occurs at the 
commencement of the test prior to the glucose load of 1.75g/kg (max 75g), bloods are 
taken 2 hours later; some protocols involve 30 minute sampling during the two-hour 
period. First phase insulin secretion and hepatic Si determine the rise in plasma glucose 
over the first hour of the test, whereas later decline in glucose is due to the peripheral Si 
of the muscle and second phase insulin secretion. Values of insulin and glucose obtained 
during the test can be used to calculate derived indices of Si, which have reasonable 
correlation with the clamp 254 268. The fasting and 2-hour blood glucose levels are used for 
diagnosis of normal, pre-diabetes and frank diabetes.  
 
During oral ingestion, 30-40% of glucose uptake occurs in the splanchnic circulation due 
to incomplete suppression of hepatic glucose production via this route. Therefore during 
the OGTT, 60-70% of the glucose is taken up by skeletal muscle tissue in the periphery. 
The fasting glucose measure gives an indication of hepatic glucose output. Values 
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obtained during the test and particularly the 2-hour levels are the combined result of 
peripheral glucose uptake and endogenous hepatic glucose production. Although there 
are no established reference ranges for the 1-hour level, there is increasing evidence that 
the value may have some clinical utility. A 1-hour level of 8.6mmol/L has been proposed 
as a cut-off to identify those who may be at risk of the development of T2DM and 
additional cardiovascular risk 272 273. The results of an OGTT may vary within the same 
individual. There is a coefficient of variation of 8% and 20% respectively for the fasting 
and 2 hour levels respectively 274. This high variation makes the test less than perfect. The 
OGTT allows for the measurement of two derived surrogate indices of Si: 1) the whole 
body insulin sensitivity index (WBISI) and the 2) insulin sensitivity index (ISI) 275. The 
WBISI has been validated in both adults 276 and children 254 to show good correlation 
with the gold standard clamp technique with R=0.78. 
d. Whole body insulin sensitivity index (WBISI)/ Matsuda Index 
 
The whole body insulin sensitivity (Matsuda Index) is calculated with measures obtained 
during the oral glucose tolerance test and the correlation with the clamp in adult studies 
is approximately R=0.70, as it reflects a combination of hepatic and peripheral insulin 
resistance 276. The WBISI has also been validated in the paediatric population and it 
shows similar correlation with clamp studies, R=0.78 254. Similar correlations have been 
shown in adult studies 276 277. The oral glucose tolerance test is more acceptable to 
patients as there is less risk of complications and it is less labour intensive than the clamp 
technique. It is therefore a good option for clinical use and for screening individuals at 
high risk of dysglycaemia.  
 
Due to the relative ease of performing an oral glucose tolerance test in our study venue 
we chose to use the Matsuda or WBISI index to determine the primary study outcome. 
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The results of this test would also identify as part of routine clinical care any individuals 
with T2DM who may require further definitive treatment. The WBISI is a commonly 
used validated proxy measure of the hyperinsulinaemic-euglycaemic clamp with high 
correlation 276 and excellent reproducibility on repeated measurement 278. 
1.2.8.2 Less invasive measures derived from fasting blood samples 
Less invasive measures of insulin resistance include the fasting plasma insulin level, 
HOMA-IR, Quantitative Insulin Sensitivity Check Index (QUICKI) and Fasting Plasma 
Glucose-to-Insulin Ratio (G/I) also known as the insulinogenic index 266. These derived 
proxy measures have the advantage of being economical as well as simple and easy to 
perform. These surrogate measures have been found to have excellent correlation with 
the gold standard clamp studies in non-diabetic individuals 268. Their ease of applicability 
in large populations allow for widespread use in epidemiological studies of insulin 
resistance.  HOMA and QUICKI have been shown to better reflect hepatic insulin 
resistance 279.  
 
Studies performed in adolescents at two different ages, 13 and 15 years, showed only 
modest correlation of these measures with the gold standard clamp derived M sensitivity, 
with values ranging from 0.48 (fasting insulin and FGIR)~0.54 (QUICKI), with similar 
correlations at age 15 years, with the exception of the FGIR which showed much lower 
correlation of 0.25 270. Experts have agreed that the fasting surrogate measures such as 
the HOMA-IR do not offer any additional benefit over the fasting insulin, which is 
highly correlated ~0.99 with HOMA-IR 280.   
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a. Fasting plasma insulin concentration 
Fasting plasma insulin levels can be obtained after an overnight fast and high levels 
indicate biochemical insulin resistance. Although, this method is easy to perform and 
inexpensive, there are some limitations to its applicability in the clinical setting. A single 
fasting insulin level may vary considerably in an individual as it represents not only the 
degree of insulin resistance but also reflects pulsatile secretion from the pancreas and is 
participant to the pharmacokinetic processes of distribution and clearance; variation in 
any of these elements will alter the result 281. The fasting insulin result is only reliable in 
individuals with normal glucose tolerance as those with glucose dysregulation have 
diminished ß cell production of insulin and will exhibit lower fasting levels due to the 
underlying pathology.  
 
The fasting insulin level is subject to inter-assay variation and there is no standard 
reference range for children 282. In addition, there is wide variation seen in the correlation 
between the fasting insulin level and clamp studies in children. Paediatric studies 
comparing the fasting insulin level to clamp derived Si results have shown a wide 
variation with correlations ranging from 0.42-0.91 268 270. Studies in non-diabetic adults 
have wide ranges with fasting insulin cut off levels ranging between 7.2mU/L 283-
18mU/L 284. Further limiting the diagnostic use of a fasting insulin level is the lack of 
consensus regarding the cut off value for insulin resistance in the paediatric cohort. The 
American Heart Association (AHA) provides the following clinical guidelines for fasting 
plasma insulin levels which may prove useful for screening high risk individuals if there is 
a strong clinical suspicion: Normal <15 mU/L, borderline high 15-20 mU/L, high>20 
mU/L 285. Most studies to date in both children and adults utilise the fasting insulin or 
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HOMA-IR index as outcome measures. Ten and Maclaren suggested a fasting level >15 
µU/mL or >75µU/mL at 2 hours was indicative of insulin resistance 286. In contrast, a 
recent consensus statement examining childhood insulin resistance has discouraged 
routine clinical use of the fasting insulin level 280. However, research suggests that the use 
of the fasting insulin measure may be still provide a reliable estimate in adults 128 and in 
early adolescent pubertal participants 287, independent of ethnicity. Despite the many 
limitations, the fasting insulin level may be useful in large population based research 
studies to evaluate biochemical insulin resistance in patients with normal glucose 
tolerance.  
 
b. HOMA-IR 
Given the limitation of a single fasting glucose measure particularly in patients with 
impairments in glucose tolerance, this measure adds a further dimension incorporating 
the fasting glucose level. The HOMA-IR (homeostasis model assessment of insulin 
resistance) is easily calculated from fasting measures of insulin and glucose [fasting 
insulin (μU/mL)] x [fasting glucose (mmol/L)]/22.5 288.  It is a validated proxy for 
assessing insulin sensitivity from a single fasting blood glucose and insulin level and can 
be used in clinical settings, provided ß cell function is not severely impaired.  
 
The HOMA-IR index correlates well with clamp derived glucose disposal 276 288 and Si 
derived from the FSIVGTT 289. In adolescents this correlation was moderate with 
r=0.49~0.53, being higher in older and heavier children 270. Highlighting the variability of 
research results, Gungor et al 268, showed higher correlation for measures derived from 
fasting insulin and glucose in their paediatric study, including 156 children from AA and 
Caucasian backgrounds, with r=0.91~0.92 for HOMA-IR, QUICKI and fasting insulin 
respectively. Higher Si is associated with a lower value, normal values between 1.21-1.45, 
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with levels between 2.61-2.89 in insulin resistant individuals 288. However further studies 
have shown values up to 3.8 may in fact be normal in adults 290. Several other surrogate 
measures of Si exist, however the HOMA-IR shows greater consistency in the evaluation 
of insulin resistance in adolescents 291.  
 
Although is it widely accepted that obese and overweight adolescents are more likely to 
be insulin resistant, young people whose BMI lies in the upper normal range may also be 
at risk.  A cross-sectional analysis in American children of varying BMI, showed a trend 
of increasing HOMA-IR as BMI progressed from the 75th centile (OR 4.277) to above 
the 95th centile (OR 17.907) 182. Screening for children with BMI scores within the upper 
normal range may detect insulin resistance and provide new opportunities for early 
intervention in T2DM. In adolescents, a normal HOMA-IR does not exclude insulin 
resistance 292 and therefore an individual should proceed to further investigation in the 
setting of additional risk factors. Although a practical method, the calculation of the 
HOMA-IR is based on solitary basal measures of glucose and insulin and may not 
provide the best assessment of insulin resistance of obesity that may become more 
apparent under dynamic conditions of insulin stimulated secretion and peripheral glucose 
uptake and may not confer any advantage over the fasting insulin alone. HOMA-IR 
correlates highly with the fasting insulin level R=0.95 and the addition of the fasting 
glucose levels may add little discriminative power as they vary in a relatively tight range in 
comparison to the fasting insulin level.  
c. QUICKI 
The QUICKI method of determining insulin resistance also incorporates the fasting 
blood glucose and insulin measurements. It is considered a more accurate representation 
of insulin sensitivity when compared to HOMA-IR and fasting insulin. It is calculated 
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using the following formula: (1/[log[fasting insulin (μU/mL)]+log[fasting glucose 
(mg/dL)] 293 294. It can be used in both non-diabetic and diabetic patients however it is 
less accurate in those who are insulin sensitive. Similar to adult studies, Uwaifo et al 
showed that in children the QUICKI index had better correlation with Si derived from 
the clamp studies with R=0.69267 
1.2.9 Clinical insulin resistance  
Routine clinical examination findings may allude to the presence of underlying insulin 
resistance. Irregular menstrual cycles in the female adolescent or general dermatological 
findings of AN are important discriminating features in the clinical assessment.   
1.2.9.1 Polycystic ovary syndrome 
Polycystic ovary syndrome (PCOS) can be defined by various criteria. The Rotterdam 
criteria, includes oligo-anovulation, clinical and/or biochemical hyper-androgenism and 
polycystic ovaries 295. Obese adolescents are at risk of developing PCOS that may lead to 
infertility and increased cardiovascular risk. Most adolescent females with PCOS have 
features of the metabolic syndrome or insulin resistance. This syndrome is characterised 
by clinical and biochemical androgen excess, polycystic ovaries and menstrual irregularity. 
Insulin resistance is present in approximately 50% of young women with this disorder 
and the presence of PCOS is an indicator of heightened cardiovascular risk. Weight 
reduction and the use of insulin sensitizing agents such as metformin may improve 
ovulation by reducing androgen levels 296. Metformin administered to premenarchal girls 
with early adrenarche and low birth weight delayed the onset of PCOS features with 
greater effectiveness when given at a younger age (8-12 years rather than 12-14 years of 
age) 297.   
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1.2.9.2 Acanthosis nigricans 
Acanthosis nigricans (AN) is a clinical feature often present in overweight individuals 
with insulin resistance. AN develops in the skin flexures of the neck, axillae and groin 
and transforms the appearance of the skin with hyperpigmentation, hyperkeratosis and 
papillomatosis by causing epidermal growth. It has been proposed as a clinical marker of 
insulin resistance in obese children as it is associated with higher fasting insulin levels and 
measures of insulin resistance 298. Acanthosis nigricans in adolescents appears to be 
independently associated with maternal gestational diabetes 299, non-Caucasian 
background, female gender, severe obesity 299 300 301. The presence of AN in adolescents, 
may also indicate underlying features of the metabolic syndrome 302 and glucose 
dysregulation with a quarter of participants with evidence of dysglycaemia 303. Whilst 
most studies suggest AN may discern the individual at high metabolic risk some suggest 
that the sign may be unreliable and state the degree of body fat and anthropometry 
measures (BMI SD score ≥ 3.0) be used instead to stratify risk and to target children for 
further testing 301.  
1.2.10 Treatment of insulin resistance and prediabetes 
Despite the increased rates of insulin resistance and prediabetes in the paediatric 
population, there are limited therapeutic options due to a paucity of clinical trials in this 
area. Most therapeutic strategies in high-risk adults have involved lifestyle change to 
effect weight loss 304 305.  
 
Most children and adults who develop T2DM are obese. Furthermore, increased 
adiposity is responsible for over 50% of the variance of insulin sensitivity in children. 
Dietary modification can lead to weight reduction and improved Si. In adults, modest 
weight loss of 5-10% can have proven health benefits including beneficial effects on 
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cardiovascular risk and other components of the metabolic syndrome 306. 
Pharmacological treatments are limited to the off label use of metformin although some 
research has been conducted in the use of weight loss medications. Exercise can improve 
Si without significant weight change by altering muscle sensitivity. The Look AHEAD 
study showed that an intensive lifestyle in adults had long term, sustained effects on 
weight loss, glycaemic control and cardiovascular risk factors after four years duration 307. 
In the Diabetes Prevention Program (DPP), lifestyle intervention was superior to 
pharmacological treatment in preventing the progression to T2DM in adult patients with 
pre-existing evidence of dysglycaemia 304. Medications such as metformin predominantly 
target hepatic insulin resistance, whereas weight loss may provide dual benefits at both 
the hepatic and skeletal level.  
1.2.10.1 Dietary management of insulin resistance 
Dietary guidelines in the paediatric population are limited to the traffic light guide, 
hypocaloric diet or healthy eating advice. Evaluation of individual dietary prescription in 
this cohort remains difficult as it is often undertaken as part of a lifestyle intervention 
incorporating an exercise component 308. Compounding these difficulties is the fact that 
dietary modification in adolescents often leads to weight loss 309 310 that may 
independently influence Si. The appropriate dietary prescription for prevention of T2DM 
is still being investigated in both adults and adolescents. An increased protein, low 
carbohydrate diet in conjunction with a structured exercise program proved more 
successful in producing weight and fat loss in obese women with insulin resistance after 
10 weeks. These changes were accompanied by reductions in fasting glucose 311. In 
contrast, a recent study by Garnett et al showed that energy restriction rather than 
macronutrient (protein and carbohydrate) variation led to improved Si in adolescents 
after 12 months 152. 
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Free fatty acids are implicated in the pathogenesis of insulin resistance and therefore 
altering the dietary fat content may influence insulin sensitivity. In a review of 41 studies 
conducted in adults, no clear relationship could be found between Si and quality of fat 
ingested, the negative findings and difficulty in interpretation being attributed to various 
methodology differences 312. A recent systematic review showed that lipid profile could 
be improved in young people with dietary only intervention but that measures of glucose 
homeostasis including Si showed greater improvements with exercise 154.  
 
Individually, high fibre and low glycaemic load diets result in weight loss and may 
improve Si in overweight adolescents 313 314 315. A 6-week intervention of psyllium 
supplementation altered body fat composition and reduced LDL cholesterol but did not 
enhance insulin sensitivity or reduce BMI in obese males 316. Given the interrelationship 
between BMI and insulin sensitivity, it is difficult to discern whether the change in 
insulin status is due to the diet intervention or the associated weight loss and certainly 
adult studies have shown variable results 314. These studies demonstrate the inherent 
difficulties when assessing the optimal dietary prescription for obese adolescents with 
insulin resistance and pre-diabetes as many interventions are confounding by weight loss 
and difficulties with poor compliance, making the true effects of the diet difficult to 
elucidate.  
1.2.10.2 Exercise and insulin resistance 
Exercise is a non-pharmacological treatment to augment insulin sensitivity and can 
improve whole body insulin sensitivity in adults with T2DM 317. A healthy lifestyle with 
attention to diet and incorporating regular physical activity is essential for weight 
management and good cardiovascular health. In adolescents, exercise has been shown to 
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improve insulin sensitivity 318-320, assist with weight reduction and has positive effects on 
cardio-respiratory parameters 321. Unfortunately, adolescents have become more 
sedentary and this has contributed to the development of overweight issues. According 
to a United States Survey of school students, approximately 62% of young children did 
not engage in any after school structured physical activity 322.  
 
The DPP found that in adults with IGT, exercise was superior when compared to 
metformin in reducing the progression to T2DM, with 58% reduction in lifestyle arm 
compared with 31% in the metformin group 323. Obese insulin resistant adults with 
normal glucose tolerance demonstrated more efficient glucose disposal after 6 weeks of 
physical training with lower fasting insulin, improved hepatic glucose suppression and 
increased peripheral glucose uptake 324. Physical activity is associated with greater glucose 
transport across the cell membrane resulting in enhanced skeletal and hepatic insulin 
sensitivity. Skeletal muscle contributes greatly to peripheral and whole body insulin 
sensitivity; therefore efficient glucose uptake at the cellular level will reduce progression 
to T2DM. Aerobic exercise studies have demonstrated physiological adaptations leading 
to improved muscle quality with activation of the insulin signalling cascade and glucose 
transport. Longer duration exercise interventions may result in altered body composition 
and fitness, both of which affect Si. Short-term studies, which don't influence the 
parameters above, therefore provide information with regard to the independent effect 
of exercise on gluco-regulation. Studies in adults with diabetes have shown that short 
duration of aerobic activity (ranging from a single bout to 10 days) led to improved 
whole body insulin sensitivity 317, with Winnick et al 325 demonstrating that these changes 
were due to improved peripheral skeletal muscle glucose uptake. These changes are 
thought to be due to increased insulin independent uptake in the muscle as well as 
increased GLUT 4 protein concentration which facilitates insulin mediated glucose 
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uptake 326. Further studies have shown that exercise without significant change in weight 
or body composition can result in lower insulin levels in both adults 327 and children 328 329.  
 
Most studies have focused on aerobic training of muscle characterised by low force, 
multiple repetitive contractions 321 330 331. Improvements in Si with short term moderate 
intensity aerobic activity resulted in significantly enhanced direct measures of Si ranging 
from 32% 332-37% 333, higher improvements of 59% may be seen in the absence of 
weight loss by increasing the intensity of training 331. However, relatively little is known 
about the effects of resistance training involving a smaller number of muscle 
contractions with higher force development. There are few studies examining the effect 
of resistance training in the paediatric population. However, the limited literature 
suggests positive effects on body composition with reduced fat, increased lean tissue 334 
and possibly greater enhancement in Si compared with aerobic exercise 335. In healthy 
adults, a short duration strength-training program led to an attenuated insulin response 
during oral glucose tolerance, suggestive of improved Si, which correlated with a gain in 
lean tissue during the study 336. Similarly, a cross-sectional study of over one thousand 
adolescents demonstrated that greater muscular strength is associated with Si 337. 
 
Lee et al attempted to distinguish the effect of aerobic versus anaerobic exercise in the 
adolescent cohort and discovered that any exercise type (aerobic and resistance) led to 
decreased hepatic and visceral fat, however only resistance training was associated with a 
27% improvement in Si after the 3 month intervention 338. Yaspelkis et al showed in small 
animals that resistance and aerobic training led to similar qualitative changes with 
increased GLUT 4 proteins in the muscle, independent of the amount of lean tissue 256.  
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Obese adolescents with hyperinsulinaemia have decreased levels of physical fitness when 
compared to obese counterparts when matched for BMI 339. Children with T2DM who 
have reduced Si demonstrated reduced VO2peak and early evidence of cardiovascular 
impairment 340. Elevated insulin levels, may independently affect the cardiovascular 
system, causing fluid retention and raised blood pressure with increased heart rate due to 
increased sympathetic nervous activity. Insulin may suppress fatty acid oxidation and 
thereby might reduce the amount of energy substrates required for muscle activity 341. 
Insulin causes vasodilation in skeletal muscle 342 343 this physiologic action is 
compromised in patients with T2DM 344and insulin resistance 235 and may explain 
reduced exercise ability in these individuals. Exercise leads to improved Si in children and 
adolescents, often without significant change in body composition 328 330 345. Furthermore, 
van der Heijden et al showed that the enhanced Si could be attributed to increased 
peripheral uptake at the muscle and improved hepatic insulin sensitivity 331.  
 
Cardiovascular fitness (CRF), rather than total body composition may better predict Si in 
children, providing evidence of qualitative changes at the muscle level and enhanced 
peripheral glucose uptake 346. High level of CRF and muscular strength are associated 
with greater Si in children 347 and adults 348. In post-pubertal females, the degree of 
physical fitness as measured by V02max (maximal oxygen consumption) predicted insulin 
sensitivity to a greater extent than the amount of body fat and BMI 349.  
 
The role of unorthodox forms of resistance training, such as whole body vibration 
training (WBVT) on weight loss and Si is unclear and difficult to quantify due to a variety 
of training protocols 350. Initial studies in small animals showed favourable effects with 
fat loss 351 that have been recently confirmed by others352. Untrained females who 
participated in WBVT had small increases in fat free mass (FFM) but no change in total 
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body fat or weight 353. Studies in obese adults show that fat loss may occur in 
combination with resistance or aerobic training effects but may be minimal 354 with 
possible effects on BMI 355 and visceral adiposity 356. A study in T2DM patients found 
significantly reduced anthropometry measures after 12 weeks WBVT compared with 
controls 357. Weight loss may occur through increased lipolysis and reduced adipogenesis 
with sympathetic nervous system activation; gains in FFM or by increasing energy 
expenditure 358. However, the effects may also be mediated through multiple interactions 
between the musculoskeletal, endocrine, nervous and circulatory systems.  
 
Resistance training, involves higher forces but a small number of repetitive contractions.  
This training leads to changes in the physiological properties of the skeletal muscle by 
upregulating GLUT 4 receptors, activating and enhancing the insulin-signalling cascade, 
whereas in aerobic training, the oxidative capacity of the muscle is increased. This may 
improve the quality of the skeletal muscle with favourable effects on glucose metabolism, 
independent of changes in muscle bulk and mass 256. This is pertinent given that skeletal 
muscle accounts for majority of insulin mediated peripheral glucose disposal.  
 
Resistance training programs can lead to significant body composition changes in 
overweight children within short periods of time. Sgro et al showed a reduction in fat 
mass within an 8-week period that was sustained after cessation of the training program. 
Four months of training led to improved muscle performance with demonstrated 
significant change in strength and power, but no changes in body mass index or bone 
mineral content was detected 359. After 10 weeks of resistance training, young male 
adolescents showed improved Si during an oral glucose tolerance with concomitant 
changes in lean tissue mass 336. 
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1.2.11 Pharmacological management of insulin resistance 
a. Metformin 
 
Metformin, a biguanide is the main pharmacological treatment of paediatric T2DM 360. It 
is an anti-hyperglycaemic, insulin sensitising agent, whose effects may be mediated 
through increased peripheral glucose disposal and reduced hepatic gluconeogenesis and 
gastrointestinal absorption, whilst maintaining insulin levels low 361 362. Metformin does 
not have any effect on insulin secretion or ß cell function. In obese adults with T2DM, 
metformin treatment is associated with favourable effects on glycaemic control, weight, 
appetite and lipid profile 363 364 365. In addition, it has positive effects on gluco-regulation 
in at risk obese adults decreasing fasting glucose and insulin levels 363. In adults, the use 
of metformin reduced progression from IGT to T2DM 323. Adolescents and adult 
women with PCOS and insulin resistance, show enhanced Si and androgen profile after 
treatment with metformin 366.  
 
The clinical indication of metformin has also been extended to “off label” use in obese 
paediatric patients with insulin resistance, often in conjunction with lifestyle prescription. 
A meta-analysis of three studies comparing an intervention of metformin with or without 
lifestyle change found favourable metabolic effects with decreased fasting insulin, 
lowered HOMA-IR and reduced BMI 367. These findings were confirmed in another 
study in younger, severely obese children aged 6-12 years 368. Others have failed to show 
change in weight but have demonstrated improved Si 369. New data from the TODAY 
study 370 confirmed the therapeutic effect of metformin monotherapy and showed it to 
be successful in maintaining glycaemic control in 50% of adolescent patients with T2DM 
aged 10-17 years. Interestingly, the adjunctive use of rosiglitazone, a pioglitazone 
enhanced this effect on glycaemic control with no additional benefit of pharmacotherapy 
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and lifestyle measures over medication-based treatment alone. However, in adults, 
thiazolidinedione class of drugs are associated with a high risk of cardiovascular 
morbidity. 
 
Metformin has been trialled in adolescents in a randomised placebo control trial with no 
significant difference in weight loss of the group compared to placebo, there was a 
greater BMI reduction in females suggesting gender differences in response 371. In adults 
with IGT, metformin in conjunction with lifestyle measures can halt the progression to 
T2DM 323. Studies in children have been conflicting. The addition of metformin to a very 
low calorie diet in obese adolescents can lead to greater weight and fat loss and enhanced 
measures of insulin sensitivity, compared to controls 372. Freemark et al 373 showed a small 
decrease in BMI SD and reduced fasting glucose and insulin levels with 6 months of 
metformin treatment in a small group of obese adolescents; however the baseline BMI in 
the treatment group. There were no changes in Si as assessed by minimal model but 
fasting glucose to insulin, QUICKI and HOMA-IR did reduce slightly. Another study of 
28 obese adolescents showed improved body composition and BMI but no change in 
insulin sensitivity 374. In combination with a lifestyle program, some studies have shown 
some benefit with reduced BMI and enhanced insulin sensitivity 375 and others have 
shown no change in either parameter 371. A systematic review showed a moderate effect 
of metformin treatment on BMI and insulin resistance measures. Only five trials met the 
inclusion criteria, however the meta-analysis showed that metformin reduced BMI by 
1.42kg/m2 and reduced HOMA-IR by 2.01, however the analysis involved short-term 
studies with small numbers from high-risk populations 376. The most common side 
effects related to treatment with metformin appear to be mild and mainly due to 
gastrointestinal upset 368.  
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There are conflicting data with the regard to the use of metformin in adolescents with 
insulin resistance. Most studies have simultaneously incorporated a lifestyle program 
making it difficult to ascertain the beneficial effect of the pharmacological treatment. 
When used alone with placebo in obese adolescents, metformin assisted with weight loss 
and reduced fasting insulin levels 372 373. In addition to these effects, Srinivasan et al 
showed a positive effect on body composition but no change in insulin sensitivity 374. 
The small body of literature would suggest that metformin might reduce progression to 
T2DM when used an adjunct to a lifestyle intervention due to its proven effects on 
fasting glucose and insulin. Clarson et al showed improved BMI in insulin resistant 
adolescents but no change in measures of insulin resistance, but improvements in lipid 
profile 377 
b. Other medications 
 
Thiazolidinedione enhance insulin sensitivity by altering the distribution of adipose tissue 
from the visceral compartment to the subcutaneous compartment. They also reduced 
IHCL and IMCL and reduce ectopic storage of fat in theses organs. Sibutramine and 
orlistat are used in adults to assist with weight management. Studies in adolescents have 
shown significant change in weight loss in the short term particularly in combination 
with lifestyle change however, gastrointestinal side effects with orlistat and tachycardia 
with sibutramine may preclude the use of these agents in adolescents 378. 
 
 
1.3 Whole Body Vibration Training  
 
Whole body vibration training (WBVT), a novel form of resistance training has been 
mostly researched in adult populations. It can improve muscle strength 379-381, power 382 
and flexibility 383-385producing similar 380 or superior results compared to resistance 
exercise but in shorter period of time386 387. The effects of WBVT on bone morphology is 
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unclear with positive results in small animals 388 389 and postmenopausal women at risk of 
osteoporosis 390 which might be mediated through a decrease in bone resorption, 391 
enhanced muscle bone interaction through increase muscle amount and strength 381 392 or 
direct effects 358 388. Recent reviews however, suggest a weak effect of WBVT on bone or 
muscle parameters 393 with some demonstrating no effects  394 395 this may be attributed to 
the variability in study protocols 396. 
 
Trained athletes may benefit from the strength effects of WBVT 397 398 and there is 
growing evidence that untrained adults may also be able to boost muscle performance 380 
particularly when combined with other resistance activities 379 399; longer duration trials 
may produce greater results 400.  
 
The low impact nature of this training may provide a non-pharmacological way of 
improving both muscle and bone parameters in vulnerable populations. The amplitude 
(A), frequency (f) and acceleration (a) are three characteristics of the vibration that can be 
modified to suit different patient groups. Although, assessing the effectiveness of WBVT 
exercise in research trials can be difficult due to the variability in study protocols 350 393 401.  
 
The WBVT platform delivers sinusoidal high frequency low amplitude vertical vibrations. 
The platforms are capable of delivering vibration via two main methods (Figure 1.5), 
including a side to side alternation as used in this study or vertical vibration, which is 
thought to be less physiological and results in greater transmission of vibration to the 
upper body and head 402. If the stimulus is applied to the lower limb (i.e. person stands 
on the platform for training) then there is regional activation of muscles of the lower 
limb and trunk, particularly leg extensors to dampen the stimulus 403 404. The plantar 
flexor muscles may be strengthened more than the proximally located muscles due to the 
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proximity to the vibration stimulus. Muscle activation occurs unconsciously through the 
tonic vibration reflex in combination with the stretch reflex with some modulation from 
the higher centres. The frequency generally ranges from 15-60Hz and amplitude (1-
15mm), there are a variety of training protocols. The optimal duration of intervention is 
still participant to speculation. However, most studies describe times ranging from 1-30 
minutes 393 405. 
 
The neuromuscular effects of WBVT remain unclear. In animal studies, the vibration 
stimulus activates the tonic vibration reflex mediated by the golgi tendon organs and Ib 
afferents in the muscle spindle. In humans the same stimulus may inhibit the H reflex 406 
407 or stimulate the tonic vibration and muscle reflexes 408 409. Using animal studies, 
Matthews proposed that WBVT elicited the well-known stretch reflex (Figure 1.6) and 
that the vibration led to stretch of the 1a afferents of the muscle spindle 410.  
 
 
Figure 1.5 Methods of whole body vibration training (WBVT) 
The two different methods of delivering whole body vibration training are shown above. 
Side to side alternating as used in GalileoTM 2000 (left) and vertical vibration transmission (right) adapted 
from 402 
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taken from 411 
Figure 1.6 Stretch reflex arc 
The stimulus delivered by the tendon hammer causes stretch in the muscle spindle which leads to 
increased activity in Ia afferents and an increase in the activity of α motor neurons that innervate the same 
muscle. Ia afferents also excite the motor neurons that innervate synergistic muscles (Quadriceps femoris) 
and inhibit the motor neurons that innervate antagonists (Hamstrings). 
 
Several studies have shown that this is also applicable to humans and have used 
electromyography to investigate the effect of an applied vibration to muscle and have 
found that as well as producing a motion artefact 412, vibration appears to produce an 
EMG signal similar to that evoked by passive stretching 413. It is postulated that the early 
changes in muscle force are due to heightened excitability of muscle spindle Ia afferents, 
which activates motor neurons and results in muscle contraction through the tonic 
vibration reflex as well an increased sensitivity of the stretch reflex (Figure 1.7) 353 414. 
WBVT may modulate spinal cord neuro-excitability, through inhibition of the H reflex as 
shown in patients with spinal cord injury and without voluntary muscle function 406. 
Longer periods of training may stimulate hormones such as growth hormone and 
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testosterone that facilitate muscle development 415. Similar to resistance training effects, 
muscle hypertrophy could also occur as a local adaptation.  
 
Figure 1.7 Effect of whole body vibration on spinal reflex and higher centres  
The quick change in muscle length and the joint rotation caused by vibration trigger both alpha and 
gamma motor neurons to fire to module muscle stiffness. Higher centres are also involved via a long loop. 
Taken from 387 
 
WBVT has a good safety profile and has been utilised in studies in children with physical 
disability. However, most studies have investigated the musculoskeletal effects of the 
vibration exercise and have not carefully examined the possible effects on other organ 
systems. Isolated case reports of side effects have included two reports of intraocular 
lens dislocation in elderly adults 416 and one possible case of vitreous haemorrhage 417. A 
young athlete with asymptomatic nephrolithiasis developed significant morbidity 
following a bout of vibration 418.  
1.3.1 Bone effects 
Exercise can improve bone mineral density and bone health in children 419, however 
compliance with exercise regimes may be difficult in this time poor society. Exercise 
provides a known benefit on peak bone mass in young people and may assist in reducing 
pathological fractures from osteoporosis in later life 420. Bone remodelling occurs in 
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response to strain which leads to slight bone deformation 421. WBVT can deliver a low 
mechanical stimulus to alter bone morphometry and bone strength with significantly less 
strain on the bone than that delivered by physical exercise and possibly within shorter 
periods of time. The effects were non-dose dependent and not uniform through the 
skeletal with greatest gains seen in the proximal tibial metaphyses and no effect in the 
femur or vertebra of the animals 388. Aeronautical space programs have used WBVT to 
limit bone loss associated with weightlessness based on the results of studies in 
volunteers simulating similar conditions. One study conducted in healthy male volunteers 
undertaking 56 days of bed rest resulted in preserved muscle size and function and 
reduced bone loss compared to a control group 422.  
 
Initial studies examining the use of WBVT on the skeleton were performed in small 
animals. The most striking results were seen in the hind limb bones of sheep 
demonstrated a 34.2% increase in proximal femur trabecular density compared to a 
control group. Similar results with >30% improvement in trabecular bone volume was 
seen in the tibia of adult mice subjected to a series of increasing accelerations 388. Further 
animal studies by Xie et al 423, showed that brief periods of WBVT could improve bone 
formation and reduce bone resorption by approximately 30%, whilst still maintaining 
bone quality in the growing skeleton, suggesting this may have a useful role in reducing 
incidence of osteoporosis by assisting peak bone formation in adolescents and young 
adults. Mice subjected to conditions of unloading that simulated the weightlessness 
experienced in space or paralysis maintained remodelling parameters in the skeleton 
similar to control rats 424. 
 
Several RCTs have examined the effect of WBVT in populations at risk of bone disease. 
In post-menopausal females randomised to WBVT, resistance or control groups, WBVT 
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was the only intervention to significantly improve BMD at the hip by 0.93%, p<0.05, 
after the 6 months intervention. Interestingly, in the same study, isometric and dynamic 
muscle strength were improved by 15% and 16%, p<0.01 respectively 425. A double blind, 
placebo controlled study in a similar population showed a similar trend with mild 
improvements in femoral neck BMD 2.17%, p=0.06, in highly compliant participants 
followed prospectively for a year 390. A year of WBVT for just 10 minutes per day led to 
mild improvements in femoral cortical and vertebral trabecular bone after a year of 
WBVT in young women with low BMD 426. 
 
Studies in children have been limited to small pilots, however Ward et al 427, confirmed 
improvements in bone quality in children with physical disability with an increase of 
6.3% in proximal tibia volumetric trabecular bone mineral density after 6 months 
compared to a reduction in those children using a placebo device, despite compliance of 
44% to the exercise protocol 427. A recent RCT study examining 26 adolescents with and 
without Down syndrome, showed 20 weeks of WBVT increased BMC and BMD in both 
groups but to larger extent in those without Down Syndrome 428. A 10-week study in 
overweight Latino males429, showed that increases in BMC and BMD might be due to 
decreased bone resorption. Regional changes in vBMD and areal BMD were 
demonstrated in healthy children with forearm loading after 12 weeks WBVT 430. A 6-
month study in children with cerebral palsy showed cortical bone parameters could be 
improved431. In contrast, another 6 month pilot study of children with cerebral palsy did 
not show any positive change in bone mineral density 432. 
1.3.2 Muscle effects 
WBVT incorporated into paediatric physiotherapy programs may result in functional 
improvements in children with cerebral palsy 432 433 and other children with reduced 
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mobility 434. In children with this disability, Stark et al 433, showed improvements in bone 
mineral density, bone mineral content and muscle mass after undertaking 6 months of 
therapy including 3 months of home based WBVT with the Galileo® platform.  Similarly 
brief periods of WBVT led to improved muscle force and tilt table tolerance in recently 
immobilised children with fractures due to osteogenesis imperfecta 435. A recent study in 
children with Down syndrome demonstrated a trend to increased lean tissue mass (LTM) 
after 20 weeks compared with a control arm436. 
 
In postmenopausal women a program of 24 weeks of WBVT led to greater increases in 
the height of countermovement jump compared to resistance training and controls with 
concomitant enhancements in isometric and dynamic knee extensor muscle strength 437. 
Young untrained female participants involved in a 6 month WBVT intervention 
demonstrated similar strength gains to women who undertook a mixed aerobic and 
resistance training program 353. Blottner et al demonstrated preservation of isometric 
plantar flexion force, likely due to increased soleus muscle fibre size in young males 
subjected to 56 days of bed rest. In postmenopausal women postural balance, isometric 
strength (15%) and dynamic strength (16.5%) were seen after 6 months of WBV training 
compared with a control group 425.  
 
Muscle efficiency with improvements in muscle force during jump testing has been 
shown in adults with cystic fibrosis 438. Peak average power during squat jump can be 
increased by 6.8% and 7.3% in trained and untrained participants after a single bout of 
very high, 50Hz vibration suggesting that this may be an alternative to traditional 
methods of power training for elite athletes 439. Chronic WBVT can improve muscle 
strength when compared to a passive control group however, in a systematic review 
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Nordlund showed that in 4 out of 5 studies, WBVT proved no superior benefit when 
compared to controls performing similar exercise 401.  
 
In addition to muscle effects, it has been suggested that neuromuscular efficiency is 
improved with this form of training particularly through enhanced and improved 
coordination of motor units 440 415. However detrimental effects on nerve conduction 
times have been observed in monkeys with variation of frequency of vibration 441. These 
positive results in the children with physical disability suggest that WBVT may have a 
clinical role in physiotherapy regimes and is safe for use in the vulnerable group. Taken 
together, these studies suggest that functional improvements in trained and untrained 
individuals and attenuation of muscle atrophy in conditions of disuse such as prolonged 
immobilisation.  
1.3.3 Circulation effects 
Reduced tissue perfusion at high frequency of vibration particularly with hand held 
devices is a well described occupational hazard known as the hand arm vibration 
syndrome 442. Long term occupational exposure to high frequency vibration may lead to 
vertebral morbidity and neurological side effects 442. Whole body vibration training 
protocols adopted in human research trials have utilised frequencies much lower than 
those delivered in the occupational setting. The nature of the vibration is also different 
being delivered as sinusoidal rather than vertically. It appears that the lower frequency 
and shorter duration vibration may be beneficial and appears to enhance local skeletal 
muscle blood flow as demonstrated in Doppler flow studies of the popliteal artery at 
26Hz 443. In addition to the effects on arterial flow, peripheral blood circulation is 
enhanced by improved venous drainage and lymphatic flow 444. 
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1.3.4 Metabolic and body composition effects of WBVT 
WBVT is a form of efficient resistance exercise, which has been shown to increase 
muscle blood flow and mass. The vibration platforms have often been marketed for their 
weight loss properties. Some recent studies conducted in adults demonstrate small 
amounts of fat loss355 and anthropometry change355 445. There are some studies, which 
show increased energy expenditure, carbohydrate and fat oxidation and well as increased 
oxygen consumption 446. These physiological changes may alter body composition and 
may influence metabolism, particularly glucose homeostasis. Studies conducted in 
patients with T2DM have shown improvement in HbA1c447 and adiposity 357.  It is 
important to note that the study by Lee et al 447 was conducted over a 6-week period and 
therefore the stated difference in HbA1c may not be accurate given that HbA1c has a 
recommended measurement interval of 3 months due to the life span to the red blood 
cell.  
 
Murine studies have demonstrated positive effects on body composition with moderate 
decreases of 34.2% in torso fat. Studies in mice have indicated low magnitude mechanical 
stimulus in the form of WBVT may reduce differentiation of mesenchymal stem cells 
into the adipocyte lineage by 22%; with a trend to improved glucose tolerance and 
improvement in metabolic profile indicators such as free fatty acids and triglycerides 351. 
Untrained females showed slight gains in lean tissue mass after twenty-four weeks of 
WBV (35-40hZ, 2.5-5.0mm) however body fat and weight was not altered 353. A 
randomised control trial in adults showed that WBVT in conjunction with a diet 
intervention produced sustained weight loss of 5% after 12 months, with a greater loss of 
VAT compared to an aerobic fitness intervention 448. A review of the potential weight 
loss properties of this exercise showed minimal change to body composition but 
difficulties with comparison due to the variety of protocols 350.  
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Further studies are required to confirm this result, however, if WBVT does lead to 
greater VAT weight loss it may translate into positive metabolic outcomes. Therefore, it 
appears that energy expenditure may be positively affected by WBVT on its own or in 
conjunction with an exercise regime. There are limited studies in both animals and 
humans that examine the effects of WBVT on body composition. To date are no studies 
in overweight insulin resistant children which examine body composition and insulin 
sensitivity change.  
1.3.5 Hormonal effects 
Hormones may mediate some of the positive effects of WBVT on muscle and bone. 
WBVT may alter the secretion of hormones. In addition to the direct mechanical effects 
of WBVT on the skeletal muscle, several authors have discovered that several hormones 
may fluctuate about this form of exercise; some of these hormones influence osteoblastic 
and osteoclastic activity. Growth hormone, insulin like growth factor 1 (IGF-1), cortisol 
and testosterone all influence bone cell activity. Bosco et al 415, found that 10 repetitions 
of WBVT of 1 min duration in young males resulted in increased plasma testosterone 
and growth hormone levels with decreased levels of cortisol. Di Loreto showed that a 
similar regime in a similar aged cohort resulted in additional findings of plasma glucose 
level at 30 minutes and sympathetic stimulation with increased secretion of noradrenaline 
but unlike the previous study did not find any change in GH, IGF-1 or cortisol or 
adrenaline levels 449. They concluded that due to the lack of effect on the endocrine 
system, that this type of exercise would not ameliorate fat mass in obese participants.  
There is little paediatric evidence as to the optimum duration and frequency of WBVT. 
Effects on metabolic parameters have been shown after 6 weeks in adults however most 
studies indicate that a longer duration is required for change to muscle and bone 
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parameters. We chose a 3-month intermediate period due to the inclusion of participants 
obese adolescents) who generally display high attrition rates during research interventions 
of extended duration.  
 
 
1.4 Bone as an endocrine organ 
 
The role of bone in the regulation of glucose homeostasis remains unclear. A close 
endocrine interaction between bone and glucose metabolism can already be seen through 
insulin’s anabolic effects on bone, mediated by insulin like growth factor (IGF-1)450. 
Emerging evidence investigating bone-derived proteins and 25-hydroxyvitamin D 
(25OHD) have shown a possible reciprocal relationship between bone and energy 
metabolism, suggesting that bone may function as an endocrine organ 451.  
1.4.1 Insulin sensitivity and bone 
 
Studies in small animals have shown a link between bone and energy metabolism. Leptin 
derived from adipose tissue and insulin via IGF-1 can independently regulate bone. 
Osteocalcin (OCN) released by the osteoblast can increase insulin secretion via a direct 
effect on the pancreatic beta cell 452. Osteocalcin is derived from the osteoblast and is 
involved in bone formation. Women with gestational diabetes, a state associated with 
insulin resistance and glycaemic stress have elevated levels of OCN during pregnancy, 
which return to nondiabetic levels 3 months after the pregnancy. Observational cohort 
studies in humans have confirmed a similar relationship. Total OCN has been related to 
the metabolic syndrome in adults. Osteocalcin undergoes post-translational modification 
and results in a carboxylated and undercarboxylated form 453. The ratio between 
undercarboxylated and carboxylated OCN shows a strong association to insulin 
sensitivity measures in children. It is thought that the undercarboxylated form plays a 
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direct role in mediating insulin sensitivity by affecting adiponectin, which has insulin 
sensitising properties 454.  
 
1.4.2 Vitamin D 
Vitamin D is measured as 25-hydroxyvitamin D (25OHD) in the plasma. Vitamin D 
plays an important role in bone health and as a regulator of calcium homeostasis. Plasma 
levels are influenced by many factors including: ethnicity, dietary intake and sun exposure. 
Markers of increased adiposity including elevated BMI are also associated with 
hypovitaminosis D in both adolescents and adults 455.  Vitamin D is fat soluble, and is 
sequestered in adipose tissue that may explain the inverse association between fat and 
low circulating levels.  
 
Recent studies have also focussed on the possible extra-skeletal effects of 25OHD 
including a putative role in glucose homeostasis. The optimal 25OHD levels for extra-
skeletal benefit are unknown. Low vitamin D levels in adults has been associated with 
insulin resistance 456, lower ß cell function and presence of T2DM 456 457. Independent of 
adiposity, adolescents with low 25OHD levels were found to have higher HBA1c and 
lower insulin sensitivity as measured by QUICKI 458. An inverse association has been 
found between Vitamin D and insulin sensitivity as assessed by clamp studies 459. 
However, Rajakumar et al 460 showed no relationship of serum 25OHD to insulin 
sensitivity as measured by clamp in a cross sectional of youth with normal glucose 
tolerance. No link between 25OHD deficiency and cardiovascular and metabolic disease 
was shown in a recent umbrella review of 137 clinical outcomes 461. It is possible that low 
vitamin D levels may be a marker of poor underlying health or obesity acting as 
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confounders in observational research studies. Interventional RCTs in children failed to 
show that Vitamin D supplementation improved cardio-metabolic parameters 462.  
 
Insulin resistance and obesity are pro-inflammatory states as indicated by the elevated hs-
CRP levels, a putative reason for the observed relationship between hypovitaminosis D 
and glucose and cardio metabolic outcomes may be related to this inflammatory process 
given that macrophages, a key component of this cascade have receptors for 1,25 
Vitamin D 463-465. 
 
Recent consensus suggest a 25OHD level >50nmol/L to prevent childhood nutritional 
rickets 466. The therapeutic target to optimise skeletal and extra skeletal manifestations 
remains unclear; however in North America a level above 50nmol/L is considered a 
therapeutic target 467 468.  
1.4.3 Osteocalcin 
Osteocalcin (OCN) is protein hormone formed by osteoblasts in bone. OCN is 
carboxylated with glutamic acid during post-translational modification to Gla-OCN. 
Decarboxylation by activated osteoclasts results in under-carboxylated OCN Glu-OCN. 
It is thought that the metabolic effects of osteocalcin are mediated by the 
undercarboxylated fraction. OCN may modulate energy balance in several ways including 
proliferation of ß cells and stimulation of insulin secretion possibly through increased 
adiponectin expression in fat cells. Animal studies showed that OCN knockout mice had 
decreased ß cell proliferation and glucose intolerance with insulin resistance 451.   Further 
studies in humans have not been equally as convincing. In older adults, indirect measures 
of insulin sensitivity such as HOMA-IR have been associated with higher total OCN. 
Adults with elevated BMI have lower under carboxylated OCN. There is limited data in 
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children. A study of young adults using clamp derived measures of Si showed a 
significant association with total and carboxylated OCN with measures of adiposity 
including BMI and SBP but borderline relationship to insulin sensitivity, after correcting 
for BMI 469. 
 
 
 
1.5 Aims and objectives 
 
Childhood obesity and insulin resistance is increasing and despite further knowledge in 
this field, there are many questions to be answered regarding the most appropriate 
management for the obese insulin adolescent. The study was conducted to determine the 
efficacy and acceptability of WBVT, a novel resistance based exercise intervention in 
association with a standard lifestyle prescription. By addressing the following aims, we 
will provide further knowledge to healthcare providers in the area of paediatric obesity 
and insulin resistance about the efficacy of lifestyle programs and whether novel types of 
resistance exercise are suitable for adolescents.  
Primary aim 
To explore whether WBVT could improve insulin sensitivity in obese adolescents with 
clinical insulin resistance.  
Hypothesis 
 
We employed a randomised controlled trial designed to test the hypothesis that three 
months of whole body vibration training in addition to a prescribed diet and exercise 
intervention would enhance the effect of the lifestyle interventions by improving insulin 
sensitivity and metabolic profile in overweight adolescents with hyperinsulinaemia. We 
speculated that WBVT would lead to an increase in fat free mass (FFM) that would 
increase non-insulin mediated peripheral glucose uptake. The intervention effect of 
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WBVT is discussed in Chapter 4 – “Does Whole Body Vibration Training improve 
insulin sensitivity in overweight adolescents?” 
 
Secondary aims 
 
1. Provide further information about recruitment patterns to an obesity 
intervention trial and describe any noticeable differences. 
2. Highlight clinical examination and ethnographic features common to adolescents 
with insulin resistance in Greater Western Sydney (GWS) and determine the 
presence of metabolic co-morbidities in the participants and their relatives.  
3. Determine any anthropometric similarities seen in adolescents with insulin 
resistance and to examine any gender differences. 
4. Review any modifiable dietary and lifestyle features present in the obese 
adolescent. 
5. To examine correlations and interrelations between baseline biochemical 
metabolic profile indicators and clinical examination features.  
6. To provide a cross-sectional snapshot of the bone health of obese, insulin 
resistant adolescents in a multi-ethnic demographic using clinical densitometry 
and pQCT.  
7. Evaluate relationships between bone parameters, bone turnover markers, 
Vitamin D, anthropometry and measures of insulin sensitivity. 
8. Determine the cardiorespiratory profile of the obese insulin resistant adolescent 
and discover any intervention effect. 
9. Examine possible limitations to exercise by using Mechanography, a functional 
assessment tool for muscle strength and power. 
Chapter 3 – “What are the metabolic characteristics of obese adolescents living in 
Greater Western Sydney?” study addresses aims 1-5. Chapter 5 “Does obesity or insulin 
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resistance affect musculoskeletal health?” further explores aims 6-7. Aims 8-9 are 
addressed in Chapter 6 “Are there limitations to exercise in the obese insulin resistant 
adolescent?”
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2.1 Overview 
 
This thesis is centred around the VIBRATE study, a randomised controlled trial (RCT), 
designed primarily to investigate the effect of three months of whole body vibration 
training (WBVT) in addition to a prescribed diet and exercise intervention on insulin 
sensitivity in overweight adolescents with hyperinsulinaemia. We hypothesised that 
WBVT, a unique form of resistance exercise would enhance insulin sensitivity by 
improving muscle mass, thereby assisting peripheral glucose uptake to a greater degree 
than lifestyle intervention alone. In addition, secondary outcome measures explored 
included: body composition change (fat, muscle and bone); muscle performance (power 
and force); aerobic fitness and metabolic profile indicators. The participants were 
prescribed the same lifestyle intervention (including a diet and exercise component) with 
half of the participants being randomised to the WBVT intervention at the 
commencement of the study. The trial was registered with the Australian New Zealand 
Clinical Trials Registry (ANZCTR) ACTRN12608000509369.  
 
Ethics approval 
The study was conducted at The Children’s Hospital at Westmead (CHW) and received 
local Ethics Committee approval (approval number 07/CHW/20) prior to being 
conducted. The parents and/or legal guardians gave written informed consent and the 
young people gave their assent to participate in this research study.  
 
2.2 Outcome measures 
i. Primary 
The primary outcome of the study was change in insulin sensitivity (Si) during the 3-
month trial. This was estimated using the validated proxy measure of whole body insulin 
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sensitivity index (WBISI) according to the formula: 10000/√[(fasting insulin x fasting 
glucose) x (mean 2hr glucose x mean 2hr insulin)] 254 276 from measures derived from an 
oral glucose tolerance test conducted at baseline and at 3 months. Although conducted 
over a short time frame of 3 months, it was appreciated that potential confounding 
variables may have included: changes in adiposity, pubertal status, physical fitness and 
activity levels and adherence to WBVT. 
ii. Secondary 
Secondary outcome measures examined the following changes over 3 months: body 
composition (anthropometry, BMI, WtHR); musculoskeletal parameters derived from 
DXA and pQCT; born turnover markers (urine deoxypyridinoline cross links (DPD), 
Procollagen type 1 N propeptide (P1NP), Osteocalcin (OCN), C-terminal telopeptide of 
type 1 collagen (CTX)); metabolic profile indicators (blood pressure, hs-CRP, total 
cholesterol, HDL-cholesterol and triglycerides); physical fitness measures (VO2peak and 
exercise time) and single and two leg jump force and power derived from Leonardo® 
Mechanography. 
2.3 Role of the candidate 
 
The candidate designed the study with guidance from the co-investigators, submitted 
four successful grant applications and obtained ethics clearance prior to implementing 
the trial at CHW. This involved participant recruitment, co-ordination of clinical testing, 
performing the clinical evaluation and Mechanography, being trained in various 
techniques including PQCT (by Ms Julie Briody, Department of Nuclear Medicine, The 
Children’s Hospital at Westmead) and use of the Galileo® Home vibration platform and 
Leonardo Mechanograph® GRFP, by a representative from Novotec Medical GmbH, 
interpretation and analysis of data with feedback to the participants, their families and 
referring doctors at the conclusion of the trial. Professor Christopher Cowell, 
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A/Professor Craig Munns and Professor Louise Baur, provided academic supervision to 
the candidate, during the conduct of the trial. 
2.4 Participants  
i.  Inclusion criteria 
Participants recruited to the VIBRATE study were adolescents aged 10 to 18 years who 
were referred to the Endocrinology and Weight Management clinics at CHW. Potential 
candidates were overweight or obese as defined by the International Obesity Task Force 
(IOTF)60 with evidence of clinical insulin resistance with acanthosis nigricans (AN) 470, 
and/ or raised fasting insulin levels >120pmol/L (20mU/L) but <300pmol/L (50mU/L) 
[the lower cut-off was based on the 90th centile derived from local CHW endocrinology 
clinic data of insulin resistant adolescents] 471. In November 2008, the lower cut off was 
revised to 90pmol/L (15mU/L) in line with quoted paediatric reference ranges for 
hyperinsulinaemia suggested by the American Heart Association (AHA)285. Participants 
with evidence of pre diabetes as defined by the American Diabetes Association (ADA)472 
with fasting blood glucose: 5.6-6.9mmol/L and/ or 2 hour post load glucose level 7.8-
11.1mmol/L were also considered for participation to achieve recruitment targets.    
ii. Exclusion criteria 
The following excluded the participant from the study: 
• Type 1 or Type 2 diabetes 
• Secondary causes of obesity 
• Weight greater than 120kg (due to technical issues with DXA machine and 
weight threshold of the Galileo® Home vibration platform) 
• Psychiatric disturbance or significant medical illness 
• Inability to take part in physical activity 
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• Taking weight loss medications, insulin sensitisers or medications known to cause 
and/or affect weight gain 
• Pregnancy 
iii. Sample size 
The sample size calculation was based on previous analysis of whole body insulin 
sensitivity obtained from local clinic data at CHW 471. We assumed a clinical significant 
difference in WBISI of 0.6 SD between each treatment arm during the trial. In order to 
have an 80% chance of detecting a significant difference at the two-sided 5% level, a 
total of 17 participants would be required in each arm. Initial sample size of 42, 
accounted for a dropout rate of 20%, based on previous obesity studies [personal 
communication Prof L Baur]. This figure is consistent with local data that had 
demonstrated dropout rates of 12-18% in children participating in paediatric obesity 
trials 147. After review by the local Ethics Committee, a 40% drop out rate was suggested 
which increased the total number of participants to 48 (24 adolescents in each arm of the 
study).  The actual dropout rate of 2.3% was less than anticipated and therefore we were 
given permission to close the study early when 43 participants had been enrolled. 
iv. Randomisation 
Treatment allocation to the intervention and standard arm of the trial was performed 
centrally by minimisation 473 using computer-based software, MINIM 474. Minimisation 
ensured that prognostic factors were continually balanced between the study groups. The 
tally of participants was updated during the study to ensure balanced allocation. To 
account for potential confounding influences, participants were randomised into 
treatment groups stratified by gender (male or female) and pubertal status (pre pubertal 
Tanner stage I-II and post pubertal Tanner stage III-V) 475. A Consolidated Standards of 
Reporting Trials (CONSORT) flowchart for the VIBRATE study is shown in Figure 2.1. 
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Figure 2.1 CONSORT diagram for the VIBRATE study 
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vi. Blinding 
The candidate was not blinded to the allocated intervention to allow for adverse event 
reporting. Assessors of all primary and secondary outcome measures were blinded to the 
treatment allocated including: the two clinical nurse consultants who assisted with the 
oral glucose tolerance tests, anthropometry and blood pressure measurements; the 
nuclear medicine scientists who performed the dual energy x-ray absorptiometry (DXA) 
and peripheral quantitative computed tomography (pQCT); the exercise physiologist and 
sports medicine physician at CHISM (Children’s Hospital Institute of Sports Medicine) 
and person assisting with the Leonardo MechanographyTM tests. 
vii. Statistical analysis 
Intent to treat analysis was performed. All data shown are expressed as mean ± SD or 
have been converted to percentages. Statistical analysis was performed with SPSS 
software version 18.0 (SPSS, Chicago, IL). If the data showed normal distribution, 
independent samples Student t tests were used to determine differences between the 
groups. Non-normally distributed data was log transformed to normality; if this was not 
possible then a Mann Whitney test was conducted. Individual changes over the 3-month 
period were analysed with paired t tests. Bivariate correlations were performed to 
examine strength and direction of associations between two variables with Pearson’s 
correlation coefficient reported for normally distributed variables and Spearman’s rho 
reported for nonparametric analysis. Scatter plots were created and provided with the 
regression line. Partial correlations were performed as above controlling to control for 
the effect of other contributory variables. To study the linear relationship between a 
dependent variable and several independent variables a multivariate linear regression 
analysis was performed with potentially relevant independent variables.  
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2.5 Recruitment 
 
The study was advertised through multiple methods including: word of mouth at weekly 
CHW endocrinology departmental meetings; via a generic paragraph developed for 
inclusion in electronic bulletins such as The Bandaged Bear Bulletin (CHW staff weekly 
email hospital communiqué) and Paediatric Pot-Pourri (Royal Australasian College of 
Paediatricians weekly e-bulletin); through small flyers placed in the waiting area of the 
Bandaged Bear Outpatients clinic at CHW and by letters to local General Practitioners 
(GPs); postal recruitment however, was not required (Appendix A). Potential participants 
were referred to the study by the treating clinician after fulfilling the inclusion criteria. 
Upon referral, the candidate met/ phoned the family to gauge interest. A written patient 
information sheet (Appendix B) was provided at first contact or sent in the mail after 
telephone contact. A follow-up phone call a week later was made to discuss concerns and 
to confirm interest and availability for the recruitment interview.  
i. Recruitment interview 
At the first visit, the candidate obtained written informed consent/ assent and performed 
a full physical examination and pubertal staging 475. Further personal and family medical 
history plus demographic information was recorded on two specially developed clinical 
evaluation forms (Appendix C). The candidate assisted the participant and their family to 
complete dietary checklists and surveys (Appendix D). Randomisation to the treatment 
arm occurred at this visit. A second visit was scheduled for baseline anthropometry, 
investigations (OGTT, pQCT, DXA, Leonardo® mechanography, V02peak fitness test) 
sports medicine and nutrition consultations. 
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2.6 Interventions 
 
All participants were prescribed standardised lifestyle measures. Those randomised to the 
WBVT intervention were loaned a Galileo® Home platform and instructed on safe use 
by the candidate prior to commencement. The duration of the trial was 3 months. 
a. Lifestyle Intervention 
All participants received a lifestyle intervention, which comprised individualised 
nutritional coaching by two experienced paediatric weight management dietitians 
specialised in the care of children and adolescents with obesity and insulin resistance.  
The Team at CHISM provided the sports medicine consultation and fitness assessment. 
All participants had clearly defined weight loss and physical activity goals. This was a 
contemporary clinical intervention offered to all overweight patients of the endocrine 
clinic at CHW. The schedule for the lifestyle intervention can be seen in Figure 2.2.  
Nutrition coaching 
At baseline, each participant and their parent/s met with one of two specialised weight 
management dietitians. Nutrition intervention employed a structured meal plan tailored 
on an individual basis and incorporating an energy restriction of 500-1000kJ/ day (6000-
7000kJ for adolescents aged 10-14 years; 7000-8000kJ for those 10-18 years). The 
coaching model employed is routinely used by the Weight Management Services at CHW 
to assist with motivation and adherence to lifestyle recommendations. At the initial 
meeting, the dietitian introduced their role, gauged interest for nutritional change and 
provided an individualised eating plan based on a moderate carbohydrate (CHO) diet 
(Appendix E). Nutrient targets included: 40-45% total CHO, 30% protein, 25% fat 
(<10% saturated) aiming for 30-45g total carbohydrate, 20-30g total protein, 10-20g total 
fat for main meals with 20-30g total carbohydrate, 10-20g total protein, 5-10g total fat 
for snacks. Standard checklists were adhered to during this consultation with an 
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emphasis on eating a regular breakfast, discussion of hungry periods during the day, 
increased protein at meals, snacks choices and reduction of carbohydrate intake at night. 
Participants were encouraged to drink water as the main beverage. The dietitian called 
the participant and their family 24 hours later to discuss any concerns. A follow-up face-
to-face appointment with the dietitian was scheduled during week 2 of the study. The 
dietitian contacted the family by phone during weeks 6 and 10 to monitor progress. The 
timeline for nutritional counselling can be seen in Figure 2.2. 
Exercise prescription and fitness testing 
Participants were referred to CHISM for aerobic fitness testing and an exercise 
prescription. Participants were encouraged to keep an exercise diary or calendar, limit 
small screen time to less than 2 hours per day, engage in 30-40 minutes of moderate 
intensity physical activity four times per week and participate in a team sport. A sample 
prescription can be seen in APPENDIX F. A follow up sports medicine consultation 
was scheduled at the conclusion of the study during week 12. The exercise program 
incorporated an age-appropriate mix of both aerobic and resistance training. In addition, 
an increase in incidental physical activity and active transport with concomitant decrease 
in sedentary behaviours was encouraged.  
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Figure 2.2 VIBRATE study measurement schedule 
 Wk 0 Wk 2 Wk 4 Wk 6 Wk 8 Wk 10 Wk 12 
 
Clinical assessment        
Tanner Stage ★      ★ 
Medical review ★      ★ 
Anthropometry        
Height ★      ★ 
Weight ★      ★ 
Waist ★      ★ 
Metabolic tests        
OGTT ★      ★ 
hsCRP, lipid profile, LFTs ★      ★ 
Bone turnover markers        
Urine deoxypyridinoline ★      ★ 
P1NP ★      ★ 
CTX ★      ★ 
 
Body composition        
DEXA ★      ★ 
PQCT ★      ★ 
LeonardoTM 
Mechanography 
       
Single leg jump ★      ★ 
Two leg jump ★      ★ 
Lifestyle intervention        
Nutrition coaching ★ ★  ★  ★  
Fitness test 
VO2peak 
★      ★ 
Exercise prescription ★       
Therapeutic phone contact 
 
Checklists & surveys 
 
 ★ ★ ★ ★ ★  
CLASS 
Diet checklist 
★ 
 
★ 
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b. Whole body vibration training 
Participants assigned to the intervention arm were supplied with and instructed by the 
candidate on the safe use of a side alternating whole body vibration platform (Figure 2.3), 
Galileo Sport® (Novotec GmbH, Pforzheim, Germany). Written instructions were also 
attached to each platform as a quick reference guide. The training protocol was home 
based with parental supervision. The 12-week WBVT program was outlined in a training 
diary provided at randomisation and included a one-week period of increasing training 
intensity to prevent injury (APPENDIX G). Each daily training session incorporated 3x3 
minute blocks of WBVT at variable frequencies (starting at 12Hz for first 3 minutes and 
increasing to 18-20Hz for the 2nd and 3rd blocks, interspersed with 2x3 minute rest 
periods; amplitude on the platform varied from 0-6mm, depending on the position of the 
legs).  
 
 
 
Figure 2.3 Difference between side-alternating and vertical vibration training taken from 
409 The Galileo Sport® (Novotec GmbH, Pforzheim, Germany) was used in this study and provides side 
alternating vibration training (right side); this movement is more physiological).  
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Figure 2.4 demonstrates the commonly used terminology to describe vibration training. 
Legs were bent at 45 degrees at the knee with foot placement on standard marker 2 
imprinted on the platform surface by the manufacturer (Figure 2.5). The position was 
chosen to maximally exercise the large muscles of the legs and buttock and to prevent 
excessive vibration transmission to the spine. The training was performed in socks or 
thin-soled shoes to minimise dampening of the vibration. This vibration protocol was 
adapted from previous research studies 427 434 in the paediatric cohort due to efficacy and 
tolerability. It was also piloted in a cross section of overweight insulin resistant children 
derived from our endocrine clinic for tolerability and feasibility prior to commencement 
of the study. The device had a factory inbuilt electronic timer that recorded the number 
of minutes in use and which was used in conjunction with the vibration training diary 
and fortnightly therapeutic contact to assess compliance to the WBVT intervention and 
determine any specific difficulties or adverse events. A home visit was organised during 
week one to assess correct use of the vibration plate. 
 
The vibration platform was located in the patient’s family home and use by other family 
members was discouraged, however, if this occurred the participant or parent was to 
record this time in the vibration diary. Figure 2.6 shows a participant performing WBVT 
in their home. Full adherence with the prescribed training protocol would constitute a 
usage of 739 minutes. At the completion of the training period, the candidate checked 
the platform compliance meter and subtracted time used/ if any, by other family 
members (as recorded in the vibration training diary).  The actual compliance time for 
each participant was calculated by subtracting this amount from 739 minutes. Percentage 
compliance time was calculated by multiplying by 100, to obtain a percentage value (%).  
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Figure 2.4 Variables in whole body vibration training  
Amplitude (A), frequency 1/T, displacement (P) taken from 476 
 
Figure 2.5 Whole body vibration platform used in VIBRATE study 
Galileo® Sport with foot placement markers (0,1,2,3) and remote control taken from 477 with permission. 
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Figure 2.6 Participant in the VIBRATE study  
Participant in the VIBRATE trial using the Galileo Home ™ platform in their bedroom  
(photograph taken by Adam Hollingworth, Sun Herald 19/10/2008, page 27). 
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c. Therapeutic contact 
The candidate provided therapeutic phone contact to each participant on a fortnightly 
basis according to the schedule (Figure 2.2) to monitor adherence to the program, 
troubleshoot any issues raised by the young person and to record any adverse events. A 
standardised coaching protocol was employed for therapeutic contact.  
 
2.7 Details of measurements 
 
Measurements taken during the trial are listed below and included in Figure 2.2. 
 
a. Clinical Evaluation 
Medical and family history 
 
In addition to the medical and family history, the candidate collected demographic 
information at the recruitment interview using the clinical evaluation form (Appendix C).  
Pubertal staging 
To classify pubertal status, Tanner and Whitehouse staging 475 was performed by the 
candidate at baseline and at the end of the study. 
Acanthosis nigricans 
The presence of acanthosis nigricans at the neck and axillae was noted and quantitatively 
graded at baseline and 3 months using the Burke scale 470. Skin colour was noted 
according to the Fitzpatrick scale 478. 
Blood pressure 
An automated blood pressure device (Dinamap 1846SX; Critikon Inc, Tampa, FL) was 
used to measure blood pressure (mmHg) according to standard procedures, on the right 
arm with an appropriately sized cuff, whilst the adolescent was seated 479. Three measures 
were taken and the average of the last two measures was used for analysis. 
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Anthropometry 
Height, weight and waist circumference were measured by one of two endocrine clinical 
nurse consultants according to standard procedure 480; both were blinded to the study 
intervention. Weight was measured once to the nearest 0.1kg, in light clothing using 
digital scales (Wedderburn, Summer Hill, NSW, Australia). Three height measurements 
were recorded to the nearest 0.1cm using a wall mounted Harpenden Stadiometer 
(Holtain Ltd, Crymmych, Dyfed, Wales, UK). The average of the three height measures 
was used in calculation of body mass index and data analysis. Horizontal waist 
circumference at the umbilicus was measured using a flexible steel tape to the nearest 
0.1cm, using the left hand under technique.  
 
The waist to height ratio (WHtR), was calculated as: waist circumference (cm)/ height 
(cm), with a ratio of <0.5 considered ideal to reduce cardiovascular risk 90. The BMI was 
calculated according to the formula: weight in kg/height (m)2 . Height, weight and BMI 
were converted to z-scores with the LMS excel add in 481 using the reference data from 
the Center for Disease Control (CDC)132. Waist to height ratio, rather than waist 
circumference z-scores was used for analysis as there are no Australian national standards 
for waist circumference in children and it has been shown that WHtR exhibits similar 
CVD risk clustering to the measurement of central adiposity 91.  
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b. Body composition  
Dual energy x-ray absorptiometry (DXA) 
 
Body composition was assessed using DXA as it has high reproducibility, with low 
coefficients of variation in paediatric patients 482. Previous studies at CHW have 
established extensive normative DXA data on children and adolescents 483 484. 
 
DXA (Prodigy, GE-Lunar Corporation, Madison, WI, USA) with proprietary enCORE® 
software version 8.6 was used to measure body composition including: total and regional 
(trunk, legs, arms) bone mineral density; bone mineral content (BMC), bone area, lean 
tissue mass (LTM) and fat at baseline and 3 months. The DXA scans were performed by 
two experienced scientists (Ms Julie Briody and Mrs Madeleine Thompson) within the 
Department of Nuclear Medicine at The Children’s Hospital at Westmead. The 
manufacturer recommended scan mode was used for scan acquisition. For this 
enCORE® version, the “Standard” mode was used for participants with an average 
tissue thickness less than < 13 cm, and the “Thick” mode was used for participants with 
tissue thicknesses over 13cm. Participant tissue thickness was estimated by the 
enCORE® software from the participant’s height and weight.   
 
Prior to the scan, any x-ray attenuating materials on the participant were removed. 
Participant positioning on the scanner table was standardised. Participants were 
instructed to lie supine on the centre of the scanner table, with both arms close to the 
body and hands curled into loose fists. A participant whose width was close to, or 
exceeded, 60 cm (the maximum scan width) was tightly swaddled with a sheet to reduce 
their width and permit inclusion of their whole body in the scan.  A vertical reference 
line on the centre of the table and a horizontal line at the top of the table provided 
landmarks for central positioning. Velcro straps at the ankles were fastened to prevent 
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movement artefacts. This technique has been used in previous obesity studies at CHW 485. 
A sample DXA scan may be seen in Figure 2.7. A “Standard” scan required the 
participants to lie still for less than 4 minutes (< 10 minutes if “Thick” scan mode was 
used). The effective radiation dose for each scan was less than 1 uSv which is less than 
that normally received daily from natural sources of radiation (effective dose of 6 µ
Sv/day). 
 
Variables analysed included changes in bone mineral content (BMC) relative to body 
height and projected bone area, lean body mass and fat mass. Analysis of skeletal 
subregions (head, upper limbs, trunk, pelvis, lower limbs) was performed to assess the 
site-specificity of the changes. Z-scores were calculated using in house data based on 
previously published studies. The in vivo coefficients of variation for total body BMC, 
total BMD, LTM and %fat mass were 0.74, 1.1, 0.82, and 1.59%, respectively 483 486.  
 
 
Figure 2.7 DXA scan of participant in the VIBRATE study  
 
Reference lines in white delimit the regions for calculation of regional fat and bone mineral density 
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c. Metabolic profile measures 
Oral glucose tolerance test 
Patients were admitted to the Turner Day Stay ward at CHW, after an overnight fast and 
underwent a standard oral glucose tolerance test (OGTT). Anaesthetic cream was placed 
over a large vein in the antecubital fossa or hand. A 22g cannula was inserted for blood 
glucose and insulin sampling. At baseline bloods were withdrawn from the cannula for 
electrolytes, LFTs, fasting insulin, glucose, C-reactive protein (CRP) and lipid profiles, 
and analysed in the Biochemistry Laboratory at The Children’s Hospital at Westmead. 
Children were given a glucose containing drink LucozadeTM 1.75g/kg to a maximum 
dose of 75g and consumed this within 5 minutes.  Bloods were taken for insulin and 
glucose at 30, 60, 90 and 120 min. Plasma glucose concentration was measured 
immediately on the Dade Dimension ARX  (Dade Behring Inc, IL, USA) using the 
hexokinase-glucose-6-phosphate dehydrogenase method with plasma insulin levels 
determined by commercial radioimmunoassay kits, inter and intra-assay coefficient of 
variation 6.0 and 4.4%, respectively (Millipore, Missouri, USA). An extra 10mL of blood 
was centrifuged and divided in 4 microtubes and stored at -80oC for batch analysis of 
bone serum turnover markers.  
 
Whole body insulin sensitivity index (ISI) was calculated using the formula: 
ISI = 10,000/ √[(fasting insulin (IU/ml) x fasting glucose (mg/dl)] x (mean 2hr insulin (IU/ml) x mean 2 
hr glucose(mg/dl))] 276 
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Surrogate measures of insulin resistance 
The insulin and glucose value at baseline (time 0) was used to calculate a surrogate 
measure of insulin resistance.  
The homeostasis model of insulin resistance (HOMA-IR) was calculated using the 
formula: HOMA-IR = fasting insulin (mU/L) x fasting glucose (mmol/L)/ 22.5 
 
Metabolic blood profile 
Blood was collected at baseline and 3 months for analysis in the Biochemistry Laboratory 
at CHW according to standard technique. The following bloods were analysed:  
• Glucose measurements were analysed on a Vitros DT60 analyser (Ortho-Clinical 
Diagnostics Inc, Raritan, NJ, USA) 
• Metabolic bloods including hs-CRP and lipid profile were analysed on the Vitros 
5, 1 FS analyser (Ortho-Clinical Diagnostics Inc, Raritan, NJ, USA).  
• Plasma insulin levels determined by commercial radioimmunoassay kits 
(Millipore, Missouri, USA). 
Serum creatinine, urea and LFTs were analysed in the Biochemistry laboratory using 
standard automatic enzymatic methods.  
d. Bone measures 
Peripheral Quantitative Computed Tomography 
 
Peripheral quantitative computed tomography (pQCT) of the non-dominant tibia was 
performed using a Stratec XCT-2000L (Stratec Medizintechik GmbH, Pforzheim, 
Germany) with proprietary software version 6.00B 0.61 for measurements and analyses. 
Scans were performed at baseline and 3 months. The participant was required to stay still 
for about 5 minutes. The foot was placed in a rest and strapped into place for the 
examination. The effective radiation dose of the pQCT was < 0.3 microSv per scan. 
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Total effective radiation dose for this study was < 3 microSv. The length of the tibia was 
measured with a standard measuring tape from the medial malleolus to the medial 
femoral condyle. 487 A scout view of the distal epiphyses allowed for consistent 
placement of a reference line in the middle of the distal cortical end of the tibia. The scan 
site was in the diaphyseal region, 66% of the limb length proximal to the reference 
position. The following parameters were measured at the tibial diaphysis: muscle cross 
sectional area (MCSA, mm2) and polar stress strain index (pSSI, mm3); in addition 
cortical volumetric BMD (vBMD) and cortical bone mineral content (BMC) were 
calculated and converted to z scores at this site. Conversion from pQCT raw data to sex- 
and age-matched z scores was based on published paediatric reference data 488.   
 
The tibia was acquired with a voxel size of 0.4mm and a scan speed of 20 mm/s was 
used. The slice thickness of the machine was 2.4 mm. For analysis of the images, a single 
operator (Ms Julie Briody) manually placed regions of interest around the tibia, fibula and 
whole leg cross section and then used the LOOP analysis function. The settings for 
CALCBD and CORTBD were based on those used by Moyer-Mileur 488. For the vBMD 
and BMC, CORTBD settings were Cort Mode 1 and Threshold 711 mg/cm3. CORTBD 
settings for Strength–strain index (SSI) were Cort Mode 1 and a Threshold of280 
mg/cm3. The parameters used for the muscle analysis (for removal of subcutaneous fat) 
were: CALCBD Contour Mode 3, Peel Mode 1, Threshold 50 mg/cm3 and a F03F05 
Filter (this noise suppression filter helps to differentiate muscle, fat and bone and 
combines a 3x3 median filter with a threshold range of -500 to 500 mg/cm3 with a 5x5 
median filter with a threshold range of -500 to 300 mg/cm3). In some patients this 
analysis failed so an additional F05 filter was required. 
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Bone turnover markers 
Urine  
The second urine sample of the day was collected and covered with aluminium foil to 
protect it from light. The sample was analysed for deoxypyridinoline cross-links by the 
Endocrinology laboratory at CHW using chemiluminescent competitive immunoassay 
kits (Immulite®1000, Siemens Healthcare, UK) that has a coefficient of variation (CV) 
of 9.5% at 98.8 nmol/l to 17.5% at 23.0 nmol/l. 
 
Serum 
The following bone turnover markers were analysed in batches by the staff in the 
Endocrinology Laboratory at CHW: 
• Osteocalcin was analysed by chemiluminescent immunoassay using the 
IMMULITE® 1000 (Siemens Healthcare, UK). 
• 25 Hydroxyvitamin Vitamin D levels were determined by using an extraction 
radioimmunoassay commercial kit (DiaSorin Inc, MN, USA) with serum CV 
12.6–10.8% (19.8–280.0 nmol/L) and 9.7–9.5% (45.0–154.5 nmol/L) for kit 
controls. 
• CTX and PINP were measured via chemiluminescent immunoassay (CTX-I 
CrossLaps® assay kit, IDS Ltd, UK) with manufacturer within run coefficient of 
variation 2.1-4.9% and (Intact PINP assay kit, IDS Ltd, UK), respectively on the 
IDS-iSYS Multi-Discipline Automated Analyser (Immunodiagnostic Systems Ltd, 
England, UK) with manufacturer within run coefficient of variation of 2.6-3.0%. 
The manufacturer’s reference range for adults was used for reporting the normative data 
ranges. 
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e. Fitness and muscle performance 
VO2peak fitness test 
At baseline, participants performed a supervised VO2peak fitness test on a Trackmaster 
TMX425 treadmill according to a standard Bruce Protocol 489-491. In the standard Bruce 
protocol, the starting point is 1.7 mph at a 10% grade. Stage 2 is 2.5 mph at a 12% grade. 
Stage 3 is 3.4 mph at a 14% grade, with continual increments in grade and speed at 3-
minute increments. This protocol includes 3-minute periods to allow achievement of a 
steady state before workload is increased. This test was repeated at the conclusion of the 
trial to evaluate change in aerobic fitness. VO2peak was obtained by continuously analysing 
gas exchange variables using the Medgraphics CPX/D breath-by-breath gas exchange 
system (Medgraphics Corporation, St Paul, Minnesota). Participants breathed through a 
mouthpiece attached to a lightweight pneumotach and in line analysers measured O2 and 
CO2. Anaerobic threshold was determined using the V-slope method. Peak oxygen 
uptake was defined by a heart rate greater than 185 beats per minute and peak 
Respiratory Exchange Ratio (RER) exceeded 1.10; lower values for heart rate and RER 
were unlikely to reflect exhaustive exercise.  
 
A paediatric exercise physiologist blinded to the treatment intervention conducted the 
testing and encouraged each child to continue until the point of severe fatigue. The end 
point was determined to have occurred when the child refused to continue despite verbal 
encouragement. The participant was able to stop the test at any time by pressing the 
emergency stop button or by placing their legs on the stationary part of the treadmill. At 
the end of the test, each participant was questioned about the reason for cessation i.e. 
short of breath, muscular fatigue or other reason. 
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Leonardo® mechanography 
 
Although muscle CSA derived from pQCT has been used as a surrogate measure of 
muscle strength, the correlation between muscle CSA and muscle strength is unknown. 
Muscle strength in the shin was measured using ground reaction force testing. Peak jump 
force (N), Power (kW) and efficiency (s) of jump was assessed in all participants at 
baseline and 3 months during the single leg and two-leg jump on the Leonardo 
Mechanograph® Ground Reaction Force Plate (GRFP) (Novotec Medical GmbH, 
Pforzheim, Germany). The child was instructed to jump as high as possible. Three jumps 
were performed and the jump that resulted in the maximum peak jump force was used 
for analysis. The raw score and values adjusted for weight and height were evaluated. The 
countermovement jump or single two leg jump (s2LJ) provides an assessment of 
anaerobic peak power output and can be matched for mass, age and gender. The child 
was also instructed to repeatedly hop on the fore foot without making heel contact. This 
multiple 1 leg jump (m1LJ) estimates the maximal muscular force of the lower limb and 
allows evaluation of the muscle tendon complex and energy storage capacity 492 493. A 
screen capture of the data provided during Mechanography can be seen in Figure 2.8. 
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Figure 2.8 Leonardo® Mechanography taken with permission from Novotec Medical 
Screen shot of data obtained during the multiple one leg jump showing power (kW) and force (kN) 
 
f. Surveys, checklists and diary 
The participants completed these tasks with parental or guardian assistance.  
Diet checklist 
In the absence of appropriate biomarkers for dietary intake, diet checklists similar to 
those used in previous studies assessed adherence to the prescribed diet 485. Each 
participant completed a 7 day diet checklist (APPENDIX C) at baseline and 3 months, 
the checklist had been adapted from previous studies 494 and used in a recent study of 
insulin resistant adolescents 153. 
 
Fitness and physical activity  
 
Physical activity and sedentary behaviours were measured by a validated questionnaire 
(APPENDIX C), Children’s Leisure Activities Study Survey (CLASS).  CLASS assesses a 
   
  CHAPTER 2 METHODS 
93 
range of physical activity and sedentary behaviours, has been validated for use among 
children aged 5-6 and 10-12 years, and has been used by adolescents 13-16 years in the 
Nepean Study 495.  
 
Whole body vibration training diary 
 
The adherence to WBVT was assessed by documentation in the WBVT training diary 
(APPENDIX G). Participants were asked to note any specific issues during the training 
session and record use of the platform by other family members, to assist with 
determining compliance.  
 
2.8 Summary 
 
This chapter provides the methods for the VIBRATE study including the primary and 
secondary study aims, patient recruitment, schedule of the interventions and the methods 
employed for data collection and statistical analysis. Chapter 3 will examine the 
demographic and metabolic features of the cohort, Chapter 4 will provide results from 
the RCT examining the effect of WBVT on the primary outcome of insulin sensitivity 
and will also include analysis of the secondary outcomes of metabolic profile indicators; 
Chapter 5 will explore the results of body composition and musculoskeletal variables and 
Chapter 6 will provide further data pertaining to the cardiorespiratory fitness of the 
cohort.  
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CHAPTER 3  
What are the metabolic characteristics of obese insulin 
resistant adolescents living in Greater Western Sydney? 
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3.1 Introduction  
 
In the obese adolescent, insulin resistance clusters with other co-morbid metabolic 
conditions such as PCOS, NAFLD and hypertension (HT).  Many children are 
diagnosed with biochemical or clinical insulin resistance after referral to a specialist for 
evaluation. Further knowledge about the adolescent at risk of metabolic syndrome will 
allow for early, targeted intervention of metabolic risk factors and allow rational 
investigation/ screening of those who may have accompanying insulin resistance. 
 
At baseline, all participants in the VIBRATE study underwent comprehensive clinical 
assessment and anthropometrical assessment. Fasting serum metabolic profile indicators 
were taken during the OGTT. To evaluate sedentary behaviours and activity validated 
activity surveys were completed and nutrition checklists done to review daily intake of 
common food groups.  
 
The purpose of this chapter is to provide a snapshot of the obese adolescent in Greater 
Western Sydney (GWS) by fulfilling the following aims: 
• Provide further information about the recruitment pattern and describe any 
noticeable differences. 
• Highlight clinical examination and ethnographic features common to adolescents 
with insulin resistance in Greater Western Sydney (GWS). 
• Demonstrate the prevalence of co-existent features of the metabolic syndrome in 
obese adolescents and their close relatives.  
• Determine any anthropometric similarities seen in adolescents with insulin 
resistance and to examine any gender differences. 
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• Review any modifiable dietary and lifestyle features present in the obese 
adolescent? 
• To examine correlations and interrelations between baseline biochemical 
metabolic profile indicators and clinical examination features.  
 
3.2 Demographics 
3.2.1 Study participants 
 
Of the 43 overweight and/ or obese adolescents sequentially enrolled in VIBRATE 
study, 14 (32.6%) were male and 29 (67.4%) were female. Composition of the groups can 
be seen in Figure 3.1. Participants ranged in age from 10.1 to 17.4 years at randomisation; 
mean age of the participants was 13.3 years (SD±2.1). All had the presence of acanthosis 
nigricans and/ or elevated fasting insulin levels >15mU/L 285 in addition to an increased 
BMI which was at least in the overweight range 60, as per study inclusion criteria.  
 
Figure 3.1 Recruitment and randomisation for the VIBRATE study  
This diagram shows the composition of the intervention groups. 
Open to recruitment June 2008 43 participants enrolled                    14M 29F                target n=48 
Vibration  n=21 
14  Female 
7 Male 
Lifestyle n=22 
15 Female 
7 Male 
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3.2.2 Demographic and ethnicity data 
All participants and their families lived in the GWS region, comprised of 14 local 
government areas as seen in Figure 3.2. 
 
Figure 3.2 Local government areas of Greater Western Sydney 
Map showing the 14 local government areas of Greater Western Sydney taken from 496 
 
Ethnicity data was self-reported and categorised according to the child and parental 
birthplace and divided into categories consistent with the Australian Bureau of Statistics 
(ABS) Census Classifications Index 497. The majority of participants in the study 
identified as being from populations at high risk of developing the metabolic syndrome 
including: Middle Eastern, 13 participants (30%); South East Asian, 6 participants (19%); 
Indian, 6 participants (19%); Southern European, 4 participants (9%); Pacific Islander, 2 
participants (5%) and African 1 participant (2%); 8 adolescents (19%) identified as 
Caucasian Australian (Figure 3.3). 
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Figure 3.3 Ethnicity of participants in VIBRATE study  
Self/ parental reported ethnicity as per ABS Census Classifications Index 497 
 
3.3 Metabolic profile  
3.3.1 Metabolic syndrome in participants 
At baseline, 43 participants were assessed for features of the metabolic syndrome using 
data obtained from anthropometry (WC, BMI z-score) and metabolic bloods (HDL-C, 
TG, fasting glucose). Selected paediatric definitions of the metabolic syndrome were 
applied to the data as shown in Figure 3.4. The prevalence of the metabolic syndrome in 
the cohort ranged from 23-44% depending on the criteria used for the analysis. The 
modified NCEP ATP III definition identified the highest proportion of individuals and 
the most females with the metabolic syndrome compared to the other classifications. 
The prevalence of the metabolic syndrome was similar between the genders, 21-43% of 
males and 21-45% of females had sufficient clustering of risk factors to identify them as 
having the metabolic syndrome. Post-pubertal females were more likely to have enough 
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risk factors to be diagnosed with the metabolic syndrome.  Adolescents of Middle 
Eastern ethnicity were more likely to have more than one risk factor for metabolic 
disease (Figure 3.5). 
 
 
Figure 3.4 Metabolic syndrome in the participants 
This histogram shows the number of adolescents in the VIBRATE study with features of the metabolic 
syndrome according to several paediatric definitions.  
NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) 116; IDF 
(International Diabetes Federation) 122; Weiss 241; Cook 498 and De Ferranti 499. The modified NCEP ATP 
III criteria includes three of the following measures: waist circumference >90th centile for age and sex; 
systolic or diastolic blood pressure >90th centile for age, sex and height; TG >1.24mmol/L; HDL-C 
<1.03mmol/L; fasting glucose >5.55mmol/L.116. The IDF definition for metabolic syndrome in children 
and adolescents include: elevated waist circumference >90th centile for age (adult age and ethnicity specific 
cut-off used for adolescents>16 years; triglycerides >1.7mmol/L; HDL-cholesterol<1.03mmol/L; SBP 
>130mmHg or DBP >85mmHg; fasting glucose >5.6mmol/L.  
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Figure 3.5 IDF122 features of the metabolic syndrome according to ethnicity 
The IDF definition for metabolic syndrome in children and adolescents include: elevated waist 
circumference >90th centile for age (adult age and ethnicity specific cut-off used for adolescents>16 years; 
triglycerides >1.7mmol/L; HDL-cholesterol<1.03mmol/L; SBP >130mmHg or DBP >85mmHg; fasting 
glucose >5.6mmol/L.  
 
3.3.2 Features of the metabolic syndrome in close relatives 
To obtain this data, the parent/ caregiver was asked about family history of metabolic 
disease. There was a significant clustering of features of the metabolic syndrome in both 
first and second degree relatives as illustrated in Figure 3.6. Obesity was reported most 
commonly amongst the first-degree relatives followed by T2DM. Amongst second-
degree relatives, which included grandparents, uncles and aunts, the most common 
metabolic disease was T2DM (26 participants), followed by HT (22 participants) and 
CVD (19 participants). 
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Figure 3.6 Metabolic diseases in first and second-degree family members 
Histogram showing metabolic disease in first and second-degree family members (Obesity, CVD  
 
Cardiovascular disease, Type 2 diabetes T2DM, Polycystic ovary syndrome PCOS, Hypertension HT) 
 
 
3.4 Clinical measurement and assessment 
3.4.1 Baseline anthropometry and pubertal status  
Baseline anthropometry and metabolic indicators according to gender and pubertal status 
can be seen in Table 3.2. At baseline there were no significant differences in average age 
or anthropometry between the sexes or intervention groups, apart from baseline height 
in males which was higher and approached significance p=0.06. Adolescents had a mean 
BMI in the obese range 500 with central adiposity indicated by elevated waist 
circumference and waist to height ratio. Almost two thirds (63%) of the study population 
was female, with most being in late puberty (Tanner stage III-V). Overall there were 
significantly more late pubertal individuals recruited to the study as indicated in Table 3.1.   
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Table 3.1 Pubertal status of the participants 
 
 Pubertal status of the participants N=43 
Pubertal status Early  Late Total T test 
Males 6 8 14 0.01* 
Females 10 19 29 <0.001* 
*indicates significant result chi squared test Early (Tanner I-II)  Late (Tanner  III-V) 
 
 
Table 3.2 Baseline anthropometry and blood pressure 
Measure Group 
(N=43) 
Male Female Early 
puberty 
(n=16) 
Late 
puberty 
(n=27) 
 
 
Age (years) 
 
 
13.3 (0.3) 
 
13.8 (2.0) 
 
13.1 (2.1) 
 
11.3 (1.0) 
 
14.5 (1.6)b# 
Weight (kg) 
 
82.5 (2.4) 82.7 (15.0) 82.4 (16.1) 72.4 (10.4)b# 88.4 (15.1) 
Height (cm) 
 
161.6 (1.4) 165.3 (8.8) 159.8 (8.8) 155.6 (8.6) 165.1 (7.5)b# 
BMI (kg/m2) 
 
31.5 (0.8) 30.2 (4.2) 32.2 (5.4) 29.6 (3.0) 32.5 (5.8) 
BMI z-score 
 
2.1 (0.4) 2.1 (0.5) 2.2 (0.4) 2.2 (0.3) 2.1 (0.5) 
WC (cm) 
 
102.4 (1.8) 102.1 (12.1) 102.6 (12.2) 99.4 (9.3) 104.2 (13.3) 
WtHR 
 
0.63 (0.01) 0.62 (0.08) 0.64 (0.08) 0.64 (0.1) 0.63 (0.1) 
Pubertal stage 
Early: Late  
 
16: 27 7: 7 9: 20 16 27 
Systolic BP (mmHg) 
 
119.5 (2.0) 121.1 (13.7) 118.7 (13.2) 116.4 (12.2) 121.3 (13.7) 
Diastolic BP (mmHg) 
 
65.9 (1.2) 69.8 (8.4) 64.0 (7.4)a* 63.3 (7.0) 67.4 (8.5) 
SBP z-score 1.0 (0.9) 1.5 (0.9)a* 0.7 (0.9) 0.8 (0.8) 
 
1.1 (1.0) 
DBP z-score 0.4 (1.2) 0.4 (1.4) 0.4 (1.2) 
 
0.5 (1.2) 0.4 (1.3) 
Data are presented as mean ± SD score early Tanner stages I-II late Tanner stage III-V *p<0.05 #p<0.01 
aIndicates significant result males versus females  
bindicates significant results early versus late puberty *p<0.05 #p<0.01 
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3.4.2 Blood pressure 
 
Females had significantly lower diastolic blood pressure (p=0.03) compared to males at 
the start of the study as seen in Table 3.2. Males had higher SBP z score compared with 
females. The gender disparity was more evident, particularly for SBP z score when 
pubertal participants were selected as shown in Table 3.3. 
 
Table 3.3 Blood pressure comparison in pubertal participants  
 
 N = 27 DBP 
(mmHg) 
SBP 
(mmHg) 
DBP  
z-score 
SBP  
z-score 
Male 8 74 (8) 124 (14) 0.4 (1.6) 1.8 (0.9) 
Female 19 65 (7) 120 (14) 0.4 (1.2) 0.8 (0.9) 
P value  0.014* 0.504 0.976 0.009** 
Mean (SD) Student t test *p<0.05 **p<0.01 
 
 
 
Participants had evidence of diastolic hypertension (Figure 3.7): 15/43 participants had 
an elevated diastolic blood pressure (DBP) at baseline; 5 participants had pre 
hypertension (DBP 90-95th centile for age) and 10/43 (23.3%) participants measured a 
DBP>95th centile for age, in the hypertensive range.  
 
 
 
 
 
 
Figure 3.7 Diastolic hypertension (mmHg) in the participants n=43 
 
Blood pressure measured in mmHg Early Puberty (Tanner I-II) and Late Puberty (Tanner III-V) 
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Systolic blood pressure (SBP) measurement showed similar trends (Figure 3.8) with 3/43 
participants classified with pre hypertension and 10/43 (23.3%) participants with systolic 
hypertension. The majority of those presenting with elevated blood pressure were late 
pubertal males. 
 
 
 
 
 
 
Figure 3.8 Grade 1 Systolic hypertension (mmHg) in the participants n=43 
 
Blood pressure measured in mmHg Early Puberty Tanner I-II and Late Puberty Tanner III-V 
 
 
3.4.3 Acanthosis nigricans 
Almost two thirds (28/43) of the cohort presented with AN and all had dark skin 
(Fitzpatrick grade IV-VI 478). None of the Caucasian or Southern European participants 
had this dermatological feature. 
 
 
0
2
4
6
8
10
12
Total Male Female
N
um
be
r 
of
 p
ar
ti
ci
pa
nt
s 
Systolic hypertensionEarly pubertyLate puberty
   
  CHAPTER 3 METABOLIC CHARACTERISTICS 
105 
3.5 Biochemical measures 
3.5.1 Metabolic profile indicators 
At the start of the study all participants had fasting blood drawn for measurement of 
fasting lipid profile, fasting insulin and glucose and hs-CRP. The fasting insulin and 
glucose level was used to calculate the surrogate measure of insulin resistance, HOMA-
IR. Table 3.4 provides the biochemical measures obtained at baseline in the group, 
stratified according to gender and pubertal status. There were no gender differences for 
fasting measures of glucose, insulin or lipid profile at the commencement to the study. 
The calculated proxy index of insulin resistance (HOMA-IR) was high across the groups. 
a. Liver function tests 
Liver function tests analysis revealed elevated transaminases with mean AST increased 
above the normal range. ALT levels whilst still in the normal range were significantly 
higher in males when compared to females (p=0.007). Liver function tests show mean 
for total, intervention groups and gender AST and ALT was elevated outside the normal 
range.   
b. Lipid profile 
There was a high prevalence of dyslipidaemia at baseline, 25/43 (58%) participants had 
an abnormal lipid profile with elevation of total cholesterol (TC), low-density lipoprotein 
C (LDL-C), triglycerides (TG) and/or evidence of low high-density lipoprotein-C (HDL-
C) fraction at baseline.  
c. hs- CRP 
There was no difference between hs-CRP at baseline for gender or pubertal status. 
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Table 3.4 Biochemical measures of metabolic profile indicators 
 Whole group 
(n=43) 
Males 
(n=14) 
Females 
(n=29) 
Early 
Puberty 
Late 
Puberty 
 
Fasting glucose (mmol/L) 
 
5.0 (0.5) 5.0 (0.4) 5.0 (0.5) 5.2 (0.5) 4.9 (0.4)  
2 hr glucose (mmol/L) 
 
6.2 (1.2) 6.2 (0.7) 6.2 (1.3) 6.1 (0.8) 6.3 (1.4)  
Fasting insulin (pmol/L) 
 
203 (58) 201 (48) 204 (63) 203 (59) 203 (58)  
2 hr insulin (pmol/L) 
 
1047 (594) 1133 (548) 1004 (620) 969 (571) 1092 (613)  
HOMA-IR 
 
7.6 (2.5) 6.5 (1.6) 6.6 (2.4) 6.8 (2.3) 6.5 (2.1)  
WBISI 
 
1.74 (0.8) 1.6 (0.5) 1.8 (1.0) 1.9 (0.9) 1.6 (0.8)  
hs-CRP (mg/L) 
 
6.1 (6.2) 5.4 (4.3) 6.4 (7.0) 6.5 (3.1) 5.1 (3.0)  
Lipid Profile 
 
Total cholesterol (mmol/L) 
 
4.2 (0.9) 4.3 (0.9) 4.1 (0.9) 4.3 (0.7) 4.2 (0.9)  
LDL cholesterol (mmol/L) 
 
2.6 (0.7) 2.8 (0.8) 2.6 (0.7) 2.6 (0.6) 2.7 (0.8)  
HDL-C (mmol/L) 
 
1.1 (0.3) 1.1 (0.6) 1.1 (0.5) 1.1 (0.3) 1.1 (0.2)  
TG (mmol/L) 
 
1.1 (0.5) 1.3 (0.8) 1.1 (0.5) 1.2 (0.6) 1.1 (0.5)  
Liver Function tests 
 
Aspart Transaminase (AST) 
 
55 (30) 59 (18) 53 (34) 62 (34) 51 (26)  
Alanine Transaminase (ALT) 
 
 31 (20) 46 (27)**a 24 (9) 28 (8) 33 (24)**b  
Alkaline Phosphatase 188 (103) 216 (93) 175 (106) 265 (76) 143 (89)  
       
Data are presented as mean±SD *indicates Student t-test p<0.05 **indicates p<0.01 
a indicates baseline difference males versus females   bindicates baseline difference early versus late puberty 
 
Normal ranges 
Total cholesterol 3.0-5.2mmol/L 
HDL cholesterol >1.0 mmol/L 
LDL cholesterol 1.7-3.4 mmol/L 
Triglycerides <1.5mmol/L 
AST 10-50 U/L 
ALT 0-45 U/L 
ALP 50-350 U/L 
Fasting glucose <5.6mmol/L 
CRP mg/L normal (0-10) 
HOMA-IR <1.5 288 
d. Glucose 
At baseline, fasting glucose displayed a normal Gaussian distribution (Figure 3.9) within 
the range 3.9-5.9mmol/L and there were no gender or group differences. Six participants 
had evidence of pre-diabetes with IFG with levels ≥ 5.6mmol/L. The mean 2 hr glucose 
was similar for the group with no differences for gender or pubertal status.  
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Figure 3.9 Distribution of fasting glucose levels for the VIBRATE participants 
e. Fasting insulin and HOMA-IR 
 
As a group the mean (SD) fasting insulin was elevated at 203pmol/L (58) with no gender 
or pubertal differences. The group was highly insulin resistant as per inclusion criteria 
and as indicated by the mean HOMA-IR level of 7.6 (2.5).  
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3.6 Research investigations 
 
3.6.1 Whole body insulin sensitivity index (WBISI) 
Consistent with what is known about physiological insulin resistance which peaks in 
Tanner stage 3, later pubertal participants (Tanner 3-5) had lower WBISI compared with 
early pubertal participants (Tanner 1-2) as seen in Figure 3.10 and higher WC was 
associated with reduced insulin sensitivity (Figure 3.11).  
 
 
 
Figure 3.10 Relationship between waist circumference and insulin sensitivity 
This plot shows a negative correlation between increasing waist circumference and insulin sensitivity. 
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3.6.2 CLASS activity questionnaire 
Males and females showed no difference in levels of activity or sedentary behaviour 
times at baseline. Pubertal status did influence these lifestyle behaviours (Table 3.5). 
 
Table 3.5 CLASS leisure and activity data as baseline 
 Total 
N=41 
Males 
N=14 
Females 
N=27 
Early  
Puberty 
N=16 
Late  
Puberty 
N=25 
%Sedentary time week 21.9 ± 12.0 24.8 ± 13.3 20.4 ± 11.1 20.0 ± 6.4 23.4 ± 14.4 
%Active time week 4.6 ± 3.1 5.1   ± 3.5 4.3   ± 3.0 4.2   ± 3.0 4.8   ± 3.3 
Active time (min) 460 ± 317 513 ± 356 433 ± 299 418 ± 297 487 ± 333 
Sedentary time week 
(min) 
2208 ±1206 2500 ± 1342 2057 ± 1126 1975 ± 641 2358 ± 1452 
 
Completion of the CLASS questionnaire in 41 participants at baseline showed no 
difference in activity or sedentary times for boys and girls. However, % time engaged in 
sedentary activities far exceeded %active time per week, which amounted to <5% in all 
participants. 
 
3.7 Correlations between metabolic indicators and 
anthropometry 
 
Increased anthropometry measures (BMI, WC, WtHR) were positively correlated with 
greater insulin resistance (HOMA-IR) and adverse lipid profile with increased TG. 
Increased TG showed positive association with hepatocyte injury with increase in 
transaminases (AST and ALT). An inflammatory state was associated with increased BMI, 
elevated SBP and insulin resistance (HOMA-IR) at baseline as shown in Table 3.6. 
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Table 3.6 Correlation between metabolic profile indicators at baseline 
 
 WH Waist 
HOMA-
IR 
TG HDL LDL TG AST ALT SBP DBP CRP 
 BMI z-
score 
0.755** 0.646** 0.346* 0.378* NS 0.335* NS NS NS NS NS 0.318* 
 W/H  0.889** 0.342* 0.431** 0.453** 0.362* NS NS NS NS NS NS 
 Waist   0.383* 0.401** 0.372* 0.384* NS NS NS NS NS NS 
 HOMA-
IR 
   NS NS NS NS NS NS NS NS 0.431** 
 TC     NS 0.891** 0.503** NS NS 0.325* NS NS 
 HDL      NS NS NS NS NS NS NS 
 LDL       NS NS NS 0.316* NS NS 
 TG        0.346* 0.331* NS NS NS 
 AST         NS NS NS NS 
 ALT          NS 0.433** NS 
 SBP           0.523** 0.435** 
 DBP            NS 
Pearson’s correlation coefficient significance ≤0.01** (2 tailed); * ≤0.05 (2 tailed) NS not significant 
BMI Body mass index WtHR waist to height ratio HOMA-IR Homeostasis model assessment of insulin resistance TC Total 
cholesterol HDL High-density lipoprotein-C LDL Low density lipoprotein TG Triglycerides AST Aspart Transaminase ALT Alanine 
transaminase SBP Systolic blood pressure DBP Diastolic blood pressure 
 
 
 
3.8 Discussion 
 
The results in this chapter present a cross sectional snapshot of the unique metabolic and 
ethnographic risk factors of the overweight adolescent living in Greater Western Sydney.  
 
The study population was derived from a multi-ethnic demographic of GWS. More than 
80% of the study participants had origins from populations considered to be at high risk 
of the metabolic syndrome 501 with only 19% identifying as Caucasian. Almost one third 
of adolescents in this study were from a Middle Eastern or North African background 
(Figure 3.3). The prevalence of high-risk ethnicities within our cohort demonstrates the 
genetic susceptibility to insulin resistance and components of the metabolic syndrome 502.  
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A family history of cardiovascular risk factors and T2DM is known to contribute to 
individual disease risk 503-505. In the VIBRATE cohort, there was clustering of the 
metabolic syndrome in both first and second-degree relatives; obesity was more 
prevalent in first-degree relatives and the metabolic sequelae of obesity (T2DM, HT and 
CVD) in second degree relatives (Figure 3.6). For overseas born Australians, those born 
in South Eastern Europe, North Africa and the Middle East are considered to be at 
higher risk of developing T2DM 506. Holdenson et al also included the South Pacific 
Islands, Central and Southern Asia in their evaluation of high-risk ethnicities. Of concern, 
the prevalence of T2DM in Middle Eastern and North African adults was highest 
amongst all groups in Australia with odds ratios of 3.60 and 2.43 for males and females 
respectively 501. The ethnicities of the insulin resistant adolescents in our study almost 
mirror the local Australian data in adults.  
 
Within our cohort, eight participants had an overweight mother and ten reported an 
overweight father; six participants reported that both parents were obese. Whilst 
multifactorial, the inheritance of obesity is likely to be high with parental obesity more 
than doubling risk of developing overweight in later life 174. Some studies suggest that 
childhood obesity is closely aligned to parental weight status 47 507-509, however we did not 
see this in our study and this may be due to the body composition differences in our 
multicultural cohort with a predominance of central adiposity. 
 
The prevalence of T2DM in the extended family of our participants was increased with 
30.2% of first-degree and 60.5% of second-degree relatives reportedly with the disease 
(Figure 3.6). Our results are consistent with other studies, showing a strong genetic 
inheritability of T2DM, whereby children are more likely to be overweight or obese, if 
the parental BMI particularly maternal weight is increased 54 174. Our data may also 
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provide some insight into the timeline of pathogenesis of T2DM and cardiovascular 
disease progression with the first appearance of obesity and insulin resistance in 
adolescence and early adulthood and loss of compensatory changes and the development 
of T2DM and cardiovascular disease in the second generation. A parental history of 
T2DM has been found to increase prevalence of BMI and other adverse anthropometric 
measures such as increased WC)510, skinfold thickness and BMI 511, a similar association 
has been seen in children whose parents have the metabolic syndrome 512.  
 
Female adolescents accounted for 67.4% of our study population and this may be related 
to several factors including: the differences in health seeking behaviours amongst males 
and females and the differential perception of weight as an issue between the genders.  
Females are more likely to seek medical attention throughout life and these behaviours 
are often developed during adolescence. Adolescent females have a more accurate 
perception of their weight status 513 514 515 516 517 compared to adolescent males and 
therefore more likely to seek assistance through weight loss programs or try to lose 
weight 517.  
 
Weight perception is multifactorial and includes cultural and social influences. The 
perception of the weight as a marker of attractiveness 518 may encourage recruitment of 
female adolescents into weight related research programs, however we did not examined 
this in our study. Parental concern is a major determinant in weight management of the 
young person 519. Studies have shown that parents are more likely to raise concerns about 
their overweight in their daughters 520, if they themselves are obese or suffer from a 
chronic disease 56. Overweight adolescents in general have more difficulty discriminating 
their weight status compared to obese individuals but females were more likely to 
accurately perceive their weight as being above the healthy weight range 521. Recognition 
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of overweight is a fundamental step towards weight loss through lifestyle and 
behavioural change.  
 
In addition to external concerns about body weight, many overweight adolescents are 
referred for tertiary investigation due to the presence of acanthosis nigricans (AN), a 
significant and sometimes unsightly discolouration of the skin in visible area. 
 
Gender attitudes to healthcare could explain differences we observed during the 
recruitment phase. Australian and international studies show that adolescent females 
were more likely to seek help from their close relatives or a health practitioner compared 
to their male counterparts. Booth et al found that late adolescent males aged 13-16 years 
were least likely to access health care 522. During the adolescent period, males access 
health care less frequently than females whose health seeking behaviours show an 
increased uptake 523. 
 
There are many socio-cultural determinants of weight. These ethnic differences in weight 
perceptions may positively and negatively influence the health related behaviours of 
adolescents 513. We had a disproportionate number of individuals from ethnic minority 
groups and most of the participants 81.4% presented with a BMI in the obese range 
(Table 3.2). It raises the question about the late presentation of these children rather than 
at the earliest signs of overweight.  The delay in presentation may be due to self and 
family perceptions of overweight 57 56. Weight may be gauged comparatively to relatives 
and hence not considered to be an issue. In a large study by Brener et al, a quarter of 
overweight individuals self-reported in the underweight range 514. Within cultural groups 
there may be disparate views of increased weight. In the USA, African American (AA) 
women were more likely to accept a higher BMI as being the norm compared to white 
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counterparts 524, whilst obese Hispanic adolescent males were misperceived by family as 
being of normal weight 57. Increased body weight has been considered a sign of health 
and prosperity particularly in the Pacific nations 525 and this may delay presentation to 
health professionals until co-morbidities develop. A majority of the participants derived 
from a Middle Eastern background, where traditionally and for religious reasons many 
are unable to participate in physical activity 526, whether these reasons continue to be 
relevant for second generation Australian children remains to be determined.  
 
The average BMI in our participants was in the obese range by adult standards at 
31.5kg/m2. As BMI does not account for the percentage or distribution of body fat, it 
has been suggested that Indigenous Australians and those from an Asian background 
have lower BMI thresholds for overweight and obesity to reduce cardiovascular risk 527. 
This is because they have a higher percentage of body fat than white people for the same 
age, sex and BMI 67. Ethnicity is also a determinant of body shape and composition and 
may account for the increased waist circumference in both males and females in our 
study. The average waist circumference of 102cm is in excess of the national adult 
recommendations 14. In addition to lower BMI thresholds for high-risk populations, the 
waist circumference measure is likely to provide a better assessment of metabolic risk 
and adverse adiposity. 
 
The average fasting insulin level in the group was 203pmol/L (33.8mU/L), much higher 
than the inclusion criteria to the study of 90pmol/L (15mU/L) (Table 3.4). Whilst there 
are no paediatric reference ranges, levels greater than 20mU/L are likely to signify high 
insulin resistance in a child 285. The HOMA –IR at baseline was high averaging 7.62, 
higher than the cut-offs (5.22 and 3.82 pubertal boys and girls) proposed by Kurtolglu 528 
and considerably higher than the suggested adult limit of 2.5 266 288. WBISI was low at 
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1.74 with levels <2.5 suggestive of insulin resistance 266; some researchers suggest that the 
degree of insulin resistance is more closely linked to metabolic risk 529. Six participants 
(14%) (Figure 3.9) in our study already had evidence of impaired glucose tolerance (IGT), 
a pre-diabetic state suggesting that progression to T2DM may occur more quickly in this 
age group and require more aggressive intervention 61 192. Since the start of our study, an 
international working party 280 has indicated that the fasting insulin and proxy measures 
poorly define individual risk of insulin resistance likely due to pulsatile variation and 
physiological changes during puberty.  
 
There was a high prevalence of the metabolic syndrome in our study population ranging 
from 23-44% (Figure 3.5) depending on the various definitions applied, this is not an 
unexpected finding given the interrelationship between the pathophysiology of insulin 
resistance and the metabolic syndrome. We also identified more pubertal than pre-
pubertal individuals with metabolic syndrome indicating that even earlier recognition and 
action during childhood may be required to prevent metabolic decline during 
adolescence. 
 
There is no standard definition of the metabolic syndrome in children, therefore use of 
adult guidelines may lead to under or overestimation of the actual prevalence depending 
on the cut off levels. In addition, the effect of puberty should be considered in any 
definition of the metabolic syndrome in an adolescent due to presence of physiological 
insulin resistance and variability in metabolic profile indicators 118. Our data is consistent 
with overseas studies of high-risk paediatric populations where prevalence rates of the 
metabolic syndrome ranged from 33-39% 530 499 498. In the USA, AA children, who are at 
high metabolic risk of T2DM may not be correctly identified because of less 
dysglycaemia 531. Therefore in some populations with known high risk treating known 
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CVD risk factors may prove more beneficial to future health than waiting for the a 
clustering of components that fall under the umbrella of the metabolic syndrome 531. 
 
A strong association between puberty and metabolic health occurs in overweight and 
obese children. The hormonal milieu associated with puberty has been shown to convert 
previously metabolic healthy obese (MHO) children into metabolic unhealthy obese 
(MUO) children 117. A considerable proportion of participants in the study were female 
and a greater majority of patients were pubertal which has possibly conferred an 
additional metabolic stress. Interestingly, the modified NCEP III-ATP definition of the 
metabolic syndrome identified a greater proportion of female participants with the 
metabolic syndrome. This definition had the lowest cut off for triglycerides compared to 
the other definitions presented in this thesis. Therefore consideration of the triglyceride 
fraction may be another discriminating factor and assist to correctly identify those at 
highest risk.  We did not see any difference between serum lipids in early or late puberty 
but it is known that gender differences in the lipid profile develop during this time with 
reductions in the HDL-C in males 532. The changes in the various lipid fractions may be 
influenced by sex steroid hormones particularly testosterone 533.  
 
All adolescents in our study classified with dark skin (Fitzpatrick Type IV to VI) 478 
presented with the dermatological finding of AN, whereas this was absent in children 
with light skin. This indicates that whilst AN may be a reliable clinical indicator of 
underlying insulin resistance in dark skinned individuals 300, children from a Caucasian 
background or who have lighter skin may be missed and not referred for further 
evaluation by primary health care providers. 
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Adolescent females in our cohort had a lower absolute diastolic blood pressure (DBP) 
compared with males who had a higher SBP z score (Table 3.3). The difference in SBP 
between the genders is expected, as sexual dimorphism in this trait is known to have 
origins in adolescence. This result may also suggest later hypertension in males could be 
prevented by lifestyle modification during the adolescent years. At baseline, we 
discovered a high prevalence of prehypertension (19% of cohort) and Grade 1 systolic 
(24%) (Figure 3.8) and diastolic (24%) hypertension (Figure 3.7), particularly in pubertal 
males 534. The recognition of hypertension is important in young people as it is co-
morbidly seen in one quarter of youth with T2DM 535 and may accelerate atherosclerotic 
processes 536. The Framingham Heart Study showed that DBP was the best predictor of 
coronary events later in life in younger people compared to the SBP (more predictive of 
events in older persons) 537, indicating that closer consideration to both blood pressure 
components may be required in younger persons. One of the limitations to our BP data 
is that we used an automated blood pressure method rather than the manual technique 
that would have allowed better discrimination of the fourth and fifth Korotkoff sounds 
and DBP 534. Also, we only measured BP on one occasion rather than at different time 
points. The use of ambulatory blood pressure monitoring would have allowed us to 
better evaluate this cardiovascular risk factor and remove the element of “white coat 
hypertension” which is often present in a clinical setting. 
 
The mean AST level was increased in both genders and across pubertal stages in our 
participants. Elevated transaminases are a surrogate indicator of non-alcoholic fatty liver 
disease (NAFLD), strongly clustering with obesity and T2DM. We found that ALT levels 
positively correlated with total cholesterol and triglycerides in both sexes but seemed to 
do so more strongly in boys. The male participants had significantly higher mean ALT 
levels when compared with females. Our reference range for ALT is not gender 
   
  CHAPTER 3 METABOLIC CHARACTERISTICS 
118 
dependent and some have proposed that lower thresholds: ALT>30IU/L and 19IU/L 
for boys and girls, respectively, as males have higher liver enzymes than females 538 539. 
Using these gender specific cut off values a disconcerting number of participants: 20/29 
females and 11/14 males raised transaminases however, our in house reference range 
demonstrated only 5 participants with an elevated ALT level above the normal range.  
 
The clinical significance of these results cannot be determined given we did not perform 
contemporary liver ultrasounds. NAFLD is a recognised complication of rising obesity 
rates in young people and is associated with elevated liver transaminases. Nadeau et al 540 
found a prevalence of 14.3% elevated ALT and 14.3% elevated AST with a higher 
occurrence in Hispanic and in males. The aetiology of NAFLD remains unclear however 
accumulation of triglycerides within the hepatocyte is a key pathogenic step in this 
disease 541. We showed a positive correlation between triglycerides and to a lesser extent 
total cholesterol and liver transaminases (ALT and AST) which is similar to other studies 
that have shown hypertriglyceridemia as significant risk factor for NAFLD 540. Dietary 
checklists were completed at baseline but were found to be incomplete and based on 
recall and therefore not reliable for analysis.  
 
Participants had an inactive lifestyle as evidenced by low activity times and high 
percentage of sedentary behaviours with small screen times exceeding 2 hours per day. 
Inactivity is associated with increased weight, adverse lipid profile, elevated systolic blood 
pressure and T2DM 542-545. The cardiorespiratory fitness of the participants is further 
evaluated in Chapter 6.  
 
The implementation of lifestyle change in children may alleviate the later health burden 
expected due to cardiovascular disease and the metabolic syndrome. The American Heart 
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Association (AHA) Scientific Statement on Cardiovascular Health in Childhood 
recommended that key lifestyle factors be addressed to improve the cardiovascular health 
of children and adolescents. The areas targeted for improvement included: regular 
physical activity with a reduction in sedentary activity; weight management and dietary 
counselling; clinical assessment of insulin resistance and T2DM risk; early detection and 
management of hypertension and dyslipidaemia 285. Ho and colleagues confirmed that 
metabolic risk factors could be ameliorated through lifestyle interventions which 
included dietary modification with a structured supervised exercise program potentiating 
these effects 154. Clinicians should encourage young adolescents to be physically active as 
a decline in fitness into adulthood is linked to T2DM 546 and health practitioners may 
need to be mindful of peers, family and neighbourhood when encouraging behavioural 
change 145. 
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CHAPTER 4  
Does Whole Body Vibration Training improve insulin 
sensitivity in overweight adolescents? 
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4.1 Introduction and Aims 
 
Overweight remains a major health concern in Australian adolescents 547 33 despite 
national 7 and international evidence 548 to suggest rates are stabilising.  With the rise in 
obesity there has been a significant increase in the prevalence of metabolic co-
morbidities including insulin resistance, a known precursor to the development of 
T2DM, metabolic syndrome and early CVD 549 550. Early recognition and management of 
those at risk of T2DM can prevent disease progression. Physical activity, lifestyle change 
and selected pharmacotherapy may enhance Si through weight loss 280 and through 
weight independent body composition change 328 551. 
 
Whilst there are many metabolic and other health benefits of exercise 552, the most 
appropriate type of physical activity for young people at risk of T2DM remains to be 
elucidated 553. Aerobic or anaerobic exercise may enhance metabolic health due to effects 
on different physiological pathways which may occur independent of weight loss 328 551. 
Increased muscle mass may increase the peripheral glucose disposal of glucose but an 
exercise regime which involves an aerobic component may cause changes in the ability of 
the muscle to response to insulin through post receptor binding effects. Enhanced Si, 
with weight loss and exercise are likely to have different physiological mechanisms 554. 
  
Whole body vibration training is a form of resistance training that has received a lot of 
recent interest regarding its possible weight loss benefits, purported to occur with 
minimal effort and maximal efficiency. However, interventional research studies in adults 
have only demonstrated at best, very modest 355 555 fat loss. Similar to other forms of 
resistance training, WBVT leads to muscle activation 556 inducing changes in muscular 
strength, performance 404 and metabolism 557. Muscle plays a key role in post-prandial 
glucose disposal 558 and certainly studies in adolescents have demonstrated that changes 
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at the muscle level may be associated with enhanced insulin sensitivity 337 559. There are no 
studies examining the possible effect of WBVT on glucose regulation. Therefore we 
explored whether WBVT would improve insulin sensitivity in obese adolescents with 
clinical insulin resistance either with associated body composition change or independent 
of weight loss when compared to a lifestyle intervention.  
 
The management of obesity in young people is challenging and therefore, an examination 
of the adherence and retention of participants in our study will be discussed to advise 
future obesity intervention programs. The results for the primary outcome of insulin 
sensitivity and secondary effects on the anthropometry and metabolic profile indicators 
will be provided in this chapter. The effects of WBVT on musculoskeletal architecture 
and turnover and body composition will be discussed in Chapter 5. The effects of the 
intervention on functional performance indices of cardiorespiratory fitness and muscle 
performance will be examined and discussed in Chapter 6. 
 
 
The primary aim of the study was to test within an RCT the hypothesis that three 
months of whole body vibration training in addition to a prescribed diet and exercise 
intervention would enhance the effects of the lifestyle interventions by improving insulin 
sensitivity in overweight adolescents with hyperinsulinaemia. The details of the 
randomised groups can be seen in Chapter 3. We speculated that the WBVT intervention 
would increase muscle mass in the lower limbs and would enhance peripheral non-
insulin mediated glucose uptake compared to those adolescents who received lifestyle 
intervention (diet and exercise) alone. Secondary effects on anthropometry, body 
composition and metabolic profile indicators will also be examined in this chapter. 
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4.2 Participant flow during the trial 
 
The recruitment inclusion and exclusion criteria for the study have been previously 
discussed in Chapter 2.1.3. Fifty three adolescents were assessed for study eligibility, one 
adolescent declined to participate, three failed to attend baseline investigations on two 
separate occasions and six did not meet inclusion criteria as follows: one adolescent was 
diagnosed with T2DM during baseline investigation; four had fasting insulin levels 
outside the specified range and one adolescent had a weight greater than 120kg.  
 
The study opened in June 2008 with the aim of enrolling forty-eight participants and 
closed to recruitment in October 2010 after permission from the local ethics committee 
due to a lower than anticipated dropout rate. Forty-three participants were randomised 
into the study by minimisation 473, 22 participants were allocated to the standard lifestyle 
intervention with all receiving this intervention over 3 months as per protocol. One 
participant in the standard arm declined to attend for final testing due to higher school 
examinations. All 21 participants allocated to the WBVT intervention completed the trial.  
Gender and pubertal status were equally represented in the two intervention arms. A 
CONSORT (Consolidated Standards of Reporting Trials) flow diagram 560 561 can be seen 
in Chapter 2 (Figure 2.1). 
 
The study had high 3-month retention with a dropout rate of just 2.3%, considerably less 
than the anticipated attrition rate of 40%.  
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4.3 Intervention effects 
4.3.1 Effect on anthropometry and body composition 
a. Anthropometry 
 
Baseline anthropometry can be seen in Table 4.1. At the start of the study, the two 
intervention groups were homogeneous to anthropometry measures. 
 
 
Table 4.1 Anthropometry at baseline and 3 months 
 Baseline 3 months 
 Lifestyle Vibration P value Lifestyle Vibration P value 
N 22 21  21 21  
Age (years) 13.25 ± 2.13 13.41 ± 2.11 0.80 13.36 ± 2.0 13.74 ± 2.12 0.60 
Gender. No. (%)       
     Female 15 (68.2) 14 (66.7) 0.92 14 (66.7) 14 (66.7)  
     Male 7 (31.8) 7 (33.3)  7 (33.3) 7 (33.3)  
Height (cm) 160.7 ± 9.9 162.5 ± 8.3 0.52 161.5 ± 9.9 163.5 ± 8.3 0.45 
Weight (kg) 81.6± 19.1 83.4 ± 11.1 0.70 79.4 ± 18.9 84.3 ± 12.3 0.32 
BMI (kg/m2) 31.4 ± 5.9 31.6 ± 4.2 0.90 30.4 ± 6.3 31.5 ± 4.54 0.29 
BMI z-score 2.10 ± 0.5 2.14 ± 0.4 0.79 2.00 ± 0.5 2.14 ± 0.38 0.38 
Waist (cm) 102.4 ± 14.8 102.5 ± 8.8 0.97 98.6 ± 16.1 100.9 ± 10.2 0.57 
Waist-height-ratio 0.64 ± 0.1 0.63 ± 0.1 0.80 0.62 ± 0.1 0.62 ± 0.1 0.80 
Data presented as mean ± SD  * indicates a significant result p<0.05   ** indicates a significant result p<0.01 Student t test 
 
Between group differences 
The effect of the interventions on anthropometry can be seen in Table 4.2.  
There was a tendency to greater raw and z-score weight loss in the lifestyle group when 
compared to the vibration arm although these results did not reach significance (p=0.08 
and p=0.07 respectively). Lifestyle change resulted in a significantly reduced BMI z-score 
-0.1 (p=0.039), with decreased absolute BMI -0.8kg/m2 (p=0.05); there were no 
significant changes in height between the two groups at the end of the study p=0.5, 
suggesting that the weight loss in the lifestyle group contributed to the observed BMI 
changes.  
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Table 4.2 Absolute 3-month treatment effects on anthropometry 
Δ change over 3 months 
 
Lifestyle WBVT P value 
Weight (kg) 
 
-0.9  ± 3.7 0.9 ± 2.7 0.08 
Weight z-score -0.04 ± 0.1 0.02 ± 0.1 0.07 
Waist (cm) 
 
-2.8  ± 4.2 -1.5 ± 3.4 0.6 
Waist/height ratio (<0.5) -0.02 ± 0.03 -0.01 ± 0.02 0.25 
Height (cm) 1.1 ± 0.9 1.2 ± 1.0 0.5 
BMI (kg/m2) -0.1 ± 0.1 -0.02 ± 0.1 0.05 
BMI z-score -0.8 ± 1.2 -0.08 ± 0.8 0.039* 
Data presented as mean ± SD  * indicates a significant result p<0.05  - independent samples student t-test p<0.05 
 
Measures of central adiposity including waist circumference and waist to height ratio 
were slightly reduced at the end of the study in both groups (Lifestyle -2.8cm vs. WBVT 
-1.5cm; p=0.6) but this did not reach significance. Mean waist circumference remained 
elevated in both groups at the end of the trial (98.6 cm vs. 100.9 cm; p=0.570, Lifestyle 
vs. WBVT) in excess of the national Australian guidelines for adult males and females 1. 
 
Lifestyle effects 
When the groups were examined separately and longitudinally, there were significant 
changes pre and post intervention in anthropometry including reductions (mean ± % 
change) in waist circumference (-2.82cm, -2.8%; p=0.005); WHR (-0.02, -3.1%; p=0.001) 
and absolute BMI (-0.8kg/m2, -2.6%; p=0.009). In contrast, the only significant change 
in the WBVT group was a lower waist to height ratio (-0.01, -1.6%; p=0.008). As 
expected during adolescence, both groups demonstrated linear growth after 3 months 
with significant changes in height (1.2 cm, 0.8%, p<0.01) vs. (1.1cm, 0.7%; p<0.01) in 
the WBVT and lifestyle groups respectively. 
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DXA 
Table 4.3 Adiposity at baseline for the total cohort and intervention groups 
 
DATA PRESENTED AS MEAN (SD) * SIGNIFICANT RESULT STUDENT T TEST P<0.01 OR **P<0.001 WITH COMPARISON 
MADE BETWEEN GENDER IN EACH GROUP I.E. TOTAL, LIFESTYLE AND VIBRATION. N=42 GROUP TOTAL AS ONE 
PARTICIPANT IN LIFESTYLE ARM WAS UNABLE TO HAVE DXA SCAN. 
 
 
 
 
b. Body composition change between the groups 
At baseline, females had more total and trunk fat compared with males as shown in 
Table 4.3.  Males in the lifestyle group has significantly less total and trunk fat compared 
with females in this group. In the vibration group, males had greater fat z-score 
compared with females at baseline.  
 
The significant decrease in BMI z score in the lifestyle group, did not result in altered 
body composition with no change in total body fat or lean tissue as seen in Table 4.4. 
Participants who performed the WBVT training showed considerable but non-significant 
gains in total lean tissue mass 184.6 g (lifestyle) vs. 588.4g (WBVT); p=0.500) as seen in 
Table 4.5.  
 
 
Total 
N=42 
Lifestyle 
N=21 
Vibration 
N=21 
Gender M 
N=13 
F 
N=29 
M 
N=6 
F 
N=15 
M 
N=7 
F 
N=14 
%Total fat 38.1 (7.4) 47.5 (6.3)* 34.3 (6.3)* 49.4 (4.6) 43.4 (4.6) 46.1 (6.2) 
Fat z-score 3.2 (1.1) 3.1 (0.8) 2.7 (0.9) 3.4 (0.7) 4.0 (0.7)** 2.9 (0.8) 
%Fat trunk 40.9 (6.4) 49.1 (5.1)* 37.5 (7.1)** 50.5 (4.5) 43.8 (4.1) 47.7 (5.4) 
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pQCT 
pQCT analysis revealed significantly decreased muscle fat cross-sectional area at the 66% 
site in the lower limb in the LIFESTYLE arm,  -175.7mm2 vs. -16.9mm2 ; p=0.029. 
Conversely, greater increases in muscle cross-sectional area were seen in the 
VIBRATION group 153.4mm2 vs. 73.4mm2, but this was not significant p=0.559. 
 
Table 4.4 Change in DXA body composition measures after 3 months 
Data mean ± SD Lifestyle Vibration P value 
    
Total body fat (%) -0.94 ± 2.37 -0.14 ± 1.82 0.229 
Trunk fat (%) -0.83 ± 3.50 0.33 ± 2.65 0.234 
Trunk lean tissue mass (g) 19.76 ± 1464.49 114.1 ± 1186.84 0.820 
Total lean tissue mass (g) 184.57 ± 2142.39 588.44 ± 1678.04 0.500 
Lean tissue mass/ height z-score -0.25 ± 0.81 -0.09 ± 0.43 0.431 
Leg fat (%) -1.03 ± 2.10 -0.75 ± 1.67 0.637 
Leg lean tissue (g)  38.18 ± 726.19 411.49 ± 562.92 0.070 
Data presented as mean ±SD Independent samples Student t test 
 
 
 
 
 
Table 4.5 Within group soft tissue change 
 Lifestyle Vibration 
Parameter Pre Post ∆ change Pre Post ∆ change 
Total fat % 45.1 (8.6) 44.1 (9.0) -1 (1.2) 45.2 (5.7) 45.0 (6.7) -0.1 (1.0) 
Total fat 
z-score 
3.2 (0.8) 3.0 (0.8) -0.2 (0.3)* 3.2 (0.9) 3.2 (1.0) 0.0 (0.2) 
Trunk fat % 46.8 (8.0) 46.0 (8.1) -0.8 (3.5) 46.4 (5.2) 46.7 (6.5) -0.3 (2.6) 
LTM/ Ht 
z-score 
1.6 (2.4) 1.4  (2.4) -0.3 (0.8) 1.8 (1.9) 1.7 (1.9) -0.1 (0.4) 
Leg fat% 47.4 (10.1) 46.4 (11.0) -1.0 (2.1)* 48.0 (7.1) 47.2 (7.7) -0.8 (1.8) 
Legs LTM (g) 14460 (3466) 14498 (3320) -38 (727) 14869 (1938) 15280 (2150) 412** (562) 
Mean (SD) * significant result independent Student t test p<0.05 ** p<0.01 comparing pre/post values in each group 
LTM/Ht Lean tissue mass for height 
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4.3.2 Effect on insulin sensitivity and related parameters 
At baseline there were no significant differences between the intervention groups for 
insulin sensitivity, glucose or insulin (Table 4.6).  Both groups were highly insulin 
resistant with (mean ± SD) HOMA-IR score 7.6 (2.9) vs. 7.6 (2.1) and demonstrated 
reduced insulin sensitivity with calculated WBISI 1.9 (0.9) vs. 1.6 (0.8); p=0.4, in the 
lifestyle and WBVT groups respectively. 
 
Within group longitudinal analysis revealed clinically favourable albeit non-significant 
changes in insulin sensitivity within the lifestyle group with improved final HOMA-IR 
and WBISI (Table 4.7) 
 
Table 4.6 Baseline and final insulin sensitivity and glycaemic markers 
 Baseline Final 
 
Lifestyle WBVT P value Lifestyle WBVT P value 
Fasting 
glucose 
(mmol/L) 
 
5.1 ± 0.5 4.9 ± 0.3 0.2 4.8 ± 0.6 4.9 ± 0.4 0.6 
Fasting  
Insulin 
pmol/L 
 
200 ± 62 207 ± 56 0.7 189 ± 105 236 ± 95 0.1 
HOMA IR 
 
7.6 ± 2.9 7.6 ± 2.1 0.8 6.9 ± 4.6 8.6 ± 3.7 0.2 
WBISI  
 
 
1.9 ± 0.9 1.6 ± 0.8 0.4 2.1 ± 0.9 1.7 ± 0.9 0.2 
Acanthosis 
nigricans 
score 
2.36 ± 1.4 2.67 ± 1.4 0.5 2.23 ± 1.3 2.62 ± 1.3 0.3 
 
 
Mean ± SD  independent samples student t-test p 
 
After 3-months, fasting glucose had decreased significantly by -0.3mmol/L (p=0.047) in 
the lifestyle cohort but there were no other significant absolute improvements in insulin 
sensitivity measures as seen in Table 4.7.  
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Table 4.7 Absolute changes in insulin sensitivity and glycaemic markers 
Absolute change over 3 months 
 Lifestyle WBVT p value 
Fasting glucose (mmol/L) 
 
-0.3 ± 0.5 0.00 ± 0.3 0.047* 
Fasting insulin  (pmol/L) 
 
-10  ± 105 -29 ± 99 0.222 
HOMA-IR 
 
-0.98 ± 4.17 0.93 ± 3.17 0.100 
WBISI 
 
0.25 ± 0.46 0.10 ± 0.66 0.537 
 
*significant result - independent samples student t-test p<0.05 
 
Given that compliance was sub-optimal in the WBVT intervention group. The WBVT 
group was divided into high and low compliance groups based on the median of 
platform time usage. A comparison between the high compliance and standard group 
revealed no significant difference in the primary outcome measure, WBISI and the 
lifestyle intervention. However, it must be noted compliance to the lifestyle intervention 
is unknown and based on verbal telephone reports from patient and family. 
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Table 4.8 Metabolic profile indicators at baseline and after 3 months 
 Pre intervention Post intervention Absolute change 
 Lifestyle Vibration P value       Lifestyle Vibration P value ∆Lifestyle ∆Vibration P value 
N 22 21  21 21  21 21  
Age (years) 13.25 ± 2.13 13.41 ± 2.11 0.800 14.79 ± 2.13 15.03 ± 2.27 0.729    
Gender. No. (%)          
Female 15 (68.2) 14 (66.7) 0.918 14 (66.7) 14 (66.7)     
Male 7 (31.8) 7 (33.3)  7 (33.3) 7 (33.3)     
BP systolic (mmHg) 121 ± 14 118 ± 13 0.493 119 ± 11 119 ± 14 0.961 -3 ± 14 1 ± 14 0.916 
BP diastolic (mmHg) 
 
67 ± 8 64 ± 8 0.264 66 ± 9 64 ± 7 0.355 -1 ± 11 -1 ± 10 0.418 
Cholesterol mmol/L          
Total 4.24 ± 0.99 4.14 ± 0.72 0.700 4.11 ± 0.72 4.23 ± 0.54 0.564 -0.2 ± 0.6 0.1 ± 0.4 0.204 
HDL 1.09 ± 0.29 1.10 ± 0.21 0.946 1.05 ± 0.21 1.10 ± 0.16 0.478 -0.04 ± 0.2 0.0 ± 0.2 0.582 
LDL 2.66 ± 0.91 2.60 ± 0.56 0.798 2.57 ± 0.67 2.53 ± 0.45 0.827 -0.06 ± 0.5 -0.01 ± 0.4 0.766 
Triglycerides 
 
1.20 ± 0.62 1.09 ± 0.45 0.515 1.06 ± 0.48 1.25 ± 0.47 0.227 -0.14 ± 0.5 0.14 ± 0.4 0.036* 
Liver function tests u/l          
AST 52 ± 28 58 ± 32 0.523 55 ± 29 65 ± 36 0.344 3 ± 43 7 ± 51 0.768 
ALT 33 ± 19 30 ± 21 0.617 26 ± 16 30 ± 23 0.507 -7 ± 17 0 ± 8 0.139 
C-reactive protein (mg/L) 7.04 ± 8.22 5.10 ± 3.02 0.316 4.70 ± 4.06 5.64 ± 4.85 0.502 -2.6 ± 7.2 0.29 ± 4.3 0.129 
          
Student t test * indicates a significant result p<0.05  ** indicates a significant result p<0.01 groups compared pre/post 
Normal ranges  
Total cholesterol 3.0-5.2mmol/L 
HDL cholesterol 0.8-1.5mmol/L 
LDL cholesterol 1.7-3.4 
Triglycerides 0.6-1.7mmol/L 
AST 10-50 U/L 
ALT 0-45 U/L 
ALP 50-350 U/L 
Glucose range <5.6mmol/L 
C reactive protein <10mg/L 
AST aspart aminotransferase 
ALT alanine aminotransferase
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4.3.3 Effect on metabolic profile indicators 
Adolescents had a normal lipid profile at baseline with mean levels within normal ranges 
for total cholesterol, triglycerides, HDL and LDL cholesterol as shown in Table 4.8 At 
the start of the study 21 (11M) participants had abnormal liver function tests with mean 
AST in both groups outside the normal range 52u/l (28) vs. 58u/l (32), normal range 10-
50, possibly reflecting early liver function enzyme derangements.  
 
Lipid profile improved in the lifestyle group with significant change in triglycerides  
-0.14mmol/L (0.5) vs. 0.14mmol/L (0.4), p=0.036. C reactive protein levels were 
elevated at baseline, consistent with the degree of obesity and insulin resistance, after 3 
months there was an improvement in the lifestyle arm -2.6mg/L (7.2) vs. 0.29mg/L 
(4.34) but this was not significant p=0.1
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Table 4.9 Partial correlations between anthropometry, fasting measures of insulin 
resistance and selected metabolic profile indicators for group at baseline (n=43) 
Controlled variables 
Gender 
Pubertal status 
HOMA IR WBISI Glucose Insulin hs-CRP SBP 
Waist 0.404** -0.479** 0.345* 0.339* NS NS 
Weight 0.495** -0.484** NS 0.375* 0.401* 0.418** 
BMI 0.441** -0.416** 0.468** 0.335* 0.353** NS 
W/H ratio 0.342* -0.408** 0.424** NS NS NS 
HOMA IR  -0.866*** 0.594*** 0.968*** 0.428** NS 
WBISI -0.866***  -0.498** -0.863*** -0.323* NS 
hs-CRP 0.428** -0.323* NS 0.388*  0.463** 
p< 0.05 level (2 tailed) ** p< 0.01 level (2 tailed) ***p<0.001(2 tailed) 
hs-CRP high sensitivity C-reactive protein W/H waist to height ratio HOMA-IR homeostasis model assessment of 
insulin resistance WBISI whole body insulin sensitivity index SBP systolic blood pressure 
 
 
 
4.4 Correlations between anthropometry, insulin sensitivity 
and selected serum metabolic profile indicators 
 
Significant associations between anthropometry measures and insulin sensitivity were 
seen at baseline including: positive associations between HOMA-IR and waist, weight, 
BMI and WtHR ratio; conversely WBISI showed more significant negative correlations 
with the same parameters. Fasting glucose and insulin were also moderately correlated 
with BMI and central adiposity measures (Table 4.9). The hs-CRP, a marker of low-grade 
inflammation was positively associated with increased weight, BMI, systolic blood 
pressure, insulin resistance HOMA-IR and negatively correlated with WBISI. 
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Partial correlations controlling for gender and pubertal status revealed significant 
associations between absolute changes for the entire group (N=42) at the end of the trial 
including: moderate correlation between raw ∆BMI with ∆waist circumference and ∆hs-
CRP. Changes in HOMA-IR were significantly correlated with ∆hs-CRP. The change in 
serum triglycerides correlated with ∆ALT levels. As expected, absolute changes in fasting 
insulin and glucose correlated with changes in the proxy measures HOMA-IR and 
WBISI (which are directly derived from these levels). These results can be seen in Table 
4.10. 
 
Table 4.10 Partial correlations between absolute changes in metabolic variables and 
anthropometry (adjusted for BMI and puberty) 
∆ value Insulin Glucose BMI Waist WBISI HOMAIR ALT hs-CRP 
Insulin - NS NS NS 
0.697**
* 
0.975*** NS 0.478** 
Glucose NS - NS NS NS 0.371* NS NS 
BMI kg/m2 NS NS - 0.409** NS NS NS 0.419** 
WBISI -0.697*** NS NS NS - -0.645*** NS NS 
Waist cm NS NS 0.409** - NS NS NS 0.466** 
hs-CRP 0.478**  0.419** 0.466** NS 0.493** NS - 
TG NS NS NS NS NS NS 
0.346
* 
0.346* 
p< 0.05 level (2 tailed) ** p< 0.01 level (2 tailed) ***p<0.001(2 tailed) 
All bloods reported are fasting measures 
BMI body mass index WBISI whole body insulin sensitivity index  
HOMA IR Homeostasis model assessment of insulin resistance 
ALT Alanine transaminase hs CRP C-reactive protein  
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4.5 Side effects, adherence to intervention and safety  
 
No adverse events were recorded in either intervention arm; this was monitored during 
the fortnightly phone contact. Participants were encouraged to be compliant to the 
allocated intervention via a standard phone coaching method. Adherence to the lifestyle 
component of the study was obtained verbally during the phone contact.  
 
Compliance to the vibration intervention ranged from 50 minutes (7%) to 1353 minutes 
(183%). The mean compliance time as determined from the inbuilt timer and vibration 
diary entries averaged 460 ± 325 minutes (mean ± SD). Full compliance to the training 
program was indicated by a training time of 743 minutes. Three (14%) participants were 
fully compliant to the therapy and a further 3 adolescents (14%) were poorly adherent to 
the prescribed regime with <25% of predicted platform use. Males had a higher average 
use of the platform, 72% versus 58%, but this was not significant.  
 
 
4.6 Discussion 
 
In this randomised control trial, we investigated whether a novel resistance based 
exercise, whole body vibration training (WBVT), could enhance insulin sensitivity Si in 
our cohort of obese adolescents with clinical insulin resistance. To our knowledge, this is 
the first randomised control trial designed to investigate the metabolic and 
anthropometric effects of WBVT in the obese adolescent population.  
 
Our results confirm the benefit of lifestyle intervention in the management of paediatric 
obesity with significant BMI reductions in those who received this treatment, exclusively. 
The study also demonstrated that significant changes to anthropometry measures are 
possible in a relatively short time period and in real life settings, with only occasional 
therapeutic contact. Our results are applicable to the real life setting. For example, an 
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exercise prescription incorporating the NHMRC guidelines 14 along with nutritionist 
involvement may assist in BMI reduction in the obese adolescent in the primary care 
setting. 
 
The addition of WBVT to standard lifestyle prescription did not enhance insulin 
sensitivity and did not lead to additional weight loss but did lead to an increase in 
peripheral lean tissue mass within this group at the end of the study. 
 
Our results are not surprising, given that lifestyle change with adjunctive use of 
pharmacotherapy is regarded as first line in the management of paediatric obesity and 
insulin resistance 280 154. In established cases of paediatric T2DM, a combination of 
metformin plus lifestyle intervention did not result in weight loss and was not more 
effective than metformin monotherapy. Both the aforementioned treatments were less 
effective than dual pharmacotherapy with rosiglitazone and metformin. This highlights 
the need for a multipronged approach to T2DM but may indicate that the disease 
process is more aggressive in younger patients and needs to be managed accordingly 562.  
 
After 3 months, those participants in the lifestyle arm demonstrated a BMI change of  
-0.8kg/m2 (-2.6%) equating to a significant BMI z score change of -0.1 (-4.8%), this 
result is comparable to a recent study in obese adolescents which showed BMI SDS 
change of -0.1 to -0.2 563 with an unsupervised home based intervention over a longer 
period of 8 months. The observed BMI loss in our lifestyle arm was accompanied by 
minimal change in body composition with only a slight loss of total body fat ~1% 
(p=0.229). Paediatric studies have determined that a BMI z-score change of 0.25 equates 
to a fat loss of 2.9% 564 and certainly our results show equivalence with these data. A 
study from our own centre with a supervised physical activity component demonstrated -
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6.8% and -2.4%, BMI and %fat loss, respectively and improved WBISI score of 0.2 152 
after 1 year. 
 
The decreased BMI within the lifestyle group was associated with significant pre and post 
group changes in central adiposity (WC and WtHR) and body composition (lower total 
fat z score). Within the WBVT group, the only significant difference in anthropometry 
pre and post intervention was the WtHR, which in the absence of significant BMI may 
be attributed to increased linear growth, which occurred similarly in both adolescent 
groups. It is interesting that whilst both groups were provided the same lifestyle program 
the WBVT group did not show appreciable change in BMI. The WBVT intervention 
may have been viewed as a “magic cure” and easy method of weight reduction and may 
have influenced compliance to the lifestyle intervention in this group.  
 
In agreement with the literature, we showed that positive BMI changes were associated 
with clinically favourable albeit non-significant enhancements in insulin sensitivity in the 
lifestyle participants 332 563 154 152 with improved WBISI (0.25 versus 0.10; p=0.537) and 
HOMA IR (-0.98 versus 0.93; p=0.2) in the lifestyle and WBVT groups, respectively. 
Our results are similar to other paediatric studies which show that metabolic health 
parameters can be improved without significant differences in anthropometry or body 
composition 328 329 563 551.  
 
Lifestyle intervention with an exercise and dietary component resulted in lower fasting 
blood glucose levels (p=0.047) at the end of the study, this is similar to observations in 
obese adults which have shown reduced hepatic insulin resistance and lower glucose 
production with exercise training and caloric restriction 565. The significant changes in the 
fasting glucose may represent an improved metabolic health status and reduced diabetes 
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risk as research has shown that glucose levels within the normal range correlate with 
cardiovascular health in children and adults 196 and may indicate progression to T2DM in 
adulthood 566 197. 
 
We hypothesised that WBVT would lead to regional changes in body composition with 
greater accrual of lean tissue mass in the lower limbs with possible increased peripheral 
glucose disposal through non-insulin dependent mechanisms. We also believed the 
exercise could serve a dual purpose by increasing muscular strength 400 and allow for 
more active participation in physical activity. As we did not directly observe the physical 
activity of the participants during the trial, it remains unclear whether WBVT had any 
conditioning effect in these adolescents. However, speculated changes in lean tissue were 
observed after three months in this group. We found that total lean body tissue increased 
by 588g (WBVT) vs. 185g (Lifestyle); p=0.50. When pre and post intervention levels 
were compared within the WBVT group, lean tissue increased in the legs by 412g (2.8%) 
above baseline (P=0.003). Further results regarding muscle and bone change will be 
discussed in Chapter 5. This resistance exercise did not show any effect on adipose 
tissues measures on DXA analysis. 
 
Our results are consistent with data from Roelants et al 353 that showed a 2.2% increase in 
lean tissue with 24 weeks of WBVT in a similarly untrained cohort, with no change to fat 
parameters. Whilst our results are consistent with the above, they are discordant with 
small animal 351 and recent adult studies showing modest loss in VAT 448 and improved 
anthropometry with WBVT 355. The significant gains in peripheral lean tissue may well 
have been due to a direct effect of this form of training on muscle spindles and enhanced 
neuromuscular excitation 387 567.  
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Lean tissue changes in the lower limbs were accompanied by changes measurable on 
pQCT analysis including significantly decreased fat cross sectional area (tibial 66% site) 
in lifestyle participants and non-significant increases in muscle cross sectional area in 
those undertaking WBVT. Intramyocellular lipids are implicated in the development of 
skeletal muscle resistance and decrease with weight loss, therefore the significantly 
decreased levels we observed with the lifestyle program may have contributed to the 
enhancements in Si we saw in this group after 3 months 568. Muscle hypertrophy and an 
increase in muscle cross sectional area would be anticipated structural changes in the 
muscle of the lower limbs being targeted by this intervention 381 393 569. It is possible that 
some of the increased weight seen in the WBVT group at the end of the study could be 
attributed to the gains in lean tissue.  
 
Compliance to the WBVT exercise was inconsistent; despite the novelty of the 
intervention, the short exercise program (15 minutes per day) and the ability to perform 
this in the home environment. The variable compliance to WBVT may have reflected 
this group’s compliance to the standard lifestyle prescription and reflects general 
motivational issues in this age group to activities conducted in real life and unsupervised 
settings. An intervention such as WBVT done with relatively little effort and prescribed 
as an adjunct to standard lifestyle change may be viewed as a “magic cure” by those 
participants and may be seen as preferable to the relatively more difficult lifestyle 
program. Non-adherence to the lifestyle component could account for the static or 
increased weight and BMI measures within this group. The compliance of both groups 
to the standard exercise and nutritional coaching is unclear, as there was no formal 
method to assess daily activity and implementation of nutritional advice apart from self-
report during fortnightly therapeutic contact.  
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In addition, to the insulin resistance state accompanying obesity, some adolescents in our 
study were pubertal which confers an additional state of physiological insulin resistance. 
This underlying process is likely to influence any examination of Si particularly long-term 
studies where Si may spontaneously improve as the adolescent transitions through 
puberty. Similarly, cardiovascular risk factors show similar variation during puberty 570. 
Despite attempting to control for the effects of physiological variation by randomisation 
according to gender and pubertal status, it is possible that individual variation in both Si 
and other metabolic factors as participants progressed towards a higher Tanner stage 
may have influenced our primary and secondary outcome results independent of any 
weight change.  
 
Furthermore, our study demographic was multicultural and we did not stratify according 
to ethnicity and thereby genetic variations in insulin sensitivity may not have been fully 
appreciated when we evaluated our results287 571. Consideration of ethnicity of the study 
population is important in weight loss trials as the literature suggest that those from 
Caucasian backgrounds may have more successful outcomes 572. In an attempt to 
correctly identify adolescents at risk of disease progression we included adolescents with 
elevated fasting insulin and clinical features of acanthosis nigricans. Since our trial was 
conducted, the use of a single fasting insulin measure to define an insulin resistant state 
has been discouraged due to difficulties with interpretation during puberty and high 
inter-assay variability 280.  
 
Our study confirms that cardiovascular risk factors cluster in the obese adolescent. We 
demonstrated a correlation (after correcting for the effects of puberty and gender) of 
BMI and central adiposity with Si measures, which in turn was associated with metabolic 
profile indicators. The interrelation between obesity, insulin resistance and adverse 
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cardiovascular health profile measures observed again at the end of the study with 
correlations showing absolute change in BMI, waist and HOMA-IR was associated with 
change in the serum hs-CRP. This result highlights the anti-inflammatory effects of an 
exercise intervention and weight loss on underlying chronic inflammatory mediators. As 
the lifestyle group showed positive changes in BMI, anthropometry and measures of 
insulin resistance, we would expect that metabolic profile indicators would also show 
positive changes. Indeed, we demonstrated clinically measurable but non-significant 
reductions in hs-CRP -2.6mg/L and ALT -4mmol/L and significant improvements in 
triglyceride levels -0.14mmol/L, (p=0.036). Insulin resistance is a pro-inflammatory state 
associated with high circulating level of C-reactive protein 573 and any improvements in Si 
and body composition should lead to an attenuation of this underlying inflammatory 
state as we observed. 
 
The decreased BMI or the adoption of a healthier diet with a reduced intake of saturated 
fats and/or the addition of Omega-3 polyunsaturated fatty acids may in part be 
responsible for the change in triglyceride levels 574. Additionally, triglycerides are involved 
in pathogenesis of hepatic insulin resistance, which directly influences fasting glucose 
levels. Reduced triglycerides in our cohort are likely due to altered nutrition habits in this 
cohort and weight loss in this group. Both groups received nutritional coaching and it is 
interesting to note that changes to the lipid profile was only observed in one group, 
suggesting either poor compliance to aspects of the lifestyle program or additional 
factors such as transition through puberty determining this metabolic profile indicator. 
 
Participation of obese adolescents in research studies is associated with many barriers at 
various stages in the process. The use of the whole body vibration platform was seen as a 
novel intervention and the possible randomisation into this arm of the study sparked 
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curiosity amongst the children and their families. We approached only 48 families to 
obtain our recruitment target of 43, indicating that most were keen to participate. 
Possible reasons for the recruitment success include the fact that adolescents were 
already attending specialist clinics for management of obesity related co-morbidity and 
had significant concerns about personal health and risks of developing T2DM. In 
addition, many had a strong family history of obesity and metabolic disease and may 
have been encouraged to participate by their caregivers. 
 
Motivating young obese adolescents to engage in physical activity programs can often be 
difficult due to body image issues and poor fitness levels. Many studies have shown that 
once involved in a research program, the dropout rates within this cohort are 
considerable. The VIBRATE study had a good 3 month study retention, with only 1 
participant withdrawing for final testing. The low dropout rate of 2.3% is considerably 
less than similar Australian RCTs involving obese adolescents where attrition can amount 
to as much as 20-30% 575. The male participant who withdrew from the study was older 
and had the highest BMI amongst the 14 males at 36.8kg/m2, it is known that in 
adolescent studies, adolescents with higher BMI contribute more to attrition rates 576 577. 
The low dropout rate may be related to frequent and personalised therapeutic 
monitoring during the progress of the study and the use of small non-monetary 
incentives at the completion of major testing encounters. The provision of small 
incentives has been found to be the most effective strategy to minimise dropout rates in 
this age target group 578.  
 
The participants had contact with one study co-ordinator (KR) throughout the trial and 
this allowed a good rapport to be developed between the researcher and the participant/ 
family that may have contributed to the high retention rates during the study. Smith et al 
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2014, determined a “good relationship between facilitator and participant” as crucial to 
the smooth running of any research program involving overweight adolescents 579. 
Research staff, play an integral role in minimising drop out during intervention studies. 
Allowing the adolescent to have ownership in the trial and outlining the health benefits 
of weight loss and the possible reduction in the risk of T2DM may improve compliance.  
 
There were no adverse events during the trial and the novel intervention was well 
tolerated by all participants. To lessen unnecessary transmission of the vibration through 
the spine we ensured participants were correctly trained about the correct use of the 
platform including the adoption of a flexed training stance 580. The positioning of the 
participant on the platform 393 403, either standing upright or with flexed stance, the 
inclusion of rest periods interspersed with training 581 and training protocol 405, may have 
differential effects on bone and/or muscle parameters and therefore may have affected 
some of our outcome measures.  
 
The adolescents’ compliance to the vibration intervention was variable and ranged from 
7-183% of predicted, indicating that some individuals were highly committed to this 
resistance training whereas others only used it for a couple of days during the three 
months. The adherence likely reflects the fact that unsupervised interventions require a 
highly motivated participant and or parent. It is unclear whether some of the use was by 
other family members as actual compliance times were extrapolated from the inbuilt 
compliance monitor and vibration diary entries. Similar RCT studies of a vibration 
intervention in adults have recommended that unsupervised interventions are not likely 
to produce positive results 582. Similarly, it is difficult to determine whether the 
participants were compliant with the lifestyle component as this was gauged by weekly 
telephone contact and not direct participation in a structured observed exercise program. 
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Of concern, the waist circumference of these young people remained elevated well above 
Australian recommendations for adult measurements. Central adiposity reflects the 
accumulation of visceral fat deposits known to contribute to increased metabolic risk and 
is likely to be carried in young adulthood. In our study, change in BMI was associated 
with change in waist circumference, suggesting that manipulation of either weight status 
or height could ameliorate waist measures. Therefore weight interventions during the 
pubertal transition are crucial because both of these factors can be altered and lead to 
significant BMI decreases. Weight loss is key to ameliorating both insulin resistance and 
the degree of overweight and indeed is considered a cornerstone to the management as 
highlighted in consensus statements 280 29. Most research involves participation in various 
research programs similar to the VIBRATE study which incorporates a lifestyle program 
including elements of nutritional education and increased activity. 
 
There may be several reasons as to why we did not see any change in insulin sensitivity 
between the two groups, including poor motivation and adherence to treatment, small 
sample size and short study duration. In addition, the development of insulin resistance 
involves a complex interplay of many organ systems as well as environmental and genetic 
factors. The program length may have been too short to elicit change as most WBVT 
studies now involve 6-9 month interventions. Both interventions in this study were given 
via prescription rather than directly monitored and whilst reflect “real life settings” are 
likely to suffer from poor adherence in this adolescent age group. Our WBVT training 
program and protocol may not have effectively targeted muscle training. Furthermore, 
since our study protocol was performed, the use of fasting insulin and glucose derived 
proxy measures has since been discouraged from routine use. Essentially the use of a 
fasting insulin level is now not recommended in clinical practice settings as there are 
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known difficulties with both interpretation of result and variability of assay measures. We 
acknowledge that this is an issue particularly when interpreting the fasting insulin and 
HOMA-IR results. Despite this the use of the WBISI continues in research settings and 
is a validated proxy measure and shows good correlation and good reproducibility with 
the gold standard clamp study.  
 
This is the first randomised controlled trial to investigate effects of whole body vibration 
training on insulin sensitivity in an obese adolescent cohort. Although in this study we 
did not demonstrate any significant enhancement in insulin sensitivity on group 
comparison at the conclusion of the 3-month trial, there were considerable positive 
metabolic gains in anthropometry, insulin resistance and glucose homeostasis after a 
short time period in the lifestyle arm. Our study, confirms the benefit of lifestyle 
intervention in the management of both insulin resistance and obesity. Cumulatively the 
small changes that resulted within a short period of time are likely to have improved 
underlying metabolic health. Adherence is a major consideration when an intervention is 
conducted in a home based and everyday setting and therefore programs need to provide 
age appropriate and interesting activities in addition to establishing rapport with 
participants and their families.   
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CHAPTER 5  
Does obesity or insulin resistance affect adolescent 
musculoskeletal health? 
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5.1 Introduction 
 
The adolescent years are a crucial period for the establishment of peak bone mass 420 583 584. 
Similar to obesity 585, bone health parameters established during childhood track into 
adulthood and may affect lifetime risk of osteoporosis 586. Skeletal integrity and bone 
strength continually adapt to mechanical strain through a process of bone modelling and 
remodelling, this is most apparent during puberty where longitudinal growth of bone and 
increased muscle force render bone vulnerable 587 588. Efforts to optimise peak bone mass 
during the formative years may reduce the later incidence of skeletal fractures 589 590.  
 
Obesity in adults is associated with increased bone mineral density 591, in part due to the 
biomechanical loading conferred by greater weight and stronger muscle forces exerted on 
the skeleton 592 593. In addition to the biomechanical factors, hormones such as leptin and 
oestradiol released from fat tissue may positively affect bone development 139. Conversely, 
adipocytokines released from visceral adipose deposits may negatively affect bone 
mineralisation 594. Independent of the above, further detrimental effects on bone accrual 
may occur in insulin resistance which often co-exists in the obese patient 595 596 597 598.   
 
The effect of obesity, visceral adiposity and hyperinsulinaemia on the bone health of 
young people remains unclear. Some studies show that overweight in children is 
associated with increased bone mass 138 599 which may be related to advanced skeletal 
development 600 601, greater lean tissue mass 602 and the effect of hormones from adipose 
deposits 139. However, other studies propose that bone mass 134 and BMD 603 are actually 
reduced in obese adolescents making them vulnerable to increased fractures during this 
period of maximal growth 135 140. The difficulty in determining any conclusive relationship 
is in part due to limitations with clinical densitometry that underestimates areal BMD 
(aBMD) in the rapidly growing child whose bones are continually changing shape and 
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size 604. Therefore any evaluation of BMD in the adolescent must consider the 
physiological processes of growth and puberty in addition to other external modulators.  
 
The osteoblast, integral to bone formation, expresses insulin receptors and may play an 
integral role in the link between skeletal system and energy regulation 605. The effect may 
be mediated by osteocalcin, a protein produced by the osteoblast 606. Similarly, 25OHD, 
another integral hormone in bone and mineral metabolism has proposed roles in the 
development of T2DM, metabolic disease and the pathogenesis of CVD 607 608 609. The 
metabolic and glucose regulating effects of Vitamin D may be mediated by interaction on 
its receptors in adipocytes 610, muscle cells 611 and by indirect effects on pancreatic insulin 
secretion through the activated form of Vitamin D 1,25 (OH) D2.  
 
Lifestyle measures, incorporating dietary restriction remains central to the management 
of increased weight and related co-morbidities. However, weight loss achieved through 
these health measures may have detrimental effects on BMD 612 613 614. Physical activity 
interventions often prescribed in conjunction with dietary modification increase BMD in 
both adults and children 590 419 and may attenuate the decreases in BMD seen with weight 
loss 615. The most appropriate physical activity prescription to produce weight loss, 
improve metabolic status and optimise peak bone mass during adolescence remains 
unclear.  
 
Resistance training creates greater mechanical strain leading to higher bone deformation, 
repair and remodelling and greater bone accrual 616 617. WBVT is a resistance exercise, 
with an anabolic effect on bone comparable to more intense resistance training as 
demonstrated in obese adults 355. The effect of WBVT on BMD related parameters in the 
paediatric population is inconsistent, as most studies have involved children with 
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underlying bone health issues and training protocols have varied. Despite this lack of 
clarity, some studies have demonstrated improved BMD 434 whilst others have shown 
functional improvements in mobility without positive bone effects 432. The 
musculoskeletal effects of WBVT in overweight, insulin resistant youth is unclear.  
 
This chapter aims to provide a cross-sectional snapshot of the bone health of obese, 
insulin resistant adolescents in a multi-ethnic demographic. The secondary effects of the 
study interventions, WBVT and lifestyle intervention were examined using clinical 
densitometry and pQCT. We evaluated relationships between bone parameters, bone 
turnover markers, Vitamin D, anthropometry and measures of insulin sensitivity to 
further evaluate the role of the skeleton in energy metabolism and the possible effects of 
body composition on the bone health.  
 
5.2 Bone architecture 
5.2.1 Dual energy x-ray absorptiometry  
a. Baseline 
 
There were no differences in DXA parameters between the intervention groups at 
baseline as seen in Table 5.1. There was no evidence of any underlying muscle or bone 
pathology with normal BMC for LTM. All DXA parameters (Total BMC and BMD, 
BMD legs and BMD trunk) were normal relative to weight apart from males who had 
low weight adjusted total BMC and BMD.  DXA values for height were normal but were 
high compared to age matched controls. There were significant gender differences at 
baseline and females displayed higher z scores for several parameters including: BMC for 
weight and age; total BMD and regionally had evidence of higher BMD in the lower 
limbs and trunk for certain z-score parameters as shown in Table 5.1. 
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Table 5.1 Baseline DXA parameters by group and gender 
 
Data presented as age, height and weight z-scores; BMC/LTM total z score 
*significant result with *p<0.05 **p<0.01 on independent samples Student t test  
 
b. Intervention effects 
Comparing the two groups, WBVT had significant increase in total BMD height z score 
(p=0.021) as seen in Figure 5.1 and Table 5.2.  Total BMD raw score was also increased 
in this group (p=0.040) after 3 months. The changes in total BMD in the WBVT group 
were associated with regional changes with higher BMD legs for age z score (p=0.036) 
compared with the lifestyle arm (Table 5.2). Notably, LTM showed clinically significant 
increases (588g vs. 184g) in this group after 3 months but this did not achieve statistical 
significance (p=0.5).  
  
 Entire 
Group 
n=42 
Standard 
N=21 
Vibration 
N=21 
P 
value 
Male 
N=13 
Female 
N=29 
P 
value 
        
BMC/ LTM 
 
-0.3 ± 2.0 -0.2 ± 2.4 -0.4 ± 1.6 0.783 -0.3 ± 2.2 -0.4 ± 1.6 0.889 
Total BMC        
Age 2.4 ± 1.9 2.2 ± 2.1 2.6 ± 1.6 0.454 1.3 ± 1.1 2.9 ± 1.9 0.002** 
Ht 1.0 ± 1.4 1.0 ± 1.3 1.0 ± 1.5 0.968 0.5 ± 1.6 1.2 ± -.2 0.139 
Wt -1.2 ± 1.7 -1.1 ± 1.7 -1.2 ± 1.8 0.790 -2.4 ± 1.3 -0.6 ± 1.6 0.001** 
 
BMD total 
       
Age 1.8 ± 1.3 1.7 ± 1.4 1.9 ± 1.2 0.750 1.1 ± 1.0 2.1 ± 1.3 0.02* 
Ht 0.5 ± 1.2 0.4 ± 1.1 0.6 ± 1.3 0.711 0.4 ± 1.4 0.5 ± 1.1 0.669 
Wt -1.6 ± 1.2 -1.6 ± 1.2 -1.5 ± 1.2 0.917 -2.0 ± 1.3 -1.4 ± 1.1 0.113 
 
BMD Legs 
       
Age 2.0 ± 1.3 2.0 ± 1.4 2.3 ± 1.2 0.487 2.0 ± 1.2 2.2 ± 1.4 0.600 
Ht 1.1 ± 1.3 1.1 ± 1.1 1.2 ± 1.6 0.858 1.1 ± 1.5 1.1 ± 1.3 0.987 
Wt -0.6 ± 1.2 -0.8 ± 1.1 -0.8 ± 1.3 0.997 -1.4 ± 1.2 -0.5 ± 1.1 0.02* 
 
BMD Trunk 
       
Age 1.6 ± 1.4 1.5 ± 1.6 1.7 ± 1.2 0.605 1.0 ± 0.8 1.8 ± 1.5 0.028* 
Ht 0.2 ± 0.4 0.1 ± 0.4 0.2 ± 0.5 0.622 0.1 ± 0.5 0.2 ± 0.4 0.552 
Wt -0.9 ± 1.4 -1.0 ± 1.6 -0.9 ± 1.1 0.947 -1.6 ± 0.8 -0.7 ± 1.4 0.01* 
   
  CHAPTER 5 ADOLESCENT MUSCULOSKELETAL HEALTH 
150 
Table 5.2 DXA intervention effects after 3 months (absolute change) 
 Lifestyle Vibration P value 
N           21            21  
DXA     
Bone mineral content/ Lean tissue mass (BMC/LTM) Z-score   0.365 ± 1.15   0.302 ± 1.02 0.852 
Bone mineral density (legs) – age z-score   -0.020 ± 0.34  -0.002 ± 0.33 0.036a 
Bone mineral density (legs) – height z-score  -0.147 ± 0.32   0.033 ± 0.31 0.052 
Bone mineral density (legs) – weight z-score     0.09 ± 0.305     0.22 ± 0.21 0.104 
Bone mineral density (total) – raw score g/cm2   0.006 ± 0.02   0.014 ± 0.01 0.040a 
Bone mineral density (total) – age z-score    -0.10 ± 0.32   0.004 ± 0.29 0.300 
Bone mineral density (total) – height z-score    -0.05 ± 0.25     0.07 ± 0.15 0.021a 
Bone mineral content – raw value (g)    94.89 ± 151.54 104.61 ± 150.06 0.836 
Bone mineral content – height z-score   0.090 ± 0.66     0.16 ± 0.57 0.667 
Lean tissue mass (g) 184.57 ± 2142.39 588.44 ± 1678.04 0.500 
Lean tissue mass/ height z-score   - 0.25 ± 0.81    -0.09 ± 0.43 0.431 
Leg fat (%)    -1.03 ± 2.10    -0.75 ± 1.67 0.637 
Leg lean tissue (g)    38.18 ± 726.19 411.49 ± 562.92 0.070 
Total body fat (%)    -0.94 ± 2.37    -0.14 ± 1.82 0.229 
Total body fat age z-score     -0.15 ± 0.32    -0.04 ± 0.25 0.217 
Trunk fat (%)    -0.83 ± 3.50     0.33 ± 2.65 0.234 
Trunk lean tissue mass (g)   19.76 ± 1464.49   114.1 ± 1186.84 0.820 
a indicates a significant result 
 
 
 
Figure 5.1 Change in BMD at the end of the study 
Boxplot showing absolute change in BMD Ht z is significantly increased in the WBVT arm  
*P<0.05 Student t test 
  
* 
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c. Longitudinal within group changes 
Within group changes can be seen in Table 5.3. There were contrasting regional changes 
in BMD. Within the lifestyle group, BMD (legs) showed decreased age p=0.016 and ht z 
scores p=0.047. In contrast, the WBVT group demonstrated increased BMD (legs) 
p<0.001 and BMD (trunk), p=0.005 for weight z-scores. Significant positive increases in 
total BMC (weight) in both groups (p=0.013 and 0.002, in lifestyle and vibration group 
respectively) were accompanied by increased total BMD (weight) after 3 months as might 
be expected during the pubertal growth phase. 
 
 
Table 5.3 Within group changes during 3-month intervention 
  Lifestyle Pre 
Lifestyle 
Post 
P value 
 
Vibration 
Pre 
Vibration  
Post  P value 
 
BMC/ LTM 
 
 -0.2 ± 2.4 0.1 ± 2.2 0.161 -0.4 ± 1.6  -0.1 ± 1.9 0.189 
Total BMC        
Age  2.2 ± 2.1 2.3 ± 1.9 0.496 2.6 ± 1.6 2.7 ± 1.9 0.390 
Ht  1.0 ± 1.3 1.0 ± 1.1 0.394 1.0 ± 1.5  1.1 ± 1.6 0.213 
Wt  -1.1 ± 1.7 -0.7 ± 1.9 0.013* -1.2 ± 1.8 -0.8 ± 1.7 0.002* 
 
BMD total 
       
Age  1.7 ± 1.4 1.6 ± 1.3 0.187 1.9 ± 1.2 1.9 ± 1.3 0.953 
Ht  0.4 ± 1.1  0.4 ± 1.2 0.380 0.6 ± 1.3  0.6 ± 1.3 0.064 
Wt  -1.6 ± 1.2 -1.4 ± 1.3 0.014* -1.6 ± 1.2 -1.4 ± 1.2 <0.001** 
 
BMD Legs 
       
Age  2.0 ± 1.4 1.8 ± 1.5 0.016* 2.3 ± 1.2 2.3 ± 1.2 0.984 
Ht  1.1 ± 1.1 1.0 ± 1.0 0.047* 1.2 ± 1.6  1.2 ± 1.6 0.636 
Wt 
 
 -0.8 ± 1.1 -0.7 ± 1.1 0.198 -0.8 ± 1.3 -0.6 ± 1.3 <0.001** 
BMD Trunk        
Age  1.5 ± 1.6 1.4 ± 0.3 0.086 1.7 ± 1.2 1.8 ± 1.3 0.448 
Ht  0.1 ± 0.4  0.1 ± 0.4 0.174 0.2 ± 0.5 0.3 ± 0.5 0.223 
Wt  -1.0 ± 1.6 -0.8 ± 1.7 0.289 -0.9 ± 1.1 -0.7 ± 1.1 0.005* 
Significant result *p<0.05 **p<0.001 using paired samples t test 
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5.2.2  Peripheral quantitative computed tomography  
a. Baseline 
The adolescents had normal results on pQCT. There were group differences despite 
equal randomisation according to gender and pubertal status. The WBVT group had 
significantly greater total tibial cross sectional area (raw and z-score) and higher strength 
strain indices (pSSI). Gender differences were seen with males having significantly 
stronger bones and increased cross sectional area compared with females (Table 5.4). 
 
 
Table 5.4 Baseline PQCT parameters by group and gender 
66% tibia site 
Whole 
group 
N=41 
Lifestyle  
N=20 
Vibration 
N=21 
Males  
N=14 
Females 
N=27 
      
Cortical BMC 307 ± 58 295 ± 64 319 ± 51 332 ± 66 294 ± 50 
Cortical BMC z-score 1.1 ± 1.7 0.8 ± 1.9 1.4 ± 1.5 1.3 ± 2.8 0.9 ± 0.8 
Cortical CSA (cm2) 286 ± 49 274 ± 54 298 ± 42 313 ± 52 272 ± 42b 
Relative CSA (cm2) 51 ± 7 52 ± 7 50 ± 7 50 ± 7 51 ± 7 
Total CSA (cm2) 570 ± 95 536 ± 98 603 ± 80a 635 ± 80 537 ± 84b 
Total CSA z-score 1.2 ± 1.6 0.7 ± 1.2 1.8 ± 1.8a 1.8 ± 2.4 1.0 ± 0.9 
pSSI 2334 ± 530 2147 ± 563 2512 ± 439a 2630 ± 528 2181 ± 471b 
pSSi z-score 2.2 ± 2.3 1.5 ± 2.2 2.8 ± 2.4 3.5 ± 3.5 1.5 ± 1.0a 
Cortical vBMD (mg/cm3) 1072 ± 46 1075 ± 49 1069 ± 45 1080 ± 47 1055 ± 42 
Total vBMD (mg/cm3) 620 ± 82 629 ± 80 611 ± 84 629 ± 79 603 ± 88 
Cortical vBMD z-score 0.9 ± 1.3 1.1 ± 1.5 0.7 ± 0.9 1.4 ± 1.8 0.6 ± 0.7 
CSA fat mm2 4508 ± 1304 4471 ± 1473 4543 ± 1158 3785 ± 936 4869 ± 1325 
CSA muscle mm2 6396 ± 1101 6127 ± 1159 6651 ± 1005 6592 ± 805 6298 ± 1225 
a significant result p<0.05 b significant result p<0.001 on Student t test comparing standard vs. WBVT and males vs. females 
BMC bone mineral content (mg), CSA cross sectional area PSSI strength strain index vBMD volumetric bone mineral density 
mg/cm3 
 
 
b. Intervention effects 
 
Cortical BMC was preserved in the WBVT arm group. The cross sectional area of fat 
was significantly decreased in the lifestyle group after 3 months (Table 5.5).  
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Table 5.5 Change in pQCT variables after 3-month interventions 
Tibia 66% site Lifestyle N=21 
Vibration 
N=21 P value 
pQCT    
Cortical bone mineral content (mg)     1.11 ± 7.46     5.21 ± 9.40 0.138 
Cortical bone mineral content z-score    -0.18 ± 0.24    -0.02 ± 0.23 0.042a 
Cortical cross sectional area (cm2)     1.88 ± 5.33     4.12 ± 8.12 0.314 
Relative cross sectional area (cm2)    -1.31 ± 3.11     0.31 ± 2.13 0.060 
Total cross sectional area (cm2)   19.08 ± 37.58     2.51 ± 24.52 0.104 
Total cross sectional area z-score     0.25 ± 0.90    -0.13 ± 0.58 0.222 
PSSI strength strain index 102.84 ± 213.29   57.87 ± 88.75 0.109 
PSSI strength strain index z-score      0.28 ± 1.21     0.00 ± 0.47 0.381 
Cortical volumetric bone mineral density vBMD mg/cm3    -2.72 ± 14.63     2.81 ± 9.96 0.588 
Cortical volumetric bone mineral density z-score     -0.02 ± 0.53    -0.07 ± 0.27 0.344 
Total volumetric bone mineral density (mg/cm3)  -12.15 ± 37.63     3.94 ± 20.22 0.167 
Cross sectional area fat mm2 -175.69± 226.25  -16.92 ± 211.58 0.029a 
Cross sectional area muscle mm2   73.36 ± 489.27 153.37 ± 349.53 0.559 
 
5.3 Bone and mineral metabolism  
5.3.1 Serum markers 
a. Vitamin D 
 
Vitamin D status was similar across the intervention groups at baseline as shown in 
Table 5.6. Thirty-eight samples were sufficient for analysis with 5 samples being 
unsuitable. As a group the participants n=38 (14M) appeared 25OHD sufficient with a 
mean level >50nmol/L. However, on subgroup analysis, 9 participants had levels 
<50nmol/L: seven had mild Vitamin D insufficiency, 1 male participant had moderate 
deficiency and one veiled female had severe deficiency with a serum level of 12nmol/L. 
All participants with Vitamin D<50nmol/L had dark skin. Individuals with dark skin had 
significantly lower 25OHD levels, 46nmol/L versus 72nmol/L (p<0.005). Almost one 
quarter of sampled participants (n=9) was considered Vitamin D deficient according to 
commonly used Australian criteria 618. The US definition identified 63% of participants as 
being insufficient or deficient 619.  
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Table 5.6 Vitamin D and bone turnover markers at baseline 
Measure Entire group Lifestyle Vibration  
Dark 
N=18 
6m 
Fair 
N=25 
8m 
P Value  
Dark 
Vs. Fair 
P value 
Lifestyle 
Vs. Wbvt 
25 OHD  
(nmol/L) 
n=38 
 
61 ± 22 
 
56 ± 22 66 ± 21 46 ± 21 72 ± 14 P<0.005* 0.16 
 
 
OCN 
nmol/L 
n=43 
4.2 ± 3.1 
 
4.1 ± 3.4 4.3 ± 3.6 3.3 ± 2.1 4.8 ± 3.6 0.12 0.78 
 
 
 
PINP 
(ng/mL) 
n=43 
447 ± 355 430 ± 377 463 ± 338 372 ± 297 500 ± 388 0.25 0.76 
 
 
 
CTx 
(ng/mL) 
n=43 
1.8 ± 1.1 
 
1.7 ± 1.2 1.8 ± 1.0 1.4 ± 0.7 2.1 ± 1.3 0.05 0.91 
 
 
 
Urine  
DPD 
N=37 
12.6 ± 6.6 
 
12.2 ± 6.0 12.9 ± 7.3 13.0 ± 7.7 12.3 ± 5.9 0.78 0.76 
CTx (C-terminal collagen cross-linked peptide) 0.033-6.000ng/mL 
DPD (free deoxypyridinoline crosslinks/creatinine): 3.0-7.4nmol/L creatinine range 4.5-26nM/mM later 6.8-40 females 
3.4-38.8 young female older male 1.1-26 
PINP (amino-terminal propeptide of type 1 collagen) Manufacturer assay normal range adults (2-230ng/mL)  
25OHD (25-hydroxyvitaminD): sufficiency >50nmol/L 
OCN (Osteocalcin) 1.7-7.7nmol/L 
 
b. Bone formation markers 
Bone formation markers OCN and P1NP showed no differences at baseline for skin 
colour or group. Subgroup analysis showed that males n=14 had significantly (p=0.021) 
higher mean serum OCN levels at baseline compared to females. 
 
c. Bone resorption markers 
 
Bone resorption markers serum CTX and urine DPD were not different at baseline and 
showed no difference between those participants with dark or light skin despite the 
presence of 25OHD insufficiency in 50% of participants with dark skin.   
5.3.2. Urine markers 
Free urine deoxypyridinoline crosslinks were assessed in relation to creatinine, giving the 
urine free deoxypyridinoline crosslinks/ creatinine ratio. The entire group (mean n=37) 
was similar to the intervention subgroups and skin pigmentation groups. Samples were 
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missing due to the inability to urinate for the test and some were not analysed due to 
contamination by red blood cells in females.  
5.3.3 Intervention effects on 25OHD and bone turnover markers 
There was much variability of 25OHD levels during the three-month trial period. Of 
those participants with complete pre/ post 25OHD data five adolescents had 
spontaneous improvement in 25OHD levels with four becoming sufficient after 3 
months. The 25OHD levels of two participants dropped into the insufficient range at 
final testing. After 3 months there was no difference in 25OHD levels as shown in Table 
5.7. The only bone turnover marker to show significant changes was OCN and this was 
decreased in the WBVT arm (p=0.024). Within the groups, bone formation was 
increased in the lifestyle group when osteocalcin was analysed however, P1NP did not 
show a similar increase. 
Table 5.7 Intervention effects on Vitamin D and bone turnover markers 
Marker Lifestyle Vibration P value 
25 OHD 
(nmol/L) 
N=38 
6 (17) -2 (12) 0.109 
CTX 
N=42 
0.1 (0.5) -0.15 (0.7) 0.201 
P1NP 
(ug/L) 
N=42 
-9 (115) -39 (155) 0.486 
Osteocalcin 
(nmol/L) 
N=41 
0.3 (1.1) -0.7 (1.6) 0.024* 
Urine 
DPD 
(nmol/L) 
N=36 
4.2 (9.9) 0.4 (6.0) 0.178 
*indicates significant result using independent samples Student t test p<0.05 Data presented as mean (SD)   
CTx (C-terminal collagen cross-linked peptide) 0.033-6.000ng/mL 
DPD (free deoxypyridinoline crosslinks/creatinine): 3.0-7.4nmol/L creatinine range 4.5-26nM/mM later 6.8-40 females 
3.4-38.8 young female older male 1.1-26 
PINP (amino-terminal propeptide of type 1 collagen) Manufacturer assay normal range adults (2-230ng/mL)  
25OHD (25-hydroxyvitaminD): sufficiency >50nmol/L 
OCN (Osteocalcin) 1.7-7.7nmol/L 
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5.4 Relationships between bone and insulin sensitivity 
 
Participants with dark skin and those with 25OHD levels <50nmol/L were significantly 
more insulin resistant and had decreased peripheral insulin sensitivity as shown in Table 
5.8. CTX was significantly increased in the light skin group suggesting increased bone 
turnover however urinary measures of bone resorption did not show this same trend.  
 
Table 5.8 Relationship of baseline Vitamin D and skin colour to bone turnover and 
insulin sensitivity markers 
Vitamin D 
status/ skin 
colour 
Deficient 
 
Sufficient 
 P value Dark  
Light 
 P value 
 9 (1M) 29 (11M)  18 (6M) 25 (8M)  
 
25OHD 
(nmol/L)N=38 
37 (12) 68 (18) P<0.01** 46 (21) 72 (14) <0.01** 
HOMA-IR  
N=43 
9.8 (2.0) 7.1 (2.2) 0.002** 8.6 (2.2) 6.9 (2.4) 0.021* 
Fasting insulin  
(pmol/L) 
N=43 
250 (48) 188 (50) 0.003** 227 (53) 186 (56) 0.022* 
WBISI 
N=43 
1.24 (0.6) 1.8 (0.8) 0.042* 1.37 (0.5) 2.00 (0.9) 0.012* 
Fasting glucose 
(mmol/L) 
N=43 
 
5.3 (0.5) 5.0 (0.4) 0.102 5.1 (0.4) 5.0 (0.5) 0.242 
Osteocalcin  
(nmol/L) 
N=43 
3.4 (2.2) 3.9 (2.4) 0.544 3.3 (2.1) 4.8 (3.6) 0.116 
P1NP 
(ug/L) 
N=43 
382 (336) 416 (268) 0.760 372 (297) 500 (388) 0.248 
CTX 
(ng/L) 
N=43 
1.3 (0.8) 1.8 (1.0) 0.138 1.4 (0.7) 2.1 (1.3) 0.032* 
Urine 
DPD 
N=37 
16.0 (8.7) 11.5 (5.5) 0.099 13.0 (7.7) 12.3 (6.0) 0.776 
*  p<0.05 **p<0.01 Independent samples student t test 
Fasting glucose normal <5.6mmol/L, fasting insulin <90pmol/L 
CTx (C-terminal collagen cross-linked peptide) 0.033-6.000ng/mL 
DPD (free deoxypyridinoline crosslinks/creatinine): 3.0-7.4nmol/L creatinine range 4.5-26nM/mM later 6.8-40 females 
3.4-38.8 young female older male 1.1-26 
PINP (amino-terminal propeptide of type 1 collagen) Manufacturer assay normal range adults (2-230ng/mL)  
25OHD (25-hydroxyvitaminD): sufficiency >50nmol/L 
OCN (Osteocalcin) 1.7-7.7nmol/L 
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5.4.1 Correlations and regression models 
Table 5.9 DXA correlations between body composition and anthropometry 
Variables BMC (raw)  BMD (raw)  BMD/Ht  
 R p R p R p 
Age 0.528 <0.001** 0.723 <0.001** 0.411 0.007* 
Height 0.726 <0.001** 0.486 0.001* -0.198 0.209 
Weight 0.328 0.012* 0.594 <0.001** 0.289 0.063 
Waist -0.092 0.560 0.220 0.162 0.152 0.335 
W/H ratio 0.425 0.005* -0.02 0.901 0.232 0.140 
BMI -0.041 0.796 0.372 0.012* 0.479 0.001* 
Puberty 0.566 <0.001** 0.670 <0.001** 0.359 0.020* 
% LTM 0.309 0.046* 0.252 0.107 0.051 0.751 
Gender 0.145 0.359 0.061 0.699 -0.068 0.669 
Spearman’s correlation coefficients against anthropometry and body composition 
* significant <0.05 **p<0.001 
 
Correlations were performed between anthropometry, body composition and selected 
DXA variables (Table 5.9). Bone mass as determined by raw BMC score showed strong 
positive correlation with height and moderate positive correlations with age, pubertal 
status and weak positive correlations with %LTM and weight. BMD raw score 
demonstrated strong positive correlations with age and pubertal status; moderate positive 
correlations with weight and height and weak correlation with BMI. BMD when adjusted 
for height z score only showed moderate positive correlations with age and BMI with 
weaker positive association with pubertal status. 
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5.4.2 Partial Correlations 
Table 5.10 Partial correlations between raw values of BMD and BMC and selected 
measures of insulin sensitivity and anthropometry 
Variable 
 
Controlling for age, height, weight, puberty and gender code 
BMD 
(raw) 
BMC 
(raw) 
Waist -0.314 -0.413* 
WtHR ratio -0.308 -0.414* 
CRP -0.137 0.040 
Insulin -0.111 -0.286 
WBISI 0.159 0.194 
HOMA-IR 0.023 -0.045 
%Sedentary time 0.247 0.117 
*p<0.05 significant result 
 
 
 
Regression analysis 
 
Regression models to examine the effect of the independent variables of age, Ht, weight, 
WtHR, pubertal status, BMI, %LTM, waist, WBISI and BMI z-score on bone measures 
of BMD and BMC were calculated (Table 5.11). Significant predictors for BMC (height) 
included waist, BMI at baseline and absolute weight adjusted R2=0.495, P<0.001. 
 
Table 5.11 Regression models for explaining variance in BMD and BMC for height  
  BMD height z-score BMC for height z-score 
Model Variable Coefficient 
ß±s.e. 
95% CI P R2 Model Variable Coefficient 
ß±s.e. 
95% CI P R2 
1 BMI 0.10 
(0.04) 
0.024  
to 0.174 
0.01** 0.16 1 Waist -0.04 
(0.02) 
-0.08 
to -0.001 
0.047* 0.10 
2 BMI 0.22 
(0.05) 
0.12  
to 0.32 
<0.01** 0.36 2 Waist -0.12 
(0.03) 
-0.018 
to -0.07 
<0.01 0.41 
 Waist -0.07 
(0.02) 
-0.12  
to -0.03 
   BMI 0.25 
(0.06) 
0.13 
to 0.36 
  
3 BMI 0.25 
(0.05) 
0.15 
 to 0.35 
<0.01** 0.44 3 Waist -0.10 
(0.03) 
-0.15  
to -0.05 
<0.01 0.50 
 Waist -0.07  
(0.021) 
-0.11  
to -0.02 
   BMI 0.32 
(0.06) 
0.20  
to 0.45 
  
 %LTM 0.05  
(0.02) 
0.01  
to 0.10 
   Weight -0.05 
(0.02) 
   
 
To examine whether an interaction occurred between waist, BMI, weight and bone 
variables, an interaction term was calculated waist*BMI, to reduce collinearity, centred 
variables were calculated for the product and the individual variables.  The individual 
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variables remained significant but the product of the variables was not significant, 
suggesting no interaction. Similarly, waist and BMI were also associated with BMD 
(height) z-score, however %LTM was an additional predictor in this model adjusted 
R2=0.435, p<0.0001. Proxy measures of insulin sensitivity were not predictors in any 
models.  
 
5.5 Discussion 
 
We examined the longitudinal effects of clinical insulin resistance and obesity on the 
bone health of adolescents at baseline and in response to two separate interventions over 
three months. Cross-sectional analysis revealed that participants as a group had higher 
total aBMD and BMC compared to same age peers but normal aBMD for height and 
weight with the exclusion of males who had low BMC/aBMD adjusted for weight. The 
increased aBMD and BMC for age could be attributed to early puberty and skeletal 
advancement in obese adolescents 620 due to higher circulating IGF-1, oestradiol and 
leptin levels 600 601; with further maturational influences from hyperinsulinaemia 621. In this 
study we did not perform contemporary bone age x-rays or measure serum IGF-1, 
oestradiol or leptin but we did show strong correlations between BMC and height; 
aBMD (raw score) with age/ puberty and BMD (Ht) with age/BMI and can infer that 
these hormones were actively involved. 
 
At baseline, there were gender differences between total BMC and BMD (age and 
weight) with pubertal females demonstrating higher BMC and BMD compared with their 
male counterparts. This difference is likely due to the fact that boys accrue more bone 
and lean tissue in the post-pubertal period 622 under the influence of testosterone 623. 
Furthermore, bone mineral accrual is closely aligned with the attainment of peak height 
velocity and this is known to occur earlier in females 620 624. Faulkner et al 625 estimated 
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maximal growth around 12.67± 0.99 years in females and 14.14 ± 1.05 years in males. 
The mean age of males and females in our study was 13.8 ± 2.0 and 13.1 ± 2.1 years 
respectively suggesting that most females in our study had already attained peak growth 
velocity whilst this was yet to occur for the males. Further evidence of sexual 
dimorphism was evident with males displaying decreased BMC and BMD for weight 
with z-scores -2.4 and -2.0 respectively, demonstrating variable effect of increasing 
adiposity between the sexes during puberty 626, with bone mineral accrual in females 
being greatly influenced by the secretion of fat derived hormones such as oestradiol and 
leptin 623 627 628; with excess adiposity being less important to bone mineralisation in males 
623 629. In males particularly, the relatively low bone mass for weight may contribute to an 
increased fracture risk with relative skeletal weakness as bones increase in area but are 
incompletely mineralised 135 625. During normal pubertal development, there is often a lag 
between the BMC accrual with increases in muscle accompanied by subsequent increases 
in bone development 625 and in obese children, concomitant rapid increases in weight 
may result in increased porosity and decreased strength with failure to compensate for 
increased loading 134. This lag in bone BMC accrual may contribute to the observed 
increased risk of fractures during adolescence 630. 
 
As bone is primarily affected by changes in lean tissue mass, it fails to adequately adapt to 
an increase in biomechanical loading conferred by excess adiposity, which doesn’t 
participate in muscle bone interaction. Bone mineral content for lean tissue mass (BMC/ 
LTM) was normal for the group and both genders at baseline indicating that there was 
no underlying bone or muscle pathology.  
 
Central to our hypothesis was that WBVT might lead to an increase in LTM and thereby 
enhance peripheral insulin sensitivity through non-insulin mediated glucose uptake in the 
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muscle. The resistance activity was efficacious, with substantial increases in LTM, 
amounting to almost 600g and significantly higher BMD parameters including: total 
aBMD (raw and height) and legs aBMD (age) albeit without associated change to insulin 
sensitivity. This result reinforces the importance of the muscle bone interaction 421 587 and 
is consistent with studies demonstrating the influence of LTM on BMD in both obese 134, 
insulin resistant 631 and normal weight children 632. Our regression model also 
confirmed %LTM as an important predictor of BMD together with waist circumference 
and BMI. Waist, BMI and weight were important predictors of BMC.  
 
WBVT has been shown to alter body composition 445, muscle mass and function 395 633-635 
and BMD. However in older adults where this intervention has been mostly studied, 
there exists only weak evidence for an effect on bone and muscle parameters 386 393 394. 
Determining the actual nature of the effect of WBVT is difficult due to the variability in 
study protocols and diversity of populations studied 393, particularly in children where 
most WBVT trials have been undertaken in those with disabling medical conditions 636 637 
with few results in healthy children 430. The mixed results we observed on bone and 
muscle parameters could be due to the WBVT protocol which included: a flexed knee 
stance; 3 rest periods and higher vibration frequency ranging from 18-24 Hz. The 
adequate intervention period for WBVT has been suggested to be at least 8 weeks’ 
duration with frequency settings between 20-30Hz 393. The addition of rest periods into 
the training program has been shown to enhance the osteogenic effect on the bone 581 
whilst the flexed knee positioning is thought to maximises resistance training effects to 
the muscle by dampening transmission to the spine 638.  
 
We included physical activity and dietary coaching in our study with the aim of 
improving insulin sensitivity through weight loss and body composition change. The 
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lifestyle arm performed an aerobic based intervention and demonstrated significantly 
decreased BMI and fasting glucose, clinical improvements in Si and significant increases 
in OCN, a marker of bone formation. This result is consistent with paediatric 604 639 and 
adult studies 640 641 which have shown that weight loss improved Si and increased total 
OCN levels, suggesting a possible role of OCN in energy regulation 642-644. Simple 
correlations between OCN, WBISI and fasting glucose were weak correlations and may 
be due to measurement of total rather than undercarboxylated osteocalcin (uOCN), 
which is thought to be more active in glucose regulation 645 646. Despite this, selected 
studies have indicated an association between total OCN with Si 641 647 and metabolic 
markers 648 649 650. Unlike other studies 391 the increased BMD in the WBVT group could 
not be accounted for by a decrease in bone turnover with no significant differences in 
bone resorptive measures. There was no association between BMC or aBMD and proxy 
markers of insulin sensitivity controlling for height, weight, age, gender or pubertal status. 
 
Analysis of the bone turnover markers may have been affected by: sample degradation; 
the high within person variation of up to 12% for the serum and urine markers of bone 
turnover 651; variation of OCN with age 652, gender and growth 653 and fasting status 654. 
OCN is highly variable in puberty and mirrors peak growth velocity, which is gender 
specific 653 655. 
 
Recent evidence suggests that an increased waist circumference in adolescents may 
adversely affect BMC and BMD 656 657. We found that increased waist circumference and 
WtHR ratio in our participants was negatively associated with raw BMD and BMC after 
controlling for the effects of (age, height, puberty and gender) and any interaction effects, 
possibly due to pro-inflammatory adipocytokines produced by visceral adipose deposits 
594 658 659 and decreased osteoblast proliferation in those with insulin resistance 660. 
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Furthermore, we showed that increased total and central adiposity was associated with 
lower circulating 25OHD, a hormone integral to bone and mineral metabolism.  
 
Areal BMD may be overestimated in young obese children due to larger bones. To 
overcome this limitation, we investigated bone parameters with pQCT at the 66% site of 
the tibia. We found that males had evidence of larger and stronger bones. Cortical BMC 
was preserved in adolescents who undertook the vibration intervention but was reduced 
in the lifestyle group who also showed a significant decrease in BMI z-score 661 which 
may more accurately represent subtle changes in fat loss rather than DXA soft tissue 
analysis 564. The preservation of BMC could be attributed to the resistance training effects 
of the WBVT with enhanced muscle bone interaction or the relative loss of BMC in the 
lifestyle group, who also demonstrated significant changes with a reduction in both BMI 
and leg fat cross-sectional area on pQCT. In adults, weight loss induced by dietary 
restriction is associated with decreased BMD 662 663 664 but may be attenuated with the 
addition of an exercise intervention 665 and the possible effect of exercise on the muscle 
bone unit with increased bone turnover. The decreased fat cross sectional area in the 
lifestyle group may be secondary to aerobic enhanced fat oxidation in this group who 
received an aerobic based activity prescription 666. These regional changes within the 
muscle may in part account for the enhanced peripheral Si within the lifestyle arm. 
 
In line with Australian findings, adolescents in our study who had dark skin were more 
likely to be 25OHD insufficient 667. Individuals who were 25OHD deficient and/or had 
dark skin were significantly more insulin resistant at baseline. This result could be 
secondary to sequestration of 25OHD in adipose tissue 668, an increased risk of insulin 
resistance and T2DM in ethnic minority groups with darker skin, higher sedentary 
behaviours with less sun exposure or a direct interaction of 25OHD with glucose and 
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metabolic health independent of body composition 458 607 669-671 672 and seasonal variation. 
Of the obese and overweight participants sampled at baseline, 24% presented with 
25OHD deficiency. It is difficult to ascertain prevalence rates amongst adolescents but 
apparent deficiency may be due to the higher adiposity in the obese 673 with biochemical 
Vitamin D deficiency in up to 50% of severely obese children 674. 
 
Acanthosis nigricans (AN) was an inclusion criterion for our study; this cutaneous 
marker of clinical insulin resistance has been associated with lower 25OHD levels in 
those with increased BMI 675. However, despite our findings, the role of Vitamin D in the 
metabolic syndrome and evolution of T2DM remains unclear 461. The optimal value of 
25OHD for extra-skeletal benefit is unknown and is confounded by variables such as 
increased adiposity, sunlight exposure and dietary variables that affect both metabolic 
risk and circulating 25OHD levels 462. However, some studies have indicated that higher 
than currently recommended levels may be required to produce changes to insulin 
sensitivity 676 and that supplementation of 25OHD might produce similar HOMA-IR 
reductions to metformin treatment 677. 
 
PQCT analysis did not reveal any gender differences with regard to cortical BMD; 
cortical or total vBMD but had stronger bones with larger CSA compared with females. 
This may be related to lean tissue gains during puberty 678 and known gender 
morphological differences with higher pQCT parameters of strength and bone cross 
section in males 488 679. 
 
Obesity presents a significant mechanical challenge to the musculoskeletal system of 
adolescents. Fracture rates in this population are higher and the presence of visceral 
adiposity and complications of the metabolic syndrome such as hyperinsulinism may 
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further compromise bone geometry at a time when accrual of peak bone mass is vital. 
Knowledge about the effects of Vitamin D, exercise, weight loss and bone mediators of 
glucose homeostasis is integral to optimise both skeletal and metabolic outcome and to 
reduce immediate and later fracture risk.  
 
Paediatric recommendations suggest that BMI should be targeted to manage co-
morbidities such as insulin resistance however weight loss is known to be detrimental to 
BMC and BMD in adults. Therefore, incorporating activities such as resistance training, 
known to be more osteogenic to bone would be an important non-pharmacological 
strategy to attenuate any bone loss that might occur with these measures.  
 
The aBMD and BMC values when adjusted for height were normal in this study. 
Therefore, aBMD and BMC comparisons made for height and evaluation of total BMC 
may provide a better indicator of bone health in obese children who are likely to attain 
peak height velocity at an earlier age due to accelerated skeletal development 680.   
 
There are differing opinions regarding optimal Vitamin D intake at various ages and no 
universal agreement regarding the optimal serum concentration of 25-hydroxyvitamin D 
for maintenance of bone health and possible extra-skeletal health benefits. Recent 
consensus guidelines have been published which recommend at 25OHD level 
>50nmol/L to prevent nutritional rickets in young people 466.  
 
Our results show an association between Vitamin D levels and measures of insulin 
resistance. However, 25OHD is likely to be sequestered in excess adipose tissue of the 
obese adolescent and may not be completely bioavailable for bone and mineral 
metabolism. Optimising Vitamin D levels in obese adolescents may prove an adjunctive 
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treatment to lifestyle intervention but further prospective studies in obese children need 
to be conducted. We have demonstrated that lean tissue and bone mineral density can be 
improved within a short period of time suggesting that WBVT may be an efficient way 
of producing resistance-training effects with minimal cardiovascular impact in untrained, 
obese adolescent who often lacks motivation for change. 
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CHAPTER 6  
Are there limitations to exercise in the obese insulin 
resistant adolescent? 
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6.1 Introduction and Aims 
 
Regular physical activity in adults can prevent T2DM 323, improve metabolic profile 
indicators 307 and can benefit skeletal health 552. There remains however, a paucity of 
research into the cardio-metabolic benefits of exercise in overweight children 308, but it is 
clear that aerobic exercise 321 in particular, plays a central role in weight management in 
children 14 681. Current data in obese adolescents suggest that insulin sensitivity can be 
enhanced with 682 683 or without significant body composition change 328 345 551, with greater 
effect in the older adolescent with more severe insulin resistance 320.  
 
The exact physical activity prescription to halt the progression to T2DM in at risk obese 
children remains unclear. In the paediatric population, aerobic based activities have been 
traditionally incorporated into lifestyle programs with positive effects on weight loss, 
body composition and cardiorespiratory fitness 321. In addition to weight loss 154, aerobic 
activities can increase cardiorespiratory reserve 543, which is independently associated 
with greater insulin sensitivity 684. Resistance-training activities, once thought to be 
detrimental to the growing skeleton are gaining popularity as an exercise modality in the 
obese adolescent with recognised effects on muscle strength 685-687. Strength activities 
increase lean tissue and may enhance metabolism within muscle resulting in greater 
glucose uptake 256 338 that may prove a useful adjunct in the management of paediatric 
insulin resistance.  
 
There are many barriers to the active participation of obese children in physical activity 
including but not limited to: poor levels of physical fitness and decreased 
cardiorespiratory reserve, motivational factors, poor muscle fitness and strength 33. 
Exercise capacity in children, may be further compromised, by the pathophysiological 
effects of underlying hyperinsulinaemia 341 688. In obese adolescents with greater lean 
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tissue, strength exercises may increase self-esteem and confidence for further physical 
activities, as they are likely to outperform normal weight peers. 
 
In this chapter, we present the baseline cardiorespiratory profile of the obese insulin 
resistant adolescent and examine any effect on exercise ability after a 3 month aerobic 
and strength program which incorporated the novel resistance technique of WBVT. To 
further explore the possible limitations to exercise in these youth, we examined muscle 
strength and power using Mechanography, a dynamic research tool developed to test 
parameters of motor function during activities of daily living. 
 
6.2 Cardio-respiratory fitness  
 
Baseline 
All participants (n=43) underwent treadmill fitness testing at baseline. There were no 
significant differences between the intervention groups for all measures of 
cardiorespiratory fitness, anthropometry, metabolic profile indicators or proxy markers 
of insulin sensitivity at the start of the trial (Table 6.1). The average VO2peak 
(mL/kg/min) was low representing around 85% predicted for age and gender. Of note, 
VO2peak adjusted for LTM produced results comparable to healthy peers on average 
63.7mL/kgLTM/min. Duration of the exercise testing was short and most participants 
were not able to exercise beyond ten minutes. Females had significantly higher anaerobic 
threshold and achieved better VO2% predicted, averaging almost 88% of expected 
values, suggesting better CRF. There was no difference between VO2 adjusted for LTM 
between the genders (Table 6.2). 
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Table 6.1 Baseline and final measures of cardiorespiratory fitness, anthropometry & 
metabolic profile 
a indicates significant difference p<0.05 between pre and post training values within each group 
 b indicates significant difference at <0.01 level 
  
 Whole group Lifestyle Vibration 
Cardiorespiratory 
fitness 
 
Pre 
N=43 
Post 
N=39 
Pre 
N=22 
 
Post 
N=20 
Pre 
N=21 
 
Post 
N=19 
Exercise time 
(min) 
8.6 (1.8) 9.1 (2.2)a 8.6 (2.0) 9.0 (1.5)a 8.7 (1.5) 9.3 (2.2) 
 
VO2peak 26.8 (7.0) 27.6 (8.0) 26.8 (8.2) 27.6 (8.9) 27.0 (6.3) 27.6 (7.3) 
 
VO2peak (mL/kgLTM/min) 63.7 (22.5) 65.3 (22.5) 66.3 (22.7) 67.7 (23.1) 61.1 (22.5) 63.0 (22.3) 
 
%VO2peak 
predicted 
84.4 (20.8) 86.8 (25.0) 87.3 (20.0) 86.7 (20.2) 81.7 (21.7) 87.0 (29.4) 
 
Anaerobic Threshold 55.5 (13.1) 47.2 (13.1)b 57.7 (12.0) 46.8 (12.0)a 53.5 (14.0) 47.7 (13.8) 
Anthropometry Pre 
N=43 
Post 
N=42 
Pre 
N=22 
Post 
N=21 
Pre 
N=21 
Post 
N=21 
BMI z-score 2.1 (0.4) 2.1 (0.44)b 2.1 (0.5) 2.0 (0.5)a 2.1 (0.4) 2.0 (0.4) 
 
BMi kg/m2 31.5 (5.1) 31.0 (5.4)b 31.1 (5.9) 30.3 (6.2)a 31.6 (4.2) 31.5 (4.5) 
 
Weight (kg) 81.9 (15.2) 81.9 (16.0) 81.6 (19.1) 79.4 (18.9) 83.4 (11.1) 84.3 (12.3) 
 
Waist height ratio 
 
0.63 (0.1) 0.61 (0.1) b 0.64 (0.1) 0.61 (0.1)a 0.63 (0.1) 0.62 (0.1)a 
Metabolic 
Indicators 
Pre 
N=43 
Post 
N=42 
Pre 
N=22 
Post 
N=21 
Pre 
N=21 
Post 
N=21 
DBP z-score 1.1 (0.9) 0.9 (0.9) 1.2 (0.9) 1.0 (1.0) 0.9 (0.9) 0.7 (0.8) 
 
SBP z-score 0.4 (1.3) 0.4 (1.2) 0.6 (1.3) 0.4 (1.0) 0.2 (1.3) 0.4 (1.4) 
 
HOMA-IR 
 
7.6 (2.5) 7.8 (4.3) 7.7 (2.8) 6.9 (4.6) 7.6 (2.1) 8.6 (3.7) 
Fasting glucose 
(mmol/L) 
5.0 (0.4) 4.9 (0.5)a 5.1 (0.5) 4.8 (0.6)a 4.9 (0.3) 4.9 (0.4) 
 
Fasting insulin 
(pmol/L) 
202 (58) 212 (102) 199 (62) 189 (105) 206 (56) 236 (95) 
 
WBISI 1.8 (0.8) 1.9 (0.9) 1.8 (0.9) 2.1 (0.9) 1.6 (0.8) 1.7 (0.9) 
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Table 6.2 Cardiorespiratory and mechanography measures at baseline  
 Male (n=14) Female (n=29) 
Age (years) 13.8 (2.0) 13.1 (2.1) 
Height (cm) 165.3 (9.0) 160 (8.8) 
Weight (kg) 82.7 (15) 82.4 (16.1) 
BMI (kg/m2) 30.2 (4.2) 32.2 (5.4) 
BMI z-score 2.1 (0.5) 2.2 (0.4) 
Body fat% 42.8 (8.6) 46.3 (6.2) 
VO2peak  29.0 (8.1) 25.7 (6.7) 
VO2 % predicted 72.0 (20.2) 87.8 (20.5)a 
VO2peak (mL.FFMkg-1.min-1) 64.7 (21.1) 63.3 (23.4) 
Anaerobic threshold % 44.4 (11.2) 59.4 (11.7)a 
Exercise time (min) 9.1 (2.0) 8.4 (1.7) 
Muscle force (N) m1LJ 2.0 (0.3) 1.9 (0.4) 
Muscle power (W) s2LJ 3.0 (0.9) 2.5 (0.6) 
Power efficiency % s2LJ 84.2 (17.8)a 74.5 (12.2) 
Maximal power relative to weight (w) s2LJ 36.5 (11.9)a 30.8 (5.7) 
Fmvrelm1LJ (g) m1LJ 2.5 (0.4) 2.3 (0.3) 
aindicates significant difference males and females (p<0.05) 
VO2peak peak oxygen uptake during fitness test, FFM fat free mass  
Fmvrelm1LJ Maximal voluntary force relative to body weight  N Newton W watt 
 
 
Final  
 
At the completion of the trial, results were available for n=39 participants (1M withdrew 
from trial, 2 M and 1 F declined testing). Results are presented in Table 6.2 for the 
participants who completed the study. The lifestyle intervention was associated with 
positive change in anthropometry (decreased BMI, BMI z-score and WtHR ratio) with 
decreased fasting glucose. This group was also able to exercise longer and showed 
significant decrease in anaerobic threshold. The WBVT was only associated with a 
change to central adiposity with decrease in the WtHR ratio. On group comparison, 
there were no differences for any of the cardiorespiratory parameters (Table 6.3). 
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Table 6.3 Absolute change in cardiorespiratory parameters in both intervention groups 
after 12 weeks 
Parameter Lifestyle Vibration 
N = 39 19 20 
VO2peak (mL/min) 0.7 (5.5) 0.6 (5.9) 
VO2peak (% predicted) -0.6 (16.5) 5.3 (23.9) 
VO2peak/LTM (mL/kgLTM/min) 0.3 (9.5) 1.1 (12) 
Exercise time (sec) 26.2 (55.8) 33.5  (118.2) 
Anaerobic threshold % 
 
N=42 
-10.9 (17.1) 
 
21 
-5.8 (15.8) 
 
21 
BMI z-score 
Waist height ratio 
BMI kg/m2 
-0.1 (0.1)* 
-0.02 (0.02) 
-0.8 (1.2) 
-0.02 (0.1) 
-0.01 (0.01) 
-0.1 (1.0) 
   
Data presented as mean (SD) *indicates a significant result p<0.05 
 
6.3 Mechanography  
 
Baseline 
 
Pre/ post mechanography data can be seen in Table 6.4. All participants (n=43) 
performed mechanography at baseline with no significant differences between 
intervention groups. At the end of the trial, complete data was available for 41 
participants (1 M withdrew from trial, 1 M declined testing).  
 
Although absolute muscle force and power was similar between the genders, males had 
higher muscle efficiency and were able to generate more power per unit of weight (Table 
6.2 above). Both arms of the study had poor muscle function highlighted by the low 
force and power EFI SDS scores during the s2LJ. Whilst, higher forces were generated 
with eccentric muscle contraction during the m1LJ, the peak force SDS score during the 
m1LJ was -2.7 SDS in both groups indicating very low muscle force capability. Absolute 
muscle force was strongly association to weight R=0.746, with direct increases in 
hopping force as the weight of the adolescent increased (Figure 6.1). 
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Final  
At the end of the study, the lifestyle group, showed a decrease in body weight and BMI 
z-score and this was accompanied by increased power EFISDS (4% Lifestyle vs. 1.5% 
WBVT) and significant increase in Pmaxrel compared to WBVT at the end of the study; 
both of these measures are sensitive to weight changes. Other changes to muscle force 
and power parameters were negligible between and within the groups.  
 
 
Table 6.4 Mechanography results for intervention groups at baseline and at completion 
 Lifestyle Vibration 
 
 
Pre 
N=22 
Post  
N=21 
Pre 
N=21 
Post 
N=20 
Single  
Two-Leg Jump  
    
Muscle force (kN) 1.86 (0.5) 1.88 (0.4) 2.0 (0.3) 2.0 (0.7) 
 
Force EFI SDS -1.4 No change -1.8 No change 
 
Muscle power (w) 2.60 (0.8) 2.64 (0.8) 2.7 (0.7) 2.61 (0.5) 
 
Power EFI % 77.5 (18) 80.3 (13) 77.5 (11) 84.3 (12) 
 
Power EFI SDS  -1.8 Gain 4%  -2.0 Gain 1.5% 
 
Pmaxrel (w)a 
 
32.5 (10) 33.6 (10) 32.8 (7) 32.4 (7) 
Multiple  
One-Leg Jump 
    
 
MVF (g) 2.4 (0.4) 2.4 (0.4) 2.4 (0.2) 2.4 (0.4) 
 
Peak force SDS -2.7 No change -2.7 Loss 1.5% 
All SDS data comparisons kindly provided by Dr Rainer Rawer (Novotec Medical GmbH) 
MVF maximal voluntary force during one legged jump, peak ground reaction force in relation to body weight 
EFISDS Efficiency SDS normalised to age and gender matched controls 
a indicates significant between group difference p<0.05 
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Figure 6.1 Maximum ground reaction force s2LJ in relation to body mass (kg) 
Green circles (males) and blue circles (females) and mean linear fit. 
  
R=0.746 
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6.4 Correlations between fitness, mechanography and 
metabolism 
 
Duration of exercise showed strong positive correlation to overall fitness capacity, 
VO2peak (Table 6.5) and functional muscle measures of relative power and efficiency. 
Relative muscle force per kg body weight, demonstrated moderate positive correlation to 
cardiorespiratory parameters. Similarly, VO2peak displayed strong to moderate correlations 
with mechanography measures. Increased weight negatively affected endurance and 
cardiopulmonary fitness.  
 
Table 6.5 Correlations between muscle parameters, vitamin D and cardiorespiratory 
fitness at baseline (N=43) 
 
Pearson’s 
Correlation 
r 
VO2peak 
VO2peak 
% 
Anaerobic  
Threshold 
Muscle  
Force 
(kN) 
Muscle  
Power 
(w) 
Power 
EFI % 
Weight 
(kg) 
Pmaxrel 
(w) 
FMVrel 
(g) 
Ex. Time 0.699** 0.459** -0.045 -0.095 0.253 0.654** -0.483** 0.628** 0.502** 
VO2peak   0.754** -0.132 -0.272 0.052 0.530** -0.624** 0.567** 0.556** 
VO2peak % 0.754**  0.266 -0.252 -0.052 0.306* -.0490** 0.351* 0.359* 
Anaerobic 
Threshold 
-0.132 
 
0.266  -0.058 0.027 0.127 0.063 -0.019 -0.166 
25OHD 
(n=38) 
   0.081 0.147 0.207  0.368*# 0.423** 
 **Correlation is significant at 0.01 level (2-tailed) *Correlation is significant at 0.05 level (2-tailed) 
Power EFI Power efficiency, VO2 maximal uptake 02 at exercise peak Pmaxrel maximal power for kg body weight 
FMVrel maximal force for kg body weight 25OHD Vitamin D nmol/L # Spearman’s rho 
 
On simple bivariate correlations (Table 6.6), exercise capacity as measured by VO2peak 
appeared to negatively correlate with several markers of glucose homeostasis including 
fasting glucose and HOMA-IR; a positive association was seen between WBISI and 
VO2peak. To further explore this relationship and to determine possible confounding by 
BMI, puberty, age and central adiposity, further partial correlations (Table 6.7) were 
performed controlling for these variables. The previously seen association between 
indicators of glucose sensitivity was not seen, however an association between fasting 
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glucose and %anaerobic threshold was discovered. Relative muscle power and force 
(adjusted per kg body weight) were both positively correlated with baseline 25OHD 
levels. 
 
Table 6.6 Correlations between insulin sensitivity and cardiorespiratory fitness 
 Insulin Glucose HOMA-IR WBISI Ex time VO2Peak 
Anaerobic 
Threshold 
VO2peak 
LTM 
Insulin  0.373* 0.965** -0.840** -0.252 -0.277 0.080 0.264 
Glucose 0.373*  0.592** -0.434** -0.094 -0.317* 0.197 0.285 
HOMA-IR 0.965** 0.592**  -0.827** -0.244 -0.302* 0.118 -0.281 
WBISI -0.840** -0.434** -0.827**  0.297 0.360* -0.003 0.317* 
Ex time -0.252 -0.094 -0.244 0.297  0.699** -0.045 0.641** 
VO2peak -0.277 -0.317* -0.302* 0.360* 0.699**  -0.132 0.927** 
Anaerobic 
Threshold 
0.080 0.197 0.118 -0.003 -0.045 -0.132  -0.150 
%Fat -0.206 -0.302 -0.019 0.128 -0.135 -0.172 -0.076 -0.320** 
**Correlation is significant at the 0.01 level (2-tailed) *Correlation is significant at the 0.05 level (2-tailed) 
 
Table 6.7 Partial correlations between insulin sensitivity and cardiorespiratory fitness 
Partial 
correlations  
Exercise 
time VO2peak 
Anaerobic 
threshold WBISI HOMA-IR 
 
Controlled 
variables 
 
BMI, gender, 
waist, puberty 
Ex time  0.460** -0.037 0.013 0.040 
 
VO2peak 0.460**  -0.066 0.058 0.003 
 
Anaerobic  
Threshold 
 
-0.037 -0.066  -0.122 0.174 
WBISI 0.013 0.058 -0.122  -0.848** 
 
HOMA-IR 0.040 0.003 0.174 -0.848**  
 
Glucose 0.259 -0.017 0.318* -0.381* 0.485** 
 
Insulin -0.030 -0.031 0.119 -0.851** 0.967** 
 
**Correlation is significant 0.01 level (2-tailed) *Correlation is significant 0.05 level (2-tailed) 
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6.5 Discussion 
 
We investigated the effects of a lifestyle and strength intervention on the 
cardiorespiratory fitness, muscle performance, body composition and insulin sensitivity 
of obese, insulin resistant adolescents. The 3-month lifestyle intervention led to 
improved anthropometry: BMI -0.8kg/m2 (-2.6%), BMI z-score -0.1 (-4.8%) and waist/ 
height ratio -0.03 (-4.7%) which was accompanied by clinical improvement in measures 
of insulin sensitivity: WBISI 1.8 to 2.1 (+0.3, 16.7%); HOMA-IR 7.7 to 6.9 (-0.8, 
+10.4%) and fasting glucose 5.1mmol/L to 4.8mmol/L (-0.3,-5.9%; p<0.05). Consistent 
with contemporary guidelines during the VIBRATE study, both groups were prescribed 
3-4 sessions (45-60minutes) of moderate intensity aerobic based physical activity per 
week. The magnitude of the BMI z-score reduction is in keeping with recent systematic 
reviews and meta-analyses indicating similar exercise prescriptions (mean 3-4 x week, 43-
46 minutes per session) may anticipate a 3-3.6% BMI z-score reduction within a 
timeframe of 13-16 weeks 689. The absolute BMI loss of 0.8kg/m2 was similar to 
adolescent males who undertook an eight-week lifestyle observed intervention 682. As 
demonstrated in our lifestyle group, improvements in insulin sensitivity occurred in 
conjunction with anthropometry changes 321 332 but are also possible with changes to 
body composition without significant weight loss 328 551 690. 
 
At study end, the lifestyle group had a significantly lower BMI z score: mean (SD) -0.1 
(0.1). Hunt et al proposed that a BMI z-score loss of -0.25 might equate to -2.9% 
reduction in total body fat loss 564. In comparison, we estimated that the BMI z-score 
reduction of -0.1 was associated with a -0.6% (3.5) total body fat loss as measured by 
DXA. However, there are limitations to the measurement of soft tissues in obese 
participants, particularly with smaller changes 100 101. Despite the subtle body composition 
change, our results confirm that minimal changes in BMI and body composition in the 
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course of a lifestyle program, can lead to meaningful gains in metabolic health, which can 
ameliorate T2DM risk 75 328 551 563 690-692. Presently, lifestyle interventions remain the 
mainstay of paediatric obesity management and are central to the treatment of metabolic 
co-morbidities such as insulin resistance 280 321 693. A single exercise session in sedentary 
adolescents can have insulin sensitising effects for up to 17 hours 694, reiterating the 
importance for daily physical activity. Since our study, the Australian guidelines for 
physical activity have changed and suggest that adolescents include 60 minutes per day of 
moderate to vigorous physical activity with a mix of aerobic and strength activities during 
the week 695. Greater activity per week has been associated with favourable cardio-
metabolic outcome and this may influence the results of future obesity studies 544.  
 
At baseline, all participants had reduced cardiorespiratory fitness (CRF) with an average 
VO2peak of 26.8 mL.kg-1.min-1, representing approximately 85% of predicted values for 
age and gender. Our results demonstrating a lower VO2peak, is in concordance with 
research in similarly obese cohorts where VO2peak ranged from 23.9 696 to 25.7mL.kg-
1.min-1 697. Females had greater VO2peak with higher anaerobic threshold, an indication of 
better fitness, and greater %VO2peak predicted compared with males. This was despite 
both groups having similar anthropometry and males demonstrating greater muscle 
power and efficiency at baseline. The sexual dimorphism observed with regards to the 
CRF may be due to the usual increase in CRF between 12-14 years in females, with males 
expected to increase CRF later in their adolescence 684 698. Muscle power and force are 
strongly linked to the ability to exercise on the treadmill as we showed strong 
correlations between relative Mechanography variables and exercise duration and 
intensity.  
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The assessment of CRF in obese adolescents is difficult due to standardisation of VO2peak 
for weight that naturally defaults to obese adolescents who have relatively lower 
measures of VO2peak compared with normal weight peers. Fat mass is thought to 
contribute minimally to CRF with lean tissue being directly related to fitness ability. 
Therefore, some have suggested that VO2peak be standardised per kg of LTM to provide 
more relevant results for comparison 699 700 347. However as we found in our cohort, this 
method of standardisation results in an overestimation of VO2peak for adolescents 701 and 
the lack of appropriate reference ranges makes comparison difficult.  Pinto and 
colleagues demonstrated a 20% reduction in cardiac output in adolescents with T2DM 
compared to normal weight controls VO2/ FFM indices were compared 702. This 
suggests that cardiac function may limit ability to participate in currently recommending 
exercise prescriptions involving moderate intensity activity.  
 
In adults, better cardio-pulmonary fitness correlates with better insulin sensitivity and can 
improve glycaemic control 703. The effect of a higher CRF on insulin sensitivity in youth 
remains unclear due to physiological changes in adolescence and the variability of study 
methods. Young children with high CRF demonstrate better insulin sensitivity 704 and 
reduced central adiposity 705.  The superiority of aerobic or resistance based programs in 
obese adolescents also remains to be determined. Aerobic based programs in obese 
adolescents can improve CRF independent of body composition with enhancement of 
insulin sensitivity 551. Conversely, some have shown that highly insulin resistant children 
339 and adolescents 706 may demonstrate lower exercise capacity, independent of BMI, 
with improvements in insulin sensitivity accompanied by greater exercise capacity 707.  
 
We did not show any significant improvements in VO2peak with either lifestyle or WBVT 
intervention however the participants had better exercise endurance with an increase in 
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fitness time, more evident in the lifestyle arm. The use of the fitness time may provide an 
alternative indicator of the successfulness of the intervention, particularly as we showed 
strong correlations (r=0.699) between exercise time and overall fitness capacity (VO2peak).  
 
The WBVT, strength training, did not lead to any additional enhancement to 
mechanography or insulin sensitivity parameters above that of the lifestyle intervention. 
However, body composition improved with WBVT producing substantial increases in 
FFM ~0.5kg in our obese adolescents. It is unclear whether this could be attributed to 
the intervention or maturational changes due to advancing pubertal stage. Nevertheless, 
WBVT can increase LTM as shown in older women 555 and younger participants 379 but 
others demonstrate minimal 633 or negative results 708. Fat loss may be minimally reduced 
by WBVT with body fat impedance analysis (BIA) showing reductions ranging from -
0.2% 354 to -7% 448 with possible changes to central measures of adiposity 355. Fjeldstad et 
al 555 showed in older participants that WBVT in conjunction with resistance training led 
to measurable fat loss on DXA amounting to -3.1% compared with a resistance and 
control group. The effect of WBVT on glucose metabolism is unclear, Lee et al 447 
showed a small significant decrease in HbA1c -0.06% in their group of patients with 
diabetes with WBVT against an exercising and non-exercising control this is in contrast 
to a study in obese Latino boys showing no change in HOMA-IR measures after 8 weeks 
of WBVT 429. Despite the increase in LTM we did not show any enhancement to glucose 
physiology or peripheral insulin sensitivity in our cohort. Overall the effect on WBVT on 
weight and body composition remains to be elucidated and present literature is difficult 
due to the limited studies confined mainly to adults and lack of standardisation 350 358 381 393.  
 
Resistance interventions are being included along with aerobic interventions into 
paediatric exercise programs due to comparable, if not superior, effects on body 
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composition change 709. Monteiro et al 553 showed that an aerobic plus resistance 
intervention produced slightly greater body fat reductions than aerobic activity alone (-
2.9% versus -3.6%, respectively). Lee et al showed in obese adolescent males 338 
equivalent body fat losses in their intervention groups (-2.5 vs. -2.6%, aerobic versus 
resistance). They concluded that the increased insulin sensitivity in their resistance group 
could be attributed to the observed increase in LTM. Whilst we showed an increase in 
LTM in the WBVT arm this was not significant and was not accompanied by 
enhancement of insulin sensitivity parameters.  
 
Both of the aforementioned studies and the systematic review and meta-analysis by 
Garcia-Hermoso 709 included studies in which the intervention was directly observed. 
Our results better reflect real life conditions where variable adherence to the dietary, 
aerobic lifestyle and WBVT components is likely to have influenced our observed 
outcomes. Furthermore, we are mindful that both groups undertook a dietary 
intervention and any weight loss resulting from the nutritional component may have had 
independent and variable effects on insulin sensitivity and other metabolic profile 
indicators 154 710. 
The metabolic effects of exercise in adolescents 711 712 are not as clear-cut and physical 
activity may not be as effective in adolescents with established T2DM 370. In younger 
children, Eisenmann showed that cardiorespiratory fitness was correlated to measures of 
Si 704. We observed weak correlations between fasting glucose, HOMA-IR and WBISI 
but these correlations were no longer seen when corrected for body composition (BMI, 
waist circumference), gender and pubertal status. The initial association may be 
confounded by the dual interaction of increased BMI on ability to exercise and the 
adverse metabolic risk profile conferred by increased weight. Molnar et al 339 showed that 
hyperinsulinaemia was correlated to lower exercise ability, however in this cohort, 
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distribution of body fat was not accounted for, particularly central adiposity, which 
strongly correlates with metabolic risk 706 713.  
 
As part of the fitness test we measured the ventilatory anaerobic threshold (VAT). The 
VAT indicates the point where an individual switches from aerobic to anaerobic 
metabolism and provides an indication of fitness. At baseline, the VAT was higher in 
females and decreased in the lifestyle arm, which undertook a predominately aerobic 
based training. With increased physical training we would expect a rise in anaerobic 
threshold. However, the utility of this measure remains unclear in children and 
adolescents because of maturational changes occurring during growth and puberty with 
increased accrual of LTM. In addition, the presence of hyperinsulinaemia may disrupt the 
normal metabolic response to exercise 341; preventing fatty oxidation within muscle with 
reliance on carbohydrate metabolism, and this may have influenced the physiological 
parameters seen during the fitness testing.  The VAT was higher at baseline in females 
and showed significant decreases in the group as a whole at the end of the study. Others 
have shown a physiological decrease of this parameter in mid-adolescence occurring 
slightly earlier in females (12-13 years) than males. As our study population was two-
thirds females, this decrease may in part explain this result 698. In addition weight was 
negatively correlated to all CRF parameters apart from the anaerobic threshold. 
Increased BMI may cause physical limitations to a more active lifestyle transition. 
Anecdotally, the major reason for terminating the fitness test was reported muscle fatigue 
suggesting strength exercises may be necessary prior to undertaking a fitness program.  
 
To further explore the dynamic function of the muscle, we used mechanography and 
confirmed that muscle force and power were very low at baseline, with minimal change 
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with either training intervention. We confirmed the findings of Lang et al 714 that showed 
that muscle force strongly correlated with weight of the adolescent.  
 
The only parameter to show significant increase after 12 weeks was maximal power 
relative to weight (which increased by virtue of weight loss in the lifestyle group). 
Participants were unable to generate much force (Fmaxrel) during the m1LJ, which 
requires an eccentric contraction through one leg during a hopping jump. The Fmaxrel 
which represents the force during the m1LJ, has been shown to be relatively constant 
between the ages of 6-19 years with mean 3.33g (SD 0.3) 154, this is compared to a mean 
of 2.4g (SD0.4) in our cohort. This result may indicate that adolescents may not have had 
adequate time to compensate for the increased load conferred by obesity or that they 
lacked co-ordination for the activity. The Mechanography results may indicate that 
improvements in muscle function (either through weight loss or strength exercises) need 
to occur before obese adolescents embark on more physically active sports. As over two 
thirds of our study population were adolescent females and we previously showed a high 
prevalence of Vitamin D insufficiency, optimising levels of this fat soluble hormone may 
assist in muscle function. Similar to Ward et al 715, we showed an association between this 
25OHD and muscle force and power relative to weight.  
 
Obese adolescents are often reluctant to participate in physical activity due to poor self-
esteem and decreased levels of cardiorespiratory fitness. Understanding the exercise 
performance and fitness levels of the obese adolescent can allow for tailored 
individualised exercise programs. The inclusion of resistance activities can also improve 
self-confidence and adherence in young people 716 717. Fitness testing integrates variables 
from several physiological systems including respiratory, cardiovascular function, 
autonomic and musculoskeletal. Therefore, performing exercise testing in obese 
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adolescents with obesity and insulin resistance may provide a sensitive indicator to subtle 
dysregulation due to underlying disease and may provide earlier opportunities to 
intervene. 
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In this randomised controlled trial, our primary aim was to investigate whether a novel 
resistance intervention, WBVT, could enhance the effect of standard lifestyle measures in 
high-risk obese, insulin resistant young people. However, obesity has multi-systemic 
effects, an understanding of which is important for clinical management. Therefore, in 
addition to the results of the RCT we also examined the metabolic, anthropometric, 
musculoskeletal and cardiorespiratory health of the VIBRATE cohort.  
 
In Chapter 3, we reviewed the baseline demographic, metabolic and anthropometric 
characteristics of 43 overweight adolescents with features of clinical insulin resistance 
from Greater Western Sydney, who comprised the VIBRATE cohort. Our inclusion 
criteria identified a group of insulin resistant youth as shown by the proxy measures of 
HOMA-IR and WBISI; some already had evidence of pre-diabetes. The majority of 
participants recruited to the study were female raising concerns about differential uptake 
of healthcare between genders and suggestive of the increased awareness of body image 
issues in teenage girls. Disconcertingly, the male participants in this study had the 
greatest BMI but were least represented in the study. The participants came from high-
risk ethnicities for T2DM and the metabolic syndrome and had strong family histories of 
the same in first and second-degree relatives. We confirmed that acanthosis nigricans 
(AN), a cutaneous feature of insulin resistance, could correctly identify underlying 
biochemical insulin resistance in adolescents with dark skin but could not be used as a 
discriminating factor in Caucasian individuals who were equally insulin resistant but 
lacked this feature. We demonstrated the uncertainty surrounding the definition of 
metabolic syndrome in children and adolescents but were able to show high prevalence 
rates consistent with current paediatric research, however this varied dependent on the 
definition we applied. Insulin resistance, clustered strongly with features of the metabolic 
syndrome, particularly in those of a Middle Eastern background. Our data highlights the 
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need for future definitions of the metabolic syndrome in young persons to account for 
pubertal status and gender, as lipid profile, insulin resistance and blood pressure show 
variability during this period. This was demonstrated in our cohort whereby adolescents 
already showed gender and puberty related divergence of blood pressure, with male 
adolescents having higher SBP z-score and females lower diastolic blood pressure, a 
pattern known to continue until the menopausal years in females. Many participants had 
evidence of pre-hypertension.  
 
Risk factors for the metabolic syndrome occur well before a diagnosis of T2DM and may 
combine to increase later CVD risk therefore they should be managed during puberty 
and as they manifest. Subtle liver dysfunction with mild elevation of liver transaminases 
was demonstrated which might suggest early changes of NAFLD.  Therefore, primary 
health care providers may need to opportunistically provide preventative health advice, 
particularly to males who may not seek medical care as often as females. Finally in this 
chapter, we confirmed the adolescents’ sedentary lifestyle with relatively little time 
engaged in active movement.  
 
In Chapter 4, we examined the effect of WBVT on insulin sensitivity of obese 
adolescents. The results of the RCT did not show any enhancement in insulin sensitivity 
measures, over and above the lifestyle intervention. We determined that a short-term 
lifestyle intervention that provided nutritional coaching and an aerobic exercise 
prescription could effect BMI change and was accompanied by clinical improvement in 
markers of insulin sensitivity. The improvements in peripheral insulin sensitivity without 
increases in LTM, suggest the complex aetiology of insulin resistance and the 
requirements for a multi-faceted approach. The approach should include dietary change, 
weight loss and exercise. WBVT, a novel resistance exercise was safe, well tolerated and 
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an efficient form of neuromuscular training leading to regional increases in LTM, which 
potentiated the effect of the muscle bone interaction with noticeable change in 
BMD/LTM. We retained all but one participant to the end of the trial, our high 
adherence compared with other similar obesity intervention trials indicate that the 
program was interesting and that a good rapport was developed between the research 
team, the participants and families. Despite the frequent therapeutic contact and 
motivational strategies, we found that adherence to the WBVT in an everyday setting, to 
be poor considering the activity prescription of 15 minutes per day. Current 
recommendations now discount the use of the fasting insulin measurement in the 
evaluation of insulin resistance in obese adolescents. Whilst the WBISI is a validated 
proxy measure of the gold standard euglycaemic clamp, future studies would be best to 
measure Si with methods that allow careful evaluation of insulin dynamics such as the 
FSIVGTT from which the disposition index can be obtained. 
 
In Chapter 5, we examined the baseline musculoskeletal and soft tissue characteristics of 
the obese adolescent using DXA and pQCT. In our study, obese adolescents had 
increased BMC and BMD for age (normal for weight and height) apart from males where 
excess adiposity did not confer additional mechanical loading benefits as shown by 
decreased BMC and BMD z-score. This suggests that assessment of bone health 
parameters against height would be more appropriate in overweight adolescents who are 
more physically mature. The integrity of the muscle bone unit was intact with normal 
BMD/LTM values and no disruption from the pathological changes related to peripheral 
insulin resistance. Elevated waist circumference was a notable feature of our cohort, but 
we showed that central adiposity might independently associate with less favourable 
bone and mineral parameters. Moreover, many of the obese participants were Vitamin D 
deficient, a hormone vital to bone and mineral metabolism. Increased BMI and waist 
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circumference were associated with Vitamin D insufficiency with contributory effects 
from fat tissue sequestration, a lack of sun exposure, a sedentary lifestyle and dark skin 
colour. Exploring the skeletal pancreas axis, we showed individuals with low 25OHD or 
dark skin had more unfavourable proxy measures of insulin resistance suggesting 
25OHD might play a role in glucose homeostasis. However, no such relationship was 
demonstrated with regard to bone turnover markers, particularly OCN, recently 
implicated in energy regulation.  
 
Lastly in Chapter 6, we examined the cardio-respiratory fitness of our cohort and showed 
decreased fitness capacity and poor tolerance to exercise related to decreased muscle 
force and power generation on Mechanography. These individuals showed muscle 
deconditioning for the increased weight. The vitamin D deficient state was also 
independently related to the poorer muscle function. Neither intervention led to 
improvements in cardio-respiratory parameters but relative muscle force and power were 
improved secondary to weight loss. Transition to an active lifestyle in the obese 
adolescent is limited by increased weight, poor cardiorespiratory function, low 
musculoskeletal performance and hormonal influences such as 25OHD deficiency. 
 
To the clinician at the frontline, our data has confirmed the use of the simple clinical 
examination of BMI, waist circumference, waist to height ratio and acanthosis nigricans 
combined with a history of familial metabolic disease, to identify individuals at high risk 
of insulin resistance and the metabolic syndrome. In order to prevent T2DM progression, 
lifestyle measures including dietary and exercise prescription can lead to clinically relevant 
improvement in weight and metabolic profile indicators, such as insulin sensitivity. The 
adolescent transition may provide a window of opportunity for future metabolic health 
with linear growth passively decreasing BMI. The message of weight stability rather than 
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loss could be encouraged in the pubertal child with mild overweight as they grow into 
their weight. Obese adolescents, with co-morbidities may require input from a 
multidisciplinary team to achieve BMI change through weight reduction, to produce 
metabolic enhancements with 5% weight loss shown to be beneficial in adults718. 
 
Diabetes and osteoporosis are both likely to lead to chronic and disabling health 
problems. Given the emerging data between bone and energy metabolism, improving 
bone and muscle parameters through activity and supplementing deficient micronutrients 
such as Vitamin D, may have dual effects on both skeletal health and glucose 
homeostasis in the obese adolescent.  
 
Whilst the optimum physical activity intervention for the obese adolescent with insulin 
resistance remains to be determined, we have shown that resistance training in the form 
of WBVT is safe. WBVT may be efficacious in increasing muscle quantity and strength 
and may assist in the transition of the obese adolescent to a more active lifestyle by 
providing greater self-confidence. The results from this study can inform future exercise 
based programs in obese adolescents who are often reluctant to participate in physical 
activity due to poor self-esteem and decreased levels of cardiorespiratory fitness. 
Consideration of cultural factors, an understanding of fitness parameters and functional 
assessment of muscle will permit tailored exercise prescriptions. This in combination 
with adolescent friendly environments and interesting activities may help to improve 
adherence in everyday settings.  
 
We recommend future research replicate the study with a larger sample size. We 
observed clinically significant increases in lean tissue that did not reach significance 
possibly due to the small sample size in the intervention arm. Larger numbers and the 
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addition of a control group of normal weight adolescents would allow comparison of the 
effect of puberty on muscle and bone parameters. As the intervention was conducted in 
the home environment, the recruitment of other family members such as siblings and 
parents may expand the available knowledge of the effect of WBVT at various ages. This 
would better inform the public of its use as a home based exercise tool given its retail 
popularity and affordability.  
 
The addition of a group of adolescents with T2DM would allow us to further explore the 
limitations to exercise in the obese insulin resistant adolescent compared with the 
adolescent with T2DM. Further investigations could add functional MRI studies to 
better clarify the cardiac and muscle limitations to exercise. 
 
Future studies utilising WBVT should be conducted over longer periods of time as 
recent research suggests positive results with longer duration trials of at least 6 months. 
The WBVT program should be directly observed, particularly in the adolescent in whom 
adherence is likely to confound results. To better investigate the effectiveness of WBVT 
against strength training or HIIT in addition to a control group may be informative. The 
study protocol and training stance could be varied to examine differential changes to 
muscle and bone parameters.  
 
Our study included a multi-ethnic demographic of adolescents at risk of T2DM who 
were also undergoing pubertal change. Therefore, conducting the study in late pubertal 
or post-pubertal adolescents may provide further information about the enhancement of 
insulin sensitivity, as a result of peripheral lean tissue gains and attenuate the effect of 
physiological insulin resistance during adolescence. Stratifying groups according to 
ethnicity may allow further discrimination of interventional changes. The addition of 
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bone age skeletal investigation would provide a benchmark for comparison of 
cardiorespiratory and muscle and bone parameters and would allow for more accurate 
analysis.  
 
Prospective studies should also explore factors to optimise healthcare access amongst 
obese male adolescents, due to the noticeable patterns of gender disparity and emergence 
of metabolic risk factors seen in our study. 
   
  CHAPTER 8 REFERENCES 
193 
CHAPTER 8 REFERENCES 
   
  CHAPTER 8 REFERENCES 
194 
1. NHMRC. National Health and Medical Research Council (2013) Clinical practice 
guidelines for the management of overweight and obesity in adults, adolescents 
and children in Australia. Melbourne: National Health and Medical Research 
Council. 
2. Booth ML, Dobbins T, Okely AD, et al. Trends in the prevalence of overweight and 
obesity among young Australians, 1985, 1997, and 2004. Obesity (Silver Spring) 
2007;15(5):1089-95. 
3. Australian Bureau of Statistics. National Health Survey: First Results, 2014-15, 
accessed June 2016. [Available 
from:http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/bySubject/4364.0.55.0
01~2014-15~Main Features~Children's risk factors~31.] 
4. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children 
and adolescents, 2003-2006. Jama 2008;299(20):2401-5. 
5. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in 
the United States, 2011-2012. Jama 2014;311(8):806-14. 
6. Dyer SM, Gomersall JS, Smithers LG, et al. Prevalence and Characteristics of 
Overweight and Obesity in Indigenous Australian Children: A Systematic 
Review. Crit Rev Food Sci Nutr 2015:0. 
7. Olds TS, Tomkinson GR, Ferrar KE, et al. Trends in the prevalence of childhood 
overweight and obesity in Australia between 1985 and 2008. Int J Obes (Lond) 
2010;34(1):57-66. 
8. Nichols MS, Silva-Sanigorski A, Cleary JE, et al. Decreasing trends in overweight and 
obesity among an Australian population of preschool children. Int J Obes (Lond) 
2011;35(7):916-24. 
9. Martin K, Rosenberg M, Pratt IS, et al. Prevalence of overweight, obesity and 
underweight in Western Australian school-aged children; 2008 compared with 
2003. Public Health Nutr 2014;17(12):2687-91. 
10. Xi B, Mi J, Zhao M, et al. Trends in abdominal obesity among U.S. children and 
adolescents. Pediatrics 2014;134(2):e334-9. 
11. de Wilde JA, Verkerk PH, Middelkoop BJ. Declining and stabilising trends in 
prevalence of overweight and obesity in Dutch, Turkish, Moroccan and South 
Asian children 3-16 years of age between 1999 and 2011 in the Netherlands. 
Arch Dis Child 2014;99(1):46-51. 
12. Schmidt Morgen C, Rokholm B, Sjoberg Brixval C, et al. Trends in prevalence of 
overweight and obesity in danish infants, children and adolescents--are we still on 
a plateau? PLoS One 2013;8(7):e69860. 
13. O'Dea JA, Dibley MJ. Prevalence of obesity, overweight and thinness in Australian 
children and adolescents by socioeconomic status and ethnic/cultural group in 
2006 and 2012. Int J Public Health 2014;59(5):819-28. 
14. NHMRC. Clinical Practice Guidelines for the Management of Overweight and 
Obesity in Adults, Adolescents and Children in Australia (2013). 2013. 
15. Haby MM, Markwick A, Peeters A, et al. Future predictions of body mass index and 
overweight prevalence in Australia, 2005-2025. Health Promot Int 
2012;27(2):250-60. 
16. Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public 
health. Obes Rev 2004;5 Suppl 1:4-104. 
17. Magarey AM, Daniels LA, Boulton TJ. Prevalence of overweight and obesity in 
Australian children and adolescents: reassessment of 1985 and 1995 data against 
new standard international definitions. Med J Aust 2001;174(11):561-4. 
   
  CHAPTER 8 REFERENCES 
195 
18. Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among 
Children and Adolescents in the United States, 1988-1994 Through 2013-2014. 
Jama 2016;315(21):2292-9. 
19. Haslam DW, James WP. Obesity. Lancet 2005;366(9492):1197-209. 
20. World Health Organisation. Childhood overweight and obesity. Last accessed June 
2016.  [Available from: http://www.who.int/dietphysicalactivity/childhood/en/. 
21. Saxena S, Ambler G, Cole TJ, et al. Ethnic group differences in overweight and obese 
children and young people in England: cross sectional survey. Arch Dis Child 
2004;89(1):30-6. 
22. Daniels SR, Arnett DK, Eckel RH, et al. Overweight in children and adolescents: 
pathophysiology, consequences, prevention, and treatment. Circulation 
2005;111(15):1999-2012. 
23. Gordon-Larsen P, Adair LS, Popkin BM. The relationship of ethnicity, 
socioeconomic factors, and overweight in US adolescents. Obes Res 
2003;11(1):121-9. 
24. Gonzalez-Casanova I, Sarmiento OL, Pratt M, et al. Individual, family, and 
community predictors of overweight and obesity among colombian children and 
adolescents. Prev Chronic Dis 2014;11:E134. 
25. Eidsdottir S, Kristjansson A, Sigfusdottir ID, et al. Secular trends in overweight and 
obesity among Icelandic adolescents: do parental education levels and family 
structure play a part? Scand J Public Health 2013;41(4):384-91. 
26. Ruiz M, Goldblatt P, Morrison J, et al. Impact of Low Maternal Education on Early 
Childhood Overweight and Obesity in Europe. Paediatr Perinat Epidemiol 
2016;30(3):274-84. 
27. Shrewsbury V, Wardle J. Socioeconomic status and adiposity in childhood: a 
systematic review of cross-sectional studies 1990-2005. Obesity (Silver Spring) 
2008;16(2):275-84. 
28. Wang Z, Patterson CM, Hills AP. Association between overweight or obesity and 
household income and parental body mass index in Australian youth: analysis of 
the Australian National Nutrition Survey, 1995. Asia Pac J Clin Nutr 
2002;11(3):200-5. 
29. Oude Luttikhuis H, Baur L, Jansen H, et al. Interventions for treating obesity in 
children. Cochrane Database Syst Rev 2009(1):CD001872. 
30. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. 
Jama 2001;286(22):2845-8. 
31. Lumeng JC, Gannon K, Cabral HJ, et al. Association between clinically meaningful 
behavior problems and overweight in children. Pediatrics 2003;112(5):1138-45. 
32. Pulgaron ER. Childhood obesity: a review of increased risk for physical and 
psychological comorbidities. Clin Ther 2013;35(1):A18-32. 
33. Sanders RH, Han A, Baker JS, et al. Childhood obesity and its physical and 
psychological co-morbidities: a systematic review of Australian children and 
adolescents. Eur J Pediatr 2015;174(6):715-46. 
34. Topcu S, Orhon FS, Tayfun M, et al. Anxiety, depression and self-esteem levels in 
obese children: a case-control study. J Pediatr Endocrinol Metab 2016;29(3):357-
61. 
35. Goodman E, Whitaker RC. A prospective study of the role of depression in the 
development and persistence of adolescent obesity. Pediatrics 2002;110(3):497-
504. 
36. Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after 
"The Biggest Loser" competition. Obesity (Silver Spring) 2016;24(8):1612-9. 
   
  CHAPTER 8 REFERENCES 
196 
37. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from 
altered body weight. N Engl J Med 1995;332(10):621-8. 
38. Boguszewski CL, Paz-Filho G, Velloso LA. Neuroendocrine body weight regulation: 
integration between fat tissue, gastrointestinal tract, and the brain. Endokrynol 
Pol 2010;61(2):194-206. 
39. Eyster KM. Dysfunctional hormonal regulation of metabolism in obesity. S D Med 
2011;Spec No:18-21. 
40. Wilkie HJ, Standage M, Gillison FB, et al. Multiple lifestyle behaviours and 
overweight and obesity among children aged 9-11 years: results from the UK site 
of the International Study of Childhood Obesity, Lifestyle and the Environment. 
BMJ Open 2016;6(2):e010677. 
41. Watanabe E, Lee JS, Mori K, et al. Clustering patterns of obesity-related multiple 
lifestyle behaviours and their associations with overweight and family 
environments: a cross-sectional study in Japanese preschool children. BMJ Open 
2016;6(11):e012773. 
42. Reinehr T, Hinney A, de Sousa G, et al. Definable somatic disorders in overweight 
children and adolescents. J Pediatr 2007;150(6):618-22, 22 e1-5. 
43. Foraita R, Gunther F, Gwozdz W, et al. Does the FTO gene interact with the 
socioeconomic status on the obesity development among young European 
children? Results from the IDEFICS study. Int J Obes (Lond) 2015;39(1):1-6. 
44. Reuter CP, Rosane De Moura Valim A, Gaya AR, et al. FTO polymorphism, 
cardiorespiratory fitness, and obesity in Brazilian youth. Am J Hum Biol 
2016;28(3):381-6. 
45. Rzehak P, Saffery R, Reischl E, et al. Maternal Smoking during Pregnancy and DNA-
Methylation in Children at Age 5.5 Years: Epigenome-Wide-Analysis in the 
European Childhood Obesity Project (CHOP)-Study. PLoS ONE 
2016;11(5):e0155554. 
46. Stojanoska MM, Milosevic N, Milic N, et al. The influence of phthalates and 
bisphenol A on the obesity development and glucose metabolism disorders. 
Endocrine 2017;55(3):666-81. 
47. Parrino C, Vinciguerra F, La Spina N, et al. Influence of early-life and parental factors 
on childhood overweight and obesity. J Endocrinol Invest 2016. 
48. Goosby BJ, Cheadle JE, McDade T. Birth weight, early life course BMI, and body 
size change: Chains of risk to adult inflammation? Soc Sci Med 2016;148:102-9. 
49. Whitaker RC, Dietz WH. Role of the prenatal environment in the development of 
obesity. J Pediatr 1998;132(5):768-76. 
50. Gopinath B, Baur LA, Burlutsky G, et al. Socio-economic, familial and perinatal 
factors associated with obesity in Sydney schoolchildren. J Paediatr Child Health 
2012;48(1):44-51. 
51. Ouyang F, Parker MG, Luo ZC, et al. Maternal BMI, gestational diabetes, and weight 
gain in relation to childhood obesity: The mediation effect of placental weight. 
Obesity (Silver Spring) 2016;24(4):938-46. 
52. Wake M, Hardy P, Canterford L, et al. Overweight, obesity and girth of Australian 
preschoolers: prevalence and socio-economic correlates. Int J Obes (Lond) 
2007;31(7):1044-51. 
53. Booth ML, Wake M, Armstrong T, et al. The epidemiology of overweight and 
obesity among Australian children and adolescents, 1995-97. Aust N Z J Public 
Health 2001;25(2):162-9. 
54. Wang Z, Patterson CM, Hills AP. Association between overweight or obesity and 
household income and parental body mass index in Australian youth: analysis of 
   
  CHAPTER 8 REFERENCES 
197 
the Australian National Nutrition Survey, 1995. Asia Pac J Clin Nutr 
2002;11(3):200-5. 
55. Bider-Canfield Z, Martinez MP, Wang X, et al. Maternal obesity, gestational diabetes, 
breastfeeding and childhood overweight at age 2 years. Pediatr Obes 2016. 
56. Wright DR, Lozano P, Dawson-Hahn E, et al. Parental Predictions and Perceptions 
Regarding Long-Term Childhood Obesity-Related Health Risks. Acad Pediatr 
2016. 
57. Twarog JP, Politis MD, Woods EL, et al. Is obesity becoming the new normal? Age, 
gender and racial/ethnic differences in parental misperception of obesity as being 
'About the Right Weight'. Int J Obes (Lond) 2016. 
58. Himes JH. Challenges of accurately measuring and using BMI and other indicators of 
obesity in children. Pediatrics 2009;124 Suppl 1:S3-22. 
59. Power C, Lake JK, Cole TJ. Measurement and long-term health risks of child and 
adolescent fatness. Int J Obes Relat Metab Disord 1997;21(7):507-26. 
60. Cole TJ. Establishing a standard definition for child overweight and obesity 
worldwide: international survey. Bmj 2000;320(7244):1240-40. 
61. Weiss R, Kaufman FR. Metabolic complications of childhood obesity: identifying and 
mitigating the risk. Diabetes Care 2008;31 Suppl 2:S310-6. 
62. Lam BC, Koh GC, Chen C, et al. Comparison of Body Mass Index (BMI), Body 
Adiposity Index (BAI), Waist Circumference (WC), Waist-To-Hip Ratio (WHR) 
and Waist-To-Height Ratio (WHtR) as predictors of cardiovascular disease risk 
factors in an adult population in Singapore. PLoS One 2015;10(4):e0122985. 
63. Dietz WH. Health consequences of obesity in youth: childhood predictors of adult 
disease. Pediatrics 1998;101(3 Pt 2):518-25. 
64. Lammi N, Moltchanova E, Blomstedt PA, et al. Childhood BMI trajectories and the 
risk of developing young adult-onset diabetes. Diabetologia 2009;52(3):408-14. 
65. Freedman DS, Katzmarzyk PT, Dietz WH, et al. The relation of BMI and skinfold 
thicknesses to risk factors among young and middle-aged adults: the Bogalusa 
Heart Study. Ann Hum Biol 2010;37(6):726-37. 
66. Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus 
coronary disease. N Engl J Med 2011;364(14):1315-25. 
67. Misra A, Vikram NK, Gupta R, et al. Waist circumference cutoff points and action 
levels for Asian Indians for identification of abdominal obesity. Int J Obes 
(Lond) 2006;30(1):106-11. 
68. Daniels SR, Khoury PR, Morrison JA. The utility of body mass index as a measure of 
body fatness in children and adolescents: differences by race and gender. 
Pediatrics 1997;99(6):804-7. 
69. Lear SA, Humphries KH, Kohli S, et al. The use of BMI and waist circumference as 
surrogates of body fat differs by ethnicity. Obesity (Silver Spring) 
2007;15(11):2817-24. 
70. Carroll JF, Chiapa AL, Rodriquez M, et al. Visceral fat, waist circumference, and 
BMI: impact of race/ethnicity. Obesity (Silver Spring) 2008;16(3):600-7. 
71. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United 
States: methods and development. Vital Health Stat 11 2002(246):1-190. 
72. Zhang YX, Zhao JS, Chu ZH. Children and adolescents with low body mass index 
but large waist circumference remain high risk of elevated blood pressure. Int J 
Cardiol 2016;215:23-5. 
73. Karatzi K, Moschonis G, Polychronopoulou MC, et al. Cutoff points of waist 
circumference and trunk and visceral fat for identifying children with elevated 
inflammation markers and adipokines: The Healthy Growth Study. Nutrition 
2016. 
   
  CHAPTER 8 REFERENCES 
198 
74. Lee S, Bacha F, Gungor N, et al. Waist circumference is an independent predictor of 
insulin resistance in black and white youths. J Pediatr 2006;148(2):188-94. 
75. Watts K, Bell LM, Byrne SM, et al. Waist circumference predicts cardiovascular risk 
in young Australian children. J Paediatr Child Health 2008;44(12):709-15. 
76. Sardinha LB, Santos DA, Silva AM, et al. A Comparison between BMI, Waist 
Circumference, and Waist-To-Height Ratio for Identifying Cardio-Metabolic 
Risk in Children and Adolescents. PLoS One 2016;11(2):e0149351. 
77. Maffeis C, Banzato C, Brambilla P, et al. Insulin resistance is a risk factor for high 
blood pressure regardless of body size and fat distribution in obese children. 
Nutr Metab Cardiovasc Dis 2010;20(4):266-73. 
78. Brumbaugh DE, Crume TL, Nadeau K, et al. Intramyocellular lipid is associated with 
visceral adiposity, markers of insulin resistance, and cardiovascular risk in 
prepubertal children: the EPOCH study. J Clin Endocrinol Metab 
2012;97(7):E1099-105. 
79. Larson-Meyer DE, Newcomer BR, Ravussin E, et al. Intrahepatic and 
intramyocellular lipids are determinants of insulin resistance in prepubertal 
children. Diabetologia 2011;54(4):869-75. 
80. Brambilla P, Bedogni G, Moreno LA, et al. Crossvalidation of anthropometry against 
magnetic resonance imaging for the assessment of visceral and subcutaneous 
adipose tissue in children. Int J Obes (Lond) 2006;30(1):23-30. 
81. Despres JP, Nadeau A, Tremblay A, et al. Role of deep abdominal fat in the 
association between regional adipose tissue distribution and glucose tolerance in 
obese women. Diabetes 1989;38(3):304-9. 
82. Despres JP, Moorjani S, Ferland M, et al. Adipose tissue distribution and plasma 
lipoprotein levels in obese women. Importance of intra-abdominal fat. 
Arteriosclerosis 1989;9(2):203-10. 
83. Despres JP, Moorjani S, Tremblay A, et al. Relation of high plasma triglyceride levels 
associated with obesity and regional adipose tissue distribution to plasma 
lipoprotein-lipid composition in premenopausal women. Clin Invest Med 
1989;12(6):374-80. 
84. Bauer KW, Marcus MD, El ghormli L, et al. Cardio-metabolic risk screening among 
adolescents: understanding the utility of body mass index, waist circumference 
and waist to height ratio. Pediatr Obes 2015;10(5):329-37. 
85. Lee S, Bacha F, Arslanian SA. Waist circumference, blood pressure, and lipid 
components of the metabolic syndrome. J Pediatr 2006;149(6):809-16. 
86. Kawada T, Andou T, Fukumitsu M. Waist circumference, visceral abdominal fat 
thickness and three components of metabolic syndrome. Diabetes Metab Syndr 
2016;10(1):4-6. 
87. Savva SC, Tornaritis M, Savva ME, et al. Waist circumference and waist-to-height 
ratio are better predictors of cardiovascular disease risk factors in children than 
body mass index. Int J Obes Relat Metab Disord 2000;24(11):1453-8. 
88. Eisenmann JC. Waist circumference percentiles for 7- to 15-year-old Australian 
children. Acta Paediatr 2005;94(9):1182-5. 
89. Clemente AP, Netto BD, de Carvalho-Ferreira JP, et al. [Waist circumference as a 
marker for screening nonalcoholic fatty liver disease in obese adolescents]. Rev 
Paul Pediatr 2016;34(1):47-55. 
90. Garnett SP, Baur LA, Cowell CT. Waist-to-height ratio: a simple option for 
determining excess central adiposity in young people. Int J Obes (Lond) 
2008;32(6):1028-30. 
   
  CHAPTER 8 REFERENCES 
199 
91. Graves L, Garnett SP, Cowell CT, et al. Waist-to-height ratio and cardiometabolic 
risk factors in adolescence: findings from a prospective birth cohort. Pediatr 
Obes 2013. 
92. Schwandt P, Haas GM. Is the ratio waist circumference to height (WHtR) of 0.5 a 
universal measure for abdominal adiposity in children and adolescents? Int J 
Obes (Lond) 2016. 
93. Inokuchi M, Matsuo N, Takayama JI, et al. Waist-to-height ratio centiles by age and 
sex for Japanese children based on the 1978–1981 cross-sectional national survey 
data. Int J Obes (Lond) 2015;40(1):65-70. 
94. Kahn HS, Imperatore G, Cheng YJ. A population-based comparison of BMI 
percentiles and waist-to-height ratio for identifying cardiovascular risk in youth. J 
Pediatr 2005;146(4):482-8. 
95. Freedman DS, Serdula MK, Srinivasan SR, et al. Relation of circumferences and 
skinfold thicknesses to lipid and insulin concentrations in children and 
adolescents: the Bogalusa Heart Study. Am J Clin Nutr 1999;69(2):308-17. 
 96. McCarthy HD, Ashwell M. A study of central fatness using waist-to-height ratios in 
UK children and adolescents over two decades supports the simple message--
'keep your waist circumference to less than half your height'. Int J Obes (Lond) 
2006;30(6):988-92. 
97. Adegbija O, Hoy WE, Wang Z. Waist circumference values equivalent to body mass 
index points for predicting absolute cardiovascular disease risks among adults in 
an Aboriginal community: a prospective cohort study. BMJ Open 
2015;5(11):e009185. 
98. Fuller NJ, Jebb SA, Laskey MA, et al. Four-component model for the assessment of 
body composition in humans: comparison with alternative methods, and 
evaluation of the density and hydration of fat-free mass. Clin Sci (Lond) 
1992;82(6):687-93. 
99. Lohman TG. Applicability of body composition techniques and constants for 
children and youths. Exerc Sport Sci Rev 1986;14:325-57. 
100. Knapp KM, Welsman JR, Hopkins SJ, et al. Obesity increases precision errors in 
total body dual-energy x-ray absorptiometry measurements. Journal of Clinical 
Densitometry 2015;18(2):209-16. 
101. Rajamanohara R, Robinson J, Rymer J, et al. The effect of weight and weight change 
on the long-term precision of spine and hip DXA measurements. Osteoporos Int 
2011;22(5):1503-12. 
102. Batch JA, Baur LA. 3. Management and prevention of obesity and its complications 
in children and adolescents. The Medical journal of Australia 2005;182(3):130-5. 
103. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. 
Diabetes 1988;37(12):1595-607. 
104. Tobisch B, Blatniczky L, Barkai L. Cardiometabolic risk factors and insulin 
resistance in obese children and adolescents: relation to puberty. Pediatr Obes 
2015;10(1):37-44. 
105. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple 
cardiovascular risk factors and atherosclerosis in children and young adults. The 
Bogalusa Heart Study. N Engl J Med 1998;338(23):1650-6. 
106. Sakuragi S, Abhayaratna K, Gravenmaker KJ, et al. Influence of adiposity and 
physical activity on arterial stiffness in healthy children: the lifestyle of our kids 
study. Hypertension 2009;53(4):611-6. 
107. Ho M, Benitez-Aguirre PZ, Donaghue KC, et al. Arterial elasticity in obese 
adolescents with clinical features of insulin resistance. Diab Vasc Dis Res 
2015;12(1):62-9. 
   
  CHAPTER 8 REFERENCES 
200 
108. Berenson GS, Dalferes E, Jr., Savage D, et al. Ambulatory blood pressure 
measurements in children and young adults selected by high and low casual blood 
pressure levels and parental history of hypertension: the Bogalusa Heart Study. 
Am J Med Sci 1993;305(6):374-82. 
109. Eklioglu BS, Atabek ME, Akyurek N, et al. Prediabetes and Cardiovascular 
Parameters in Obese Children and Adolescents. J Clin Res Pediatr Endocrinol 
2016;8(1):80-5. 
110. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors 
among US adolescents, 1999-2008. Pediatrics 2012;129(6):1035-41. 
111. Pettitt DJ, Nelson RG, Saad MF, et al. Diabetes and obesity in the offspring of Pima 
Indian women with diabetes during pregnancy. Diabetes Care 1993;16(1):310-4. 
112. Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for type 2 
diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. 
J Pediatr Endocrinol Metab 2001;14(8):1085-91. 
113. Phillips DI, Jones A, Goulden PA. Birth weight, stress, and the metabolic syndrome 
in adult life. Ann N Y Acad Sci 2006;1083:28-36. 
114. Pettitt DJ, Forman MR, Hanson RL, et al. Breastfeeding and incidence of non-
insulin-dependent diabetes mellitus in Pima Indians. Lancet 1997;350(9072):166-
8. 
115. Eriksson JG, Forsen T, Tuomilehto J, et al. Early adiposity rebound in childhood 
and risk of Type 2 diabetes in adult life. Diabetologia 2003;46(2):190-4. 
116. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of 
High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 
2001;285(19):2486-97. 
117. Reinehr T, Wolters B, Knop C, et al. Strong effect of pubertal status on metabolic 
health in obese children: a longitudinal study. J Clin Endocrinol Metab 
2015;100(1):301-8. 
118. Reinehr T. Metabolic Syndrome in Children and Adolescents: a Critical Approach 
Considering the Interaction between Pubertal Stage and Insulin Resistance. Curr 
Diab Rep 2016;16(1):8. 
119. Cook S, Weitzman M, Auinger P, et al. Prevalence of a metabolic syndrome 
phenotype in adolescents: findings from the third National Health and Nutrition 
Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003;157(8):821-7. 
120. Duncan GE, Li SM, Zhou XH. Prevalence and trends of a metabolic syndrome 
phenotype among u.s. Adolescents, 1999-2000. Diabetes Care 2004;27(10):2438-
43. 
121. Shaibi GQ, Goran MI. Examining metabolic syndrome definitions in overweight 
Hispanic youth: a focus on insulin resistance. J Pediatr 2008;152(2):171-6. 
122. Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and 
adolescents - an IDF consensus report. Pediatr Diabetes 2007;8(5):299-306. 
123. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. 
A Consensus Statement from the International Diabetes Federation. Diabet Med 
2006;23(5):469-80. 
124. Katzmarzyk PT, Perusse L, Malina RM, et al. Stability of indicators of the metabolic 
syndrome from childhood and adolescence to young adulthood: the Quebec 
Family Study. J Clin Epidemiol 2001;54(2):190-5. 
125. Sun SS, Liang R, Huang TT, et al. Childhood obesity predicts adult metabolic 
syndrome: the Fels Longitudinal Study. J Pediatr 2008;152(2):191-200. 
   
  CHAPTER 8 REFERENCES 
201 
126. Kursawe R, Eszlinger M, Narayan D, et al. Cellularity and adipogenic profile of the 
abdominal subcutaneous adipose tissue from obese adolescents: association with 
insulin resistance and hepatic steatosis. Diabetes 2010;59(9):2288-96. 
127. Sinaiko AR, Donahue RP, Jacobs DR, Jr., et al. Relation of weight and rate of 
increase in weight during childhood and adolescence to body size, blood 
pressure, fasting insulin, and lipids in young adults. The Minneapolis Children's 
Blood Pressure Study. Circulation 1999;99(11):1471-6. 
128. Ter Horst KW, Gilijamse PW, Koopman KE, et al. Insulin resistance in obesity can 
be reliably identified from fasting plasma insulin. Int J Obes (Lond) 2015. 
129. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among 
children and adolescents with marked obesity. N Engl J Med 2002;346(11):802-
10. 
130. Giannini C, Caprio S. Progression of -cell dysfunction in obese youth. Curr Diab 
Rep 2013;13(1):89-95. 
131. Yeckel CW, Taksali SE, Dziura J, et al. The normal glucose tolerance continuum in 
obese youth: evidence for impairment in beta-cell function independent of 
insulin resistance. J Clin Endocrinol Metab 2005;90(2):747-54. 
132. Centers for Disease Control and Prevention. National diabetes fact sheet: national 
estimates and general information on dabetes and prediabetes in the United 
States, 2011. Atlanta, GA: U.S. Dpeartment of Health and Human Services, 
Centers for Disease Control and Prevention 2011. [Last accessed June 2016 
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.] 
133. Mirbolouk M, Derakhshan A, Charkhchi P, et al. Incidence and predictors of early 
adulthood pre-diabetes/type 2 diabetes, among Iranian adolescents: the Tehran 
Lipid and Glucose Study. Pediatr Diabetes 2016. 
134. Goulding A, Taylor RW, Jones IE, et al. Overweight and obese children have low 
bone mass and area for their weight. Int J Obes Relat Metab Disord 
2000;24(5):627-32. 
135. Goulding A, Jones IE, Taylor RW, et al. More broken bones: a 4-year double cohort 
study of young girls with and without distal forearm fractures. Journal of bone 
and mineral research : the official journal of the American Society for Bone and 
Mineral Research 2000;15(10):2011-8. 
136. Taylor ED, Theim KR, Mirch MC, et al. Orthopedic complications of overweight in 
children and adolescents. Pediatrics 2006;117(6):2167-74. 
137. Goulding A, Jones IE, Taylor RW, et al. Dynamic and static tests of balance and 
postural sway in boys: effects of previous wrist bone fractures and high adiposity. 
Gait Posture 2003;17(2):136-41. 
138. Leonard MB, Shults J, Wilson BA, et al. Obesity during childhood and adolescence 
augments bone mass and bone dimensions. Am J Clin Nutr 2004;80(2):514-23. 
139. Maggio AB, Belli DC, Puigdefabregas JW, et al. High bone density in adolescents 
with obesity is related to fat mass and serum leptin concentrations. J Pediatr 
Gastroenterol Nutr 2014;58(6):723-8. 
140. Whiting SJ. Obesity is not protective for bones in childhood and adolescence. Nutr 
Rev 2002;60(1):27-30. 
141. Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: 
effects of dietary calcium, physical activity, and body mass index. Journal of bone 
and mineral research : the official journal of the American Society for Bone and 
Mineral Research 2000;15(2):322-31. 
142. Dimitri P, Bishop N, Walsh JS, et al. Obesity is a risk factor for fracture in children 
but is protective against fracture in adults: a paradox. Bone 2012;50(2):457-66. 
   
  CHAPTER 8 REFERENCES 
202 
143. Asomaning K, Bertone-Johnson ER, Nasca PC, et al. The association between body 
mass index and osteoporosis in patients referred for a bone mineral density 
examination. J Womens Health (Larchmt) 2006;15(9):1028-34. 
144. Larson NI, Wall MM, Story MT, et al. Home/family, peer, school, and 
neighborhood correlates of obesity in adolescents. Obesity (Silver Spring) 
2013;21(9):1858-69. 
145. Salvy SJ, Miles JN, Shih RA, et al. Neighborhood, Family and Peer-Level Predictors 
of Obesity-Related Health Behaviors Among Young Adolescents. J Pediatr 
Psychol 2016. 
146. Nguyen B, McGregor KA, O'Connor J, et al. Recruitment challenges and 
recommendations for adolescent obesity trials. J Paediatr Child Health 
2012;48(1):38-43. 
147. Golley RK, Magarey AM, Baur LA, et al. Twelve-month effectiveness of a parent-
led, family-focused weight-management program for prepubertal children: a 
randomized, controlled trial. Pediatrics 2007;119(3):517-25. 
148. Shrewsbury VA, Steinbeck KS, Torvaldsen S, et al. The role of parents in pre-
adolescent and adolescent overweight and obesity treatment: a systematic review 
of clinical recommendations. Obes Rev 2011;12(10):759-69. 
149. Mellin LM, Slinkard LA, Irwin CE, Jr. Adolescent obesity intervention: validation of 
the SHAPEDOWN program. J Am Diet Assoc 1987;87(3):333-8. 
150. Barlow SE, Expert C. Expert committee recommendations regarding the 
prevention, assessment, and treatment of child and adolescent overweight and 
obesity: summary report. Pediatrics 2007;120 Suppl 4:S164-92. 
151. Booth ML, Macaskill P, Lazarus R, et al. Sociodemographic distribution of measures 
of body fatness among children and adolescents in New South Wales, Australia. 
Int J Obes Relat Metab Disord 1999;23(5):456-62. 
152. Garnett SP, Gow M, Ho M, et al. Improved insulin sensitivity and body 
composition, irrespective of macronutrient intake, after a 12 month intervention 
in adolescents with pre-diabetes; RESIST a randomised control trial. BMC 
Pediatr 2014;14:289. 
153. Garnett SP, Gow M, Ho M, et al. Optimal macronutrient content of the diet for 
adolescents with prediabetes; RESIST a randomised control trial. J Clin 
Endocrinol Metab 2013;98(5):2116-25. 
154. Ho M, Garnett SP, Baur LA, et al. Impact of dietary and exercise interventions on 
weight change and metabolic outcomes in obese children and adolescents: a 
systematic review and meta-analysis of randomized trials. JAMA Pediatr 
2013;167(8):759-68. 
155. Council NHaMR. Australian Dietary Guidelines. Canberra: National Health and 
Medical Research Council, 2013. 
156. Crume TLPHD, Ogden LPHD, Maligie MBS, et al. Long-Term Impact of Neonatal 
Breastfeeding on Childhood Adiposity and Fat Distribution Among Children 
Exposed to Diabetes In Utero. Diabetes Care 2011;34(3):641-45. 
157. Kalarchian MA, Levine MD, Arslanian SA, et al. Family-based treatment of severe 
pediatric obesity: randomized, controlled trial. Pediatrics 2009;124(4):1060-8. 
158. Kalarchian MA, Levine MD, Marcus MD. Structured Dietary Interventions in the 
Treatment of Severe Pediatric Obesity: A Pilot Study. Bariatr Surg Pract Patient 
Care 2013;8(2):58-60. 
159. Ho M, Gow M, Halim J, et al. Effect of a prescriptive dietary intervention on 
psychological dimensions of eating behavior in obese adolescents. Int J Behav 
Nutr Phys Act 2013;10:119. 
   
  CHAPTER 8 REFERENCES 
203 
160. Gow ML, Ho M, Burrows TL, et al. Impact of dietary macronutrient distribution on 
BMI and cardiometabolic outcomes in overweight and obese children and 
adolescents: a systematic review. Nutr Rev 2014;72(7):453-70. 
161. Joslowski G, Halim J, Goletzke J, et al. Dietary glycemic load, insulin load, and 
weight loss in obese, insulin resistant adolescents: RESIST study. Clin Nutr 
2015;34(1):89-94. 
162. O'Sullivan TA, Bremner AP, Bremer HK, et al. Dairy product consumption, dietary 
nutrient and energy density and associations with obesity in Australian 
adolescents. J Hum Nutr Diet 2015;28(5):452-64. 
163. Wang W, Wu Y, Zhang D. Association of dairy products consumption with risk of 
obesity in children and adults: a meta-analysis of mainly cross-sectional studies. 
Ann Epidemiol 2016;26(12):870-82 e2. 
164. Vien S, Luhovyy BL, Patel BP, et al. Pre- and within-meal effects of fluid dairy 
products on appetite, food intake, glycemia, and regulatory hormones in children. 
Appl Physiol Nutr Metab 2017;42(3):302-10. 
165. Australian Government. Australia’s Physical Activity & Sedentary Behaviour 
Guidelines for Young People (13 -17 years) Canberra: Department of Health; 
2014 Last accessed June 2016. [Available from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/F01F92328E
DADA5BCA257BF0001E720D/$File/brochure PA Guidelines_A5_13-
17yrs.PDF. 
166. Astrand I, Astrand PO, Christensen EH, et al. Intermittent muscular work. Acta 
Physiol Scand 1960;48:448-53. 
167. Gibala MJ, McGee SL. Metabolic adaptations to short-term high-intensity interval 
training: a little pain for a lot of gain? Exerc Sport Sci Rev 2008;36(2):58-63. 
168. Sculthorpe NF, Herbert P, Grace F. One session of high-intensity interval training 
(HIIT) every 5 days, improves muscle power but not static balance in lifelong 
sedentary ageing men: A randomized controlled trial. Medicine (Baltimore) 
2017;96(6):e6040. 
169. Fisher G, Brown AW, Bohan Brown MM, et al. High Intensity Interval- vs 
Moderate Intensity- Training for Improving Cardiometabolic Health in 
Overweight or Obese Males: A Randomized Controlled Trial. PLoS One 
2015;10(10):e0138853. 
170. Lanzi S, Codecasa F, Cornacchia M, et al. Short-term HIIT and Fat max training 
increase aerobic and metabolic fitness in men with class II and III obesity. 
Obesity (Silver Spring) 2015;23(10):1987-94. 
171. Martin R, Buchan DS, Baker JS, et al. Sprint interval training (SIT) is an effective 
method to maintain cardiorespiratory fitness (CRF) and glucose homeostasis in 
Scottish adolescents. Biol Sport 2015;32(4):307-13. 
172. Corte de Araujo AC, Roschel H, Picanco AR, et al. Similar health benefits of 
endurance and high-intensity interval training in obese children. PLoS One 
2012;7(8):e42747. 
173. Leech RM, McNaughton SA, Timperio A. Clustering of diet, physical activity and 
sedentary behaviour among Australian children: cross-sectional and longitudinal 
associations with overweight and obesity. Int J Obes (Lond) 2015;39(7):1079-85. 
174. Whitaker RC, Wright JA, Pepe MS, et al. Predicting obesity in young adulthood 
from childhood and parental obesity. N Engl J Med 1997;337(13):869-73. 
175. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. 
International Journal of Pediatric Obesity 2006;1(1):11-25. 
   
  CHAPTER 8 REFERENCES 
204 
176. Zeller MH, Modi AC. Development and initial validation of an obesity-specific 
quality-of-life measure for children: sizing me up. Obesity (Silver Spring) 
2009;17(6):1171-7. 
177. Williams RH, & Larsen, P. R. Williams textbook of endocrinology. 11th ed. ed. 
Philadelphia, Pa: Saunders, 2008. 
178. Gonzalez-Jimenez E, Schmidt-RioValle J, Montero-Alonso MA, et al. Influence of 
Biochemical and Anthropometric Factors on the Presence of Insulin Resistance 
in Adolescents. Biol Res Nurs 2016. 
179. Cree-Green M, Triolo TM, Nadeau KJ. Etiology of insulin resistance in youth with 
type 2 diabetes. Curr Diab Rep 2013;13(1):81-8. 
180. Romualdo MC, Nobrega FJ, Escrivao MA. Insulin resistance in obese children and 
adolescents. J Pediatr (Rio J) 2014;90(6):600-7. 
181. Cruz ML, Shaibi GQ, Weigensberg MJ, et al. Pediatric obesity and insulin resistance: 
chronic disease risk and implications for treatment and prevention beyond body 
weight modification. Annu Rev Nutr 2005;25:435-68. 
182. Rodden A, Diaz V, Mainousiii A, et al. Insulin Resistance in Adolescents. J Pediatr 
2007;151(3):275-79. 
183. Yi KH, Hwang JS, Kim EY, et al. Prevalence of insulin resistance and 
cardiometabolic risk in Korean children and adolescents: a population-based 
study. Diabetes Res Clin Pract 2014;103(1):106-13. 
184. Manios Y, Moschonis G, Kourlaba G, et al. Prevalence and independent predictors 
of insulin resistance in children from Crete, Greece: the Children Study. Diabet 
Med 2008;25(1):65-72. 
185. Lee JM, Okumura MJ, Davis MM, et al. Prevalence and determinants of insulin 
resistance among U.S. adolescents: a population-based study. Diabetes care 
2006;29(11):2427-32. 
186. Bahillo-Curieses MP, Hermoso-Lopez F, Martinez-Sopena MJ, et al. Prevalence of 
insulin resistance and impaired glucose tolerance in a sample of obese Spanish 
children and adolescents. Endocrine 2012;41(2):289-95. 
187. Baranowski T, Cooper DM, Harrell J, et al. Presence of diabetes risk factors in a 
large U.S. eighth-grade cohort. Diabetes Care 2006;29(2):212-7. 
188. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling 
glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose 
sensitivity from the response to intravenous glucose. J Clin Invest 
1981;68(6):1456-67. 
189. Cobelli C, Toffolo GM, Dalla Man C, et al. Assessment of beta-cell function in 
humans, simultaneously with insulin sensitivity and hepatic extraction, from 
intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 
2007;293(1):E1-E15. 
190. Arslanian SA, Bacha F, Saad R, et al. Family history of type 2 diabetes is associated 
with decreased insulin sensitivity and an impaired balance between insulin 
sensitivity and insulin secretion in white youth. Diabetes Care 2005;28(1):115-9. 
191. Danadian K, Balasekaran G, Lewy V, et al. Insulin sensitivity in African-American 
children with and without family history of type 2 diabetes. Diabetes Care 
1999;22(8):1325-9. 
192. Weiss R, Taksali SE, Tamborlane WV, et al. Predictors of changes in glucose 
tolerance status in obese youth. Diabetes Care 2005;28(4):902-9. 
193. Ferrannini E, Gastaldelli A, Miyazaki Y, et al. beta-Cell function in subjects 
spanning the range from normal glucose tolerance to overt diabetes: a new 
analysis. J Clin Endocrinol Metab 2005;90(1):493-500. 
   
  CHAPTER 8 REFERENCES 
205 
194. Pratipanawatr W, Pratipanawatr T, Cusi K, et al. Skeletal muscle insulin resistance in 
normoglycemic subjects with a strong family history of type 2 diabetes is 
associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine 
phosphorylation. Diabetes 2001;50(11):2572-8. 
195. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance 
in development of type 2 diabetes mellitus: results of a 25-year follow-up study. 
Lancet 1992;340(8825):925-9. 
196. Di Bonito P, Sanguigno E, Forziato C, et al. Fasting plasma glucose and clustering 
of cardiometabolic risk factors in normoglycemic outpatient children and 
adolescents. Diabetes care 2011;34(6):1412-4. 
197. Gutknecht DR. Higher values of fasting plasma glucose within the normal range 
were associated with increased risk of type 2 diabetes. Evid Based Med 
2008;13(6):186. 
198. Saad MF, Knowler WC, Pettitt DJ, et al. The natural history of impaired glucose 
tolerance in the Pima Indians. N Engl J Med 1988;319(23):1500-6. 
199. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired 
glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 
1997;46(4):701-10. 
200. Weiss R, Dufour S, Taksali SE, et al. Prediabetes in obese youth: a syndrome of 
impaired glucose tolerance, severe insulin resistance, and altered myocellular and 
abdominal fat partitioning. Lancet 2003;362(9388):951-7. 
201. Barker DJ, Osmond C, Simmonds SJ, et al. The relation of small head 
circumference and thinness at birth to death from cardiovascular disease in adult 
life. Bmj 1993;306(6875):422-6. 
202. Nicholas LM, Morrison JL, Rattanatray L, et al. The early origins of obesity and 
insulin resistance: timing, programming and mechanisms. Int J Obes (Lond) 
2016;40(2):229-38. 
203. Hofman PL, Regan F, Jackson WE, et al. Premature birth and later insulin 
resistance. N Engl J Med 2004;351(21):2179-86. 
204. Derraik JG, Mathai S, Chiavaroli V, et al. Preterm birth is associated with an 
intergenerational effect on cardio-metabolic risk. Clin Endocrinol (Oxf) 
2015;83(3):439-40. 
205. Gluckman PD, Cutfield W, Hofman P, et al. The fetal, neonatal, and infant 
environments-the long-term consequences for disease risk. Early human 
development 2005;81(1):51-9. 
206. Hofman PL, Cutfield WS. Insulin sensitivity in people born pre-term, with low or 
very low birth weight and small for gestational age. J Endocrinol Invest 
2006;29(1 Suppl):2-8. 
207. Chiavaroli V, Derraik JG, Hofman PL, et al. Born Large for Gestational Age: Bigger 
Is Not Always Better. J Pediatr 2016;170:307-11. 
208. Derraik JG, Ayyavoo A, Hofman PL, et al. Increasing maternal prepregnancy body 
mass index is associated with reduced insulin sensitivity and increased blood 
pressure in their children. Clin Endocrinol (Oxf) 2015;83(3):352-6. 
209. Jefferies CA, Hofman PL, Knoblauch H, et al. Insulin resistance in healthy 
prepubertal twins. J Pediatr 2004;144(5):608-13. 
210. Jefferies CA, Hofman PL, Wong W, et al. Increased nocturnal blood pressure in 
healthy prepubertal twins. J Hypertens 2003;21(7):1319-24. 
211. Levy-Marchal C, Jaquet D. Long-term metabolic consequences of being born small 
for gestational age. Pediatr Diabetes 2004;5(3):147-53. 
212. Grella PV. Low birth weight and early life origins of adult disease: insulin resistance 
and type 2 diabetes. Clin Exp Obstet Gynecol 2007;34(1):9-13. 
   
  CHAPTER 8 REFERENCES 
206 
213. Hofman PL, Regan F, Jefferies CA, et al. Prematurity and programming: are there 
later metabolic sequelae? Metab Syndr Relat Disord 2006;4(2):101-12. 
214. Duque-Guimaraes DE, Ozanne SE. Nutritional programming of insulin resistance: 
causes and consequences. Trends in endocrinology and metabolism: TEM 
2013;24(10):525-35. 
215. Mathai S, Cutfield WS, Derraik JG, et al. Insulin sensitivity and beta-cell function in 
adults born preterm and their children. Diabetes 2012;61(10):2479-83. 
216. Ayyavoo A, Savage T, Derraik JGB, et al. First-born children have reduced insulin 
sensitivity and higher daytime blood pressure compared to later-born children. 
Journal of Clinical Endocrinology & Metabolism 2013;98(3):1248-53. 
217. Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and 
cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 
2003;88(4):1417-27. 
218. Goran MI, Lane C, Toledo-Corral C, et al. Persistence of pre-diabetes in overweight 
and obese Hispanic children: association with progressive insulin resistance, poor 
beta-cell function, and increasing visceral fat. Diabetes 2008;57(11):3007-12. 
219. Taylor RW, Grant AM, Williams SM, et al. Sex differences in regional body fat 
distribution from pre- to postpuberty. Obesity (Silver Spring) 2010;18(7):1410-6. 
220. Moran A, Jacobs DR, Jr., Steinberger J, et al. Insulin resistance during puberty: 
results from clamp studies in 357 children. Diabetes 1999;48(10):2039-44. 
221. Saad RJ, Danadian K, Lewy V, et al. Insulin resistance of puberty in African-
American children: lack of a compensatory increase in insulin secretion. Pediatr 
Diabetes 2002;3(1):4-9. 
222. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 
2001;50(11):2444-50. 
223. Staiano AE, Katzmarzyk PT. Ethnic and sex differences in body fat and visceral and 
subcutaneous adiposity in children and adolescents. Int J Obes (Lond) 
2012;36(10):1261-9. 
224. Jeffery AN, Metcalf BS, Hosking J, et al. Age before stage: insulin resistance rises 
before the onset of puberty: a 9-year longitudinal study (EarlyBird 26). Diabetes 
Care 2012;35(3):536-41. 
225. Arslanian SA, Kalhan SC. Correlations between fatty acid and glucose metabolism. 
Potential explanation of insulin resistance of puberty. Diabetes 1994;43(7):908-
14. 
226. Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin 
resistance and metabolic changes of puberty. Pediatr Res 2006;60(6):759-63. 
227. Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological 
treatment of insulin resistance. Endocr Rev 2000;21(6):585-618. 
228. Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol 
Metab 2006;20(4):665-79. 
229. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-
dependent diabetes mellitus: contributions of excessive hepatic glucose 
production and impaired tissue glucose uptake. Metabolism 1989;38(4):387-95. 
230. Wilding JP. The importance of free fatty acids in the development of Type 2 
diabetes. Diabet Med 2007;24(9):934-45. 
231. Armato J, DeFronzo RA, Abdul-Ghani M, et al. Successful treatment of prediabetes 
in clinical practice: targeting insulin resistance and beta-cell dysfunction. 
Endocrine Practice;18(3):342-50. 
232. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 
diabetes: close association with insulin resistance and hyperinsulinemia. J Clin 
Endocrinol Metab 2001;86(5):1930-5. 
   
  CHAPTER 8 REFERENCES 
207 
233. Maahs DM, Hamman RF, D'Agostino R, Jr., et al. The association between 
adiponectin/leptin ratio and diabetes type: the SEARCH for Diabetes in Youth 
Study. J Pediatr 2009;155(1):133-5, 35 e1. 
234. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose 
utilization and fatty-acid oxidation by activating AMP-activated protein kinase. 
Nat Med 2002;8(11):1288-95. 
235. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. 
Trends in endocrinology and metabolism: TEM 2000;11(9):351-6. 
236. Boden G, Chen X, Rosner J, et al. Effects of a 48-h fat infusion on insulin secretion 
and glucose utilization. Diabetes 1995;44(10):1239-42. 
237. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other 
circulating markers of inflammation in the prediction of coronary heart disease. 
N Engl J Med 2004;350(14):1387-97. 
238. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart 
disease: prospective study and updated meta-analyses. Bmj 2000;321(7255):199-
204. 
239. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of 
C-reactive protein among U.S. youth. Diabetes Care 2005;28(4):878-81. 
240. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese 
individuals. Current opinion in lipidology 2010;21(1):38-43. 
241. Weiss R, Taksali SE, Dufour S, et al. The "obese insulin-sensitive" adolescent: 
importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab 
2005;90(6):3731-7. 
242. Prince RL, Kuk JL, Ambler KA, et al. Predictors of metabolically healthy obesity in 
children. Diabetes Care 2014;37(5):1462-8. 
243. Caprio S, Hyman LD, Limb C, et al. Central adiposity and its metabolic correlates in 
obese adolescent girls. Am J Physiol 1995;269(1 Pt 1):E118-26. 
244. Taksali SE, Caprio S, Dziura J, et al. High visceral and low abdominal subcutaneous 
fat stores in the obese adolescent: a determinant of an adverse metabolic 
phenotype. Diabetes 2008;57(2):367-71. 
245. Goran MI, Gower BA. Abdominal obesity and cardiovascular risk in children. 
Coronary artery disease 1998;9(8):483-7. 
246. Maffeis C, Manfredi R, Trombetta M, et al. Insulin sensitivity is correlated with 
subcutaneous but not visceral body fat in overweight and obese prepubertal 
children. J Clin Endocrinol Metab 2008;93(6):2122-8. 
247. Lara-Castro C, Garvey WT. Intracellular lipid accumulation in liver and muscle and 
the insulin resistance syndrome. Endocrinol Metab Clin North Am 
2008;37(4):841-56. 
248. Lee JA, Laurson KR. Obesity and Insulin Resistance Screening Tools in American 
Adolescents: National Health and Nutrition Examination Survey (NHANES) 
1999 to 2010. Can J Diabetes 2016. 
249. Goran MI, Nagy TR, Treuth MS, et al. Visceral fat in white and African American 
prepubertal children. Am J Clin Nutr 1997;65(6):1703-8. 
250. Araneta MR, Barrett-Connor E. Ethnic differences in visceral adipose tissue and 
type 2 diabetes: Filipino, African-American, and white women. Obes Res 
2005;13(8):1458-65. 
251. Wang L, Sacks FM, Furtado JD, et al. Racial differences between African-American 
and white women in insulin resistance and visceral adiposity are associated with 
differences in apoCIII containing apoAI and apoB lipoproteins. Nutr Metab 
(Lond) 2014;11(1):56. 
   
  CHAPTER 8 REFERENCES 
208 
252. Goran MI, Bergman RN, Gower BA. Influence of total vs. visceral fat on insulin 
action and secretion in African American and white children. Obes Res 
2001;9(8):423-31. 
253. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling 
the mechanism. Lancet 2010;375(9733):2267-77. 
254. Yeckel CW. Validation of Insulin Sensitivity Indices from Oral Glucose Tolerance 
Test Parameters in Obese Children and Adolescents. Journal of Clinical 
Endocrinology & Metabolism 2004;89(3):1096-101. 
255. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu 
Rev Med 1998;49:235-61. 
256. Yaspelkis BB, 3rd. Resistance training improves insulin signaling and action in 
skeletal muscle. Exerc Sport Sci Rev 2006;34(1):42-6. 
257. Twigg SM, Kamp MC, Davis TM, et al. Prediabetes: a position statement from the 
Australian Diabetes Society and Australian Diabetes Educators Association. Med 
J Aust 2007;186(9):461-5. 
258. Craig ME, Jefferies C, Dabelea D, et al. ISPAD Clinical Practice Consensus 
Guidelines 2014. Definition, epidemiology, and classification of diabetes in 
children and adolescents. Pediatr Diabetes 2014;15 Suppl 20:4-17. 
259. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes 
Care 2014;37 Suppl 1:S81-90. 
260. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for 
quantifying insulin secretion and resistance. Am J Physiol 1979;237(3):E214-23. 
261. Bergman RN, Hope ID, Yang YJ, et al. Assessment of insulin sensitivity in vivo: a 
critical review. Diabetes Metab Rev 1989;5(5):411-29. 
262. Bergman RN, Prager R, Volund A, et al. Equivalence of the insulin sensitivity index 
in man derived by the minimal model method and the euglycemic glucose clamp. 
J Clin Invest 1987;79(3):790-800. 
263. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin 
sensitivity and pancreatic responsivity from the frequently sampled intravenous 
glucose tolerance test. Comput Methods Programs Biomed 1986;23(2):113-22. 
264. Coates PA, Luzio SD, Brunel P, et al. Comparison of estimates of insulin sensitivity 
from minimal model analysis of the insulin-modified frequently sampled 
intravenous glucose tolerance test and the isoglycemic hyperinsulinemic clamp in 
subjects with NIDDM. Diabetes 1995;44(6):631-5. 
265. Pratt-Phillips SE, Geor RJ, McCutcheon LJ. Comparison among the euglycemic-
hyperinsulinemic clamp, insulin-modified frequently sampled intravenous glucose 
tolerance test, and oral glucose tolerance test for assessment of insulin sensitivity 
in healthy Standardbreds. American journal of veterinary research 2015;76(1):84-
91. 
266. Monzillo LU, Hamdy O. Evaluation of insulin sensitivity in clinical practice and in 
research settings. Nutr Rev 2003;61(12):397-412. 
267. Uwaifo GI, Fallon EM, Chin J, et al. Indices of insulin action, disposal, and 
secretion derived from fasting samples and clamps in normal glucose-tolerant 
black and white children. Diabetes Care 2002;25(11):2081-7. 
268. Gungor N, Saad R, Janosky J, et al. Validation of surrogate estimates of insulin 
sensitivity and insulin secretion in children and adolescents. J Pediatr 
2004;144(1):47-55. 
269. Conwell LS, Trost SG, Brown WJ, et al. Indexes of insulin resistance and secretion 
in obese children and adolescents: a validation study. Diabetes Care 
2004;27(2):314-9. 
   
  CHAPTER 8 REFERENCES 
209 
270. Schwartz B, Jacobs DR, Jr., Moran A, et al. Measurement of insulin sensitivity in 
children: comparison between the euglycemic-hyperinsulinemic clamp and 
surrogate measures. Diabetes Care 2008;31(4):783-8. 
271. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. Effects of insulin on peripheral 
and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes 
mellitus. J Clin Invest 1985;76(1):149-55. 
272. Abdul-Ghani MA, Lyssenko V, Tuomi T, et al. Fasting versus postload plasma 
glucose concentration and the risk for future type 2 diabetes: results from the 
Botnia Study. Diabetes Care 2009;32(2):281-6. 
273. Abdul-Ghani MA, Abdul-Ghani T, Ali N, et al. One-hour plasma glucose 
concentration and the metabolic syndrome identify subjects at high risk for 
future type 2 diabetes. Diabetes Care 2008;31(8):1650-5. 
274. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, 
specific insulin and proinsulin concentrations measured by two oral glucose 
tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 
1996;39(3):298-305. 
275. Soonthornpun S, Setasuban W, Thamprasit A, et al. Novel insulin sensitivity index 
derived from oral glucose tolerance test. J Clin Endocrinol Metab 
2003;88(3):1019-23. 
276. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose 
tolerance testing: comparison with the euglycemic insulin clamp. Diabetes care 
1999;22(9):1462-70. 
277. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to 
assess insulin release and insulin sensitivity. Diabetes Care 2000;23(3):295-301. 
278. Maki KC, Rains TM, Dicklin MR, et al. Repeatability of indices of insulin sensitivity 
and secretion from standard liquid meal tests in subjects with type 2 diabetes 
mellitus or normal or impaired fasting glucose. Diabetes Technol Ther 
2010;12(11):895-900. 
279. Abdul-Ghani MA, Matsuda M, Balas B, et al. Muscle and liver insulin resistance 
indexes derived from the oral glucose tolerance test. Diabetes Care 
2007;30(1):89-94. 
280. Levy-Marchal C, Arslanian S, Cutfield W, et al. Insulin resistance in children: 
consensus, perspective, and future directions. J Clin Endocrinol Metab 
2010;95(12):5189-98. 
281. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 
1998;16(7):895-906. 
282. Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. Diabetes 
Metab 1999;25(6):459-76. 
283. Lindahl B, Asplund K, Hallmans G. High serum insulin, insulin resistance and their 
associations with cardiovascular risk factors. The northern Sweden MONICA 
population study. Journal of internal medicine 1993;234(3):263-70. 
284. Laakso M. How good a marker is insulin level for insulin resistance? Am J 
Epidemiol 1993;137(9):959-65. 
285. Williams CL. Cardiovascular Health in Childhood: A Statement for Health 
Professionals From the Committee on Atherosclerosis, Hypertension, and 
Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the 
Young, American Heart Association. Circulation 2002;106(1):143-60. 
286. Ten S. Insulin Resistance Syndrome in Children. Journal of Clinical Endocrinology 
& Metabolism 2004;89(6):2526-39. 
287. Adam TC, Hasson RE, Lane CJ, et al. Fasting indicators of insulin sensitivity: 
effects of ethnicity and pubertal status. Diabetes Care 2011;34(4):994-9. 
   
  CHAPTER 8 REFERENCES 
210 
288. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: 
insulin resistance and beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 1985;28(7):412-9. 
289. Fukushima M, Taniguchi A, Sakai M, et al. Assessment of insulin sensitivity: 
comparison between simplified evaluations and minimal model analysis. Diabetes 
Care 2000;23(7):1038-9. 
290. Ascaso JF, Romero P, Real JT, et al. [Insulin resistance quantification by fasting 
insulin plasma values and HOMA index in a non-diabetic population]. Medicina 
clinica 2001;117(14):530-3. 
291. Keskin M. Homeostasis Model Assessment Is More Reliable Than the Fasting 
Glucose/Insulin Ratio and Quantitative Insulin Sensitivity Check Index for 
Assessing Insulin Resistance Among Obese Children and Adolescents. Pediatrics 
2005;115(4):e500-e03. 
292. Sahin NM, Kinik ST, Tekindal MA. OGTT results in obese adolescents with normal 
HOMA-IR values. J Pediatr Endocrinol 2013;26(3-4):285-91. 
293. Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin 
sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. 
Am J Physiol Endocrinol Metab 2008;294(1):E15-26. 
294. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a 
surrogate index for insulin sensitivity using a calibration model. Diabetes 
2005;54(7):1914-25. 
295. Rotterdam EA-SPcwg. Revised 2003 consensus on diagnostic criteria and long-term 
health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 
2004;19(1):41-7. 
296. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinology 
& Metabolism Clinics of North America 2005;34(3):677-705, x. 
297. Ibanez L, Lopez-Bermejo A, Diaz M, et al. Early metformin therapy (age 8-12 years) 
in girls with precocious pubarche to reduce hirsutism, androgen excess, and 
oligomenorrhea in adolescence. Journal of Clinical Endocrinology & Metabolism 
2011;96(8):E1262-7. 
298. Guran T, Turan S, Akcay T, et al. Significance of acanthosis nigricans in childhood 
obesity. J Paediatr Child Health 2008;44(6):338-41. 
299. Brickman WJ, Binns HJ, Jovanovic BD, et al. Acanthosis nigricans: a common 
finding in overweight youth. Pediatric dermatology 2007;24(6):601-6. 
300. Kluczynik CEN, Mariz LS, Souza LCF, et al. Acanthosis nigricans and insulin 
resistance in overweight children and adolescents. An Bras Dermatol 
2012;87(4):531-7. 
301. Nguyen TT, Keil MF, Russell DL, et al. Relation of acanthosis nigricans to 
hyperinsulinemia and insulin sensitivity in overweight African American and 
white children. J Pediatr 2001;138(4):474-80. 
302. Kong AS, Vanderbloemen L, Skipper B, et al. Acanthosis nigricans predicts the 
clustering of metabolic syndrome components in Hispanic elementary school-
aged children. J Pediatr Endocrinol 2012;25(11-12):1095-102. 
303. Brickman WJ, Huang J, Silverman BL, et al. Acanthosis nigricans identifies youth at 
high risk for metabolic abnormalities. J Pediatr 2010;156(1):87-92. 
304. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus 
by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J 
Med 2001;344(18):1343-50. 
305. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on 
Type 2 diabetes prevention. Diabet Med 2007;24(5):451-63. 
   
  CHAPTER 8 REFERENCES 
211 
306. Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European 
clinical practice guidelines. Obes Facts 2008;1(2):106-16. 
307. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular 
risk factors in individuals with type 2 diabetes mellitus: four-year results of the 
Look AHEAD trial. Arch Intern Med 2010;170(17):1566-75. 
308. Ho M, Garnett SP, Baur L, et al. Effectiveness of lifestyle interventions in child 
obesity: systematic review with meta-analysis. Pediatrics 2012;130(6):e1647-71. 
309. Duckworth LC, Gately PJ, Radley D, et al. RCT of a high-protein diet on hunger 
motivation and weight-loss in obese children: an extension and replication. 
Obesity (Silver Spring) 2009;17(9):1808-10. 
310. Gately PJ, King NA, Greatwood HC, et al. Does a high-protein diet improve weight 
loss in overweight and obese children? Obesity (Silver Spring) 2007;15(6):1527-
34. 
311. Kreider RB, Rasmussen C, Kerksick CM, et al. A carbohydrate-restricted diet during 
resistance training promotes more favorable changes in body composition and 
markers of health in obese women with and without insulin resistance. Phys 
Sportsmed 2011;39(2):27-40. 
312. Galgani JE, Uauy RD, Aguirre CA, et al. Effect of the dietary fat quality on insulin 
sensitivity. Br J Nutr 2008;100(3):471-9. 
313. Ebbeling CB, Leidig MM, Sinclair KB, et al. A reduced-glycemic load diet in the 
treatment of adolescent obesity. Arch Pediatr Adolesc Med 2003;157(8):773-9. 
314. Thomas DE, Elliott EJ, Baur L. Low glycaemic index or low glycaemic load diets 
for overweight and obesity. The Cochrane database of systematic reviews 
2007(3):CD005105. 
315. Steffen LM, Jacobs DR, Jr., Murtaugh MA, et al. Whole grain intake is associated 
with lower body mass and greater insulin sensitivity among adolescents. Am J 
Epidemiol 2003;158(3):243-50. 
316. de Bock M, Derraik JG, Brennan CM, et al. Psyllium supplementation in 
adolescents improves fat distribution & lipid profile: a randomized, participant-
blinded, placebo-controlled, crossover trial. PLoS One 2012;7(7):e41735. 
317. Arciero PJ, Vukovich MD, Holloszy JO, et al. Comparison of short-term diet and 
exercise on insulin action in individuals with abnormal glucose tolerance. J Appl 
Physiol 1999;86(6):1930-5. 
318. Shields N. Exercise training decreases fasting insulin levels and improves insulin 
resistance in children and adolescents. J Physiother 2014;60(3):165. 
319. Mendelson M, Michallet AS, Monneret D, et al. Impact of exercise training without 
caloric restriction on inflammation, insulin resistance and visceral fat mass in 
obese adolescents. Pediatr Obes 2015;10(4):311-9. 
320. Fedewa MV, Gist NH, Evans EM, et al. Exercise and insulin resistance in youth: a 
meta-analysis. Pediatrics 2014;133(1):e163-74. 
321. Alberga AS, Frappier A, Sigal RJ, et al. A review of randomized controlled trials of 
aerobic exercise training on fitness and cardiometabolic risk factors in obese 
adolescents. Phys Sportsmed 2013;41(2):44-57. 
322. Centers for Disease C, Prevention. Physical activity levels among children aged 9-13 
years--United States, 2002. MMWR - Morbidity & Mortality Weekly Report 
2003;52(33):785-8. 
323. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of 
type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 
2002;346(6):393-403. 
324. DeFronzo RA, Sherwin RS, Kraemer N. Effect of physical training on insulin action 
in obesity. Diabetes 1987;36(12):1379-85. 
   
  CHAPTER 8 REFERENCES 
212 
325. Winnick JJ, Sherman WM, Habash DL, et al. Short-Term Aerobic Exercise Training 
in Obese Humans with Type 2 Diabetes Mellitus Improves Whole-Body Insulin 
Sensitivity through Gains in Peripheral, not Hepatic Insulin Sensitivity. Journal of 
Clinical Endocrinology & Metabolism 2007;93(3):771-78. 
326. Houmard JA, Hickey MS, Tyndall GL, et al. Seven days of exercise increase GLUT-
4 protein content in human skeletal muscle. J Appl Physiol (1985) 
1995;79(6):1936-8. 
327. Kriska AM, Pereira MA, Hanson RL, et al. Association of physical activity and 
serum insulin concentrations in two populations at high risk for type 2 diabetes 
but differing by BMI. Diabetes Care 2001;24(7):1175-80. 
328. Bell LM, Watts K, Siafarikas A, et al. Exercise alone reduces insulin resistance in 
obese children independently of changes in body composition. J Clin Endocrinol 
Metab 2007;92(11):4230-5. 
329. Kim Y, Park H. Does Regular Exercise without Weight Loss Reduce Insulin 
Resistance in Children and Adolescents? Int J Endocrinol 2013;2013:402592. 
330. Nassis GP, Papantakou K, Skenderi K, et al. Aerobic exercise training improves 
insulin sensitivity without changes in body weight, body fat, adiponectin, and 
inflammatory markers in overweight and obese girls. Metabolism 
2005;54(11):1472-9. 
331. van der Heijden GJ, Toffolo G, Manesso E, et al. Aerobic exercise increases 
peripheral and hepatic insulin sensitivity in sedentary adolescents. J Clin 
Endocrinol Metab 2009;94(11):4292-9. 
332. Many G, Hurtado M-E, Tanner C, et al. Moderate-intensity aerobic training 
program improves insulin sensitivity and inflammatory markers in a pilot study of 
morbidly obese minority teens. Pediatr Exerc Sci 2013;25(1):12-26. 
333. Conwell LS, Trost SG, Spence L, et al. The feasibility of a home-based moderate-
intensity physical activity intervention in obese children and adolescents. British 
journal of sports medicine 2010;44(4):250-5. 
334. McGuigan MR, Tatasciore M, Newton RU, et al. Eight weeks of resistance training 
can significantly alter body composition in children who are overweight or obese. 
J Strength Cond Res 2009;23(1):80-5. 
335. Damaso AR, da Silveira Campos RM, Caranti DA, et al. Aerobic plus resistance 
training was more effective in improving the visceral adiposity, metabolic profile 
and inflammatory markers than aerobic training in obese adolescents. J Sports Sci 
2014;32(15):1435-45. 
336. Miller WJ, Sherman WM, Ivy JL. Effect of strength training on glucose tolerance 
and post-glucose insulin response. Med Sci Sports Exerc 1984;16(6):539-43. 
337. Jimenez-Pavon D, Ortega FB, Valtuena J, et al. Muscular strength and markers of 
insulin resistance in European adolescents: the HELENA Study. Eur J Appl 
Physiol 2012;112(7):2455-65. 
338. Lee S, Bacha F, Hannon T, et al. Effects of aerobic versus resistance exercise 
without caloric restriction on abdominal fat, intrahepatic lipid, and insulin 
sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes 
2012;61(11):2787-95. 
339. Molnar D, Porszasz J. The effect of fasting hyperinsulinaemia on physical fitness in 
obese children. Eur J Pediatr 1990;149(8):570-3. 
340. Nadeau KJ, Zeitler PS, Bauer TA, et al. Insulin resistance in adolescents with type 2 
diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab 
2009;94(10):3687-95. 
341. Martin MJ, Horwitz DL, Nattrass M, et al. Effects of mild hyperinsulinemia on the 
metabolic response to exercise. Metabolism 1981;30(7):688-94. 
   
  CHAPTER 8 REFERENCES 
213 
342. Montero D. Hemodynamic actions of insulin: beyond the endothelium. Front 
Physiol 2013;4:389. 
343. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994;267(2 Pt 1):E187-
202. 
344. Lalande S, Gusso S, Hofman PL, et al. Reduced leg blood flow during submaximal 
exercise in type 2 diabetes. Med Sci Sports Exerc 2008;40(4):612-7. 
345. Shaibi GQ, Cruz ML, Ball GD, et al. Effects of resistance training on insulin 
sensitivity in overweight Latino adolescent males. Med Sci Sports Exerc 
2006;38(7):1208-15. 
346. Allen DB, Nemeth BA, Clark RR, et al. Fitness is a stronger predictor of fasting 
insulin levels than fatness in overweight male middle-school children. J Pediatr 
2007;150(4):383-7. 
347. Ahn B, McMurray R, Harrell J. Scaling of VO2max and its relationship with insulin 
resistance in children. Pediatr Exerc Sci 2013;25(1):43-51. 
348. Haufe S, Engeli S, Budziarek P, et al. Cardiorespiratory fitness and insulin sensitivity 
in overweight or obese subjects may be linked through intrahepatic lipid content. 
Diabetes 2010;59(7):1640-7. 
349. Kasa-Vubu JZ, Lee CC, Rosenthal A, et al. Cardiovascular fitness and exercise as 
determinants of insulin resistance in postpubertal adolescent females. J Clin 
Endocrinol Metab 2005;90(2):849-54. 
350. Cochrane DJ. Is vibration exercise a useful addition to a weight management 
program? Scand J Med Sci Sports 2012;22(6):705-13. 
351. Rubin CT, Capilla E, Luu YK, et al. Adipogenesis is inhibited by brief, daily 
exposure to high-frequency, extremely low-magnitude mechanical signals. Proc 
Natl Acad Sci U S A 2007;104(45):17879-84. 
352. Huang CC, Tseng TL, Huang WC, et al. Whole-body vibration training effect on 
physical performance and obesity in mice. International journal of medical 
sciences 2014;11(12):1218-27. 
353. Roelants M, Delecluse C, Goris M, et al. Effects of 24 weeks of whole body 
vibration training on body composition and muscle strength in untrained 
females. Int J Sports Med 2004;25(1):1-5. 
354. Wilms B, Frick J, Ernst B, et al. Whole body vibration added to endurance training 
in obese women - a pilot study. Int J Sports Med 2012;33(9):740-3. 
355. Zaki ME. Effects of whole body vibration and resistance training on bone mineral 
density and anthropometry in obese postmenopausal women. J Osteoporos 
2014;2014:702589. 
356. Vissers D, Hens W, Taeymans J, et al. The effect of exercise on visceral adipose 
tissue in overweight adults: a systematic review and meta-analysis. PLoS One 
2013;8(2):e56415. 
357. Sanudo B, Alfonso-Rosa R, Del Pozo-Cruz B, et al. Whole body vibration training 
improves leg blood flow and adiposity in patients with type 2 diabetes mellitus. 
Eur J Appl Physiol 2013;113(9):2245-52. 
358. Cristi-Montero C, Cuevas MJ, Collado PS. Whole-body vibration training as 
complement to programs aimed at weight loss. Nutr Hosp 2013;28(5):1365-71. 
359. Sgro M, McGuigan MR, Pettigrew S, et al. The effect of duration of resistance 
training interventions in children who are overweight or obese. J Strength Cond 
Res 2009;23(4):1263-70. 
360. Jones KL, Arslanian S, Peterokova VA, et al. Effect of metformin in pediatric 
patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 
2002;25(1):89-94. 
   
  CHAPTER 8 REFERENCES 
214 
361. Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin 
sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 
1986;12(6):346-50. 
362. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321(18):1231-45. 
363. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the 
metabolic abnormalities associated with upper-body fat distribution. BIGPRO 
Study Group. Diabetes Care 1996;19(9):920-6. 
364. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss 
in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 
1998;6(1):47-53. 
365. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-
dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J 
Med 1995;333(9):541-9. 
366. Arslanian SA, Lewy V, Danadian K, et al. Metformin therapy in obese adolescents 
with polycystic ovary syndrome and impaired glucose tolerance: amelioration of 
exaggerated adrenal response to adrenocorticotropin with reduction of 
insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87(4):1555-9. 
367. Quinn SM, Baur LA, Garnett SP, et al. Treatment of clinical insulin resistance in 
children: a systematic review. Obes Rev 2010;11(10):722-30. 
368. Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and 
body composition in obese insulin-resistant children: a randomized clinical trial. 
Diabetes 2011;60(2):477-85. 
369. Wiegand S, l'Allemand D, Hubel H, et al. Metformin and placebo therapy both 
improve weight management and fasting insulin in obese insulin-resistant 
adolescents: a prospective, placebo-controlled, randomized study. Eur J 
Endocrinol 2010;163(4):585-92. 
370. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth 
with type 2 diabetes. N Engl J Med 2012;366(24):2247-56. 
371. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle 
modification program in adolescents with insulin resistance. J Pediatr 
2008;152(6):817-22. 
372. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in 
normoglycemic morbidly obese adolescents. Metabolism 2001;50(12):1457-61. 
373. Freemark M, Bursey D. The effects of metformin on body mass index and glucose 
tolerance in obese adolescents with fasting hyperinsulinemia and a family history 
of type 2 diabetes. Pediatrics 2001;107(4):E55. 
374. Srinivasan S. Randomized, Controlled Trial of Metformin for Obesity and Insulin 
Resistance in Children and Adolescents: Improvement in Body Composition and 
Fasting Insulin. Journal of Clinical Endocrinology & Metabolism 
2006;91(6):2074-80. 
375. Atabek ME, Pirgon O. Use of metformin in obese adolescents with 
hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled 
clinical trial. J Pediatr Endocrinol Metab 2008;21(4):339-48. 
376. Park MH, Kinra S, Ward KJ, et al. Metformin for obesity in children and 
adolescents: a systematic review. Diabetes Care 2009;32(9):1743-5. 
377. Clarson CL, Mahmud FH, Baker JE, et al. Metformin in combination with 
structured lifestyle intervention improved body mass index in obese adolescents, 
but did not improve insulin resistance. Endocrine 2009;36(1):141-6. 
378. Garcia Diaz E, Martin Folgueras T. Systematic review of the clinical efficacy of 
sibutramine and orlistat in weigth loss, quality of life and its adverse effects in 
obese adolescents. Nutr Hosp 2011;26(3):451-7. 
   
  CHAPTER 8 REFERENCES 
215 
379. Osawa Y, Oguma Y. Effects of resistance training with whole-body vibration on 
muscle fitness in untrained adults. Scand J Med Sci Sports 2013;23(1):84-95. 
380. Delecluse C, Roelants M, Verschueren S. Strength increase after whole-body 
vibration compared with resistance training. Medicine & Science in Sports & 
Exercise 2003;35(6):1033-41. 
381. Machado A, Garcia-Lopez D, Gonzalez-Gallego J, et al. Whole-body vibration 
training increases muscle strength and mass in older women: a randomized-
controlled trial. Scand J Med Sci Sports 2010;20(2):200-7. 
382. Wilcock IM, Whatman C, Harris N, et al. Vibration training: could it enhance the 
strength, power, or speed of athletes? Journal of Strength & Conditioning 
Research 2009;23(2):593-603. 
383. Sands WA, McNeal JR, Stone MH, et al. Flexibility enhancement with vibration: 
Acute and long-term. Med Sci Sports Exerc 2006;38(4):720-5. 
384. Gerodimos V, Zafeiridis A, Karatrantou K, et al. The acute effects of different 
whole-body vibration amplitudes and frequencies on flexibility and vertical 
jumping performance. J Sci Med Sport 2010;13(4):438-43. 
385. Di Giminiani R, Manno R, Scrimaglio R, et al. Effects of individualized whole-body 
vibration on muscle flexibility and mechanical power. Journal of Sports Medicine 
& Physical Fitness 2010;50(2):139-51. 
386. Bemben DA, Palmer IJ, Bemben MG, et al. Effects of combined whole-body 
vibration and resistance training on muscular strength and bone metabolism in 
postmenopausal women. Bone 2010;47(3):650-6. 
387. Cardinale M, Bosco C. The use of vibration as an exercise intervention. Exercise 
and sport sciences reviews 2003;31(1):3-7. 
388. Rubin C, Turner AS, Bain S, et al. Anabolism. Low mechanical signals strengthen 
long bones. Nature 2001;412(6847):603-4. 
389. Christiansen BA, Silva MJ. The effect of varying magnitudes of whole-body 
vibration on several skeletal sites in mice. Annals of biomedical engineering 
2006;34(7):1149-56. 
390. Rubin C, Recker R, Cullen D, et al. Prevention of postmenopausal bone loss by a 
low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing 
compliance, efficacy, and safety. J Bone Miner Res 2004;19(3):343-51. 
391. Turner S, Torode M, Climstein M, et al. A randomized controlled trial of whole 
body vibration exposure on markers of bone turnover in postmenopausal 
women. J Osteoporos 2011;2011:710387. 
392. Von Stengel S, Kemmler W, Bebenek M, et al. Effects of whole-body vibration 
training on different devices on bone mineral density. Med Sci Sports Exerc 
2011;43(6):1071-9. 
393. Mikhael M, Orr R, Fiatarone Singh MA. The effect of whole body vibration 
exposure on muscle or bone morphology and function in older adults: a 
systematic review of the literature. Maturitas 2010;66(2):150-7. 
394. Liphardt AM, Schipilow J, Hanley DA, et al. Bone quality in osteopenic 
postmenopausal women is not improved after 12 months of whole-body 
vibration training. Osteoporos Int 2015;26(3):911-20. 
395. Verschueren SM, Bogaerts A, Delecluse C, et al. The effects of whole-body 
vibration training and vitamin D supplementation on muscle strength, muscle 
mass, and bone density in institutionalized elderly women: a 6-month 
randomized, controlled trial. J Bone Miner Res 2011;26(1):42-9. 
396. Prisby RD, Lafage-Proust M-H, Malaval L, et al. Effects of whole body vibration on 
the skeleton and other organ systems in man and animal models: what we know 
and what we need to know. Ageing Res Rev 2008;7(4):319-29. 
   
  CHAPTER 8 REFERENCES 
216 
397. Fagnani F, Giombini A, Di Cesare A, et al. The effects of a whole-body vibration 
program on muscle performance and flexibility in female athletes. Am J Phys 
Med Rehabil 2006;85(12):956-62. 
398. Oosthuyse T, Viedge A, McVeigh J, et al. Anaerobic power in road cyclists is 
improved after 10 weeks of whole-body vibration training. J Strength Cond Res 
2013;27(2):485-94. 
399. Osawa Y, Oguma Y. Effects of whole-body vibration on resistance training for 
untrained adults. J Sports Sci Med 2011;10(2):328-37. 
400. Rehn B, Lidstrom J, Skoglund J, et al. Effects on leg muscular performance from 
whole-body vibration exercise: a systematic review. Scand J Med Sci Sports 
2007;17(1):2-11. 
401. Nordlund MM, Thorstensson A. Strength training effects of whole-body vibration? 
Scand J Med Sci Sports 2007;17(1):12-7. 
402. Abercromby AFJ, Amonette WE, Layne CS, et al. Vibration exposure and 
biodynamic responses during whole-body vibration training. Medicine & Science 
in Sports & Exercise 2007;39(10):1794-800. 
403. Rees SS, Murphy AJ, Watsford ML. Effects of whole-body vibration exercise on 
lower-extremity muscle strength and power in an older population: a randomized 
clinical trial. Phys Ther 2008;88(4):462-70. 
404. Roelants M, Verschueren SM, Delecluse C, et al. Whole-body-vibration-induced 
increase in leg muscle activity during different squat exercises. J Strength Cond 
Res 2006;20(1):124-9. 
405. Jordan MJ, Norris SR, Smith DJ, et al. Vibration training: an overview of the area, 
training consequences, and future considerations. J Strength Cond Res 
2005;19(2):459-66. 
406. Sayenko DG, Masani K, Alizadeh-Meghrazi M, et al. Acute effects of whole body 
vibration during passive standing on soleus H-reflex in subjects with and without 
spinal cord injury. Neurosci Lett 2010;482(1):66-70. 
407. Ritzmann R, Kramer A, Gollhofer A, et al. The effect of whole body vibration on 
the H-reflex, the stretch reflex, and the short-latency response during hopping. 
Scand J Med Sci Sports 2013;23(3):331-9. 
408. Rittweger J, Mutschelknauss M, Felsenberg D. Acute changes in neuromuscular 
excitability after exhaustive whole body vibration exercise as compared to 
exhaustion by squatting exercise. Clin Physiol Funct Imaging 2003;23(2):81-6. 
409. Rittweger J. Vibration as an exercise modality: how it may work, and what its 
potential might be. Eur J Appl Physiol 2010;108(5):877-904. 
410. Matthews PB. Reflex activation of the soleus muscle of the decerebrate cat by 
vibration. Nature 1966;209(5019):204-5. 
411. Wikipedia.  [Available from: https://en.wikipedia.org/wiki/Patellar_reflex - 
/media/File:Patellar_tendon_reflex_arc.png ] Last accessed June 2016. 
412. Abercromby AFJ, Amonette WE, Layne CS, et al. Variation in neuromuscular 
responses during acute whole-body vibration exercise. Medicine & Science in 
Sports & Exercise 2007;39(9):1642-50. 
413. Ritzmann R, Kramer A, Gruber M, et al. EMG activity during whole body 
vibration: motion artifacts or stretch reflexes? Eur J Appl Physiol 
2010;110(1):143-51. 
414. Cardinale M, Pope MH. The effects of whole body vibration on humans: dangerous 
or advantageous? Acta Physiol Hung 2003;90(3):195-206. 
415. Bosco C, Iacovelli M, Tsarpela O, et al. Hormonal responses to whole-body 
vibration in men. Eur J Appl Physiol 2000;81(6):449-54. 
   
  CHAPTER 8 REFERENCES 
217 
416. Vela JI, Andreu D, Diaz-Cascajosa J, et al. Intraocular lens dislocation after whole-
body vibration. J Cataract Refract Surg 2010;36(10):1790-1. 
417. Bertschinger DR, Dosso A. [Vitreous hemorrhage and whole-body vibration 
training--is there an association?]. Journal Francais d Opthalmologie 
2008;31(8):e17. 
418. Monteleone G, De Lorenzo A, Sgroi M, et al. Contraindications for whole body 
vibration training: a case of nephrolitiasis. Journal of Sports Medicine & Physical 
Fitness 2007;47(4):443-5. 
419. Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children 
and adolescents: a review of controlled trials. Bone 2007;40(1):14-27. 
420. Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian 
females and its implication for the prevention of osteoporosis. Inference from a 
cross-sectional model. J Clin Invest 1994;93(2):799-808. 
421. Frost HM. Bone "mass" and the "mechanostat": a proposal. Anat Rec 
1987;219(1):1-9. 
422. Rittweger J, Beller G, Armbrecht G, et al. Prevention of bone loss during 56 days of 
strict bed rest by side-alternating resistive vibration exercise. Bone 
2010;46(1):137-47. 
423. Xie L, Jacobson JM, Choi ES, et al. Low-level mechanical vibrations can influence 
bone resorption and bone formation in the growing skeleton. Bone 
2006;39(5):1059-66. 
424. Rubin C, Xu G, Judex S. The anabolic activity of bone tissue, suppressed by disuse, 
is normalized by brief exposure to extremely low-magnitude mechanical stimuli. 
FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 2001;15(12):2225-9. 
425. Verschueren SM, Roelants M, Delecluse C, et al. Effect of 6-month whole body 
vibration training on hip density, muscle strength, and postural control in 
postmenopausal women: a randomized controlled pilot study. J Bone Miner Res 
2004;19(3):352-9. 
426. Gilsanz V, Wren TA, Sanchez M, et al. Low-level, high-frequency mechanical 
signals enhance musculoskeletal development of young women with low BMD. J 
Bone Miner Res 2006;21(9):1464-74. 
427. Ward K, Alsop C, Caulton J, et al. Low magnitude mechanical loading is osteogenic 
in children with disabling conditions. J Bone Miner Res 2004;19(3):360-9. 
428. Matute-Llorente A, Gonzalez-Aguero A, Gomez-Cabello A, et al. Effect of whole-
body vibration training on bone mass in adolescents with and without Down 
syndrome: a randomized controlled trial. Osteoporos Int 2015. 
429. Erceg DN, Anderson LJ, Nickles CM, et al. Changes in Bone Biomarkers, BMC, 
and Insulin Resistance Following a 10-Week Whole Body Vibration Exercise 
Program in Overweight Latino Boys. International journal of medical sciences 
2015;12(6):494-501. 
430. Binkley TL, Parupsky EC, Kleinsasser BA, et al. Feasibility, compliance, and efficacy 
of a randomized controlled trial using vibration in pre-pubertal children. J 
Musculoskelet Neuronal Interact 2014;14(3):294-302. 
431. Wren TA, Lee DC, Hara R, et al. Effect of high-frequency, low-magnitude vibration 
on bone and muscle in children with cerebral palsy. J Pediatr Orthop 
2010;30(7):732-8. 
432. Ruck J, Chabot G, Rauch F. Vibration treatment in cerebral palsy: A randomized 
controlled pilot study. J Musculoskelet Neuronal Interact 2010;10(1):77-83. 
   
  CHAPTER 8 REFERENCES 
218 
433. Stark C, Nikopoulou-Smyrni P, Stabrey A, et al. Effect of a new physiotherapy 
concept on bone mineral density, muscle force and gross motor function in 
children with bilateral cerebral palsy. J 2010;10(2):151-8. 
434. Semler O, Fricke O, Vezyroglou K, et al. Preliminary results on the mobility after 
whole body vibration in immobilized children and adolescents. J Musculoskelet 
Neuronal Interact 2007;7(1):77-81. 
435. Semler O, Fricke O, Vezyroglou K, et al. Results of a prospective pilot trial on 
mobility after whole body vibration in children and adolescents with osteogenesis 
imperfecta. Clin Rehabil 2008;22(5):387-94. 
436. Gonzalez-Aguero A, Matute-Llorente A, Gomez-Cabello A, et al. Effects of whole 
body vibration training on body composition in adolescents with Down 
syndrome. Res Dev Disabil 2013;34(5):1426-33. 
437. Roelants M, Delecluse C, Verschueren SM. Whole-body-vibration training increases 
knee-extension strength and speed of movement in older women. J Am Geriatr 
Soc 2004;52(6):901-8. 
438. Roth J, Wust M, Rawer R, et al. Whole body vibration in cystic fibrosis--a pilot 
study. J 2008;8(2):179-87. 
439. Ronnestad BR. Acute effects of various whole-body vibration frequencies on lower-
body power in trained and untrained subjects. Journal of Strength & 
Conditioning Research 2009;23(4):1309-15. 
440. Blottner D, Salanova M, Puttmann B, et al. Human skeletal muscle structure and 
function preserved by vibration muscle exercise following 55 days of bed rest. 
Eur J Appl Physiol 2006;97(3):261-71. 
441. Floyd WN, Broderson AB, Goodno JF. Effect of whole-body vibration on 
peripheral nerve conduction time in the rhesus monkey. Aerosp Med 
1973;44(3):281-5. 
442. Bovenzi M. Health risks from occupational exposures to mechanical vibration. La 
Medicina del lavoro 2006;97(3):535-41. 
443. Kerschan-Schindl K, Grampp S, Henk C, et al. Whole-body vibration exercise leads 
to alterations in muscle blood volume. Clin Physiol 2001;21(3):377-82. 
444. Stewart JM, Karman C, Montgomery LD, et al. Plantar vibration improves leg fluid 
flow in perimenopausal women. American journal of physiology Regulatory, 
integrative and comparative physiology 2005;288(3):R623-9. 
445. Milanese C, Piscitelli F, Zenti MG, et al. Ten-week whole-body vibration training 
improves body composition and muscle strength in obese women. International 
journal of medical sciences 2013;10(3):307-11. 
446. Garatachea N, Jimenez A, Bresciani G, et al. The effects of movement velocity 
during squatting on energy expenditure and substrate utilization in whole-body 
vibration. Journal of Strength & Conditioning Research 2007;21(2):594-8. 
447. Lee K, Lee S, Song C. Whole-body vibration training improves balance, muscle 
strength and glycosylated hemoglobin in elderly patients with diabetic 
neuropathy. Tohoku J Exp Med 2013;231(4):305-14. 
448. Vissers D, Verrijken A, Mertens I, et al. Effect of long-term whole body vibration 
training on visceral adipose tissue: a preliminary report. Obes Facts 2010;3(2):93-
100. 
449. Di Loreto C, Ranchelli A, Lucidi P, et al. Effects of whole-body vibration exercise 
on the endocrine system of healthy men. Journal of endocrinological 
investigation 2004;27(4):323-7. 
450. Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent 
effects on bone matrix formation and cell replication. Endocrinology 
1988;122(1):254-60. 
   
  CHAPTER 8 REFERENCES 
219 
451. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Journal 
of musculoskeletal & neuronal interactions 2008;8(4):351. 
452. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the 
skeleton. Cell 2007;130(3):456-69. 
453. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem 
2000;37(Pt 4):432-46. 
454. Prats-Puig A, Mas-Parareda M, Riera-Perez E, et al. Carboxylation of osteocalcin 
affects its association with metabolic parameters in healthy children. Diabetes 
Care 2010;33(3):661-3. 
455. Cheng S, Massaro JM, Fox CS, et al. Adiposity, cardiometabolic risk, and vitamin D 
status: the Framingham Heart Study. Diabetes 2010;59(1):242-8. 
456. Forouhi NG, Luan J, Cooper A, et al. Baseline serum 25-hydroxy vitamin d is 
predictive of future glycemic status and insulin resistance: the Medical Research 
Council Ely Prospective Study 1990-2000. Diabetes 2008;57(10):2619-25. 
457. Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin 
resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. 
Diabetes Care 2010;33(6):1379-81. 
458. Alemzadeh R, Kichler J, Babar G, et al. Hypovitaminosis D in obese children and 
adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. 
Metabolism 2008;57(2):183-91. 
459. Chiu KC, Chu A, Go VL, et al. Hypovitaminosis D is associated with insulin 
resistance and beta cell dysfunction. Am J Clin Nutr 2004;79(5):820-5. 
460. Rajakumar K, de las Heras J, Lee S, et al. 25-hydroxyvitamin D concentrations and 
in vivo insulin sensitivity and beta-cell function relative to insulin sensitivity in 
black and white youth.[Erratum appears in Diabetes Care. 2012 Oct;35(10):2108]. 
Diabetes Care 2012;35(3):627-33. 
461. Theodoratou E, Tzoulaki I, Zgaga L, et al. Vitamin D and multiple health outcomes: 
umbrella review of systematic reviews and meta-analyses of observational studies 
and randomised trials. Bmj 2014;348:g2035. 
462. Dolinsky DH, Armstrong S, Mangarelli C, et al. The association between vitamin D 
and cardiometabolic risk factors in children: a systematic review. Clin Pediatr 
(Phila) 2013;52(3):210-23. 
463. Riek AE, Oh J, Bernal-Mizrachi C. 1,25(OH)2 vitamin D suppresses macrophage 
migration and reverses atherogenic cholesterol metabolism in type 2 diabetic 
patients. J Steroid Biochem Mol Biol 2013;136:309-12. 
464. Riek AE, Oh J, Sprague JE, et al. Vitamin D suppression of endoplasmic reticulum 
stress promotes an antiatherogenic monocyte/macrophage phenotype in type 2 
diabetic patients. J Biol Chem 2012;287(46):38482-94. 
465. Oh J, Riek AE, Darwech I, et al. Deletion of macrophage Vitamin D receptor 
promotes insulin resistance and monocyte cholesterol transport to accelerate 
atherosclerosis in mice. Cell Rep 2015;10(11):1872-86. 
466. Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on 
Prevention and Management of Nutritional Rickets. The Journal of clinical 
endocrinology and metabolism 2016;101(2):394-415. 
467. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference 
intakes for calcium and vitamin D from the Institute of Medicine: what clinicians 
need to know. The Journal of clinical endocrinology and metabolism 
2011;96(1):53-8. 
468. Holick MF. Vitamin D deficiency. The New England journal of medicine 
2007;357(3):266-81. 
   
  CHAPTER 8 REFERENCES 
220 
469. Polgreen LE, Jacobs DR, Jr., Nathan BM, et al. Association of osteocalcin with 
obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity 
(Silver Spring) 2012;20(11):2194-201. 
470. Burke JP, Hale DE, Hazuda HP, et al. A quantitative scale of acanthosis nigricans. 
Diabetes Care 1999;22(10):1655-9. 
471. Garnett SP, Srinivasan S, Birt SG, et al. Evaluation of glycaemic status in young 
people with clinical insulin resistance; fasting glucose, fasting insulin or an oral 
glucose tolerance test? Clin Endocrinol (Oxf) 2010;72(4):475-80. 
472. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes 
Care 2008;31 Suppl 1:S55-60. 
473. Altman DG, Bland JM. Treatment allocation by minimisation. Bmj 
2005;330(7495):843. 
474. Evans SR, P; Day, S. Minim: allocation by minimisation in clinical trials 2014 
[Available from: http://www-users.york.ac.uk/~mb55/guide/minim.htm. 
475. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, 
height velocity, weight velocity, and stages of puberty. Arch Dis Child 
1976;51(3):170-9. 
476. Rauch F, Sievanen H, Boonen S, et al. Reporting whole-body vibration intervention 
studies: recommendations of the International Society of Musculoskeletal and 
Neuronal Interactions. J Musculoskelet Neuronal Interact 2010;10(3):193-8. 
477. Novotec Medical. Galileo Sport  [Available from: 
http://www.galileowholebodyvibration.com.au/products-basic.html  
478. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. 
Arch Dermatol 1988;124(6):869-71. 
479. Garnett SP, Baur LA, Srinivasan S, et al. Body mass index and waist circumference 
in midchildhood and adverse cardiovascular disease risk clustering in 
adolescence. Am J Clin Nutr 2007;86(3):549-55. 
480. Norton K WN, Carter L, Kerr D, Gore C, Marfell-, M. J. Measurement techniques in 
anthropometry. . Sydney: University of NSW Press, 1996. 
481. Pan HC, T. lmsGrowth, a Microsoft Excel add-in to access growth references based 
on the LMS method (Version 2.68). 2009. Available online: 
http://www.healthforallchildren.co.uk/ (accessed on 26 April 2011). Pan, H.; 
Cole, T. lmsGrowth, a Microsoft Excel add-in to access growth references based 
on the LMS method (Version 2.68). 2009. Available online: 
http://www.healthforallchildren.co.uk/ (accessed on 26 April 2011). 
 482. Margulies L, Horlick M, Thornton JC, et al. Reproducibility of pediatric whole body 
bone and body composition measures by dual-energy X-ray absorptiometry using 
the GE Lunar Prodigy. Journal of clinical densitometry : the official journal of 
the International Society for Clinical Densitometry 2005;8(3):298-304. 
483. Ogle GD, Allen JR, Humphries IR, et al. Body-composition assessment by dual-
energy x-ray absorptiometry in subjects aged 4-26 y. Am J Clin Nutr 
1995;61(4):746-53. 
484. Cowell CT, Briody J, Lloyd-Jones S, et al. Fat distribution in children and 
adolescents--the influence of sex and hormones. Horm Res 1997;48 Suppl 5:93-
100. 
485. Garnett SP, Baur LA, Noakes M, et al. Researching Effective Strategies to Improve 
Insulin Sensitivity in Children and Teenagers - RESIST. A randomised control 
trial investigating the effects of two different diets on insulin sensitivity in young 
people with insulin resistance and/or pre-diabetes. BMC Public Health 
2010;10:575. 
   
  CHAPTER 8 REFERENCES 
221 
486. Lu PW, Briody JN, Ogle GD, et al. Bone mineral density of total body, spine, and 
femoral neck in children and young adults: a cross-sectional and longitudinal 
study. Journal of bone and mineral research : the official journal of the American 
Society for Bone and Mineral Research 1994;9(9):1451-8. 
487. Spender QW, Cronk CE, Charney EB, et al. Assessment of linear growth of 
children with cerebral palsy: use of alternative measures to height or length. Dev 
Med Child Neurol 1989;31(2):206-14. 
488. Moyer-Mileur LJ, Quick JL, Murray MA. Peripheral quantitative computed 
tomography of the tibia: pediatric reference values. Journal of clinical 
densitometry : the official journal of the International Society for Clinical 
Densitometry 2008;11(2):283-94. 
489. Bruce RA, Blackmon JR, Jones JW, et al. Exercising Testing in Adult Normal 
Subjects and Cardiac Patients. Pediatrics 1963;32:SUPPL 742-56. 
490. Bruce RA. Exercise testing of patients with coronary heart disease. Principles and 
normal standards for evaluation. Ann Clin Res 1971;3(6):323-32. 
491. Unnithan VB, Murray LA, Timmons JA, et al. Reproducibility of cardiorespiratory 
measurements during submaximal and maximal running in children. Br J Sports 
Med 1995;29(1):66-71. 
492. Fricke O, Weidler J, Tutlewski B, et al. Mechanography--a new device for the 
assessment of muscle function in pediatrics. Pediatric research 2006;59(1):46-9. 
493. Novotec Medical. https://www.galileo-training.com/de-
english/products/leonardo-mechanograph/mechanography/test-procedures-
assessments.html - m1lh   
494. Noakes M, Keogh JB, Foster PR, et al. Effect of an energy-restricted, high-protein, 
low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight 
loss, body composition, nutritional status, and markers of cardiovascular health 
in obese women. Am J Clin Nutr 2005;81(6):1298-306. 
495. Telford A SJ, Jolley D, Crawford D. Reliability and validity of physical activity 
questionnaires for children: the Children’s Leisure Activities Study Survey 
(CLASS). Pediatr Exerc Sci 2004;16:64-79. 
496. NSW Government Department of Industry. GWS local government areas  
[Available from: http://www.industry.nsw.gov.au] Last accessed June 2017. 
497. Statistics Australia. Census Dictionary Australia 2006. 2006 (2901.0). 
498. Cook S, Auinger P, Li C, et al. Metabolic syndrome rates in United States 
adolescents, from the National Health and Nutrition Examination Survey, 1999-
2002. J Pediatr 2008;152(2):165-70. 
499. de Ferranti SD, Gauvreau K, Ludwig DS, et al. Prevalence of the metabolic 
syndrome in American adolescents: findings from the Third National Health and 
Nutrition Examination Survey. Circulation 2004;110(16):2494-7. 
500. Lobstein T, Jackson-Leach R. Child overweight and obesity in the USA: prevalence 
rates according to IOTF definitions. Int J Pediatr Obes 2007;2(1):62-4. 
501. AIHW: Holdenson Z CL, Phillips G & Waters A-M 2003a. A picture of diabetes in 
overseas-born Australians. Bulletin No. 9. AIHW Cat. No. AUS 38. Canberra: 
AIHW. 
502. IDF Diabetes Atlas Brussels, Belgium: International Diabetes Federation; 2015 [7th 
Edition:[Available from: http://www.diabetesatlas.org] Last accessed June 2017. 
503. Sabo RT, Lu Z, Deng X, et al. Parental and offspring associations of the metabolic 
syndrome in the Fels Longitudinal Study. Am J Clin Nutr 2012;96(3):461-6. 
504. Bener A, Darwish S, Al-Hamaq AO, et al. The potential impact of family history of 
metabolic syndrome and risk of type 2 diabetes mellitus: In a highly endogamous 
population. Indian J Endocrinol Metab 2014;18(2):202-9. 
   
  CHAPTER 8 REFERENCES 
222 
505. Lipinska A, Koczaj-Bremer M, Jankowski K, et al. Does family history of metabolic 
syndrome affect the metabolic profile phenotype in young healthy individuals? 
Diabetol Metab Syndr 2014;6:75. 
506. A AIoHaW. Diabetes. Australian Facts 2008. Australian Institute of Health and 
Welfare, Canberra: IDiabetes Series No. 8. 2008. 
507. Kosti RI, Panagiotakos DB, Tountas Y, et al. Parental Body Mass Index in 
association with the prevalence of overweight/obesity among adolescents in 
Greece; dietary and lifestyle habits in the context of the family environment: the 
Vyronas study. Appetite 2008;51(1):218-22. 
508. Koomanaee S, Tabrizi M, Naderi N, et al. Parental Anthropometric Indices and 
Obesity in Children. Acta Med Iran 2016;54(4):270-5. 
509. Khurana I, Kaspi A, Ziemann M, et al. DNA methylation regulates hypothalamic 
gene expression linking parental diet during pregnancy to the offspring's risk of 
obesity in Psammomys obesus. Int J Obes (Lond) 2016. 
510. Berenson GS, Bao W, Srinivasan SR. Abnormal characteristics in young offspring of 
parents with non-insulin-dependent diabetes mellitus. The Bogalusa Heart Study. 
Am J Epidemiol 1996;144(10):962-7. 
511. Morrison JA, Friedman LA, Wang P, et al. Metabolic syndrome in childhood 
predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years 
later. J Pediatr 2008;152(2):201-6. 
512. Pankow JS, Jacobs DR, Jr., Steinberger J, et al. Insulin resistance and cardiovascular 
disease risk factors in children of parents with the insulin resistance (metabolic) 
syndrome. Diabetes Care 2004;27(3):775-80. 
513. Alwan H, Viswanathan B, Paccaud F, et al. Is Accurate Perception of Body Image 
Associated with Appropriate Weight-Control Behavior among Adolescents of 
the Seychelles. J Obes 2011;2011:817242. 
514. Brener ND, Eaton DK, Lowry R, et al. The association between weight perception 
and BMI among high school students. Obes Res 2004;12(11):1866-74. 
515. Tienboon P, Rutishauser IH, Wahlqvist ML. Adolescents' perception of body 
weight and parents' weight for height status. J Adolesc Health 1994;15(3):263-8. 
516. Yan AF, Zhang G, Wang MQ, et al. Weight perception and weight control practice 
in a multiethnic sample of US adolescents. South Med J 2009;102(4):354-60. 
517. Wang Y, Liang H, Chen X. Measured body mass index, body weight perception, 
dissatisfaction and control practices in urban, low-income African American 
adolescents. BMC Public Health 2009;9:183. 
518. Colabianchi N, Ievers-Landis CE, Borawski EA. Weight preoccupation as a 
function of observed physical attractiveness: ethnic differences among normal-
weight adolescent females. J Pediatr Psychol 2006;31(8):803-12. 
519. McKee C, Long L, Southward LH, et al. The Role of Parental Misperception of 
Child's Body Weight in Childhood Obesity. J Pediatr Nurs 2016;31(2):196-203. 
520. Moore LC, Harris CV, Bradlyn AS. Exploring the relationship between parental 
concern and the management of childhood obesity. Matern Child Health J 
2012;16(4):902-8. 
521. Yang K, Turk MT, Allison VL, et al. Body mass index self-perception and weight 
management behaviors during late adolescence. J Sch Health 2014;84(10):654-60. 
522. Booth ML, Bernard D, Quine S, et al. Access to health care among Australian 
adolescents young people's perspectives and their sociodemographic distribution. 
J Adolesc Health 2004;34(1):97-103. 
523. Marcell AV, Klein JD, Fischer I, et al. Male adolescent use of health care services: 
where are the boys? J Adolesc Health 2002;30(1):35-43. 
   
  CHAPTER 8 REFERENCES 
223 
524. Thomas S, Ness RB, Thurston RC, et al. Racial differences in perception of healthy 
body weight in midlife women: results from the Do Stage Transitions Result in 
Detectable Effects study. Menopause 2013;20(3):269-73. 
525. Davis J, Busch J, Hammatt Z, et al. The relationship between ethnicity and obesity 
in Asian and Pacific Islander populations: a literature review. Ethn Dis 
2004;14(1):111-8. 
526. Kanter R, Caballero B. Global gender disparities in obesity: a review. Adv Nutr 
2012;3(4):491-8. 
527. Consultation WHOE. Appropriate body-mass index for Asian populations and its 
implications for policy and intervention strategies. Lancet 2004;363(9403):157-63. 
528. Kurtoglu S, Hatipoglu N, Mazicioglu M, et al. Insulin resistance in obese children 
and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal 
periods. J Clin Res Pediatr Endocrinol 2010;2(3):100-6. 
529. Reinehr T, de Sousa G, Andler W. Longitudinal analyses among overweight, insulin 
resistance, and cardiovascular risk factors in children. Obes Res 
2005;13(10):1824-33. 
530. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in 
children and adolescents. N Engl J Med 2004;350(23):2362-74. 
531. Deboer MD. Ethnicity, obesity and the metabolic syndrome: implications on 
assessing risk and targeting intervention. Expert Rev Endocrinol Metab 
2011;6(2):279-89. 
532. Morrison JA, Sprecher DL, Biro FM, et al. Serum testosterone associates with lower 
high-density lipoprotein cholesterol in black and white males, 10 to 15 years of 
age, through lowered apolipoprotein AI and AII concentrations. Metabolism 
2002;51(4):432-7. 
533. Guven A, Sanisoglu SY. Pubertal progression and serum lipid profile in obese 
children. J Pediatr Endocrinol Metab 2008;21(2):135-46. 
534. National High Blood Pressure Education Program Working Group on High Blood 
Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and 
treatment of high blood pressure in children and adolescents. Pediatrics 
2004;114(2 Suppl 4th Report):555-76. 
535. Rodriguez BL, Dabelea D, Liese AD, et al. Prevalence and correlates of elevated 
blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in 
youth study. J Pediatr 2010;157(2):245-51 e1. 
536. Wadwa RP, Urbina EM, Anderson AM, et al. Measures of arterial stiffness in youth 
with type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. 
Diabetes Care 2010;33(4):881-6. 
537. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to 
coronary heart disease risk change with aging? The Framingham Heart Study. 
Circulation 2001;103(9):1245-9. 
538. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration 
and risk of mortality from liver diseases: prospective cohort study. BMJ 
2004;328(7446):983. 
539. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum 
alanine aminotransferase levels. Ann Intern Med 2002;137(1):1-10. 
540. Nadeau KJ, Ehlers LB, Zeitler PS, et al. Treatment of non-alcoholic fatty liver 
disease with metformin versus lifestyle intervention in insulin-resistant 
adolescents. Pediatr Diabetes 2009;10(1):5-13. 
541. AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 
2015;16(5):393-405. 
   
  CHAPTER 8 REFERENCES 
224 
542. Ascenso A, Palmeira A, Pedro LM, et al. Physical activity and cardiorespiratory 
fitness, but not sedentary behavior, are associated with carotid intima-media 
thickness in obese adolescents. Eur J Pediatr 2016;175(3):391-8. 
543. Hay J, Wittmeier K, MacIntosh A, et al. Physical activity intensity and type 2 
diabetes risk in overweight youth: a randomized trial. Int J Obes (Lond) 
2016;40(4):607-14. 
544. Janssen I, Wong SL, Colley R, et al. The fractionalization of physical activity 
throughout the week is associated with the cardiometabolic health of children 
and youth. BMC Public Health 2013;13:554. 
545. Martinez-Gomez D, Eisenmann JC, Warnberg J, et al. Associations of physical 
activity, cardiorespiratory fitness and fatness with low-grade inflammation in 
adolescents: the AFINOS Study. Int J Obes (Lond) 2010;34(10):1501-7. 
546. Dwyer T, Magnussen CG, Schmidt MD, et al. Decline in physical fitness from 
childhood to adulthood associated with increased obesity and insulin resistance in 
adults. Diabetes care 2009;32(4):683-7. 
547. Sabin MA, Kao KT, Juonala M, et al. Viewpoint article: Childhood obesity--looking 
back over 50 years to begin to look forward. J Paediatr Child Health 
2015;51(1):82-6. 
548. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity among 
children in the United States, 1999-2012. JAMA Pediatr 2014;168(6):561-6. 
549. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome 
responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic 
cardiovascular disease. Diabetes Care 1991;14(3):173-94. 
550. Nelson RA, Bremer AA. Insulin resistance and metabolic syndrome in the pediatric 
population. Metabolic Syndrome & Related Disorders 2010;8(1):1-14. 
551. Nassis G, Papantakou K, Skenderi K, et al. Aerobic exercise training improves 
insulin sensitivity without changes in body weight, body fat, adiponectin, and 
inflammatory markers in overweight and obese girls. Metabolism: clinical and 
experimental 2005;54(11):1472-79. 
552. Hunter P. Exercise in a bottle: Elucidating how exercise conveys health benefits 
might lead to new therapeutic options for a range of diseases from cancer to 
metabolic syndrome. EMBO Rep 2016. 
553. Monteiro PA, Chen KY, Lira FS, et al. Concurrent and aerobic exercise training 
promote similar benefits in body composition and metabolic profiles in obese 
adolescents. Lipids Health Dis 2015;14:153. 
554. Hulver MW, Zheng D, Tanner CJ, et al. Adiponectin is not altered with exercise 
training despite enhanced insulin action. Am J Physiol Endocrinol Metab 
2002;283(4):E861-5. 
555. Fjeldstad C, Palmer IJ, Bemben MG, et al. Whole-body vibration augments 
resistance training effects on body composition in postmenopausal women. 
Maturitas 2009;63(1):79-83. 
556. Bosco C, Colli R, Introini E, et al. Adaptive responses of human skeletal muscle to 
vibration exposure. Clin Physiol 1999;19(2):183-7. 
557. Rittweger J, Schiessl H, Felsenberg D. Oxygen uptake during whole-body vibration 
exercise: comparison with squatting as a slow voluntary movement. Eur J Appl 
Physiol 2001;86(2):169-73. 
558. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect 
in type 2 diabetes. Diabetes Care 2009;32 Suppl 2:S157-63. 
559. Lee S, Kim Y, White DA, et al. Relationships between insulin sensitivity, skeletal 
muscle mass and muscle quality in obese adolescent boys. Eur J Clin Nutr 
2012;66(12):1366-8. 
   
  CHAPTER 8 REFERENCES 
225 
560. Moher D, Schulz KF, Altman D, et al. The CONSORT statement: revised 
recommendations for improving the quality of reports of parallel-group 
randomized trials. Jama 2001;285(15):1987-91. 
561. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised 
recommendations for improving the quality of reports of parallel-group 
randomised trials. Lancet 2001;357(9263):1191-4. 
562. Narasimhan S, Weinstock RS. Youth-onset type 2 diabetes mellitus: lessons learned 
from the TODAY study. Mayo Clin Proc 2014;89(6):806-16. 
563. Springer F, Ballweg V, Schweizer R, et al. Changes in whole-body fat distribution, 
intrahepatic lipids, and insulin resistance of obese adolescents during a low-level 
lifestyle intervention. Eur J Pediatr 2015;174(12):1603-12. 
564. Hunt LP, Ford A, Sabin MA, et al. Clinical measures of adiposity and percentage fat 
loss: which measure most accurately reflects fat loss and what should we aim for? 
Arch Dis Child 2007;92(5):399-403. 
565. Haus JM, Solomon TP, Marchetti CM, et al. Free fatty acid-induced hepatic insulin 
resistance is attenuated following lifestyle intervention in obese individuals with 
impaired glucose tolerance. J Clin Endocrinol Metab 2010;95(1):323-7. 
566. Brambilla P, La Valle E, Falbo R, et al. Normal Fasting Plasma Glucose and Risk of 
Type 2 Diabetes. Diabetes Care 2011. 
567. Rauch F. Vibration therapy. Dev Med Child Neurol 2009;51 Suppl 4:166-8. 
568. Berggren JR, Hulver MW, Dohm GL, et al. Weight loss and exercise: implications 
for muscle lipid metabolism and insulin action. Med Sci Sports Exerc 
2004;36(7):1191-5. 
569. Schoenfeld BJ, Ogborn DI, Krieger JW. Effect of repetition duration during 
resistance training on muscle hypertrophy: a systematic review and meta-analysis. 
Sports Med 2015;45(4):577-85. 
570. Reinehr T, Toschke AM. Onset of puberty and cardiovascular risk factors in 
untreated obese children and adolescents: a 1-year follow-up study. Arch Pediatr 
Adolesc Med 2009;163(8):709-15. 
571. Dowling AR, Nedorezov LB, Qiu X, et al. Genetic factors modulate the impact of 
pubertal androgen excess on insulin sensitivity and fertility. PLoS One 
2013;8(11):e79849. 
572. Baxter KA, Ware RS, Batch JA, et al. Predicting success: factors associated with 
weight change in obese youth undertaking a weight management program. Obes 
Res Clin Pract 2013;7(2):e147-e54. 
573. Festa A, D'Agostino R, Jr., Howard G, et al. Chronic subclinical inflammation as 
part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis 
Study (IRAS). Circulation 2000;102(1):42-7. 
574. Juarez-Lopez C, Klunder-Klunder M, Madrigal-Azcarate A, et al. Omega-3 
polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese 
children and adolescents. Pediatr Diabetes 2013;14(5):377-83. 
575. Warren JM, Golley RK, Collins CE, et al. Randomised controlled trials in 
overweight children: practicalities and realities. Int J Pediatr Obes 2007;2(2):73-
85. 
576. Denzer C, Reithofer E, Wabitsch M, et al. The outcome of childhood obesity 
management depends highly upon patient compliance. Eur J Pediatr 
2004;163(2):99-104. 
577. Pinelli L, Elerdini N, Faith MS, et al. Childhood obesity: results of a multicenter 
study of obesity treatment in Italy. J Pediatr Endocrinol Metab 1999;12 Suppl 
3:795-9. 
   
  CHAPTER 8 REFERENCES 
226 
578. Seymour K. Using incentives: Encouraging and recognising participation in youth 
research. Youth Studies Australia 2012;Volume 31(3):51-59. 
579. Smith KL, Straker LM, McManus A, et al. Barriers and enablers for participation in 
healthy lifestyle programs by adolescents who are overweight: a qualitative study 
of the opinions of adolescents, their parents and community stakeholders. BMC 
Pediatr 2014;14:53. 
580. Abercromby AF, Amonette WE, Layne CS, et al. Vibration exposure and 
biodynamic responses during whole-body vibration training. Med Sci Sports 
Exerc 2007;39(10):1794-800. 
581. Robling AG, Hinant FM, Burr DB, et al. Shorter, more frequent mechanical loading 
sessions enhance bone mass. Med Sci Sports Exerc 2002;34(2):196-202. 
582. Emerenziani GP, Meucci M, Gallotta MC, et al. Whole body vibration: 
unsupervised training or combined with a supervised multi-purpose exercise for 
fitness? J Sports Sci 2014;32(11):1033-41. 
583. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass 
accumulation in healthy adolescents: evidence for a marked reduction after 16 
years of age at the levels of lumbar spine and femoral neck in female subjects. 
The Journal of clinical endocrinology and metabolism 1992;75(4):1060-5. 
584. Weaver CM. Adolescence: the period of dramatic bone growth. Endocrine 
2002;17(1):43-8. 
585. Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from 
childhood obesity: a systematic review and meta-analysis. Obes Rev 
2016;17(2):95-107. 
586. Foley S, Quinn S, Jones G. Tracking of bone mass from childhood to adolescence 
and factors that predict deviation from tracking. Bone 2009;44(5):752-7. 
587. Rauch F, Schoenau E. The developing bone: slave or master of its cells and 
molecules? Pediatric research 2001;50(3):309-14. 
588. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 
1993;14(4):595-608. 
589. Turner JG, Gilchrist NL, Ayling EM, et al. Factors affecting bone mineral density in 
high school girls. N Z Med J 1992;105(930):95-6. 
590. Daly RM, Rich PA, Klein R. Influence of high impact loading on ultrasound bone 
measurements in children: a cross-sectional report. Calcified tissue international 
1997;60(5):401-4. 
591. Yang S, Shen X. Association and relative importance of multiple obesity measures 
with bone mineral density: the National Health and Nutrition Examination 
Survey 2005-2006. Arch Osteoporos 2015;10:14. 
592. Maimoun L, Mura T, Leprieur E, et al. Impact of obesity on bone mass throughout 
adult life: Influence of gender and severity of obesity. Bone 2015. 
593. Frost HM, Schonau E. The "muscle-bone unit" in children and adolescents: a 2000 
overview. Journal of pediatric endocrinology & metabolism : JPEM 
2000;13(6):571-90. 
594. Campos RM, Lazaretti-Castro M, Mello MT, et al. Influence of visceral and 
subcutaneous fat in bone mineral density of obese adolescents. Arq Bras 
Endocrinol Metabol 2012;56(1):12-8. 
595. Farr JN, Khosla S. Determinants of bone strength and quality in diabetes mellitus in 
humans. Bone 2016;82:28-34. 
596. Ivaska KK, Heliovaara MK, Ebeling P, et al. The effects of acute hyperinsulinemia 
on bone metabolism. Endocrine connections 2015;4(3):155-62. 
   
  CHAPTER 8 REFERENCES 
227 
597. Abrahamsen B, Rohold A, Henriksen JE, et al. Correlations between insulin 
sensitivity and bone mineral density in non-diabetic men. Diabet Med 
2000;17(2):124-9. 
598. Mathen PG, Thabah MM, Zachariah B, et al. Decreased Bone Mineral Density at 
the Femoral Neck and Lumbar Spine in South Indian Patients with Type 2 
Diabetes. J Clin Diagn Res 2015;9(9):OC08-12. 
599. El Hage R, Moussa E, Jacob C. Bone mineral content and density in obese, 
overweight, and normal-weighted sedentary adolescent girls. The Journal of 
adolescent health : official publication of the Society for Adolescent Medicine 
2010;47(6):591-5. 
600. Klein KO, Larmore KA, de Lancey E, et al. Effect of obesity on estradiol level, and 
its relationship to leptin, bone maturation, and bone mineral density in children. J 
Clin Endocrinol Metab 1998;83(10):3469-75. 
601. Klein KO, Newfield RS, Hassink SG. Bone maturation along the spectrum from 
normal weight to obesity: a complex interplay of sex, growth factors and weight 
gain. Journal of pediatric endocrinology & metabolism : JPEM 2016;29(3):311-8. 
602. Petit MA, Beck TJ, Shults J, et al. Proximal femur bone geometry is appropriately 
adapted to lean mass in overweight children and adolescents. Bone 
2005;36(3):568-76. 
603. El Hage Z, Theunynck D, Jacob C, et al. Bone mineral content and density in obese, 
overweight and normal weight adolescent boys. J Med Liban 2013;61(3):148-54. 
604. Binkovitz LA, Henwood MJ. Pediatric DXA: technique and interpretation. Pediatr 
Radiol 2007;37(1):21-31. 
605. Fulzele K, DiGirolamo DJ, Liu Z, et al. Disruption of the insulin-like growth factor 
type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 
2007;282(35):25649-58. 
606. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the 
skeleton. Cell 2007;130(3):456-69. 
607. Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an 
Endocrine Society scientific statement. Endocr Rev 2012;33(3):456-92. 
608. Juonala M, Voipio A, Pahkala K, et al. Childhood 25-OH vitamin D levels and 
carotid intima-media thickness in adulthood: the cardiovascular risk in young 
Finns study. J Clin Endocrinol Metab 2015;100(4):1469-76. 
609. Shaw NJ, Mughal MZ. Vitamin D and child health: part 2 (extraskeletal and other 
aspects). Arch Dis Child 2013;98(5):368-72. 
610. Shi H, Norman AW, Okamura WH, et al. 1alpha,25-Dihydroxyvitamin D3 
modulates human adipocyte metabolism via nongenomic action. FASEB J 
2001;15(14):2751-3. 
611. Girgis CM, Clifton-Bligh RJ, Turner N, et al. Effects of vitamin D in skeletal 
muscle: falls, strength, athletic performance and insulin sensitivity. Clin 
Endocrinol (Oxf) 2014;80(2):169-81. 
612. Van Loan MD, Johnson HL, Barbieri TF. Effect of weight loss on bone mineral 
content and bone mineral density in obese women. Am J Clin Nutr 
1998;67(4):734-8. 
613. Gossain VV, Rao DS, Carella MJ, et al. Bone mineral density (BMD) in obesity 
effect of weight loss. J Med 1999;30(5-6):367-76. 
614. Tirosh A, de Souza RJ, Sacks F, et al. Sex Differences in the Effects of Weight Loss 
Diets on Bone Mineral Density and Body Composition: POUNDS LOST Trial. 
The Journal of clinical endocrinology and metabolism 2015;100(6):2463-71. 
   
  CHAPTER 8 REFERENCES 
228 
615. Ryan AS, Nicklas BJ, Dennis KE. Aerobic exercise maintains regional bone mineral 
density during weight loss in postmenopausal women. J Appl Physiol (1985) 
1998;84(4):1305-10. 
616. Lohman T, Going S, Pamenter R, et al. Effects of resistance training on regional 
and total bone mineral density in premenopausal women: a randomized 
prospective study. Journal of bone and mineral research : the official journal of 
the American Society for Bone and Mineral Research 1995;10(7):1015-24. 
617. Layne JE, Nelson ME. The effects of progressive resistance training on bone 
density: a review. Med Sci Sports Exerc 1999;31(1):25-30. 
618. Munns C, Zacharin MR, Rodda CP, et al. Prevention and treatment of infant and 
childhood vitamin D deficiency in Australia and New Zealand: a consensus 
statement. The Medical journal of Australia 2006;185(5):268-72. 
619. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and 
prevention of vitamin D deficiency: an Endocrine Society clinical practice 
guideline. The Journal of clinical endocrinology and metabolism 2011;96(7):1911-
30. 
620. Aksglaede L, Juul A, Olsen LW, et al. Age at puberty and the emerging obesity 
epidemic. PLoS One 2009;4(12):e8450. 
621. Pinhas-Hamiel O, Benary D, Mazor-Aronovich K, et al. Advanced bone age and 
hyperinsulinemia in overweight and obese children. Endocr Pract 2014;20(1):62-
7. 
622. Nguyen TV, Maynard LM, Towne B, et al. Sex differences in bone mass acquisition 
during growth: the Fels Longitudinal Study. Journal of clinical densitometry : the 
official journal of the International Society for Clinical Densitometry 
2001;4(2):147-57. 
623. Schoenau E. Bone mass increase in puberty: what makes it happen? Horm Res 
2006;65 Suppl 2:2-10. 
624. Rogol AD, Roemmich JN, Clark PA. Growth at puberty. The Journal of adolescent 
health : official publication of the Society for Adolescent Medicine 2002;31(6 
Suppl):192-200. 
625. Faulkner RA, Davison KS, Bailey DA, et al. Size-corrected BMD decreases during 
peak linear growth: implications for fracture incidence during adolescence. 
Journal of bone and mineral research : the official journal of the American 
Society for Bone and Mineral Research 2006;21(12):1864-70. 
626. Gultekin T, Akin G, Ozer BK. Gender differences in fat patterning in children 
living in Ankara. Anthropol Anz 2005;63(4):427-37. 
627. Carvalho WR, Goncalves EM, Ribeiro RR, et al. Influence of body composition on 
bone mass in children and adolescents. Rev Assoc Med Bras 2011;57(6):662-7. 
628. Schiessl H, Frost HM, Jee WS. Estrogen and bone-muscle strength and mass 
relationships. Bone 1998;22(1):1-6. 
629. Pollock NK, Laing EM, Baile CA, et al. Is adiposity advantageous for bone 
strength? A peripheral quantitative computed tomography study in late 
adolescent females. Am J Clin Nutr 2007;86(5):1530-8. 
630. Hedstrom EM, Svensson O, Bergstrom U, et al. Epidemiology of fractures in 
children and adolescents. Acta Orthop 2010;81(1):148-53. 
631. Afghani A, Cruz ML, Goran MI. Impaired glucose tolerance and bone mineral 
content in overweight latino children with a family history of type 2 diabetes. 
Diabetes Care 2005;28(2):372-8. 
632. Manzoni P, Brambilla P, Pietrobelli A, et al. Influence of body composition on bone 
mineral content in children and adolescents. Am J Clin Nutr 1996;64(4):603-7. 
   
  CHAPTER 8 REFERENCES 
229 
633. Osawa Y, Oguma Y, Onishi S. Effects of whole-body vibration training on bone-
free lean body mass and muscle strength in young adults. J Sports Sci Med 
2011;10(1):97-104. 
634. Lee BK, Chon SC. Effect of whole body vibration training on mobility in children 
with cerebral palsy: a randomized controlled experimenter-blinded study. Clin 
Rehabil 2013;27(7):599-607. 
635. Eid MA. Effect of Whole-Body Vibration Training on Standing Balance and Muscle 
Strength in Children with Down Syndrome. Am J Phys Med Rehabil 
2015;94(8):633-43. 
636. Stark C, Hoyer-Kuhn HK, Semler O, et al. Neuromuscular training based on whole 
body vibration in children with spina bifida: a retrospective analysis of a new 
physiotherapy treatment program. Childs Nerv Syst 2015;31(2):301-9. 
637. Vry J, Schubert IJ, Semler O, et al. Whole-body vibration training in children with 
Duchenne muscular dystrophy and spinal muscular atrophy. Eur J Paediatr 
Neurol 2014;18(2):140-9. 
638. Rubin C, Pope M, Fritton JC, et al. Transmissibility of 15-hertz to 35-hertz 
vibrations to the human hip and lumbar spine: determining the physiologic 
feasibility of delivering low-level anabolic mechanical stimuli to skeletal regions at 
greatest risk of fracture because of osteoporosis. Spine (Phila Pa 1976) 
2003;28(23):2621-7. 
639. Reinehr T, Roth CL. A new link between skeleton, obesity and insulin resistance: 
relationships between osteocalcin, leptin and insulin resistance in obese children 
before and after weight loss. Int J Obes (Lond) 2010;34(5):852-8. 
640. Hinton PS, Rector RS, Thomas TR. Weight-bearing, aerobic exercise increases 
markers of bone formation during short-term weight loss in overweight and 
obese men and women. Metabolism 2006;55(12):1616-8. 
641. Fernandez-Real JM, Izquierdo M, Ortega F, et al. The relationship of serum 
osteocalcin concentration to insulin secretion, sensitivity, and disposal with 
hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009;94(1):237-
45. 
642. Ducy P. The role of osteocalcin in the endocrine cross-talk between bone 
remodelling and energy metabolism. Diabetologia 2011;54(6):1291-7. 
643. Fernandez-Real JM, Ricart W. Osteocalcin: a new link between bone and energy 
metabolism. Some evolutionary clues. Curr Opin Clin Nutr Metab Care 
2011;14(4):360-6. 
644. Chao D, Espeland MA, Farmer D, et al. Effect of voluntary weight loss on bone 
mineral density in older overweight women. Journal of the American Geriatrics 
Society 2000;48(7):753-9. 
645. Yeap BB, Alfonso H, Chubb SA, et al. Higher serum undercarboxylated osteocalcin 
and other bone turnover markers are associated with reduced diabetes risk and 
lower estradiol concentrations in older men. The Journal of clinical 
endocrinology and metabolism 2015;100(1):63-71. 
646. Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose 
homeostasis. Journal of bone and mineral research : the official journal of the 
American Society for Bone and Mineral Research 2011;26(4):677-80. 
647. Pollock NK, Bernard PJ, Gower BA, et al. Lower Uncarboxylated Osteocalcin 
Concentrations in Children with Prediabetes Is Associated with {beta}-Cell 
Function. J Clin Endocrinol Metab 2011. 
648. Zhou M, Ma X, Li H, et al. Serum osteocalcin concentrations in relation to glucose 
and lipid metabolism in Chinese individuals. European journal of endocrinology 
/ European Federation of Endocrine Societies 2009;161(5):723-9. 
   
  CHAPTER 8 REFERENCES 
230 
649. Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends in endocrinology and 
metabolism: TEM 2009;20(5):230-6. 
650. Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and calcium in type 2 diabetes. 
A systematic review and meta-analysis. The Journal of clinical endocrinology and 
metabolism 2007;92(6):2017-29. 
651. Coates P. Bone turnover markers. Aust Fam Physician 2013;42(5):285-7. 
652. Nimptsch K, Hailer S, Rohrmann S, et al. Determinants and correlates of serum 
undercarboxylated osteocalcin. Annals of nutrition & metabolism 2007;51(6):563-
70. 
653. Kanbur NO, Derman O, Sen TA, et al. Osteocalcin. A biochemical marker of bone 
turnover during puberty. International journal of adolescent medicine and health 
2002;14(3):235-44. 
654. Paldanius PM, Ivaska KK, Hovi P, et al. The effect of oral glucose tolerance test on 
serum osteocalcin and bone turnover markers in young adults. Calcified tissue 
international 2012;90(2):90-5. 
655. Sen AT, Derman O, Kinik E. The relationship between osteocalcin levels and sexual 
stages of puberty in male children. The Turkish journal of pediatrics 
2000;42(4):281-5. 
656. Junior IF, Cardoso JR, Christofaro DG, et al. The relationship between visceral fat 
thickness and bone mineral density in sedentary obese children and adolescents. 
BMC Pediatr 2013;13:37. 
657. Pollock NK, Bernard PJ, Gutin B, et al. Adolescent obesity, bone mass, and 
cardiometabolic risk factors. The Journal of pediatrics 2011;158(5):727-34. 
658. Wei J, Ferron M, Clarke CJ, et al. Bone-specific insulin resistance disrupts whole-
body glucose homeostasis via decreased osteocalcin activation. J Clin Invest 
2014;124(4):1-13. 
659. Campos RM, de Mello MT, Tock L, et al. Interaction of bone mineral density, 
adipokines and hormones in obese adolescents girls submitted in an 
interdisciplinary therapy. Journal of pediatric endocrinology & metabolism : 
JPEM 2013;26(7-8):663-8. 
660. Fulzele K, Clemens TL. Novel functions for insulin in bone. Bone 2012;50(2):452-6. 
661. Reinehr T, Kiess W, Kapellen T, et al. Insulin sensitivity among obese children and 
adolescents, according to degree of weight loss. Pediatrics 2004;114(6):1569-73. 
662. Villareal DT, Fontana L, Das SK, et al. Effect of Two-Year Caloric Restriction on 
Bone Metabolism and Bone Mineral Density in Non-Obese Younger Adults: A 
Randomized Clinical Trial. Journal of bone and mineral research : the official 
journal of the American Society for Bone and Mineral Research 2016;31(1):40-51. 
663. Zibellini J, Seimon RV, Lee CM, et al. Does Diet-Induced Weight Loss Lead to 
Bone Loss in Overweight or Obese Adults? A Systematic Review and Meta-
Analysis of Clinical Trials. Journal of bone and mineral research : the official 
journal of the American Society for Bone and Mineral Research 
2015;30(12):2168-78. 
664. Shapses SA, Sukumar D. Bone metabolism in obesity and weight loss. Annu Rev 
Nutr 2012;32:287-309. 
665. Villareal DT, Fontana L, Weiss EP, et al. Bone mineral density response to caloric 
restriction-induced weight loss or exercise-induced weight loss: a randomized 
controlled trial. Arch Intern Med 2006;166(22):2502-10. 
666. Melanson EL, MacLean PS, Hill JO. Exercise improves fat metabolism in muscle 
but does not increase 24-h fat oxidation. Exerc Sport Sci Rev 2009;37(2):93-101. 
   
  CHAPTER 8 REFERENCES 
231 
667. Munns CF, Simm PJ, Rodda CP, et al. Incidence of vitamin D deficiency rickets 
among Australian children: an Australian Paediatric Surveillance Unit study. The 
Medical journal of Australia 2012;196(7):466-8. 
668. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D 
in obesity. Am J Clin Nutr 2000;72(3):690-3. 
669. Ashraf AP, Huisingh C, Alvarez JA, et al. Insulin resistance indices are inversely 
associated with vitamin D binding protein concentrations. J Clin Endocrinol 
Metab 2014;99(1):178-83. 
670. Ganji V, Zhang X, Shaikh N, et al. Serum 25-hydroxyvitamin D concentrations are 
associated with prevalence of metabolic syndrome and various cardiometabolic 
risk factors in US children and adolescents based on assay-adjusted serum 25-
hydroxyvitamin D data from NHANES 2001-2006. Am J Clin Nutr 
2011;94(1):225-33. 
671. Nunlee-Bland G, Gambhir K, Abrams C, et al. Vitamin D deficiency and insulin 
resistance in obese African-American adolescents. J Pediatr Endocrinol 
2011;24(1-2):29-33. 
672. Reyman M, Verrijn Stuart AA, van Summeren M, et al. Vitamin D deficiency in 
childhood obesity is associated with high levels of circulating inflammatory 
mediators, and low insulin sensitivity. Int J Obes (Lond) 2014;38(1):46-52. 
673. Paxton GA, Teale GR, Nowson CA, et al. Vitamin D and health in pregnancy, 
infants, children and adolescents in Australia and New Zealand: a position 
statement. The Medical journal of Australia 2013;198(3):142-3. 
674. Smotkin-Tangorra M, Purushothaman R, Gupta A, et al. Prevalence of vitamin D 
insufficiency in obese children and adolescents. Journal of pediatric 
endocrinology & metabolism : JPEM 2007;20(7):817-23. 
675. Slyper AH, Kashmer L, Huang WM, et al. Acanthosis nigricans, vitamin D, and 
insulin resistance in obese children and adolescents. J Pediatr Endocrinol 
2014;27(11-12):1107-11. 
676. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin 
resistance in South Asian women living in New Zealand who are insulin resistant 
and vitamin D deficient - a randomised, placebo-controlled trial. The British 
journal of nutrition 2010;103(4):549-55. 
677. Belenchia AM, Tosh AK, Hillman LS, et al. Correcting vitamin D insufficiency 
improves insulin sensitivity in obese adolescents: a randomized controlled trial. 
Am J Clin Nutr 2013;97(4):774-81. 
678. Wetzsteon RJ, Petit MA, Macdonald HM, et al. Bone structure and volumetric 
BMD in overweight children: a longitudinal study. Journal of bone and mineral 
research : the official journal of the American Society for Bone and Mineral 
Research 2008;23(12):1946-53. 
679. Burrows M, Liu D, Moore S, et al. Bone microstructure at the distal tibia provides a 
strength advantage to males in late puberty: an HR-pQCT study. Journal of bone 
and mineral research : the official journal of the American Society for Bone and 
Mineral Research 2010;25(6):1423-32. 
680. Heidemann M, Holst R, Schou AJ, et al. The influence of anthropometry and body 
composition on children's bone health: the childhood health, activity and motor 
performance school (the CHAMPS) study, Denmark. Calcified tissue 
international 2015;96(2):97-104. 
681. Richardson L, Paulis WD, van Middelkoop M, et al. An overview of national clinical 
guidelines for the management of childhood obesity in primary care. Prev Med 
2013;57(5):448-55. 
   
  CHAPTER 8 REFERENCES 
232 
682. Ben Ounis O, Elloumi M, Ben Chiekh I, et al. Effects of two-month physical-
endurance and diet-restriction programmes on lipid profiles and insulin resistance 
in obese adolescent boys. Diabetes Metab 2008;34(6 Pt 1):595-600. 
683. Savoye M, Shaw M, Dziura J, et al. Effects of a weight management program on 
body composition and metabolic parameters in overweight children: a 
randomized controlled trial. Jama 2007;297(24):2697-704. 
684. Kasa-Vubu JZ. Cardiovascular Fitness and Exercise as Determinants of Insulin 
Resistance in Postpubertal Adolescent Females. Journal of Clinical 
Endocrinology & Metabolism 2004;90(2):849-54. 
685. Alberga AS, Farnesi BC, Lafleche A, et al. The effects of resistance exercise training 
on body composition and strength in obese prepubertal children. Phys 
Sportsmed 2013;41(3):103-9. 
686. Schranz N, Tomkinson G, Olds T. What is the effect of resistance training on the 
strength, body composition and psychosocial status of overweight and obese 
children and adolescents? A Systematic review and meta-analysis. Sports Med 
2013;43(9):893-907. 
687. Dietz P, Hoffmann S, Lachtermann E, et al. Influence of exclusive resistance 
training on body composition and cardiovascular risk factors in overweight or 
obese children: a systematic review. Obesity facts 2012;5(4):546-60. 
688. Morinder G, Larsson UE, Norgren S, et al. Insulin sensitivity, VO2max and body 
composition in severely obese Swedish children and adolescents. Acta Paediatr 
2009;98(1):132-8. 
689. Kelley GA, Kelley KS, Pate RR. Exercise and BMI in Overweight and Obese 
Children and Adolescents: A Systematic Review and Trial Sequential Meta-
Analysis. Biomed Res Int 2015;2015:704539. 
690. van der Heijden GJ, Wang ZJ, Chu ZD, et al. A 12-week aerobic exercise program 
reduces hepatic fat accumulation and insulin resistance in obese, Hispanic 
adolescents. Obesity (Silver Spring) 2010;18(2):384-90. 
691. Lee JM, Davis MM, Woolford SJ, et al. Waist circumference percentile thresholds 
for identifying adolescents with insulin resistance in clinical practice. Pediatr 
Diabetes 2009;10(5):336-42. 
692. Bell LM, Byrne S, Thompson A, et al. Increasing body mass index z-score is 
continuously associated with complications of overweight in children, even in the 
healthy weight range. J Clin Endocrinol Metab 2007;92(2):517-22. 
693. Sabin MA, Kiess W. Childhood obesity: Current and novel approaches. Best Pract 
Res Clin Endocrinol Metab 2015;29(3):327-38. 
694. Short KR, Pratt LV, Teague AM, et al. Postprandial improvement in insulin 
sensitivity after a single exercise session in adolescents with low aerobic fitness 
and physical activity. Pediatr Diabetes 2013;14(2):129-37. 
695. Health AGDo. Australia's Physical Activity and Sedentary Behaviour Guidelines for 
Young People (13-17 years). 2014. 
696. Gow ML, van Doorn N, Broderick CR, et al. Sustained improvements in fitness and 
exercise tolerance in obese adolescents after a 12 week exercise intervention. 
Obes Res Clin Pract 2016;10(2):178-88. 
697. Eisenmann JC, Guseman EH, Morrison K, et al. Graded Exercise Testing in a 
Pediatric Weight Management Center: The DeVos Protocol. Child Obes 
2015;11(6):657-63. 
698. Ahmad F, Kavey RE, Kveselis DA, et al. Responses of non-obese white children to 
treadmill exercise. J Pediatr 2001;139(2):284-90. 
699. Toth MJ, Goran MI, Ades PA, et al. Examination of data normalization procedures 
for expressing peak VO2 data. J Appl Physiol (1985) 1993;75(5):2288-92. 
   
  CHAPTER 8 REFERENCES 
233 
700. Dencker M, Wollmer P, Karlsson MK, et al. Body fat, abdominal fat and body fat 
distribution related to VO(2PEAK) in young children. Int J Pediatr Obes 
2011;6(2-2):e597-602. 
701. Janz KF, Burns TL, Witt JD, et al. Longitudinal analysis of scaling VO2 for 
differences in body size during puberty: the Muscatine Study. Med Sci Sports 
Exerc 1998;30(9):1436-44. 
702. Pinto TE, Gusso S, Hofman PL, et al. Systolic and diastolic abnormalities reduce 
the cardiac response to exercise in adolescents with type 2 diabetes. Diabetes 
Care 2014;37(5):1439-46. 
703. Yang Z, Scott CA, Mao C, et al. Resistance exercise versus aerobic exercise for type 
2 diabetes: a systematic review and meta-analysis. Sports Med 2014;44(4):487-99. 
704. Eisenmann JC, DuBose KD, Donnelly JE. Fatness, fitness, and insulin sensitivity 
among 7- to 9-year-old children. Obesity (Silver Spring) 2007;15(8):2135-44. 
705. Stigman S, Rintala P, Kukkonen-Harjula K, et al. Eight-year-old children with high 
cardiorespiratory fitness have lower overall and abdominal fatness. Int J Pediatr 
Obes 2009;4(2):98-105. 
706. Maggio AB, Bou Puigdefabregas JW, Schwitzgebel VM, et al. Insulin secretion 
response during oral glucose tolerance test is related to low cardiorespiratory 
fitness in obese adolescents. J Pediatr Endocrinol Metab 2015;28(5-6):539-44. 
707. McMurray RG, Bauman MJ, Harrell JS, et al. Effects of improvement in aerobic 
power on resting insulin and glucose concentrations in children. Eur J Appl 
Physiol 2000;81(1-2):132-9. 
708. Song GE, Kim K, Lee DJ, et al. Whole body vibration effects on body composition 
in the postmenopausal korean obese women: pilot study. Korean J Fam Med 
2011;32(7):399-405. 
709. Garcia-Hermoso A, Sanchez-Lopez M, Martinez-Vizcaino V. Effects of Aerobic 
Plus Resistance Exercise on Body Composition Related Variables in Pediatric 
Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled 
Trials. Pediatr Exerc Sci 2015;27(4):431-40. 
710. Goodpaster BH, Kelley DE, Wing RR, et al. Effects of weight loss on regional fat 
distribution and insulin sensitivity in obesity. Diabetes 1999;48(4):839-47. 
711. Watts K, Beye P, Siafarikas A, et al. Exercise training normalizes vascular 
dysfunction and improves central adiposity in obese adolescents. Journal of the 
American College of Cardiology 2004;43(10):1823-7. 
712. Watts K, Beye P, Siafarikas A, et al. Effects of exercise training on vascular function 
in obese children. J Pediatr 2004;144(5):620-5. 
713. McMurray RG, Hosick PA, Bugge A. Importance of proper scaling of aerobic 
power when relating to cardiometabolic risk factors in children. Ann Hum Biol 
2011;38(5):647-54. 
714. Lang I, Busche P, Rakhimi N, et al. Mechanography in childhood: references for 
grip force, multiple one-leg hopping force and whole body stiffness. J 
2013;13(2):227-35. 
715. Ward KA, Das G, Berry JL, et al. Vitamin D status and muscle function in post-
menarchal adolescent girls. Journal of Clinical Endocrinology & Metabolism 
2009;94(2):559-63. 
716. Faigenbaum AD, Westcott WL, Loud RL, et al. The effects of different resistance 
training protocols on muscular strength and endurance development in children. 
Pediatrics 1999;104(1):e5. 
717. Sothern MS, Loftin JM, Udall JN, et al. Inclusion of resistance exercise in a 
multidisciplinary outpatient treatment program for preadolescent obese children. 
South Med J 1999;92(6):585-92. 
   
  CHAPTER 8 REFERENCES 
234 
718. Franz MJ, Boucher JL, Rutten-Ramos S, et al. Lifestyle weight-loss intervention 
outcomes in overweight and obese adults with type 2 diabetes: a systematic 
review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 
2015;115(9):1447-63. 
 
   
  APPENDICES 
235 
APPENDICES
   
  APPENDIX A 
236 
 
APPENDIX A 
Is your child overweight or obese? 
 
Are they between 10- 16 years? 
 
Has your doctor told you that your child is at 
risk of Type 2 diabetes or has signs of insulin 
resistance? 
 
If so, you may be interested in a new research 
trial being conducted in the Institute of 
Endocrinology and Diabetes at The Children’s 
Hospital at Westmead 
      
This child has signs of insulin resistance (there is a darkening of the neck 
called acanthosis nigricans)            
 
What is insulin resistance? 
Overweight, Acanthosis Nigricans (darkening of skin behind neck as in picture) and 
polycystic ovaries may mean your child has insulin resistance and therefore may be 
eligible to participate in our study. 
 
    More about our study 
We are conducting a 3 month research trial to look at the effects of vibration training 
on insulin resistance in overweight adolescents. Your child will still receive the current 
standard therapies prescribed by your Endocrinologist for this condition but in 
addition half of the children recruited will be given a vibration plate to use at home for 
three months.  
 
For more information please ask your Endocrinologist for an information sheet or call 
Dr Kim Ramjan on (02) 9845-3151   
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Sydney West Area Newsletter/ CHW Bandaged Bear Bulletin 
 
Vibration Training and Insulin Resistance Study for Overweight Adolescents 
 
Prof Cowell, Dr Craig Munns, Dr Sarah Garnett and Dr Kim Ramjan are conducting a 
new randomised control research trial into the effects of whole body vibration training 
and insulin resistance in overweight adolescents. This 3 month study is now recruiting 
young people aged 10-18 years who have clinical signs of insulin resistance for e.g. 
acanthosis nigricans, high fasting insulin levels, overweight and polycystic ovarian 
syndrome. The participants will be all receive the current standard care treatment as 
prescribed by Endocrinologists at The Children’s Hospital at Westmead. In addition half 
of the participants will be randomised to receive vibration training. Participants in the 
vibration arm will be given a vibration platform to take home and use during the 3 
month trial. If you have any patients that would like to take part in this study please 
contact Dr Kim Ramjan (02) 9845- 3151 or email kimr@chw.edu.au. 
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INFORMATION SHEET 
Whole Body Vibration Training for adolescents with insulin resistance 
 
 
Investigators: 
Dr K Ramjan, Institute of Endocrinology & Diabetes, CHW. Phone 02 9845 3151 
Dr S Garnett, Division of Research, CHW.  Phone: 02 9845 3152 
Dr C Munns, Institute of Endocrinology & Diabetes, CHW. Phone 02 9845 3200 
A/Prof C Cowell, Institute of Endocrinology & Diabetes, CHW. Phone: 02 9845 3200 
 
We would like you to consider participating in a research study that will be conducted in The Institute of 
Endocrinology & Diabetes at The Children’s Hospital at Westmead. 
What is the study about? 
This is a three month study looking at the effect whole body vibration training in young people who are 
overweight and are showing signs of insulin resistance. Signs include overweight and obesity, high insulin 
levels, acanthosis nigricans (dark pigmentation often found on the neck, under the arms or in the groin) and 
polycystic ovarian syndrome, high blood pressure and high blood fats. 
Who can participate in the study? 
10 to 18 year olds who are overweight or obese who have clinical signs of insulin resistance. Your doctor will 
let you know if you can take part in the study. 
What will the study involve?  
You will be put in either a standard care or standard care plus whole body vibration training group. All 
participants will be prescribed a diet and physical activity program, this is standard treatment in our clinic for 
all adolescents who are overweight. If you are allocated to the standard care plus whole body vibration 
training group, you will be asked to stand on a vibration platform at home for 15 minutes a day for three 
months. We will lend you the platform at no cost for three months.  
 
Standard Care at The Children’s Hospital at Westmead 
 
Diet Intervention: You and your parent will be seen by one of our Weight Management dieticians at the 
beginning of the study. This is routine care for overweight children in our clinic. The dietician will review 
your diet and give you and your parent some guidelines about how to modify your diet if necessary. The 
dietician will arrange a follow up after 2 weeks and will be in contact by phone twice during the three months 
to see how things are going at home. 
Physical Activity: You will be referred to The Children’s Hospital Institute of Sports Medicine (CHISM), 
which is next to the hospital. You will have a fitness assessment and will be given an exercise prescription. 
The team at CHISM will follow you after 1 and 2 months to monitor your progress. 
Vibration training group 
If you are allocated to this group, we will lend you a vibration plate to use at home at no cost for the duration 
of the study (3 months). You will be required to stand on the vibration plate for 15 minutes a day and 
perform some basic stretches (we will teach them to you). We will ask you to keep a vibration training diary. 
 
Extra Tests 
To see if vibration training is useful in overweight adolescents with insulin resistance, we will need to do 
some further tests at the start of the study and at the end of the three months. The tests at the beginning of 
the study would need to be done anyway as they are part of routine care.  
 
Details of tests 
Corner Hawkesbury Road 
and Hainsworth Street 
 
Locked Bag 4001 
Westmead NSW 2145 
Sydney Australia 
 
DX 8213 Parramatta 
 
Tel +61 2 9845 0000 
Fax +61 2 9845 3489 
www.chw.edu.au 
ABN 53 188 579 090 
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1) Insulin sensitivity: Will be measured by an Oral Glucose Tolerance Test (OGTT). This will involve coming 
to Turner Day Stay Ward at The Children’s Hospital at Westmead at 8am after an overnight fast. After height 
and weight an IV cannula will be placed in one arm.  Local anaesthetic cream will be used so that discomfort 
will be minimised. You will be asked to drink a glass of LucozadeTM  (a sugary drink).  The cannula will be 
used to take blood at the beginning of the study and every 30 minutes for 2 hours. During the test you can 
watch a video, listen to music, read a book etc. At the end of the test you will be given lunch on the ward. 
This test will conducted by a doctor and an experienced nurse. 
2) Blood test (fasting): We will need to collect 15 ml of blood (approximately 3 teaspoons) through the 
cannula after it is inserted. No additional blood tests will be necessary. 
3) Body composition: Will be measured by Dual energy X ray absorptiometry (DXA). This scan is non-
invasive, painless and measures the amount of body fat compared to muscle in the body. Two Xray beams 
are passed through the body to give an image of soft tissue on the computer. This will involve you lying still 
on a table for approximately 10 minutes while we perform the scan. We will also measure the muscle and 
bone in your leg with a pQCT (Peripheral Quantitative Computer Tomography) scan. This is non invasive 
and painless. You will need to place your lower leg on a leg rest in the machine; it will be strapped in place if 
necessary. The test will take 5 minutes. These scans involve exposure to a very small amount of radiation.  As 
part of everyday living, everyone is exposed to naturally occurring background radiation and receives a dose 
of about 2000-3000 microsieverts (mSv) each year. The effective dose from this study is less than 5.6 microSv. 
At this dose, no harmful effects of radiation have been demonstrated and the risk is negligible. 
4) Fitness test: This will involve running on a treadmill at The Children’s Hospital Institute of Sports 
Medicine. You will be asked to exercise until you feel you are exhausted. Monitoring of heart rate will be 
undertaken. The test can be stopped at any time. This will take approximately 30 minutes.  
5) Grading of acanthosis nigricans: The degree of acanthosis nigricans will be assessed by your doctor. In 
addition, photographs of the affected skin areas will be taken to assess if the treatment helps the skin 
condition. 
6) Anthropometry: We would like to measure your height, weight and waist circumference.  
7) Questionnaires: We would like you to complete questionnaires about your diet and physical activity and 
your vibration training (if applicable). This will take approximately 15-20minutes. You may need the help of 
your parents to complete these forms. 
Are there any benefits for my participation in the study? 
You will be informed of your results which will be explained to you in detail. The results may help you 
manage your insulin resistance. 
Are there any side-effects and risk associated with this study? 
There are no side effects or risks associated with this study. However, the effects of the small dose of 
radiation received in this study could affect an unborn baby. You should not become pregnant while on this 
study. We can provide further pregnancy counselling if requested. The vibration is very gentle, but some 
adolescents may find the feeling uncomfortable. At all times you will be able to stop the vibration if you 
become uncomfortable. When the vibration finishes some adolescents may have a tingling feeling in their legs 
and feet. While not painful, you may not like this feeling. The blood tests may cause some local pain and 
bruising, but we will apply some numbing cream to the area. 
Other information: 
Your anonymity and confidentiality will be maintained. In order to meet these requirements we will only 
report grouped data. Your information will be kept confidential and stored for a period of 5-10 years after 
publication, after which time information will be destroyed. Participation in this project is voluntary and if 
you decide not to take part or decide to withdraw at any time this will not otherwise affect your care at the 
Hospital. 
If you have any questions about the conduct of this study, please do not hesitate to discuss them with Kim 
Ramjan (02 9845 3151) or any of the other investigators listed above. 
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This project has been approved by The Children’s Hospital at Westmead Ethics Committee.  If you have any 
concerns about the conduct of this study, please do not hesitate to contact Carolyn Casey, Secretary of the 
Ethics Committee (02 9845 1316). 
This Information Sheet is for you to keep. We will also give you a copy of the signed consent form.  
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INFORMATION SHEET  
Whole Body Vibration Training for adolescents with insulin resistance 
 
 
 
Investigators: 
Dr K Ramjan, Institute of Endocrinology & Diabetes, CHW Phone 02 9845 3151 
Dr S Garnett, Division of Research, CHW.  Phone: 02 9845 3152 
Dr C Munns, Institute of Endocrinology & Diabetes, CHW. Phone 02 9845 3200 
A/Prof C Cowell, Institute of Endocrinology & Diabetes, CHW. Phone: 02 9845 3200 
 
We would like you to consider letting your child participate in a research study that will be conducted in The 
Institute of Endocrinology & Diabetes at The Children’s Hospital at Westmead. 
What is the study about? 
This is a three month study looking at the effect of whole body vibration training in young people who are 
overweight and are showing signs of insulin resistance. Signs include overweight and obesity, high insulin 
levels, acanthosis nigricans (dark pigmentation often found on the neck, under the arms or in the groin) and 
polycystic ovarian syndrome, high blood pressure and high blood fats. 
Who can participate in the study? 
10 to 18 year olds who are overweight or obese who have clinical signs of insulin resistance.  
What will the study involve?  
Your child will be put in either a standard care or standard care plus whole body vibration training group. All 
participants will be prescribed a diet and physical activity program; this is standard treatment in our clinic for 
all adolescents who are overweight. If your child is allocated to the standard care plus whole body vibration 
training group, they will be asked to stand on a vibration platform at home for 15 minutes a day for three 
months. We will lend your child the plate at no cost for three months.  
 
Standard Care at The Children’s Hospital at Westmead 
 
Diet Intervention: You and your child will be seen by one of our Weight Management dieticians at the 
beginning of the study. This is routine care for overweight children in our clinic. The dietician will review 
your child’s diet and give you some guidelines about how to modify your child’s diet if necessary. The 
dietician will arrange a follow up after 2 weeks and will be in contact by phone twice during the three months 
to see how things are going at home. 
Physical Activity: Your child will be referred to The Children’s Hospital Institute of Sports Medicine 
(CHISM), which is next to the hospital. Your child will have a fitness assessment and will be given an exercise 
prescription. The team at CHISM will observe you child after 1 and 2 months to monitor progress. 
Vibration training group 
If your child is allocated to this group, we will lend them a vibration plate to use at home at no cost for the 
duration of the study (3 months). Your child will be required to stand on the vibration plate for 15 minutes a 
day and perform some basic stretches (we will teach them to your child). We will ask your child to keep a 
vibration training diary. 
Extra Tests 
To see if vibration training is useful in overweight children with insulin resistance, we will need to do some 
further tests at the start of the study and at the end of the three months. The tests at the beginning of the 
study would need to be done anyway as they are part of routine care.  
 
Details of tests 
Corner Hawkesbury Road 
and Hainsworth Street 
 
Locked Bag 4001 
Westmead NSW 2145 
Sydney Australia 
 
DX 8213 Parramatta 
 
Tel +61 2 9845 0000 
Fax +61 2 9845 3489 
www.chw.edu.au 
ABN 53 188 579 090 
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1) Insulin sensitivity will be measured by an Oral Glucose Tolerance Test (OGTT). This will involve 
bringing your child to Turner Day Stay ward at The Children’s Hospital at Westmead at 8am after an 
overnight fast. After height and weight an IV cannula will be placed in one arm.  Local anaesthetic cream will 
be used so that discomfort will be minimised. Your child will be asked to drink a glass LucozadeTM (a sugary 
drink).  The cannula will be used to take blood at the beginning of the study and every 30 minutes for 2 hours. 
During the test your child can watch a video, listen to music, read a book etc. At the end of the test your 
child will be given lunch on the ward. This test will conducted by a doctor and an experienced nurse. 
2) Blood test (fasting): We will need to collect 15 ml of blood (approximately 3 teaspoons) from the 
cannula after it has been inserted. No additional blood tests will need to be taken. 
3) Body composition: will be measured by Dual energy X ray absorptiometry (DXA). This scan is non-
invasive, painless and measures the amount of body fat compared to muscle in the body. Two Xray beams 
are passed through the body to give an image of soft tissue on the computer. This will involve your child 
lying still on a table for approximately 10 minutes while we perform the scan. We will also measure the 
muscle and bone in your child’s leg with a pQCT (Peripheral Quantitative Computer Tomography) scan. This 
is non invasive and painless. Your child will need to place their lower leg on a leg rest in the machine; it will 
be strapped in place if necessary. The test will take 5 minutes. These scans involve exposure to a very small 
amount of radiation.  As part of everyday living, everyone is exposed to naturally occurring background 
radiation and receives a dose of about 2000-3000 microsieverts (mSv) each year. The effective dose from this 
study is less than 5.6 microSv. At this dose, no harmful effects of radiation have been demonstrated and the 
risk is negligible. 
4) Fitness test: This will involve running on a treadmill at The Children’s Hospital Institute of Sports 
Medicine. Your child will be asked to exercise until they feel they are exhausted. Monitoring of heart rate will 
be undertaken. The test can be stopped at any time. This will take approximately 30 minutes.  
5) Grading of acanthosis nigricans: The degree of acanthosis nigricans will be assessed by your child’s 
doctor. In addition, photographs of the effected skin areas will be taken to assess if the treatment help the 
skin condition. 
6) Anthropometry: We would like to measure your child’s height, weight and waist circumference.  
7) Questionnaires: We would like your child to complete questionnaires about their diet and physical 
activity and their vibration training (if applicable). Your child may require 15-20 minutes of your time to assist 
them to complete these forms. 
Are there any benefits for my child participating in the study? 
You will be informed of your child’s results which will be explained to you in detail. The results may help you 
manage insulin resistance in your child. 
Are there any side-effects and risk associated with this study? 
There are no side effects or risks associated with this study. However, the effects of the small dose of 
radiation received in this study could affect an unborn baby. Your child should not become pregnant while 
on this study. If requested we can provide counselling regarding pregnancy. The vibration is very gentle, but 
some children may find the feeling uncomfortable. At all times you will be able to stop the vibration if your 
child becomes uncomfortable. When the vibration finishes some children may have a tingling feeling in their 
legs and feet. While not painful, some children may not like this feeling. The blood tests may cause some local 
pain and bruising, but we will apply some numbing cream to the area. 
Other information: 
Your child’s anonymity and confidentiality will be maintained. In order to meet these requirements we will 
only report grouped data. Your information will be kept confidential and stored for a period of 5-10 years 
after publication, after which time information will be destroyed. Participation in this project is voluntary and 
if you decide not to take part or decide to withdraw at any time this will not otherwise affect your child’s care 
at the Hospital. If you have any questions about the conduct of this study, please do not hesitate to discuss 
them with Kim Ramjan (02 9845 3151) or any of the other investigators listed above. 
This project has been approved by The Children’s Hospital at Westmead Ethics Committee.  If you have any 
concerns about the conduct of this study, please do not hesitate to contact Carolyn Casey, Secretary of the 
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Ethics Committee (02 9845 1316). This Information Sheet is for you to keep. We will also give you a copy of 
the signed consent form. 
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Clinical Evaluation Form    APPENDIX C 
Child’s Anthropometry 
 
Date of evaluation (dd/mm/yy)______/_______/______  Measured by (circle):  KR/ SG/ SB/ Consultant 
 
 Trial 1 Trial 2 Trial 3 Average 
Height (cm)     
Weight (kg)     
Waist Circumference (cm)     
 
Acanthosis Nigricans & Hirsutism & PCOS & Fatty Liver 
 
Acanthosis Nigricans  Don’t Know/No/Yes 
 
Sites    □ Neck  □ Axilla □ Knuckles □ Knee  
 
Grade at neck   □ 1 □ 2  □ 3 □ 4 
 
Hirsutism    Don’t Know/No/ Yes 
 
Sites    □ Face □ Abdomen □ Legs 
 
Measured by (circle)   KR/ Consultant 
 
PCOS    Don’t Know/No/Yes 
 
Fatty Liver   Don’t Know/No/Yes 
 
Blood Pressure 
 
Blood pressure measured (circle)    Yes/ No 
 
Cuff Size:      □ Child  □ Small Adult  □ Adult  □ Don’t Know 
 
Blood Pressure 
 
BP Systolic 1 _________________BP Systolic 2__________________  BP Systolic 3  _____________ 
 
BP Diastolic1_________________BP Diastolic 2_________________   BP Diastolic3______________ 
 
Pubertal Staging 
Pubertal staging performed (circle)   Don’t know/No/Yes 
     Measured/ Self reported 
 
Acne (circle)     Don’t know/No/Yes 
 
Girls 
Menarche attained     Don’t know/ No/Yes   Date ____/_____/____ 
 
Breast Stage     □ 1   □ 2   □ 3   □ 4   □ 5  
 
Pubic Hair     □ 1   □ 2   □ 3   □ 4   □ 5 
  
Boys 
Testes (ml) Right     __________ml 
 
Testes (ml) Left     __________ml 
 
Genital Stage     □ Don’t know □ 1   □ 2   □ 3   □ 4   □ 5 
 
Pubic Hair     □ Don’t know □ 1   □ 2   □ 3   □ 4   □ 5 
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Clinical Evaluation Form 
 
Child Medical History 
 
Does the child have any other medical problems? (circle) Yes/ No  
 
Please list any other medical problems:  
___________________________________________________________________________________ 
 
 
Family History 
 
Overweight/ Obesity 
 
Is any one else in your family overweight? (circle)   Don’t know/No/Yes 
 
If yes, please choose from list:      Sibling/ Mother/ Father/ Grandparent/ Aunt/ Uncle 
 
What is their current treatment:      Don’t know/Lifestyle/ Metformin/ Orlistat (Xenical)/  
        Sibutramine (Reductil)    
 
Diabetes 
 
Is there a family history of diabetes? (circle)      Don’t know/No/Yes 
 
If yes, please choose from list:      Sibling/ Mother/ Father/ Grandparent/ Aunt/ Uncle 
 
What type of diabetes? (circle)      Don’t know/Type 1/ Type 2/ Other 
 
What is their current treatment:       Don’t Know /Lifestyle/Oral hypoglycaemics/Insulin 
 
 
Hypertension 
 
Is there a family history of hypertension? (circle)    Don’t know/No/Yes 
 
If yes, please choose from list:     Sibling/ Mother/ Father/ Grandparent/ Aunt/ Uncle 
      
 
What is their current treatment:     Don’t know/Lifestyle/ Oral Antihypertensive 
 
 
Cardiovascular Disease 
 
Is there a family history of cardiovascular disease?  Don’t know/No/Yes 
 
If yes, please choose from list:       Sibling/ Mother/ Father/ Grandparent/ Aunt/ Uncle 
 
 
Polycystic Ovarian Syndrome 
 
Is there a family history of PCOS?        Don’t know/No/Yes 
 
If yes, please choose from the list: (circle):    Don’t know/ Sister/ Mother/ Aunt/ Grandmother 
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Interview Form 
Study:  
 
Please complete the following details and circle appropriate responses 
Child’s Details 
Child MRN____________________ Child Forename________________________________ Child Surname ____________________________ 
Date of Birth (dd/mm/yy)________/________/_________   
Address_______________________________________________________ Suburb ________________________  Postcode _____________  
Home Phone (____)____________________  Mobile Number_________________ Email ___________________________________________ 
Country of Birth (circle): 
 
Australia/ New Zealand/Pacific Islander   NW Europe (UK, Scandinavia, Germany, France)   
SE  Europe (Italy/ Greece/ Hungary/Poland)   N Africa & Middle East  
SE Asia (Thailand, Vietnam, Malaysia, Indonesia)   NE Asia (China/Japan/ Korea) 
Southern & Central Asia (India, Sri Lanka)   North America 
South America     Sub Saharan Africa 
 
Other (specify)                    ___________________________________________ 
 
If Australia, Aboriginal or Torres Strait   Yes/ No 
 
If New Zealand, NZ Maori/ Pacific Islander                 Yes/ No 
 
Language spoken at home (circle):                  English/ Italian/ Greek/ Cantonese/ Arabic/  Vietnamese/ Mandarin 
 
Other language (specify)                   ____________________________________________ 
 
Other Comments ____________________________________________________________________________________________________  
 
Mother’s Details 
 
Forename__________________________________ Surname_____________________________ Date of Birth (dd/mm/yy)____/____/______ 
Address____________________________________________________Suburb__________________________________________________ 
Postcode_______________ Home Phone (____)_________________________Work Phone (____)___________________________________ 
Mobile Phone _______________________________________Email____________________________________________________________ 
 
Country of Birth (circle):  
 
Australia/ New Zealand/Pacific Islander   NW Europe (UK, Scandinavia, Germany, France)   
SE  Europe (Italy/ Greece/ Hungary/Poland)   N Africa & Middle East  
SE Asia (Thailand, Vietnam, Malaysia, Indonesia)   NE Asia (China/Japan/ Korea)     
Southern & Central Asia (India, Sri Lanka)   North America 
South America     Sub Saharan Africa 
 
Other (specify)                    ____________________________________________ 
 
If Australia, Aboriginal or Torres Strait   Yes/ No 
 
If New Zealand, NZ Maori/ Pacific Islander                 Yes/ No 
 
Language spoken at home (circle):                  English/ Italian/ Greek/ Cantonese/ Arabic/  Vietnamese/ Mandarin 
 
Other language (specify)                   ____________________________________________ 
 
Other Comments _______________________________________________________________________________ 
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Interview Form (Continued) 
Study:  
 
Please complete the following details and circle appropriate responses 
Father’s Details 
Forename__________________________________ Surname_____________________________ Date of Birth (dd/mm/yy)____/____/______ 
Address____________________________________________________Suburb__________________________________________________ 
Postcode_______________ Home Phone (____)_________________________Work Phone (____)___________________________________ 
Mobile Phone _______________________________________Email____________________________________________________________ 
 
Country of Birth (circle):  
 
Australia/ New Zealand/Pacific Islander   NW Europe (UK, Scandinavia, Germany, France)   
SE  Europe (Italy/ Greece/ Hungary/Poland)   N Africa & Middle East  
SE Asia (Thailand, Vietnam, Malaysia, Indonesia)   NE Asia (China/Japan/ Korea)     
Southern & Central Asia (India, Sri Lanka)   North America 
South America     Sub Saharan Africa 
 
Other (specify)                    ____________________________________________ 
 
If Australia, Aboriginal or Torres Strait   Yes/ No 
 
If New Zealand, NZ Maori/ Pacific Islander                 Yes/ No 
 
Language spoken at home (circle):                  English/ Italian/ Greek/ Cantonese/ Arabic/  Vietnamese/ Mandarin 
 
Other language (specify)                   ____________________________________________ 
 
Other Comments ____________________________________________________________________________________________________ 
 
 
Relative/ Next of Kin Details 
 
 
Forename________________________________________ Surname___________________________________________________________ 
Address____________________________________________________Suburb__________________________________________________ 
Postcode_______________ Home Number (____)________________________Mobile Phone _______________________________________ 
 
GP Details 
 
Are you happy for GP to know of participation in study (circle)              Yes/No 
 
Forename________________________________________ Surname___________________________________________________________ 
Address____________________________________________________Suburb__________________________________________________ 
Postcode_______________ Work Phone (____)________________________________Other Number (____)___________________________ 
Mobile Phone _______________________________________ 
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Dietary Checklist 
 
HOW TO FILL IN THE CHECKLIST 
 
You will need to fill the checklist in each day for 7 days. 
 
Put a tick [] in the box if you have eaten the food listed in amount advised. 
 Example [lamb] or [apple]. 
 
If you have eaten the food, but have had more or less than advised, write in the amount  eaten.  Example 
[lamb 80g cooked] or [apple 200g]. 
 
Put a cross (X) if you have not eaten that food at all. 
 
List ALL foods eaten (allowed or not!) that are not specified on the checklist under  OTHER. Example  [diet 
soft drink 1 can] 
 
Name:_______________________________ 
 
Record Number:   
 
Date of Appointment: / /  
If you have any questions, please contact Kim Ramjan (02) 9845 3151 
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WEEK:………      
DATE:…………………… Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Cereal or toast        
Eggs        
Dairy (milk or yoghurt)        
Protein @ morning tea 
eg cheese, milk        
Bread, wholegrain        
Lunch protein (50-100g: palm 
size )  eg fish/ham        
Salad veg (circle number of 
serves) 
0   1   2   3   
4+ 
0   1   2   3   
4+ 
0   1   2   3   
4+ 
0   1   2   3   
4+ 
0   1   2   3   
4+ 
0   1   2   3   
4+ 0   1   2   3   4+ 
Dinner protein (150g raw weight: 
hand size)  eg beef, chicken, fish        
Potato, rice, pasta (1 cup)        
Veg (circle number of serves) 0   1   2   3   4+ 
0   1   2   3   
4+ 
0   1   2   3   
4+ 
0   1   2   3   
4+ 
0   1   2   3   
4+ 
0   1   2   3   
4+ 0   1   2   3   4+ 
Fruit (circle number of serves) 0   1   2   3+ 0   1   2   3+ 0   1   2   3+ 0   1   2   3+ 0   1   2   3+ 0   1   2   3+ 0   1   2   3+ 
Good fats eg oil, nuts, avocado        
Treats eg chocolate, chips        
 
OTHER – list        
        
Exercise (circle number of minutes) 0   30   60 0   30   60 0   30   60 0   30   60 0   30   60 0   30   60 0   30   60 
1 day off No…Yes No…Yes No…Yes No…Yes No…Yes No…Yes No…Yes 
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Leisure and Activity Questionnaire 
 
 
Please take time to answer all the questions. 
It will take about 10 - 15 minutes. 
 
 
 
 
Name:_______________________________ 
 
Record Number:   
 
Date of Appointment: / /  
 
Thanks for your help in completing this survey. 
 
If you have any questions, please contact Kim Ramjan (02) 9845 3151
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Q1 In a typical WEEK in the LAST MONTH (do NOT include school holidays), which of the following 
PHYSICAL activities do you USUALLY do and for how long Monday-Friday and Saturday-Sunday? 
PLEASE INCLUDE ACTIVITIES THAT YOU DO BEFORE SCHOOL, DURING RECESS AND LUNCH, AFTER SCHOOL AND WEEKENDS. DO 
NOT CIRCLE ACTIVITIES THAT YOU DO IN SCHOOL PE, ONLY INCLUDE ACTIVITIES THAT YOU DO IN SCHOOL SPORT FOR FOUR 
WEEKS OR MORE. FOR EXAMPLE, YOU WOULD CIRCLE ‘SOCCER’ IF YOU DO IT DURING SCHOOL SPORT FOR FOUR WEEKS OR MORE 
PER TERM. 
 
In a typical WEEK which activities do you usually 
do? 
Do you 
usually do this 
activity? 
MONDAY - FRIDAY SATURDAY - SUNDAY 
Number of times 
Monday-Friday 
Total hours/minutes 
Monday-Friday 
Number of times 
Saturday & Sunday 
Total hours/minutes 
Saturday & Sunday 
EXAMPLE: 
Cycling 
 
No      Yes 
 
2 
 
40mins 
 
1 
15mins 
Aerobics No   Yes     
Dance No   Yes     
Calisthenics/gymnastics No   Yes     
Martial Arts eg Karate No   Yes     
Tennis/ Bat tennis No   Yes     
Aussie Rules Football No   Yes     
Rugby League No   Yes     
Touch Football No   Yes     
Rugby Union No   Yes     
Soccer No   Yes     
Basketball No   Yes     
Cricket No   Yes     
Netball No   Yes     
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In a typical WEEK which activities do you usually 
do? 
Do you 
usually do this 
activity? 
MONDAY - FRIDAY SATURDAY - SUNDAY 
Number of times 
Monday-Friday 
Total hours/minutes 
Monday-Friday 
Number of times 
Saturday & Sunday 
Total hours/minutes 
Saturday & Sunday 
Baseball/softball No   Yes     
Swim laps No   Yes     
Swim for fun No   Yes     
Play with bats/rackets/ golf clubs No   Yes     
Skateboarding  No   Yes     
Roller blading No   Yes     
Ride Scooter No   Yes     
Ride Bicycle (not for transport) No   Yes     
Ride Bicycle for transport (not to or from school)  No   Yes     
Skip rope  No   Yes     
Trampolining No   Yes     
Ball Games (eg, shooting hoops, kick-to-kick) No   Yes     
Hand ball No   Yes     
Play golf No   Yes     
Horse Riding No   Yes     
Walk the dog No   Yes     
Walk for exercise No   Yes     
Walk for transport (not to or from school) No   Yes     
Hockey No        Yes     
Rowing No        Yes     
Ten Pin Bowling No       Yes      
Weight training for fitness and strength No       Yes      
Jogging, running or cross country No       Yes     
 
 
 
 
 
GO TO NEXT PAGE 
GO TO NEXT PAGE 
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In a typical WEEK which activities 
do you usually do? 
Do you usually 
do this activity? 
MONDAY - FRIDAY SATURDAY - SUNDAY 
Number of times 
Monday-Friday 
Total 
hours/minutes 
Monday-Friday 
Number of times 
Saturday & Sunday 
Total hours/minutes 
Saturday & Sunday 
Household chores 
(eg, sweeping, scrubbing floors, 
chopping wood) 
 
No      Yes  
    
Other Clubs (eg: Scouts / Guides / 
Youth groups) 
Please state; 
 
------------------------------- 
 
 
No       Yes 
    
Travel by walking to school 
(to and from school = 2 times) 
 
No   Yes 
    
Travel by cycling to school 
(to and from school = 2 times) 
 
No   Yes 
    
Physical Education (PE) class 
ACTIVITY ONLY  
(NOT Personal Development PD 
class) 
 
No   Yes 
    
Other (please state) 
-----------------------------------------------
----------------- 
 
 
 
    
 
GO TO NEXT PAGE 
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Q2 In a typical WEEK in the LAST MONTH (do NOT include school holidays), 
which of the following LEISURE activities do you USUALLY do and for how long 
Monday-Friday and Saturday-Sunday?  
 
In a typical WEEK which leisure 
activities do you usually do? 
Do you usually 
do this activity? 
Total 
hours/minutes 
Monday-Friday 
Total 
hours/minutes 
Saturday & Sunday 
 
EXAMPLE: 
Watching Television/ 
videos/DVDs 
No   Yes 15hrs 6hrs 30mins 
Watching Television/ 
videos/DVDs 
No   Yes   
Playing Playstation/ Nintendo/ 
XBOX / Computer games 
No   Yes   
Using the Computer/ internet 
(not games) 
No   Yes   
Doing homework No   Yes   
Sitting talking No   Yes   
Talking on the phone No   Yes   
Listening to music No   Yes   
Playing board games/cards No   Yes   
Playing a musical instrument No   Yes   
Reading books, magazines No   Yes   
Doing art & craft (eg. painting, 
models, beads, sewing, drawing) 
No   Yes   
Model Railways / Model Planes  
/ cars / Warhammer 
No        Yes   
Other (list) 
 
 
____________________ 
 
   
Notice that this question is different from the last one, 
because it asks you how many hours/minutes you do each 
activity and not how many times 
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Dietary Protocols – Moderate Carbohydrate 
Moderate CHO diet 
Nutrient Targets: 
40-45% Total CHO 
30% protein 
25% fat (<10% saturated)  
 
Meal Targets 
30-45g total carbohydrate 
20-30g total protein 
10-20g total fat 
Mid Meal Targets 
20-30g total carbohydrate 
10-20g total protein 
5-10g total fat 
 
Food Targets: 
Bread – 2 slices/day 
Fruit – 2 pieces 
Dairy – 4 serves 
Fats & Oils – 3 serves 
 
Main Dietary Principles 
Breakfast 
Low GI carbohydrate + protein eaten together at each meal and mid meal 
75-100g lean protein at lunch 
100-150g lean protein at dinner 
No fruit juice, soft drink, cordial 
1 meal off week 
Wholegrain low GI carbohydrates: 2 CHO exchanges @ meals/ 1-2 @ mid meals 
20g total carbohydrate in the PM meal 
No food after 9pm 
3 cups vegetables/salad/day 
 
Sample Meal Plan – Moderate CHO 
Breakfast 
2 x wholegrain bread + 2 poached eggs 
1 Up & Go Energise Breakfast drink 
¾ cup wholegrain cereal + 1 cup low fat milk + 1 fruit 
 
Mid Morning 
4 wholegrain crackers + 2 slices reduced fat cheese + 1 fruit 
Low fat flavoured milk + 1 fruit 
Protein rich snack bar +1 fruit 
 
Lunch 
75-100g lean protein + 
Wrap style bread + salad 
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Afternoon Snack 
1 dairy + serve nuts 
Billabong/Paddle Pop + 15 almonds/walnuts 
Nut Bar + Glass of low fat milk 
 
Dinner 
100-150g lean protein + 
1 potato in jacket OR ½ corn cob OR dessert 
3 cups vegetables OR salad 
 
Dessert 
<400kJ reduced fat ice cream 
100g thick style yoghurt + free fruit 
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Dietetic Intervention Outline:  Initial Consultation 30-40 minutes 
 
      
1) Introduction   Dietitian to introduce self  5 mins 
 
2) Gauge interest  Questionnaire/Weight goals 5 mins 
 
3) Describe program Overall summary of diet  5 mins 
 
4) Individual plan  Satisfying checklist   5 mins 
 
5) Resources  overview    5 mins 
 
6) Final questions  Follow up scheduled  5 mins 
 
 
Phone/email follow up – 24 hours later 
 
Checklist –  
Breakfast 
Hunger 
Protein at meals and mid meals 
Reduced CHO at night 
Extras 
Fluids 
Questions 
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Exercise advice for ________ 
 
Keep an exercise diary 
 
Limit small screen time (TV, computer, internet, Playstation, Nintendo) to less than 2 hours per day 
 
Exercise during your “hungry periods” such as after school 
 
Try and do 3-4 exercise sessions per week. 
Each session should be approximately 45-60 minutes of moderate intensity exercise. Walking alternating with 
jogging is a good activity: 
 
 
Week 1  5 minutes    (4 minutes of walking, 1 minute jogging) 
(Repeat for whole 45-60 minute session) 
 
Each week try and increase your jogging time by 30 seconds 
 
Week 2 5 minutes    (3.5 minutes walking, 1.5 minutes jogging) 
Week 3 5 minutes    (3 minutes walking, 2 minutes jogging) 
 
………………So by week 8 you should be running most of the time 
 
Try and do some competitive sport all year round 
 
Summer: Boys & Girls- Basketball, touch football, rowing,                
Six a side soccer, cricket, futsal 
Winter:   Boys - Soccer, rugby union/ League, basketball 
Girls - Soccer, netball, basketball 
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Instructions 
Please fill in this diary each day while you are training 
Record the time you spent on the vibration plate 
Record the frequency (green number displayed on vibration plate) 
Make a note of any problems you had during the week 
  
Record Number ⁯⁯⁯⁯⁯⁯⁯⁯ 
Name:__________________ 
 
Date started vibration training ⁯⁯/⁯⁯/⁯⁯ 
 
If you have any questions please call Dr Kim Ramjan (02) 9845 – 3151 
Office Use Only: Data Entered ⁯⁯⁯⁯ Date ⁯⁯/⁯⁯/⁯⁯ 
 
 
 
 
Vibration Training Activity Diary 
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Vibration Training Schedule Week 1 
 
Please write time and frequency after you have done your training 
 
  
Comments Week 1 
 
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________ 
Please write time and frequency after you have done your training 
Day Date Vibration 1 Completed  Rest 1 Vibration 2 Completed  Rest 2 Vibration 3 Completed Rest 3 Official 
Use Only 
   Time Frequency   Time Frequency   Time Frequency   
Mon  1 min; 12Hz   3 min 1 min; 12Hz   3 min 1 min; 12Hz   3 min  
Tues  1 min; 12Hz   3 min 1 min; 12Hz   3 min 1 min; 18Hz   3 min  
Wed  2 min; 12Hz   3 min 2 min; 18Hz   3 min 2 min; 18Hz   3 min  
Thurs  2 min; 12Hz   3 min 2 min; 18-20Hz   3 min 3 min; 18-20Hz   3 min  
Fri  3 min; 12Hz   3 min 3 min; 18-20Hz   3 min 3 min; 18-20Hz   3 min  
Sat  3 min; 12Hz   3 min 3 min; 18-20Hz   3 min 3 min; 18-20Hz   3 min  
Sun  3 min; 12Hz   3 min 3 min; 18-20Hz   3 min 3 min; 18-20Hz   3 min  
               
